"text","relation"
"A novel <e2>SCN5A</e2> mutation manifests as a malignant form of long QT syndrome with perinatal onset of tachycardia/<e1>bradycardia</e1>.","Association"
"A novel <e2>SCN5A</e2> mutation manifests as a malignant form of long QT syndrome with perinatal onset of <e1>tachycardia</e1>/bradycardia.","Association"
"A novel <e2>SCN5A</e2> mutation manifests as a malignant form of <e1>long QT syndrome</e1> with perinatal onset of tachycardia/bradycardia.","Association"
"CONCLUSIONS: These findings suggest that the <e1>Na(v)1.5</e1>/V1763M channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital LQTS with perinatal onset of <e2>arrhythmias</e2> that responded to lidocaine and mexiletine.","Association"
"CONCLUSIONS: These findings suggest that the <e1>Na(v)1.5</e1>/V1763M channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital LQTS with perinatal onset of <e2>arrhythmias</e2> that responded to lidocaine and mexiletine.","Association"
"CONCLUSIONS: These findings suggest that the Na(v)1.5/V1763M channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital LQTS with perinatal onset of <e1>arrhythmias</e1> that responded to lidocaine and <e2>mexiletine</e2>.","Negative_Correlation"
"CONCLUSIONS: These findings suggest that the Na(v)1.5/V1763M channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital LQTS with perinatal onset of <e1>arrhythmias</e1> that responded to <e2>lidocaine</e2> and mexiletine.","Negative_Correlation"
"CONCLUSIONS: These findings suggest that the Na(v)1.5/<e1>V1763M</e1> channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital LQTS with perinatal onset of <e2>arrhythmias</e2> that responded to lidocaine and mexiletine.","Positive_Correlation"
"CONCLUSIONS: These findings suggest that the Na(v)1.5/<e1>V1763M</e1> channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital <e2>LQTS</e2> with perinatal onset of arrhythmias that responded to lidocaine and mexiletine.","Positive_Correlation"
"RESULTS: A novel, spontaneous <e1>LQTS</e1>-3 mutation was identified in the transmembrane segment 6 of domain IV of the <e2>Na(v)1.5</e2> cardiac sodium channel, with a G-->A substitution at codon 1763, which changed a valine (GTG) to a methionine (ATG).","Association"
"RESULTS: A novel, spontaneous <e1>LQTS</e1>-3 mutation was identified in the transmembrane segment 6 of domain IV of the <e2>Na(v)1.5</e2> cardiac sodium channel, with a G-->A substitution at codon 1763, which changed a valine (GTG) to a methionine (ATG).","Association"
"RESULTS: A novel, spontaneous <e1>LQTS</e1>-3 mutation was identified in the transmembrane segment 6 of domain IV of the <e2>Na(v)1.5</e2> cardiac sodium channel, with a G-->A substitution at codon 1763, which changed a valine (GTG) to a methionine (ATG).","Association"
"RESULTS: A novel, spontaneous <e1>LQTS</e1>-3 mutation was identified in the transmembrane segment 6 of domain IV of the Na(v)1.5 cardiac sodium channel, with a G-->A substitution at codon 1763, which changed a <e2>valine (GTG) to a methionine (ATG)</e2>.","Association"
"RESULTS: A novel, spontaneous <e1>LQTS</e1>-3 mutation was identified in the transmembrane segment 6 of domain IV of the Na(v)1.5 cardiac sodium channel, with a G-->A substitution at codon 1763, which changed a <e2>valine (GTG) to a methionine (ATG)</e2>.","Association"
"RESULTS: A novel, spontaneous <e1>LQTS</e1>-3 mutation was identified in the transmembrane segment 6 of domain IV of the Na(v)1.5 cardiac sodium channel, with a G-->A substitution at codon 1763, which changed a <e2>valine (GTG) to a methionine (ATG)</e2>.","Association"
"RESULTS: A novel, spontaneous <e1>LQTS</e1>-3 mutation was identified in the transmembrane segment 6 of domain IV of the Na(v)1.5 cardiac sodium channel, with a <e2>G-->A substitution at codon 1763</e2>, which changed a valine (GTG) to a methionine (ATG).","Association"
"RESULTS: A novel, spontaneous <e1>LQTS</e1>-3 mutation was identified in the transmembrane segment 6 of domain IV of the Na(v)1.5 cardiac sodium channel, with a <e2>G-->A substitution at codon 1763</e2>, which changed a valine (GTG) to a methionine (ATG).","Association"
"RESULTS: A novel, spontaneous <e1>LQTS</e1>-3 mutation was identified in the transmembrane segment 6 of domain IV of the Na(v)1.5 cardiac sodium channel, with a <e2>G-->A substitution at codon 1763</e2>, which changed a valine (GTG) to a methionine (ATG).","Association"
"CONCLUSIONS: These findings suggest that the Na(v)1.5/V1763M channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital <e1>LQTS</e1> with perinatal onset of arrhythmias that responded to lidocaine and <e2>mexiletine</e2>.","Negative_Correlation"
"CONCLUSIONS: These findings suggest that the Na(v)1.5/V1763M channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital <e1>LQTS</e1> with perinatal onset of arrhythmias that responded to lidocaine and <e2>mexiletine</e2>.","Negative_Correlation"
"CONCLUSIONS: These findings suggest that the Na(v)1.5/V1763M channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital <e1>LQTS</e1> with perinatal onset of arrhythmias that responded to lidocaine and <e2>mexiletine</e2>.","Negative_Correlation"
"CONCLUSIONS: These findings suggest that the Na(v)1.5/V1763M channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital <e1>LQTS</e1> with perinatal onset of arrhythmias that responded to <e2>lidocaine</e2> and mexiletine.","Negative_Correlation"
"CONCLUSIONS: These findings suggest that the Na(v)1.5/V1763M channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital <e1>LQTS</e1> with perinatal onset of arrhythmias that responded to <e2>lidocaine</e2> and mexiletine.","Negative_Correlation"
"CONCLUSIONS: These findings suggest that the Na(v)1.5/V1763M channel dysfunction and possible neighboring mutants contribute to a persistent inward current due to altered inactivation kinetics and clinically congenital <e1>LQTS</e1> with perinatal onset of arrhythmias that responded to <e2>lidocaine</e2> and mexiletine.","Negative_Correlation"
"The 2:1 atrioventricular block improved to 1:1 conduction only after intravenous lidocaine infusion or a high dose of <e1>mexiletine</e1>, which also controlled the <e2>ventricular tachycardia</e2>.","Negative_Correlation"
"The 2:1 atrioventricular block improved to 1:1 conduction only after intravenous lidocaine infusion or a high dose of <e1>mexiletine</e1>, which also controlled the <e2>ventricular tachycardia</e2>.","Negative_Correlation"
"The 2:1 atrioventricular block improved to 1:1 conduction only after intravenous <e1>lidocaine</e1> infusion or a high dose of mexiletine, which also controlled the <e2>ventricular tachycardia</e2>.","Negative_Correlation"
"The 2:1 atrioventricular block improved to 1:1 conduction only after intravenous <e1>lidocaine</e1> infusion or a high dose of mexiletine, which also controlled the <e2>ventricular tachycardia</e2>.","Negative_Correlation"
"The 2:1 atrioventricular block improved to 1:1 conduction only after intravenous <e1>lidocaine</e1> infusion or a high dose of mexiletine, which also controlled the <e2>ventricular tachycardia</e2>.","Negative_Correlation"
"The 2:1 <e1>atrioventricular block</e1> improved to 1:1 conduction only after intravenous lidocaine infusion or a high dose of <e2>mexiletine</e2>, which also controlled the ventricular tachycardia.","Negative_Correlation"
"The 2:1 <e1>atrioventricular block</e1> improved to 1:1 conduction only after intravenous lidocaine infusion or a high dose of <e2>mexiletine</e2>, which also controlled the ventricular tachycardia.","Negative_Correlation"
"The 2:1 <e1>atrioventricular block</e1> improved to 1:1 conduction only after intravenous <e2>lidocaine</e2> infusion or a high dose of mexiletine, which also controlled the ventricular tachycardia.","Negative_Correlation"
"The 2:1 <e1>atrioventricular block</e1> improved to 1:1 conduction only after intravenous <e2>lidocaine</e2> infusion or a high dose of mexiletine, which also controlled the ventricular tachycardia.","Negative_Correlation"
"As a primary target for opioid drugs and peptides, the <e1>mu opioid receptor</e1> (OPRM1) plays a key role in <e2>pain</e2> perception and addiction.","Association"
"As a primary target for opioid drugs and peptides, the mu opioid receptor (<e1>OPRM1</e1>) plays a key role in <e2>pain</e2> perception and addiction.","Association"
"As a primary target for opioid drugs and peptides, the mu opioid receptor (<e1>OPRM1</e1>) plays a key role in <e2>pain</e2> perception and addiction.","Association"
"As a primary target for opioid drugs and peptides, the mu opioid receptor (<e1>OPRM1</e1>) plays a key role in <e2>pain</e2> perception and addiction.","Association"
"Genetic variants of <e1>OPRM1</e1> have been implicated in predisposition to <e2>drug addiction</e2>, in particular the single nucleotide polymorphism A118G, leading to an N40D substitution, with an allele frequency of 10-32%, and uncertain functions.","Association"
"Genetic variants of <e1>OPRM1</e1> have been implicated in predisposition to <e2>drug addiction</e2>, in particular the single nucleotide polymorphism A118G, leading to an N40D substitution, with an allele frequency of 10-32%, and uncertain functions.","Association"
"Genetic variants of <e1>OPRM1</e1> have been implicated in predisposition to <e2>drug addiction</e2>, in particular the single nucleotide polymorphism A118G, leading to an N40D substitution, with an allele frequency of 10-32%, and uncertain functions.","Association"
"Genetic variants of OPRM1 have been implicated in predisposition to <e1>drug addiction</e1>, in particular the single nucleotide polymorphism <e2>A118G</e2>, leading to an N40D substitution, with an allele frequency of 10-32%, and uncertain functions.","Association"
"Genetic variants of OPRM1 have been implicated in predisposition to <e1>drug addiction</e1>, in particular the single nucleotide polymorphism <e2>A118G</e2>, leading to an N40D substitution, with an allele frequency of 10-32%, and uncertain functions.","Association"
"Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed <e1>anthracycline</e1>-related congestive heart failure after childhood <e2>cancer</e2>.","Negative_Correlation"
"Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed <e1>anthracycline</e1>-related <e2>congestive heart failure</e2> after childhood cancer.","Positive_Correlation"
"Genetic polymorphisms in the <e1>carbonyl reductase 3</e1> gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related <e2>congestive heart failure</e2> after childhood cancer.","Association"
"Genetic polymorphisms in the carbonyl reductase 3 gene <e1>CBR3</e1> and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related <e2>congestive heart failure</e2> after childhood cancer.","Association"
"Genetic polymorphisms in the <e1>carbonyl reductase 3</e1> gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed <e2>anthracycline</e2>-related congestive heart failure after childhood cancer.","Association"
"Genetic polymorphisms in the carbonyl reductase 3 gene <e1>CBR3</e1> and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed <e2>anthracycline</e2>-related congestive heart failure after childhood cancer.","Association"
"In line, recombinant CBR3 V244 (G allele) synthesized 2.6-fold more <e1>cardiotoxic</e1> <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Positive_Correlation"
"In line, recombinant CBR3 V244 (G allele) synthesized 2.6-fold more <e1>cardiotoxic</e1> <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Positive_Correlation"
"In line, recombinant CBR3 <e1>V244</e1> (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant CBR3 V244 (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 <e1>M244</e1> (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant CBR3 <e1>V244</e1> (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant CBR3 V244 (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 <e1>M244</e1> (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant CBR3 <e1>V244</e1> (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant CBR3 V244 (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 <e1>M244</e1> (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"Thirty patients with <e2>CHF</e2> (cases) and 115 matched controls were genotyped for polymorphisms in NQO1 (NQO1*2) and CBR3 (the CBR3 <e1>valine [V] to methionine [M] substitution at position 244</e1> [V244M]).","Positive_Correlation"
"Thirty patients with <e2>CHF</e2> (cases) and 115 matched controls were genotyped for polymorphisms in NQO1 (NQO1*2) and CBR3 (the CBR3 valine [V] to methionine [M] substitution at position 244 [<e1>V244M</e1>]).","Positive_Correlation"
"Thirty patients with <e2>CHF</e2> (cases) and 115 matched controls were genotyped for polymorphisms in NQO1 (NQO1*2) and CBR3 (the CBR3 valine [V] to methionine [M] substitution at position 244 [<e1>V244</e1>M]).","Positive_Correlation"
"Thirty patients with <e2>CHF</e2> (cases) and 115 matched controls were genotyped for polymorphisms in NQO1 (NQO1*2) and CBR3 (the CBR3 valine [V] to methionine [M] substitution at position 244 [<e1>V244M</e1>]).","Positive_Correlation"
"Thirty patients with <e2>CHF</e2> (cases) and 115 matched controls were genotyped for polymorphisms in NQO1 (NQO1*2) and CBR3 (the CBR3 valine [V] to methionine [M] substitution at position 244 [<e1>V244M</e1>]).","Positive_Correlation"
"Thirty patients with <e2>CHF</e2> (cases) and 115 matched controls were genotyped for polymorphisms in NQO1 (NQO1*2) and CBR3 (the CBR3 valine [V] to methionine [M] substitution at position 244 [<e1>V244M</e1>]).","Positive_Correlation"
"Thirty patients with <e2>CHF</e2> (cases) and 115 matched controls were genotyped for polymorphisms in NQO1 (NQO1*2) and CBR3 (the CBR3 valine [V] to methionine [M] substitution at position 244 [<e1>V244</e1>M]).","Positive_Correlation"
"Thirty patients with <e2>CHF</e2> (cases) and 115 matched controls were genotyped for polymorphisms in NQO1 (NQO1*2) and CBR3 (the CBR3 valine [V] to methionine [M] substitution at position 244 [<e1>V244</e1>M]).","Positive_Correlation"
"Thirty patients with <e2>CHF</e2> (cases) and 115 matched controls were genotyped for polymorphisms in NQO1 (NQO1*2) and CBR3 (the CBR3 valine [V] to methionine [M] substitution at position 244 [<e1>V244M</e1>]).","Positive_Correlation"
"Enzyme activity assays with recombinant CBR3 isoforms (CBR3 V244 and CBR3 M244) and the <e2>anthracycline</e2> substrate doxorubicin were used to investigate the functional impact of the CBR3 <e1>V244M</e1> polymorphism.","Association"
"Enzyme activity assays with recombinant CBR3 isoforms (CBR3 <e1>V244</e1> and CBR3 M244) and the <e2>anthracycline</e2> substrate doxorubicin were used to investigate the functional impact of the CBR3 V244M polymorphism.","Association"
"Enzyme activity assays with recombinant CBR3 isoforms (CBR3 V244 and CBR3 <e1>M244</e1>) and the <e2>anthracycline</e2> substrate doxorubicin were used to investigate the functional impact of the CBR3 V244M polymorphism.","Association"
"Enzyme activity assays with recombinant CBR3 isoforms (CBR3 V244 and CBR3 M244) and the <e2>anthracycline</e2> substrate doxorubicin were used to investigate the functional impact of the CBR3 <e1>V244M</e1> polymorphism.","Association"
"Enzyme activity assays with recombinant CBR3 isoforms (CBR3 V244 and CBR3 M244) and the <e2>anthracycline</e2> substrate doxorubicin were used to investigate the functional impact of the CBR3 <e1>V244M</e1> polymorphism.","Association"
"Enzyme activity assays with recombinant CBR3 isoforms (CBR3 V244 and CBR3 M244) and the <e2>anthracycline</e2> substrate doxorubicin were used to investigate the functional impact of the CBR3 <e1>V244M</e1> polymorphism.","Association"
"Enzyme activity assays with recombinant CBR3 isoforms (CBR3 <e1>V244</e1> and CBR3 M244) and the <e2>anthracycline</e2> substrate doxorubicin were used to investigate the functional impact of the CBR3 V244M polymorphism.","Association"
"Enzyme activity assays with recombinant CBR3 isoforms (CBR3 V244 and CBR3 <e1>M244</e1>) and the <e2>anthracycline</e2> substrate doxorubicin were used to investigate the functional impact of the CBR3 V244M polymorphism.","Association"
"Enzyme activity assays with recombinant CBR3 isoforms (CBR3 <e1>V244</e1> and CBR3 M244) and the <e2>anthracycline</e2> substrate doxorubicin were used to investigate the functional impact of the CBR3 V244M polymorphism.","Association"
"Enzyme activity assays with recombinant CBR3 isoforms (CBR3 V244 and CBR3 <e1>M244</e1>) and the <e2>anthracycline</e2> substrate doxorubicin were used to investigate the functional impact of the CBR3 V244M polymorphism.","Association"
"Enzyme activity assays with recombinant CBR3 isoforms (CBR3 V244 and CBR3 M244) and the <e2>anthracycline</e2> substrate doxorubicin were used to investigate the functional impact of the CBR3 <e1>V244M</e1> polymorphism.","Association"
"BACKGROUND: Exposure to <e1>anthracyclines</e1> as part of <e2>cancer</e2> therapy has been associated with the development of congestive heart failure (CHF).","Negative_Correlation"
"BACKGROUND: Exposure to <e1>anthracycline</e1>s as part of <e2>cancer</e2> therapy has been associated with the development of congestive heart failure (CHF).","Negative_Correlation"
"BACKGROUND: Exposure to <e1>anthracyclines</e1> as part of <e2>cancer</e2> therapy has been associated with the development of congestive heart failure (CHF).","Negative_Correlation"
"BACKGROUND: Exposure to <e1>anthracycline</e1>s as part of <e2>cancer</e2> therapy has been associated with the development of congestive heart failure (CHF).","Negative_Correlation"
"BACKGROUND: Exposure to <e1>anthracyclines</e1> as part of <e2>cancer</e2> therapy has been associated with the development of congestive heart failure (CHF).","Negative_Correlation"
"BACKGROUND: Exposure to <e1>anthracycline</e1>s as part of <e2>cancer</e2> therapy has been associated with the development of congestive heart failure (CHF).","Negative_Correlation"
"BACKGROUND: Exposure to <e1>anthracycline</e1>s as part of <e2>cancer</e2> therapy has been associated with the development of congestive heart failure (CHF).","Negative_Correlation"
"BACKGROUND: Exposure to <e1>anthracycline</e1>s as part of <e2>cancer</e2> therapy has been associated with the development of congestive heart failure (CHF).","Negative_Correlation"
"CONCLUSIONS: The functional CBR3 V244M polymorphism may have an impact on the risk of <e1>anthracycline</e1>-related CHF among childhood cancer survivors by modulating the intracardiac formation of <e2>cardiotoxic</e2> anthracycline alcohol metabolites.","Positive_Correlation"
"CONCLUSIONS: The functional CBR3 V244M polymorphism may have an impact on the risk of <e1>anthracycline</e1>-related CHF among childhood cancer survivors by modulating the intracardiac formation of <e2>cardiotoxic</e2> anthracycline alcohol metabolites.","Positive_Correlation"
"CONCLUSIONS: The functional CBR3 V244M polymorphism may have an impact on the risk of <e1>anthracycline</e1>-related CHF among childhood cancer survivors by modulating the intracardiac formation of <e2>cardiotoxic</e2> anthracycline alcohol metabolites.","Positive_Correlation"
"CONCLUSIONS: The functional CBR3 V244M polymorphism may have an impact on the risk of <e1>anthracycline</e1>-related CHF among childhood cancer survivors by modulating the intracardiac formation of <e2>cardiotoxic</e2> anthracycline alcohol metabolites.","Positive_Correlation"
"CONCLUSIONS: The functional CBR3 V244M polymorphism may have an impact on the risk of <e1>anthracycline</e1>-related CHF among childhood cancer survivors by modulating the intracardiac formation of <e2>cardiotoxic</e2> anthracycline alcohol metabolites.","Positive_Correlation"
"BACKGROUND: Exposure to <e1>anthracyclines</e1> as part of cancer therapy has been associated with the development of <e2>congestive heart failure</e2> (CHF).","Positive_Correlation"
"BACKGROUND: Exposure to <e1>anthracycline</e1>s as part of cancer therapy has been associated with the development of <e2>congestive heart failure</e2> (CHF).","Positive_Correlation"
"BACKGROUND: Exposure to <e1>anthracyclines</e1> as part of cancer therapy has been associated with the development of <e2>congestive heart failure</e2> (CHF).","Positive_Correlation"
"BACKGROUND: Exposure to <e1>anthracycline</e1>s as part of cancer therapy has been associated with the development of <e2>congestive heart failure</e2> (CHF).","Positive_Correlation"
"BACKGROUND: Exposure to <e1>anthracyclines</e1> as part of cancer therapy has been associated with the development of <e2>congestive heart failure</e2> (CHF).","Positive_Correlation"
"BACKGROUND: Exposure to <e1>anthracycline</e1>s as part of cancer therapy has been associated with the development of <e2>congestive heart failure</e2> (CHF).","Positive_Correlation"
"BACKGROUND: Exposure to <e1>anthracycline</e1>s as part of cancer therapy has been associated with the development of <e2>congestive heart failure</e2> (CHF).","Positive_Correlation"
"BACKGROUND: Exposure to <e1>anthracycline</e1>s as part of cancer therapy has been associated with the development of <e2>congestive heart failure</e2> (CHF).","Positive_Correlation"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more <e2>cardiotoxic</e2> doxorubicinol per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more <e2>cardiotoxic</e2> doxorubicinol per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more <e2>cardiotoxic</e2> doxorubicinol per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more <e2>cardiotoxic</e2> doxorubicinol per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more <e2>cardiotoxic</e2> doxorubicinol per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more <e2>cardiotoxic</e2> doxorubicinol per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more <e2>cardiotoxic</e2> doxorubicinol per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more <e2>cardiotoxic</e2> doxorubicinol per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more <e2>cardiotoxic</e2> doxorubicinol per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more <e2>cardiotoxic</e2> doxorubicinol per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more <e2>cardiotoxic</e2> doxorubicinol per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more <e2>cardiotoxic</e2> doxorubicinol per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more <e2>cardiotoxic</e2> doxorubicinol per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more <e2>cardiotoxic</e2> doxorubicinol per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"In line, recombinant <e1>CBR3</e1> V244 (G allele) synthesized 2.6-fold more cardiotoxic <e2>doxorubicinol</e2> per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the <e1>carbonyl reductase 3</e1> gene CBR3) had an impact on the risk of anthracycline-related <e2>CHF</e2>.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related <e2>CHF</e2>.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related <e2>CHF</e2>.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related <e2>CHF</e2>.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related <e2>CHF</e2>.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related <e2>CHF</e2>.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related <e2>CHF</e2>.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related <e2>CHF</e2>.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related <e2>CHF</e2>.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related <e2>CHF</e2>.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related <e2>CHF</e2>.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related <e2>CHF</e2>.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related <e2>CHF</e2>.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related <e2>CHF</e2>.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related <e2>CHF</e2>.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of <e2>anthracyclines</e2> (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the <e1>carbonyl reductase 3</e1> gene CBR3) had an impact on the risk of anthracycline-related CHF.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of <e2>anthracyclines</e2> (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related CHF.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of <e2>anthracyclines</e2> (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related CHF.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of <e2>anthracyclines</e2> (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related CHF.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of <e2>anthracyclines</e2> (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related CHF.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of <e2>anthracyclines</e2> (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related CHF.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of <e2>anthracyclines</e2> (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related CHF.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of <e2>anthracyclines</e2> (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related CHF.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of <e2>anthracyclines</e2> (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related CHF.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of <e2>anthracyclines</e2> (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related CHF.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of <e2>anthracyclines</e2> (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related CHF.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of <e2>anthracyclines</e2> (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related CHF.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of <e2>anthracyclines</e2> (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related CHF.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of <e2>anthracyclines</e2> (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related CHF.","Association"
"Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of <e2>anthracyclines</e2> (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene <e1>CBR3</e1>) had an impact on the risk of anthracycline-related CHF.","Association"
"<e2>Debrisoquine</e2> phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of <e1>metoprolol</e1> and its enantiomers.","Association"
"Debrisoquine phenotype and the pharmacokinetics and <e2>beta-2 receptor</e2> pharmacodynamics of <e1>metoprolol</e1> and its enantiomers.","Negative_Correlation"
"The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher <e1>beta-1 adrenoceptor</e1> antagonistic potency of racemic <e2>metoprolol</e2> in EMs.","Negative_Correlation"
"The drug effect studied was the antagonism by metoprolol of <e1>terbutaline</e1>-induced <e2>hypokalemia</e2>.","Positive_Correlation"
"The drug effect studied was the antagonism by metoprolol of <e1>terbutaline</e1>-induced <e2>hypokalemia</e2>.","Positive_Correlation"
"The drug effect studied was the antagonism by metoprolol of <e1>terbutaline</e1>-induced <e2>hypokalemia</e2>.","Positive_Correlation"
"The drug effect studied was the antagonism by metoprolol of <e1>terbutaline</e1>-induced <e2>hypokalemia</e2>.","Positive_Correlation"
"The drug effect studied was the antagonism by metoprolol of <e1>terbutaline</e1>-induced <e2>hypokalemia</e2>.","Positive_Correlation"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the debrisoquine/<e2>sparteine</e2> type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the debrisoquine/<e2>sparteine</e2> type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the debrisoquine/<e2>sparteine</e2> type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the debrisoquine/<e2>sparteine</e2> type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the debrisoquine/<e2>sparteine</e2> type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the debrisoquine/<e2>sparteine</e2> type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the debrisoquine/<e2>sparteine</e2> type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the debrisoquine/<e2>sparteine</e2> type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the debrisoquine/<e2>sparteine</e2> type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the debrisoquine/<e2>sparteine</e2> type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the debrisoquine/<e2>sparteine</e2> type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the debrisoquine/<e2>sparteine</e2> type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the debrisoquine/<e2>sparteine</e2> type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the <e2>debrisoquine</e2>/sparteine type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the <e2>debrisoquine</e2>/sparteine type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the <e2>debrisoquine</e2>/sparteine type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the <e2>debrisoquine</e2>/sparteine type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the <e2>debrisoquine</e2>/sparteine type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the <e2>debrisoquine</e2>/sparteine type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the <e2>debrisoquine</e2>/sparteine type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the <e2>debrisoquine</e2>/sparteine type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the <e2>debrisoquine</e2>/sparteine type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the <e2>debrisoquine</e2>/sparteine type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the <e2>debrisoquine</e2>/sparteine type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the <e2>debrisoquine</e2>/sparteine type.","Association"
"The metabolism of the cardioselective beta-blocker <e1>metoprolol</e1> is under genetic control of the <e2>debrisoquine</e2>/sparteine type.","Association"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of <e2>terbutaline</e2>-induced hypokalemia.","Positive_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of <e2>terbutaline</e2>-induced hypokalemia.","Positive_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of <e2>terbutaline</e2>-induced hypokalemia.","Positive_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of <e2>terbutaline</e2>-induced hypokalemia.","Positive_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of <e2>terbutaline</e2>-induced hypokalemia.","Positive_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of <e2>terbutaline</e2>-induced hypokalemia.","Positive_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of <e2>terbutaline</e2>-induced hypokalemia.","Positive_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of <e2>terbutaline</e2>-induced hypokalemia.","Positive_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of <e2>terbutaline</e2>-induced hypokalemia.","Positive_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of <e2>terbutaline</e2>-induced hypokalemia.","Positive_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of <e2>terbutaline</e2>-induced hypokalemia.","Positive_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of <e2>terbutaline</e2>-induced hypokalemia.","Positive_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of <e2>terbutaline</e2>-induced hypokalemia.","Positive_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of terbutaline-induced <e2>hypokalemia</e2>.","Negative_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of terbutaline-induced <e2>hypokalemia</e2>.","Negative_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of terbutaline-induced <e2>hypokalemia</e2>.","Negative_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of terbutaline-induced <e2>hypokalemia</e2>.","Negative_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of terbutaline-induced <e2>hypokalemia</e2>.","Negative_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of terbutaline-induced <e2>hypokalemia</e2>.","Negative_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of terbutaline-induced <e2>hypokalemia</e2>.","Negative_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of terbutaline-induced <e2>hypokalemia</e2>.","Negative_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of terbutaline-induced <e2>hypokalemia</e2>.","Negative_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of terbutaline-induced <e2>hypokalemia</e2>.","Negative_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of terbutaline-induced <e2>hypokalemia</e2>.","Negative_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of terbutaline-induced <e2>hypokalemia</e2>.","Negative_Correlation"
"The drug effect studied was the antagonism by <e1>metoprolol</e1> of terbutaline-induced <e2>hypokalemia</e2>.","Negative_Correlation"
"We investigated if the latter also applies to the <e2>beta-2 adrenoceptor</e2> antagonism by <e1>metoprolol</e1>.","Negative_Correlation"
"We investigated if the latter also applies to the <e2>beta-2 adrenoceptor</e2> antagonism by <e1>metoprolol</e1>.","Negative_Correlation"
"We investigated if the latter also applies to the <e2>beta-2 adrenoceptor</e2> antagonism by <e1>metoprolol</e1>.","Negative_Correlation"
"We investigated if the latter also applies to the <e2>beta-2 adrenoceptor</e2> antagonism by <e1>metoprolol</e1>.","Negative_Correlation"
"We investigated if the latter also applies to the <e2>beta-2 adrenoceptor</e2> antagonism by <e1>metoprolol</e1>.","Negative_Correlation"
"We investigated if the latter also applies to the <e2>beta-2 adrenoceptor</e2> antagonism by <e1>metoprolol</e1>.","Negative_Correlation"
"We investigated if the latter also applies to the <e2>beta-2 adrenoceptor</e2> antagonism by <e1>metoprolol</e1>.","Negative_Correlation"
"We investigated if the latter also applies to the <e2>beta-2 adrenoceptor</e2> antagonism by <e1>metoprolol</e1>.","Negative_Correlation"
"We investigated if the latter also applies to the <e2>beta-2 adrenoceptor</e2> antagonism by <e1>metoprolol</e1>.","Negative_Correlation"
"We investigated if the latter also applies to the <e2>beta-2 adrenoceptor</e2> antagonism by <e1>metoprolol</e1>.","Negative_Correlation"
"We investigated if the latter also applies to the <e2>beta-2 adrenoceptor</e2> antagonism by <e1>metoprolol</e1>.","Negative_Correlation"
"We investigated if the latter also applies to the <e2>beta-2 adrenoceptor</e2> antagonism by <e1>metoprolol</e1>.","Negative_Correlation"
"We investigated if the latter also applies to the <e2>beta-2 adrenoceptor</e2> antagonism by <e1>metoprolol</e1>.","Negative_Correlation"
"The first founder <e1>DGUOK</e1> mutation associated with <e2>hepatocerebral mitochondrial DNA depletion syndrome</e2>.","Association"
"This new <e1>DGUOK</e1> homozygous mutation (c.444-62C>A) was identified in three patients from two North-African consanguineous families with combined respiratory chain deficiencies and <e2>mitochondrial DNA depletion</e2> in the liver.","Association"
"This new <e1>DGUOK</e1> homozygous mutation (c.444-62C>A) was identified in three patients from two North-African consanguineous families with combined respiratory chain deficiencies and <e2>mitochondrial DNA depletion</e2> in the liver.","Association"
"This new <e1>DGUOK</e1> homozygous mutation (c.444-62C>A) was identified in three patients from two North-African consanguineous families with combined respiratory chain deficiencies and <e2>mitochondrial DNA depletion</e2> in the liver.","Association"
"This new <e1>DGUOK</e1> homozygous mutation (c.444-62C>A) was identified in three patients from two North-African consanguineous families with combined respiratory chain deficiencies and <e2>mitochondrial DNA depletion</e2> in the liver.","Association"
"Deoxyguanosine kinase (<e1>dGK</e1>) deficiency is a frequent cause of mitochondrial DNA depletion associated with a hepatocerebral phenotype.","Association"
"This new <e1>DGUOK</e1> homozygous mutation (c.444-62C>A) was identified in three patients from two North-African consanguineous families with combined respiratory chain deficiencies and <e2>mitochondrial DNA depletion</e2> in the liver.","Association"
"This new <e1>DGUOK</e1> homozygous mutation (c.444-62C>A) was identified in three patients from two North-African consanguineous families with combined respiratory chain deficiencies and <e2>mitochondrial DNA depletion</e2> in the liver.","Association"
"Deoxyguanosine kinase (<e1>dGK</e1>) deficiency is a frequent cause of mitochondrial DNA depletion associated with a hepatocerebral phenotype.","Association"
"This new <e1>DGUOK</e1> homozygous mutation (c.444-62C>A) was identified in three patients from two North-African consanguineous families with combined <e2>respiratory chain deficiencies</e2> and mitochondrial DNA depletion in the liver.","Association"
"This new <e1>DGUOK</e1> homozygous mutation (c.444-62C>A) was identified in three patients from two North-African consanguineous families with combined <e2>respiratory chain deficiencies</e2> and mitochondrial DNA depletion in the liver.","Association"
"This new <e1>DGUOK</e1> homozygous mutation (c.444-62C>A) was identified in three patients from two North-African consanguineous families with combined <e2>respiratory chain deficiencies</e2> and mitochondrial DNA depletion in the liver.","Association"
"This new <e1>DGUOK</e1> homozygous mutation (c.444-62C>A) was identified in three patients from two North-African consanguineous families with combined <e2>respiratory chain deficiencies</e2> and mitochondrial DNA depletion in the liver.","Association"
"This new <e1>DGUOK</e1> homozygous mutation (c.444-62C>A) was identified in three patients from two North-African consanguineous families with combined <e2>respiratory chain deficiencies</e2> and mitochondrial DNA depletion in the liver.","Association"
"This new <e1>DGUOK</e1> homozygous mutation (c.444-62C>A) was identified in three patients from two North-African consanguineous families with combined <e2>respiratory chain deficiencies</e2> and mitochondrial DNA depletion in the liver.","Association"
"This new DGUOK homozygous mutation (<e1>c.444-62C>A</e1>) was identified in three patients from two North-African consanguineous families with combined respiratory chain deficiencies and <e2>mitochondrial DNA depletion</e2> in the liver.","Association"
"This new DGUOK homozygous mutation (<e1>c.444-62C>A</e1>) was identified in three patients from two North-African consanguineous families with combined <e2>respiratory chain deficiencies</e2> and mitochondrial DNA depletion in the liver.","Association"
"<e1>Adenosine A(2A) receptor</e1> gene (ADORA2A) variants may increase autistic symptoms and anxiety in <e2>autism spectrum disorder</e2>.","Association"
"Adenosine A(2A) receptor gene (<e1>ADORA2A</e1>) variants may increase autistic symptoms and anxiety in <e2>autism spectrum disorder</e2>.","Association"
"<e1>Adenosine A(2A) receptor</e1> gene (ADORA2A) variants may increase autistic symptoms and <e2>anxiety</e2> in autism spectrum disorder.","Association"
"Adenosine A(2A) receptor gene (<e1>ADORA2A</e1>) variants may increase autistic symptoms and <e2>anxiety</e2> in autism spectrum disorder.","Association"
"<e1>Adenosine A(2A) receptor</e1> gene (ADORA2A) variants may increase <e2>autistic symptoms</e2> and anxiety in autism spectrum disorder.","Association"
"Adenosine A(2A) receptor gene (<e1>ADORA2A</e1>) variants may increase <e2>autistic symptoms</e2> and anxiety in autism spectrum disorder.","Association"
"Nominal association with the disorder was observed for <e2>rs2236624</e2>-CC, and phenotypic variability in <e1>ASD</e1> symptoms was influenced by rs3761422, rs5751876 and rs35320474.","Association"
"Nominal association with the disorder was observed for <e2>rs2236624</e2>-CC, and phenotypic variability in <e1>ASD</e1> symptoms was influenced by rs3761422, rs5751876 and rs35320474.","Association"
"Nominal association with the disorder was observed for <e2>rs2236624</e2>-CC, and phenotypic variability in <e1>ASD</e1> symptoms was influenced by rs3761422, rs5751876 and rs35320474.","Association"
"Nominal association with the disorder was observed for <e2>rs2236624</e2>-CC, and phenotypic variability in <e1>ASD</e1> symptoms was influenced by rs3761422, rs5751876 and rs35320474.","Association"
"Nominal association with the disorder was observed for <e2>rs2236624</e2>-CC, and phenotypic variability in <e1>ASD</e1> symptoms was influenced by rs3761422, rs5751876 and rs35320474.","Association"
"Nominal association with the disorder was observed for <e2>rs2236624</e2>-CC, and phenotypic variability in <e1>ASD</e1> symptoms was influenced by rs3761422, rs5751876 and rs35320474.","Association"
"The <e1>adenosine A(2A) receptor</e1> gene (ADORA2A) is associated with <e2>panic disorder</e2> and is located on chromosome 22q11.23.","Association"
"The adenosine A(2A) receptor gene (<e1>ADORA2A</e1>) is associated with <e2>panic disorder</e2> and is located on chromosome 22q11.23.","Association"
"The <e1>adenosine A(2A) receptor</e1> gene (ADORA2A) is associated with <e2>panic disorder</e2> and is located on chromosome 22q11.23.","Association"
"The adenosine A(2A) receptor gene (<e1>ADORA2A</e1>) is associated with <e2>panic disorder</e2> and is located on chromosome 22q11.23.","Association"
"The adenosine A(2A) receptor gene (<e1>ADORA2A</e1>) is associated with <e2>panic disorder</e2> and is located on chromosome 22q11.23.","Association"
"The adenosine A(2A) receptor gene (<e1>ADORA2A</e1>) is associated with <e2>panic disorder</e2> and is located on chromosome 22q11.23.","Association"
"Its gene product, the <e1>adenosine A(2A) receptor</e1>, is strongly expressed in the caudate nucleus, which also is involved in <e2>ASD</e2>.","Association"
"As autistic symptoms are increased in individuals with 22q11.2 deletion syndrome, and large 22q11.2 deletions and duplications have been observed in <e2>ASD</e2> individuals, in this study, 98 individuals with ASD and 234 control individuals were genotyped for eight single-nucleotide polymorphisms in <e1>ADORA2A</e1>.","Association"
"Its gene product, the <e1>adenosine A(2A) receptor</e1>, is strongly expressed in the caudate nucleus, which also is involved in <e2>ASD</e2>.","Association"
"As autistic symptoms are increased in individuals with 22q11.2 deletion syndrome, and large 22q11.2 deletions and duplications have been observed in <e2>ASD</e2> individuals, in this study, 98 individuals with ASD and 234 control individuals were genotyped for eight single-nucleotide polymorphisms in <e1>ADORA2A</e1>.","Association"
"As autistic symptoms are increased in individuals with 22q11.2 deletion syndrome, and large 22q11.2 deletions and duplications have been observed in <e2>ASD</e2> individuals, in this study, 98 individuals with ASD and 234 control individuals were genotyped for eight single-nucleotide polymorphisms in <e1>ADORA2A</e1>.","Association"
"As autistic symptoms are increased in individuals with 22q11.2 deletion syndrome, and large 22q11.2 deletions and duplications have been observed in <e2>ASD</e2> individuals, in this study, 98 individuals with ASD and 234 control individuals were genotyped for eight single-nucleotide polymorphisms in <e1>ADORA2A</e1>.","Association"
"In addition, association of <e1>ADORA2A</e1> variants with <e2>anxiety</e2> was replicated for individuals with ASD.","Association"
"In addition, association of <e1>ADORA2A</e1> variants with <e2>anxiety</e2> was replicated for individuals with ASD.","Association"
"In addition, association of <e1>ADORA2A</e1> variants with <e2>anxiety</e2> was replicated for individuals with ASD.","Association"
"In addition, association of <e1>ADORA2A</e1> variants with <e2>anxiety</e2> was replicated for individuals with ASD.","Association"
"As <e2>autistic symptoms</e2> are increased in individuals with 22q11.2 deletion syndrome, and large 22q11.2 deletions and duplications have been observed in ASD individuals, in this study, 98 individuals with ASD and 234 control individuals were genotyped for eight single-nucleotide polymorphisms in <e1>ADORA2A</e1>.","Association"
"As <e2>autistic symptoms</e2> are increased in individuals with 22q11.2 deletion syndrome, and large 22q11.2 deletions and duplications have been observed in ASD individuals, in this study, 98 individuals with ASD and 234 control individuals were genotyped for eight single-nucleotide polymorphisms in <e1>ADORA2A</e1>.","Association"
"As <e2>autistic symptoms</e2> are increased in individuals with 22q11.2 deletion syndrome, and large 22q11.2 deletions and duplications have been observed in ASD individuals, in this study, 98 individuals with ASD and 234 control individuals were genotyped for eight single-nucleotide polymorphisms in <e1>ADORA2A</e1>.","Association"
"As <e2>autistic symptoms</e2> are increased in individuals with 22q11.2 deletion syndrome, and large 22q11.2 deletions and duplications have been observed in ASD individuals, in this study, 98 individuals with ASD and 234 control individuals were genotyped for eight single-nucleotide polymorphisms in <e1>ADORA2A</e1>.","Association"
"Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (s<e1>E164D</e1> + s<e2>I195M</e2>).","Association"
"Three patients with the triple <e1>polymerase</e1> substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the <e2>envelope</e2> gene (sE164D + sI195M).","Association"
"Three patients with the triple polymerase substitution pattern (rt<e1>V173L</e1> + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + s<e2>I195M</e2>).","Association"
"Three patients with the triple polymerase substitution pattern (rt<e1>V173L</e1> + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + s<e2>I195M</e2>).","Association"
"Three patients with the triple polymerase substitution pattern (rt<e1>V173L</e1> + rtL180M + rtM204V) had associated changes in the envelope gene (s<e2>E164D</e2> + sI195M).","Association"
"Three patients with the triple polymerase substitution pattern (rt<e1>V173L</e1> + rtL180M + rtM204V) had associated changes in the envelope gene (s<e2>E164D</e2> + sI195M).","Association"
"Three patients with the triple polymerase substitution pattern (rt<e1>V173L</e1> + rtL180M + rt<e2>M204V</e2>) had associated changes in the envelope gene (sE164D + sI195M).","Association"
"Three patients with the triple polymerase substitution pattern (rt<e1>V173L</e1> + rtL180M + rt<e2>M204V</e2>) had associated changes in the envelope gene (sE164D + sI195M).","Association"
"Three patients with the triple polymerase substitution pattern (rt<e1>V173L</e1> + rt<e2>L180M</e2> + rtM204V) had associated changes in the envelope gene (sE164D + sI195M).","Association"
"Three patients with the triple polymerase substitution pattern (rt<e1>V173L</e1> + rt<e2>L180M</e2> + rtM204V) had associated changes in the envelope gene (sE164D + sI195M).","Association"
"Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rt<e1>M204V</e1>) had associated changes in the envelope gene (sE164D + s<e2>I195M</e2>).","Association"
"Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rt<e1>M204V</e1>) had associated changes in the envelope gene (sE164D + s<e2>I195M</e2>).","Association"
"Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rt<e1>M204V</e1>) had associated changes in the envelope gene (s<e2>E164D</e2> + sI195M).","Association"
"Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rt<e1>M204V</e1>) had associated changes in the envelope gene (s<e2>E164D</e2> + sI195M).","Association"
"LAM resistance substitutions (rtL180M + rt<e1>M204V</e1>) were detected in 10 (50%) of the 20 patients with <e2>viremia</e2>.","Association"
"LAM resistance substitutions (rtL180M + rt<e1>M204V</e1>) were detected in 10 (50%) of the 20 patients with <e2>viremia</e2>.","Association"
"Three patients with the triple polymerase substitution pattern (rtV173L + rt<e1>L180M</e1> + rtM204V) had associated changes in the envelope gene (sE164D + s<e2>I195M</e2>).","Association"
"Three patients with the triple polymerase substitution pattern (rtV173L + rt<e1>L180M</e1> + rtM204V) had associated changes in the envelope gene (sE164D + s<e2>I195M</e2>).","Association"
"Three patients with the triple polymerase substitution pattern (rtV173L + rt<e1>L180M</e1> + rtM204V) had associated changes in the envelope gene (s<e2>E164D</e2> + sI195M).","Association"
"Three patients with the triple polymerase substitution pattern (rtV173L + rt<e1>L180M</e1> + rtM204V) had associated changes in the envelope gene (s<e2>E164D</e2> + sI195M).","Association"
"LAM resistance substitutions (rt<e1>L180M</e1> + rtM204V) were detected in 10 (50%) of the 20 patients with <e2>viremia</e2>.","Association"
"LAM resistance substitutions (rt<e1>L180M</e1> + rtM204V) were detected in 10 (50%) of the 20 patients with <e2>viremia</e2>.","Association"
"LAM resistance substitutions (rt<e1>L180M</e1> + rt<e2>M204V</e2>) were detected in 10 (50%) of the 20 patients with viremia.","Association"
"LAM resistance substitutions (rt<e1>L180M</e1> + rt<e2>M204V</e2>) were detected in 10 (50%) of the 20 patients with viremia.","Association"
"This study analyzed the genotype distribution and frequency of <e1>lamivudine</e1> (LAM) and <e2>tenofovir</e2> (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV).","Comparison"
"This study analyzed the genotype distribution and frequency of lamivudine (<e1>LAM</e1>) and <e2>tenofovir</e2> (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV).","Comparison"
"This study analyzed the genotype distribution and frequency of lamivudine (<e1>LAM</e1>) and <e2>tenofovir</e2> (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV).","Comparison"
"This study analyzed the genotype distribution and frequency of lamivudine (<e1>LAM</e1>) and <e2>tenofovir</e2> (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV).","Comparison"
"This study analyzed the genotype distribution and frequency of lamivudine (<e1>LAM</e1>) and <e2>tenofovir</e2> (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV).","Comparison"
"This study analyzed the genotype distribution and frequency of lamivudine (<e1>LAM</e1>) and <e2>tenofovir</e2> (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV).","Comparison"
"This study analyzed the genotype distribution and frequency of lamivudine (<e1>LAM</e1>) and <e2>tenofovir</e2> (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV).","Comparison"
"<e1>LAM</e1> resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with <e2>viremia</e2>.","Negative_Correlation"
"<e1>LAM</e1> resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with <e2>viremia</e2>.","Negative_Correlation"
"<e1>LAM</e1> resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with <e2>viremia</e2>.","Negative_Correlation"
"<e1>LAM</e1> resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with <e2>viremia</e2>.","Negative_Correlation"
"<e1>LAM</e1> resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with <e2>viremia</e2>.","Negative_Correlation"
"<e1>LAM</e1> resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with <e2>viremia</e2>.","Negative_Correlation"
"<e1>LAM</e1> resistance substitutions (rtL180M + rt<e2>M204V</e2>) were detected in 10 (50%) of the 20 patients with viremia.","Negative_Correlation"
"<e1>LAM</e1> resistance substitutions (rtL180M + rt<e2>M204V</e2>) were detected in 10 (50%) of the 20 patients with viremia.","Negative_Correlation"
"<e1>LAM</e1> resistance substitutions (rtL180M + rt<e2>M204V</e2>) were detected in 10 (50%) of the 20 patients with viremia.","Negative_Correlation"
"<e1>LAM</e1> resistance substitutions (rtL180M + rt<e2>M204V</e2>) were detected in 10 (50%) of the 20 patients with viremia.","Negative_Correlation"
"<e1>LAM</e1> resistance substitutions (rtL180M + rt<e2>M204V</e2>) were detected in 10 (50%) of the 20 patients with viremia.","Negative_Correlation"
"<e1>LAM</e1> resistance substitutions (rtL180M + rt<e2>M204V</e2>) were detected in 10 (50%) of the 20 patients with viremia.","Negative_Correlation"
"<e1>LAM</e1> resistance substitutions (rt<e2>L180M</e2> + rtM204V) were detected in 10 (50%) of the 20 patients with viremia.","Negative_Correlation"
"<e1>LAM</e1> resistance substitutions (rt<e2>L180M</e2> + rtM204V) were detected in 10 (50%) of the 20 patients with viremia.","Negative_Correlation"
"<e1>LAM</e1> resistance substitutions (rt<e2>L180M</e2> + rtM204V) were detected in 10 (50%) of the 20 patients with viremia.","Negative_Correlation"
"<e1>LAM</e1> resistance substitutions (rt<e2>L180M</e2> + rtM204V) were detected in 10 (50%) of the 20 patients with viremia.","Negative_Correlation"
"<e1>LAM</e1> resistance substitutions (rt<e2>L180M</e2> + rtM204V) were detected in 10 (50%) of the 20 patients with viremia.","Negative_Correlation"
"<e1>LAM</e1> resistance substitutions (rt<e2>L180M</e2> + rtM204V) were detected in 10 (50%) of the 20 patients with viremia.","Negative_Correlation"
"Identification of a novel <e1>FBN1</e1> gene mutation in a Chinese family with <e2>Marfan syndrome</e2>.","Association"
"PURPOSE: To identify the mutation in the <e1>fibrillin-1</e1> gene (FBN1) in a Chinese family with <e2>Marfan syndrome</e2> (MFS).","Association"
"PURPOSE: To identify the mutation in the fibrillin-1 gene (<e1>FBN1</e1>) in a Chinese family with <e2>Marfan syndrome</e2> (MFS).","Association"
"PURPOSE: To identify the mutation in the fibrillin-1 gene (<e1>FBN1</e1>) in a Chinese family with <e2>Marfan syndrome</e2> (MFS).","Association"
"PURPOSE: To identify the mutation in the fibrillin-1 gene (<e1>FBN1</e1>) in a Chinese family with <e2>Marfan syndrome</e2> (MFS).","Association"
"PURPOSE: To identify the mutation in the fibrillin-1 gene (<e1>FBN1</e1>) in a Chinese family with <e2>Marfan syndrome</e2> (MFS).","Association"
"PURPOSE: To identify the mutation in the fibrillin-1 gene (<e1>FBN1</e1>) in a Chinese family with <e2>Marfan syndrome</e2> (MFS).","Association"
"CONCLUSIONS: We indentified a novel <e2>p.S1235P</e2> mutation in FBN1, which is the causative mutation for <e1>MFS</e1> in this family.","Positive_Correlation"
"CONCLUSIONS: We indentified a novel <e2>p.S1235P</e2> mutation in FBN1, which is the causative mutation for <e1>MFS</e1> in this family.","Positive_Correlation"
"Eighty unrelated individuals with <e2>Duchenne muscular dystrophy</e2> (<e1>DMD</e1>)or Becker muscular dystrophy (BMD) were found to have deletions in the major deletion-rich region of the DMD locus.","Association"
"Absence of PKC-alpha attenuates <e1>lithium</e1>-induced <e2>nephrogenic diabetes insipidus</e2>.","Positive_Correlation"
"Absence of <e1>PKC-alpha</e1> attenuates <e2>lithium</e2>-induced nephrogenic diabetes insipidus.","Positive_Correlation"
"Absence of <e1>PKC-alpha</e1> attenuates lithium-induced <e2>nephrogenic diabetes insipidus</e2>.","Positive_Correlation"
"Urinary sodium, potassium and <e1>calcium</e1> were elevated in <e2>lithium</e2>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"The decreased capacity to concentrate urine is likely due to <e2>lithium</e2> acutely disrupting the cAMP pathway and chronically reducing <e1>urea transporter</e1> (UT-A1) and water channel (AQP2) expression in the inner medulla.","Negative_Correlation"
"The decreased capacity to concentrate urine is likely due to <e2>lithium</e2> acutely disrupting the cAMP pathway and chronically reducing urea transporter (<e1>UT-A1</e1>) and water channel (AQP2) expression in the inner medulla.","Negative_Correlation"
"The decreased capacity to concentrate urine is likely due to <e2>lithium</e2> acutely disrupting the cAMP pathway and chronically reducing urea transporter (<e1>UT-A1</e1>) and water channel (AQP2) expression in the inner medulla.","Negative_Correlation"
"The decreased capacity to concentrate urine is likely due to <e2>lithium</e2> acutely disrupting the cAMP pathway and chronically reducing urea transporter (<e1>UT-A1</e1>) and water channel (AQP2) expression in the inner medulla.","Negative_Correlation"
"The decreased capacity to concentrate urine is likely due to <e2>lithium</e2> acutely disrupting the cAMP pathway and chronically reducing urea transporter (<e1>UT-A1</e1>) and water channel (AQP2) expression in the inner medulla.","Negative_Correlation"
"The decreased capacity to concentrate urine is likely due to <e2>lithium</e2> acutely disrupting the cAMP pathway and chronically reducing urea transporter (<e1>UT-A1</e1>) and water channel (AQP2) expression in the inner medulla.","Negative_Correlation"
"Targeting an alternative signaling pathway, such as <e2>PKC</e2>-mediated signaling, may be an effective method of treating lithium-induced <e1>polyuria</e1>.","Association"
"Targeting an alternative signaling pathway, such as <e2>PKC</e2>-mediated signaling, may be an effective method of treating lithium-induced <e1>polyuria</e1>.","Association"
"Western blot analysis revealed that <e1>AQP2</e1> expression in medullary tissues was lowered after 3 and 5 days in WT mice; however, AQP2 was unchanged in <e2>PKC</e2>a KO.","Negative_Correlation"
"Western blot analysis revealed that <e1>AQP2</e1> expression in medullary tissues was lowered after 3 and 5 days in WT mice; however, AQP2 was unchanged in <e2>PKC</e2>a KO.","Negative_Correlation"
"Western blot analysis revealed that <e1>AQP2</e1> expression in medullary tissues was lowered after 3 and 5 days in WT mice; however, AQP2 was unchanged in <e2>PKC</e2>a KO.","Negative_Correlation"
"Western blot analysis revealed that <e1>AQP2</e1> expression in medullary tissues was lowered after 3 and 5 days in WT mice; however, AQP2 was unchanged in <e2>PKC</e2>a KO.","Negative_Correlation"
"Western blot analysis revealed that <e1>AQP2</e1> expression in medullary tissues was lowered after 3 and 5 days in WT mice; however, AQP2 was unchanged in <e2>PKC</e2>a KO.","Negative_Correlation"
"Western blot analysis revealed that <e1>AQP2</e1> expression in medullary tissues was lowered after 3 and 5 days in WT mice; however, AQP2 was unchanged in <e2>PKC</e2>a KO.","Negative_Correlation"
"Urinary sodium, <e2>potassium</e2> and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Urinary sodium, <e2>potassium</e2> and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Urinary sodium, <e2>potassium</e2> and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Urinary sodium, <e2>potassium</e2> and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Urinary sodium, <e2>potassium</e2> and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Urinary sodium, <e2>potassium</e2> and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Urinary sodium, <e2>potassium</e2> and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Urinary sodium, <e2>potassium</e2> and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Urinary sodium, <e2>potassium</e2> and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Urinary <e2>sodium</e2>, potassium and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Urinary <e2>sodium</e2>, potassium and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Urinary <e2>sodium</e2>, potassium and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Urinary <e2>sodium</e2>, potassium and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Urinary <e2>sodium</e2>, potassium and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Urinary <e2>sodium</e2>, potassium and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Urinary <e2>sodium</e2>, potassium and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Urinary <e2>sodium</e2>, potassium and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Urinary <e2>sodium</e2>, potassium and calcium were elevated in <e1>lithium</e1>-fed WT but not in lithium-fed PKCa KO mice.","Association"
"Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating <e1>lithium</e1>-induced <e2>polyuria</e2>.","Positive_Correlation"
"Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating <e1>lithium</e1>-induced <e2>polyuria</e2>.","Positive_Correlation"
"Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating <e1>lithium</e1>-induced <e2>polyuria</e2>.","Positive_Correlation"
"Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating <e1>lithium</e1>-induced <e2>polyuria</e2>.","Positive_Correlation"
"Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating <e1>lithium</e1>-induced <e2>polyuria</e2>.","Positive_Correlation"
"Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating <e1>lithium</e1>-induced <e2>polyuria</e2>.","Positive_Correlation"
"Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating <e1>lithium</e1>-induced <e2>polyuria</e2>.","Positive_Correlation"
"Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating <e1>lithium</e1>-induced <e2>polyuria</e2>.","Positive_Correlation"
"Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating <e1>lithium</e1>-induced <e2>polyuria</e2>.","Positive_Correlation"
"The decreased capacity to concentrate urine is likely due to <e1>lithium</e1> acutely disrupting the cAMP pathway and chronically reducing urea transporter (UT-A1) and water channel (<e2>AQP2</e2>) expression in the inner medulla.","Negative_Correlation"
"The decreased capacity to concentrate urine is likely due to <e1>lithium</e1> acutely disrupting the cAMP pathway and chronically reducing urea transporter (UT-A1) and water channel (<e2>AQP2</e2>) expression in the inner medulla.","Negative_Correlation"
"The decreased capacity to concentrate urine is likely due to <e1>lithium</e1> acutely disrupting the cAMP pathway and chronically reducing urea transporter (UT-A1) and water channel (<e2>AQP2</e2>) expression in the inner medulla.","Negative_Correlation"
"The decreased capacity to concentrate urine is likely due to <e1>lithium</e1> acutely disrupting the cAMP pathway and chronically reducing urea transporter (UT-A1) and water channel (<e2>AQP2</e2>) expression in the inner medulla.","Negative_Correlation"
"The decreased capacity to concentrate urine is likely due to <e1>lithium</e1> acutely disrupting the cAMP pathway and chronically reducing urea transporter (UT-A1) and water channel (<e2>AQP2</e2>) expression in the inner medulla.","Negative_Correlation"
"The decreased capacity to concentrate urine is likely due to <e1>lithium</e1> acutely disrupting the cAMP pathway and chronically reducing urea transporter (UT-A1) and water channel (<e2>AQP2</e2>) expression in the inner medulla.","Negative_Correlation"
"The decreased capacity to concentrate urine is likely due to <e1>lithium</e1> acutely disrupting the cAMP pathway and chronically reducing urea transporter (UT-A1) and water channel (<e2>AQP2</e2>) expression in the inner medulla.","Negative_Correlation"
"The decreased capacity to concentrate urine is likely due to <e1>lithium</e1> acutely disrupting the cAMP pathway and chronically reducing urea transporter (UT-A1) and water channel (<e2>AQP2</e2>) expression in the inner medulla.","Negative_Correlation"
"The decreased capacity to concentrate urine is likely due to <e1>lithium</e1> acutely disrupting the cAMP pathway and chronically reducing urea transporter (UT-A1) and water channel (<e2>AQP2</e2>) expression in the inner medulla.","Negative_Correlation"
"<e1>Lithium</e1>, an effective antipsychotic, induces <e2>nephrogenic diabetes insipidus</e2> (NDI) in  40% of patients.","Positive_Correlation"
"Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in <e1>lithium</e1>-induced <e2>NDI</e2>, and prevents the development of the severe polyuria associated with lithium therapy.","Positive_Correlation"
"Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in <e1>lithium</e1>-induced <e2>NDI</e2>, and prevents the development of the severe polyuria associated with lithium therapy.","Positive_Correlation"
"Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in <e1>lithium</e1>-induced <e2>NDI</e2>, and prevents the development of the severe polyuria associated with lithium therapy.","Positive_Correlation"
"Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in <e1>lithium</e1>-induced <e2>NDI</e2>, and prevents the development of the severe polyuria associated with lithium therapy.","Positive_Correlation"
"<e1>Lithium</e1>, an effective antipsychotic, induces <e2>nephrogenic diabetes insipidus</e2> (NDI) in  40% of patients.","Positive_Correlation"
"Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in <e1>lithium</e1>-induced <e2>NDI</e2>, and prevents the development of the severe polyuria associated with lithium therapy.","Positive_Correlation"
"Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in <e1>lithium</e1>-induced <e2>NDI</e2>, and prevents the development of the severe polyuria associated with lithium therapy.","Positive_Correlation"
"Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in <e1>lithium</e1>-induced <e2>NDI</e2>, and prevents the development of the severe polyuria associated with lithium therapy.","Positive_Correlation"
"Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in <e1>lithium</e1>-induced <e2>NDI</e2>, and prevents the development of the severe polyuria associated with lithium therapy.","Positive_Correlation"
"Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in <e1>lithium</e1>-induced <e2>NDI</e2>, and prevents the development of the severe polyuria associated with lithium therapy.","Positive_Correlation"
"AQP2 and <e2>UT-A1</e2> expression was lowered in 6 week lithium-treated WT animals whereas in treated <e1>PKC</e1>a KO mice, AQP2 was only reduced by 2-fold and UT-A1 expression was unaffected.","Negative_Correlation"
"AQP2 and <e2>UT-A1</e2> expression was lowered in 6 week lithium-treated WT animals whereas in treated <e1>PKCa</e1> KO mice, AQP2 was only reduced by 2-fold and UT-A1 expression was unaffected.","Negative_Correlation"
"AQP2 and <e2>UT-A1</e2> expression was lowered in 6 week lithium-treated WT animals whereas in treated <e1>PKCa</e1> KO mice, AQP2 was only reduced by 2-fold and UT-A1 expression was unaffected.","Negative_Correlation"
"AQP2 and <e2>UT-A1</e2> expression was lowered in 6 week lithium-treated WT animals whereas in treated <e1>PKCa</e1> KO mice, AQP2 was only reduced by 2-fold and UT-A1 expression was unaffected.","Negative_Correlation"
"AQP2 and <e2>UT-A1</e2> expression was lowered in 6 week lithium-treated WT animals whereas in treated <e1>PKCa</e1> KO mice, AQP2 was only reduced by 2-fold and UT-A1 expression was unaffected.","Negative_Correlation"
"AQP2 and <e2>UT-A1</e2> expression was lowered in 6 week lithium-treated WT animals whereas in treated <e1>PKCa</e1> KO mice, AQP2 was only reduced by 2-fold and UT-A1 expression was unaffected.","Negative_Correlation"
"AQP2 and <e2>UT-A1</e2> expression was lowered in 6 week lithium-treated WT animals whereas in treated <e1>PKCa</e1> KO mice, AQP2 was only reduced by 2-fold and UT-A1 expression was unaffected.","Negative_Correlation"
"AQP2 and <e2>UT-A1</e2> expression was lowered in 6 week lithium-treated WT animals whereas in treated <e1>PKCa</e1> KO mice, AQP2 was only reduced by 2-fold and UT-A1 expression was unaffected.","Negative_Correlation"
"<e2>Lithium</e2>-treated WT mice had 19-fold increased urine output whereas treated <e1>PKC</e1>a KO animals had a 4-fold increase in output.","Positive_Correlation"
"<e1>PKC-alpha</e1> null mice (PKCa KO) and strain-matched wild type (WT) controls were treated with <e2>lithium</e2> for 0, 3 or 5 days.","Positive_Correlation"
"<e2>Lithium</e2>-treated WT mice had 19-fold increased urine output whereas treated <e1>PKCa</e1> KO animals had a 4-fold increase in output.","Positive_Correlation"
"<e2>Lithium</e2>-treated WT mice had 19-fold increased urine output whereas treated <e1>PKCa</e1> KO animals had a 4-fold increase in output.","Positive_Correlation"
"<e2>Lithium</e2>-treated WT mice had 19-fold increased urine output whereas treated <e1>PKCa</e1> KO animals had a 4-fold increase in output.","Positive_Correlation"
"<e2>Lithium</e2>-treated WT mice had 19-fold increased urine output whereas treated <e1>PKCa</e1> KO animals had a 4-fold increase in output.","Positive_Correlation"
"<e2>Lithium</e2>-treated WT mice had 19-fold increased urine output whereas treated <e1>PKCa</e1> KO animals had a 4-fold increase in output.","Positive_Correlation"
"<e2>Lithium</e2>-treated WT mice had 19-fold increased urine output whereas treated <e1>PKCa</e1> KO animals had a 4-fold increase in output.","Positive_Correlation"
"<e2>Lithium</e2>-treated WT mice had 19-fold increased urine output whereas treated <e1>PKCa</e1> KO animals had a 4-fold increase in output.","Positive_Correlation"
"Our data show that ablation of <e1>PKC</e1>a preserves AQP2 and UT-A1 protein expression and localization in lithium-induced <e2>NDI</e2>, and prevents the development of the severe polyuria associated with lithium therapy.","Positive_Correlation"
"Our data show that ablation of <e1>PKCa</e1> preserves AQP2 and UT-A1 protein expression and localization in lithium-induced <e2>NDI</e2>, and prevents the development of the severe polyuria associated with lithium therapy.","Positive_Correlation"
"Our data show that ablation of <e1>PKCa</e1> preserves AQP2 and UT-A1 protein expression and localization in lithium-induced <e2>NDI</e2>, and prevents the development of the severe polyuria associated with lithium therapy.","Positive_Correlation"
"Our data show that ablation of <e1>PKCa</e1> preserves AQP2 and UT-A1 protein expression and localization in lithium-induced <e2>NDI</e2>, and prevents the development of the severe polyuria associated with lithium therapy.","Positive_Correlation"
"Our data show that ablation of <e1>PKCa</e1> preserves AQP2 and UT-A1 protein expression and localization in lithium-induced <e2>NDI</e2>, and prevents the development of the severe polyuria associated with lithium therapy.","Positive_Correlation"
"Our data show that ablation of <e1>PKCa</e1> preserves AQP2 and UT-A1 protein expression and localization in lithium-induced <e2>NDI</e2>, and prevents the development of the severe polyuria associated with lithium therapy.","Positive_Correlation"
"Our data show that ablation of <e1>PKCa</e1> preserves AQP2 and UT-A1 protein expression and localization in lithium-induced <e2>NDI</e2>, and prevents the development of the severe polyuria associated with lithium therapy.","Positive_Correlation"
"Our data show that ablation of <e1>PKCa</e1> preserves AQP2 and UT-A1 protein expression and localization in lithium-induced <e2>NDI</e2>, and prevents the development of the severe polyuria associated with lithium therapy.","Positive_Correlation"
"Decreased Whole-Body Fat Mass Produced by Chronic <e1>Alcohol</e1> Consumption is Associated with Activation of <e2>S6K1</e2>-Mediated Protein Synthesis and Increased Autophagy in Epididymal White Adipose Tissue.","Association"
"Lipolytic enzymes (<e2>ATGL</e2> and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"Lipolytic enzymes (<e2>ATGL</e2> and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"Lipolytic enzymes (<e2>ATGL</e2> and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"Lipolytic enzymes (<e2>ATGL</e2> and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"Lipolytic enzymes (<e2>ATGL</e2> and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"Lipolytic enzymes (<e2>ATGL</e2> and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"Lipolytic enzymes (<e2>ATGL</e2> and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"Lipolytic enzymes (<e2>ATGL</e2> and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"Lipolytic enzymes (<e2>ATGL</e2> and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"<e1>Alcohol</e1> increased Atg12-5, <e2>LC3B-I and -II</e2>, and ULK1 S555 phosphorylation, suggesting increased autophagy, while markers of apoptosis (cleaved caspase-3 and -9, and PARP) were unchanged.","Positive_Correlation"
"<e1>Alcohol</e1> increased Atg12-5, <e2>LC3B-I and -II</e2>, and ULK1 S555 phosphorylation, suggesting increased autophagy, while markers of apoptosis (cleaved caspase-3 and -9, and PARP) were unchanged.","Positive_Correlation"
"<e1>Alcohol</e1> increased Atg12-5, LC3B-I and -II, and <e2>ULK1</e2> S555 phosphorylation, suggesting increased autophagy, while markers of apoptosis (cleaved caspase-3 and -9, and PARP) were unchanged.","Positive_Correlation"
"<e1>Alcohol</e1> increased Atg12-5, LC3B-I and -II, and <e2>ULK1</e2> S555 phosphorylation, suggesting increased autophagy, while markers of apoptosis (cleaved caspase-3 and -9, and PARP) were unchanged.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of S6K1 and its downstream substrates, S6 and <e2>eIF4B</e2> was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of S6K1 and its downstream substrates, S6 and <e2>eIF4B</e2> was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of S6K1 and its downstream substrates, S6 and <e2>eIF4B</e2> was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of S6K1 and its downstream substrates, S6 and <e2>eIF4B</e2> was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of S6K1 and its downstream substrates, S6 and <e2>eIF4B</e2> was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of S6K1 and its downstream substrates, S6 and <e2>eIF4B</e2> was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of S6K1 and its downstream substrates, S6 and <e2>eIF4B</e2> was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of S6K1 and its downstream substrates, S6 and <e2>eIF4B</e2> was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of S6K1 and its downstream substrates, S6 and <e2>eIF4B</e2> was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of <e2>S6</e2>K1 and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of <e2>S6</e2>K1 and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of <e2>S6</e2>K1 and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of <e2>S6</e2>K1 and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of <e2>S6</e2>K1 and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of <e2>S6</e2>K1 and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of <e2>S6</e2>K1 and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of <e2>S6</e2>K1 and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of <e2>S6</e2>K1 and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, IL-6, and <e2>IL-1beta</e2> mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, IL-6, and <e2>IL-1beta</e2> mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, IL-6, and <e2>IL-1beta</e2> mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, IL-6, and <e2>IL-1beta</e2> mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, IL-6, and <e2>IL-1beta</e2> mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, IL-6, and <e2>IL-1beta</e2> mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, IL-6, and <e2>IL-1beta</e2> mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, IL-6, and <e2>IL-1beta</e2> mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, IL-6, and <e2>IL-1beta</e2> mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, <e2>IL-6</e2>, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, <e2>IL-6</e2>, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, <e2>IL-6</e2>, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, <e2>IL-6</e2>, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, <e2>IL-6</e2>, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, <e2>IL-6</e2>, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, <e2>IL-6</e2>, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, <e2>IL-6</e2>, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased TNF-alpha, <e2>IL-6</e2>, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased <e2>TNF-alpha</e2>, IL-6, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased <e2>TNF-alpha</e2>, IL-6, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased <e2>TNF-alpha</e2>, IL-6, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased <e2>TNF-alpha</e2>, IL-6, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased <e2>TNF-alpha</e2>, IL-6, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased <e2>TNF-alpha</e2>, IL-6, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased <e2>TNF-alpha</e2>, IL-6, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased <e2>TNF-alpha</e2>, IL-6, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Although <e1>alcohol</e1> increased <e2>TNF-alpha</e2>, IL-6, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.","Positive_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and <e2>C/EBPalpha</e2>) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and <e2>C/EBPalpha</e2>) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and <e2>C/EBPalpha</e2>) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and <e2>C/EBPalpha</e2>) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and <e2>C/EBPalpha</e2>) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and <e2>C/EBPalpha</e2>) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and <e2>C/EBPalpha</e2>) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and <e2>C/EBPalpha</e2>) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (PPARgamma and <e2>C/EBPalpha</e2>) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (<e2>PPARgamma</e2> and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (<e2>PPARgamma</e2> and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (<e2>PPARgamma</e2> and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (<e2>PPARgamma</e2> and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (<e2>PPARgamma</e2> and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (<e2>PPARgamma</e2> and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (<e2>PPARgamma</e2> and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (<e2>PPARgamma</e2> and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and HSL phosphorylation) were increased and lipogenic regulators (<e2>PPARgamma</e2> and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Negative_Correlation"
"Lipolytic enzymes (ATGL and <e2>HSL</e2> phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"Lipolytic enzymes (ATGL and <e2>HSL</e2> phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"Lipolytic enzymes (ATGL and <e2>HSL</e2> phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"Lipolytic enzymes (ATGL and <e2>HSL</e2> phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"Lipolytic enzymes (ATGL and <e2>HSL</e2> phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"Lipolytic enzymes (ATGL and <e2>HSL</e2> phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"Lipolytic enzymes (ATGL and <e2>HSL</e2> phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"Lipolytic enzymes (ATGL and <e2>HSL</e2> phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"Lipolytic enzymes (ATGL and <e2>HSL</e2> phosphorylation) were increased and lipogenic regulators (PPARgamma and C/EBPalpha) were decreased in eWAT by <e1>alcohol</e1>.","Positive_Correlation"
"Instead, a selective increase in phosphorylation of <e2>S6K1</e2> and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Association"
"Instead, a selective increase in phosphorylation of <e2>S6K1</e2> and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Association"
"Instead, a selective increase in phosphorylation of <e2>S6K1</e2> and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Association"
"Instead, a selective increase in phosphorylation of <e2>S6K1</e2> and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Association"
"Instead, a selective increase in phosphorylation of <e2>S6K1</e2> and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Association"
"Instead, a selective increase in phosphorylation of <e2>S6K1</e2> and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Association"
"Instead, a selective increase in phosphorylation of <e2>S6K1</e2> and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Association"
"Instead, a selective increase in phosphorylation of <e2>S6K1</e2> and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Association"
"Instead, a selective increase in phosphorylation of <e2>S6K1</e2> and its downstream substrates, S6 and eIF4B was detected in <e1>alcohol</e1>-fed mice.","Association"
"Nefiracetam (DM-9384) reverses <e2>apomorphine</e2>-induced <e1>amnesia</e1> of a passive avoidance response: delayed emergence of the memory retention effects.","Positive_Correlation"
"<e1>Nefiracetam</e1> (DM-9384) reverses <e2>apomorphine</e2>-induced amnesia of a passive avoidance response: delayed emergence of the memory retention effects.","Negative_Correlation"
"Nefiracetam (<e1>DM-9384</e1>) reverses <e2>apomorphine</e2>-induced amnesia of a passive avoidance response: delayed emergence of the memory retention effects.","Negative_Correlation"
"<e1>Nefiracetam</e1> (DM-9384) reverses apomorphine-induced <e2>amnesia</e2> of a passive avoidance response: delayed emergence of the memory retention effects.","Negative_Correlation"
"Nefiracetam (<e1>DM-9384</e1>) reverses apomorphine-induced <e2>amnesia</e2> of a passive avoidance response: delayed emergence of the memory retention effects.","Negative_Correlation"
"Nefiracetam is a novel pyrrolidone derivative which attenuates <e1>scopolamine</e1>-induced <e2>learning and post-training consolidation deficits</e2>.","Positive_Correlation"
"Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate <e2>amnesia</e2> induced by <e1>dopaminergic agonism</e1>.","Positive_Correlation"
"Given that <e2>apomorphine</e2> inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate <e1>amnesia</e1> induced by dopaminergic agonism.","Positive_Correlation"
"Co-administration of nefiracetam and <e2>apomorphine</e2> during training or 10h thereafter produced no significant anti-<e1>amnesic</e1> effect.","Positive_Correlation"
"Given that <e2>apomorphine</e2> inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate <e1>amnesia</e1> induced by dopaminergic agonism.","Positive_Correlation"
"<e1>Nefiracetam</e1> is a novel pyrrolidone derivative which attenuates <e2>scopolamine</e2>-induced learning and post-training consolidation deficits.","Negative_Correlation"
"<e1>Nefiracetam</e1> is a novel pyrrolidone derivative which attenuates scopolamine-induced <e2>learning and post-training consolidation deficits</e2>.","Negative_Correlation"
"Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate amnesia induced by <e2>dopaminergic agonism</e2>.","Negative_Correlation"
"Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate amnesia induced by <e2>dopaminergic agonism</e2>.","Negative_Correlation"
"Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate amnesia induced by <e2>dopaminergic agonism</e2>.","Negative_Correlation"
"Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate amnesia induced by <e2>dopaminergic agonism</e2>.","Negative_Correlation"
"Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate amnesia induced by <e2>dopaminergic agonism</e2>.","Negative_Correlation"
"Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate amnesia induced by <e2>dopaminergic agonism</e2>.","Negative_Correlation"
"Given that <e2>apomorphine</e2> inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate amnesia induced by dopaminergic agonism.","Negative_Correlation"
"Given that <e2>apomorphine</e2> inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate amnesia induced by dopaminergic agonism.","Negative_Correlation"
"Given that <e2>apomorphine</e2> inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate amnesia induced by dopaminergic agonism.","Negative_Correlation"
"Given that <e2>apomorphine</e2> inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate amnesia induced by dopaminergic agonism.","Negative_Correlation"
"Given that <e2>apomorphine</e2> inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate amnesia induced by dopaminergic agonism.","Negative_Correlation"
"Given that <e2>apomorphine</e2> inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate amnesia induced by dopaminergic agonism.","Negative_Correlation"
"Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate <e2>amnesia</e2> induced by dopaminergic agonism.","Negative_Correlation"
"Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate <e2>amnesia</e2> induced by dopaminergic agonism.","Negative_Correlation"
"Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate <e2>amnesia</e2> induced by dopaminergic agonism.","Negative_Correlation"
"Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate <e2>amnesia</e2> induced by dopaminergic agonism.","Negative_Correlation"
"Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate <e2>amnesia</e2> induced by dopaminergic agonism.","Negative_Correlation"
"Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1>nefiracetam</e1> to attenuate <e2>amnesia</e2> induced by dopaminergic agonism.","Negative_Correlation"
"<e1>Pethidine</e1>-associated <e2>seizure</e2> in a healthy adolescent receiving pethidine for postoperative pain control.","Association"
"Pethidine-associated <e2>seizure</e2> in a healthy adolescent receiving <e1>pethidine</e1> for postoperative pain control.","Association"
"<e1>Pethidine</e1>-associated seizure in a healthy adolescent receiving pethidine for <e2>postoperative pain</e2> control.","Negative_Correlation"
"Pethidine-associated seizure in a healthy adolescent receiving <e1>pethidine</e1> for <e2>postoperative pain</e2> control.","Negative_Correlation"
"A healthy 17-year-old male received standard intermittent doses of <e1>pethidine</e1> via a patient-controlled analgesia (PCA) pump for management of <e2>postoperative pain</e2> control.","Negative_Correlation"
"A healthy 17-year-old male received standard intermittent doses of <e1>pethidine</e1> via a patient-controlled analgesia (PCA) pump for management of <e2>postoperative pain</e2> control.","Negative_Correlation"
"A healthy 17-year-old male received standard intermittent doses of <e1>pethidine</e1> via a patient-controlled analgesia (PCA) pump for management of <e2>postoperative pain</e2> control.","Negative_Correlation"
"A healthy 17-year-old male received standard intermittent doses of <e1>pethidine</e1> via a patient-controlled analgesia (PCA) pump for management of <e2>postoperative pain</e2> control.","Negative_Correlation"
"A healthy 17-year-old male received standard intermittent doses of <e1>pethidine</e1> via a patient-controlled analgesia (PCA) pump for management of <e2>postoperative pain</e2> control.","Negative_Correlation"
"Recovery of tacrolimus-associated <e2>brachial neuritis</e2> after conversion to <e1>everolimus</e1> in a pediatric renal transplant recipient--case report and review of the literature.","Negative_Correlation"
"Recovery of <e1>tacrolimus</e1>-associated brachial neuritis after conversion to <e2>everolimus</e2> in a pediatric renal transplant recipient--case report and review of the literature.","Conversion"
"Recovery of <e1>tacrolimus</e1>-associated <e2>brachial neuritis</e2> after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.","Positive_Correlation"
"Improvement and eventually full recovery only occurred after <e1>TAC</e1> was completely discontinued and successfully replaced by <e2>everolimus</e2>.","Conversion"
"Improvement and eventually full recovery only occurred after <e1>TAC</e1> was completely discontinued and successfully replaced by <e2>everolimus</e2>.","Conversion"
"Improvement and eventually full recovery only occurred after <e1>TAC</e1> was completely discontinued and successfully replaced by <e2>everolimus</e2>.","Conversion"
"By identifying genes mis-expressed in mol1 mutants, we demonstrate that <e1>MOL1</e1> represses genes associated with stress-related ethylene and <e2>jasmonic acid</e2> hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.","Association"
"By identifying genes mis-expressed in mol1 mutants, we demonstrate that <e1>MOL1</e1> represses genes associated with stress-related ethylene and <e2>jasmonic acid</e2> hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.","Association"
"By identifying genes mis-expressed in mol1 mutants, we demonstrate that <e1>MOL1</e1> represses genes associated with stress-related ethylene and <e2>jasmonic acid</e2> hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.","Association"
"By identifying genes mis-expressed in mol1 mutants, we demonstrate that <e1>MOL1</e1> represses genes associated with stress-related ethylene and <e2>jasmonic acid</e2> hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.","Association"
"By identifying genes mis-expressed in mol1 mutants, we demonstrate that <e1>MOL1</e1> represses genes associated with stress-related ethylene and <e2>jasmonic acid</e2> hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.","Association"
"By identifying genes mis-expressed in mol1 mutants, we demonstrate that <e1>MOL1</e1> represses genes associated with stress-related ethylene and <e2>jasmonic acid</e2> hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.","Association"
"By identifying genes mis-expressed in <e1>mol1</e1> mutants, we demonstrate that MOL1 represses genes associated with stress-related ethylene and <e2>jasmonic acid</e2> hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.","Association"
"By identifying genes mis-expressed in mol1 mutants, we demonstrate that <e1>MOL1</e1> represses genes associated with stress-related ethylene and <e2>jasmonic acid</e2> hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.","Association"
"By identifying genes mis-expressed in mol1 mutants, we demonstrate that <e1>MOL1</e1> represses genes associated with stress-related <e2>ethylene</e2> and jasmonic acid hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.","Association"
"By identifying genes mis-expressed in mol1 mutants, we demonstrate that <e1>MOL1</e1> represses genes associated with stress-related <e2>ethylene</e2> and jasmonic acid hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.","Association"
"By identifying genes mis-expressed in mol1 mutants, we demonstrate that <e1>MOL1</e1> represses genes associated with stress-related <e2>ethylene</e2> and jasmonic acid hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.","Association"
"By identifying genes mis-expressed in mol1 mutants, we demonstrate that <e1>MOL1</e1> represses genes associated with stress-related <e2>ethylene</e2> and jasmonic acid hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.","Association"
"By identifying genes mis-expressed in mol1 mutants, we demonstrate that <e1>MOL1</e1> represses genes associated with stress-related <e2>ethylene</e2> and jasmonic acid hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.","Association"
"By identifying genes mis-expressed in mol1 mutants, we demonstrate that <e1>MOL1</e1> represses genes associated with stress-related <e2>ethylene</e2> and jasmonic acid hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.","Association"
"By identifying genes mis-expressed in <e1>mol1</e1> mutants, we demonstrate that MOL1 represses genes associated with stress-related <e2>ethylene</e2> and jasmonic acid hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.","Association"
"By identifying genes mis-expressed in mol1 mutants, we demonstrate that <e1>MOL1</e1> represses genes associated with stress-related <e2>ethylene</e2> and jasmonic acid hormone signaling pathways which have known roles in coordinating lateral growth of the Arabidopsis stem.","Association"
"Furthermore, <e1>MOL1</e1> but not PXY is able to rescue <e2>CLV1</e2> deficiency in the shoot apical meristem.","Positive_Correlation"
"Furthermore, <e1>MOL1</e1> but not PXY is able to rescue <e2>CLV1</e2> deficiency in the shoot apical meristem.","Positive_Correlation"
"Furthermore, <e1>MOL1</e1> but not PXY is able to rescue <e2>CLV1</e2> deficiency in the shoot apical meristem.","Positive_Correlation"
"Furthermore, <e1>MOL1</e1> but not PXY is able to rescue <e2>CLV1</e2> deficiency in the shoot apical meristem.","Positive_Correlation"
"Furthermore, <e1>MOL1</e1> but not PXY is able to rescue <e2>CLV1</e2> deficiency in the shoot apical meristem.","Positive_Correlation"
"Furthermore, <e1>MOL1</e1> but not PXY is able to rescue <e2>CLV1</e2> deficiency in the shoot apical meristem.","Positive_Correlation"
"Furthermore, <e1>MOL1</e1> but not PXY is able to rescue <e2>CLV1</e2> deficiency in the shoot apical meristem.","Positive_Correlation"
"By employing promoter reporter lines, we reveal that MOL1 is active in a domain that is distinct from the domain of the positively acting <e1>CLE41</e1>/<e2>PXY</e2> signaling module.","Bind"
"By employing promoter reporter lines, we reveal that MOL1 is active in a domain that is distinct from the domain of the positively acting <e1>CLE41</e1>/<e2>PXY</e2> signaling module.","Bind"
"In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced <e2>nephrotoxicity</e2>: protection by <e1>erdosteine</e1>.","Negative_Correlation"
"In vivo evidences suggesting the role of oxidative stress in pathogenesis of <e1>vancomycin</e1>-induced <e2>nephrotoxicity</e2>: protection by erdosteine.","Positive_Correlation"
"In vivo evidences suggesting the role of oxidative stress in pathogenesis of <e1>vancomycin</e1>-induced nephrotoxicity: protection by <e2>erdosteine</e2>.","Negative_Correlation"
"<e2>Erdosteine</e2> administration with VCM injections caused significantly decreased renal MDA and urinary NAG excretion, and increased <e1>SOD</e1> activity, but not CAT activity in renal tissue when compared with VCM alone.","Positive_Correlation"
"<e2>Erdosteine</e2> administration with VCM injections caused significantly decreased renal MDA and urinary NAG excretion, and increased <e1>SOD</e1> activity, but not CAT activity in renal tissue when compared with VCM alone.","Positive_Correlation"
"<e2>VCM</e2> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and <e1>catalase</e1> (CAT) activities.","Negative_Correlation"
"<e2>VCM</e2> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (<e1>CAT</e1>) activities.","Negative_Correlation"
"<e2>VCM</e2> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (<e1>CAT</e1>) activities.","Negative_Correlation"
"VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary <e1>N-acetyl-beta-d-glucosaminidase</e1> (NAG, a marker of <e2>renal tubular injury</e2>) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Association"
"VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (<e1>NAG</e1>, a marker of <e2>renal tubular injury</e2>) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Association"
"VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (<e1>NAG</e1>, a marker of <e2>renal tubular injury</e2>) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Association"
"The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e1>erdosteine</e1>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2>renal impairment</e2> in rats.","Negative_Correlation"
"The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e1>erdosteine</e1>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2>renal impairment</e2> in rats.","Negative_Correlation"
"<e1>Erdosteine</e1> showed histopathological protection against VCM-induced <e2>nephrotoxicity</e2>.","Negative_Correlation"
"<e1>Erdosteine</e1> showed histopathological protection against VCM-induced <e2>nephrotoxicity</e2>.","Negative_Correlation"
"<e1>Erdosteine</e1> showed histopathological protection against VCM-induced <e2>nephrotoxicity</e2>.","Negative_Correlation"
"The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e1>erdosteine</e1>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2>renal impairment</e2> in rats.","Negative_Correlation"
"<e1>Erdosteine</e1> showed histopathological protection against VCM-induced <e2>nephrotoxicity</e2>.","Negative_Correlation"
"The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e1>erdosteine</e1>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2>renal impairment</e2> in rats.","Negative_Correlation"
"<e1>Erdosteine</e1> administration with VCM injections caused significantly decreased renal MDA and urinary <e2>NAG</e2> excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone.","Negative_Correlation"
"<e1>Erdosteine</e1> administration with VCM injections caused significantly decreased renal MDA and urinary <e2>NAG</e2> excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone.","Negative_Correlation"
"<e1>Erdosteine</e1> administration with VCM injections caused significantly decreased renal MDA and urinary <e2>NAG</e2> excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone.","Negative_Correlation"
"<e1>Erdosteine</e1> administration with VCM injections caused significantly decreased renal MDA and urinary <e2>NAG</e2> excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone.","Negative_Correlation"
"<e1>Erdosteine</e1> administration with VCM injections caused significantly decreased renal <e2>MDA</e2> and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone.","Negative_Correlation"
"<e1>Erdosteine</e1> administration with VCM injections caused significantly decreased renal <e2>MDA</e2> and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone.","Negative_Correlation"
"<e1>Erdosteine</e1> administration with VCM injections caused significantly decreased renal <e2>MDA</e2> and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone.","Negative_Correlation"
"<e1>Erdosteine</e1> administration with VCM injections caused significantly decreased renal <e2>MDA</e2> and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone.","Negative_Correlation"
"The aims of this study were to examine <e1>vancomycin</e1> (VCM)-induced oxidative stress that promotes production of <e2>reactive oxygen species</e2> (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Association"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of <e2>reactive oxygen species</e2> (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Association"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of <e2>reactive oxygen species</e2> (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Association"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of <e2>reactive oxygen species</e2> (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Association"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of <e2>reactive oxygen species</e2> (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Association"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of <e2>reactive oxygen species</e2> (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Association"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of <e2>reactive oxygen species</e2> (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Association"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of <e2>reactive oxygen species</e2> (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Association"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of <e2>reactive oxygen species</e2> (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Association"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of <e2>reactive oxygen species</e2> (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Association"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of <e2>reactive oxygen species</e2> (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Association"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of <e2>reactive oxygen species</e2> (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Association"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of <e2>reactive oxygen species</e2> (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Association"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and <e2>necrosis</e2> in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and <e2>necrosis</e2> in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and <e2>necrosis</e2> in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and <e2>necrosis</e2> in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and <e2>necrosis</e2> in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and <e2>necrosis</e2> in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and <e2>necrosis</e2> in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and <e2>necrosis</e2> in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and <e2>necrosis</e2> in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and <e2>necrosis</e2> in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and <e2>necrosis</e2> in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and <e2>necrosis</e2> in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, <e2>desquamation</e2>, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, <e2>desquamation</e2>, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, <e2>desquamation</e2>, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, <e2>desquamation</e2>, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, <e2>desquamation</e2>, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, <e2>desquamation</e2>, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, <e2>desquamation</e2>, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, <e2>desquamation</e2>, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, <e2>desquamation</e2>, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, <e2>desquamation</e2>, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, <e2>desquamation</e2>, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, <e2>desquamation</e2>, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, <e2>atrophy</e2>, desquamation, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, <e2>atrophy</e2>, desquamation, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, <e2>atrophy</e2>, desquamation, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, <e2>atrophy</e2>, desquamation, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, <e2>atrophy</e2>, desquamation, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, <e2>atrophy</e2>, desquamation, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, <e2>atrophy</e2>, desquamation, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, <e2>atrophy</e2>, desquamation, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, <e2>atrophy</e2>, desquamation, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, <e2>atrophy</e2>, desquamation, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, <e2>atrophy</e2>, desquamation, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, <e2>atrophy</e2>, desquamation, and necrosis in <e1>VCM</e1>-treated rats more than those of the control and the erdosteine groups.","Positive_Correlation"
"The aims of this study were to examine <e1>vancomycin</e1> (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2>renal impairment</e2> in rats.","Positive_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2>renal impairment</e2> in rats.","Positive_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2>renal impairment</e2> in rats.","Positive_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2>renal impairment</e2> in rats.","Positive_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2>renal impairment</e2> in rats.","Positive_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2>renal impairment</e2> in rats.","Positive_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2>renal impairment</e2> in rats.","Positive_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2>renal impairment</e2> in rats.","Positive_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2>renal impairment</e2> in rats.","Positive_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2>renal impairment</e2> in rats.","Positive_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2>renal impairment</e2> in rats.","Positive_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2>renal impairment</e2> in rats.","Positive_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2>renal impairment</e2> in rats.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased <e2>superoxide dismutase</e2> (SOD) and catalase (CAT) activities.","Negative_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased <e2>superoxide dismutase</e2> (SOD) and catalase (CAT) activities.","Negative_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased <e2>superoxide dismutase</e2> (SOD) and catalase (CAT) activities.","Negative_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased <e2>superoxide dismutase</e2> (SOD) and catalase (CAT) activities.","Negative_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased <e2>superoxide dismutase</e2> (SOD) and catalase (CAT) activities.","Negative_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased <e2>superoxide dismutase</e2> (SOD) and catalase (CAT) activities.","Negative_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased <e2>superoxide dismutase</e2> (SOD) and catalase (CAT) activities.","Negative_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased <e2>superoxide dismutase</e2> (SOD) and catalase (CAT) activities.","Negative_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased <e2>superoxide dismutase</e2> (SOD) and catalase (CAT) activities.","Negative_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased <e2>superoxide dismutase</e2> (SOD) and catalase (CAT) activities.","Negative_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased <e2>superoxide dismutase</e2> (SOD) and catalase (CAT) activities.","Negative_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased <e2>superoxide dismutase</e2> (SOD) and catalase (CAT) activities.","Negative_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary <e2>N-acetyl-beta-d-glucosaminidase</e2> (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary <e2>N-acetyl-beta-d-glucosaminidase</e2> (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary <e2>N-acetyl-beta-d-glucosaminidase</e2> (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary <e2>N-acetyl-beta-d-glucosaminidase</e2> (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary <e2>N-acetyl-beta-d-glucosaminidase</e2> (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary <e2>N-acetyl-beta-d-glucosaminidase</e2> (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary <e2>N-acetyl-beta-d-glucosaminidase</e2> (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary <e2>N-acetyl-beta-d-glucosaminidase</e2> (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary <e2>N-acetyl-beta-d-glucosaminidase</e2> (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary <e2>N-acetyl-beta-d-glucosaminidase</e2> (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary <e2>N-acetyl-beta-d-glucosaminidase</e2> (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary <e2>N-acetyl-beta-d-glucosaminidase</e2> (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal <e2>malondialdehyde</e2> (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal <e2>malondialdehyde</e2> (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal <e2>malondialdehyde</e2> (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal <e2>malondialdehyde</e2> (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal <e2>malondialdehyde</e2> (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal <e2>malondialdehyde</e2> (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal <e2>malondialdehyde</e2> (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal <e2>malondialdehyde</e2> (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal <e2>malondialdehyde</e2> (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal <e2>malondialdehyde</e2> (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal <e2>malondialdehyde</e2> (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"<e1>VCM</e1> administration to control rats significantly increased renal <e2>malondialdehyde</e2> (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.","Positive_Correlation"
"The aims of this study were to examine <e1>vancomycin</e1> (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e2>erdosteine</e2>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Negative_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e2>erdosteine</e2>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Negative_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e2>erdosteine</e2>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Negative_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e2>erdosteine</e2>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Negative_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e2>erdosteine</e2>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Negative_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e2>erdosteine</e2>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Negative_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e2>erdosteine</e2>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Negative_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e2>erdosteine</e2>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Negative_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e2>erdosteine</e2>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Negative_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e2>erdosteine</e2>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Negative_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e2>erdosteine</e2>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Negative_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e2>erdosteine</e2>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Negative_Correlation"
"The aims of this study were to examine vancomycin (<e1>VCM</e1>)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e2>erdosteine</e2>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.","Negative_Correlation"
"Background: Heterozygous mutations in <e2>GUCA1A</e2> (MIM # 600364) have been identified to cause autosomal dominantly inherited cone dystrophy, cone rod dystrophy and <e1>macular dystrophy</e1>.","Association"
"The sequence variant c.465G>T encodes a conservative amino acid substitution, p.Glu155Asp, located in EF-hand 4, the <e1>calcium</e1> binding site of <e2>GCAP2</e2> protein.","Bind"
"The sequence variant <e1>c.465G>T</e1> encodes a conservative amino acid substitution, p.Glu155Asp, located in EF-hand 4, the <e2>calcium</e2> binding site of GCAP2 protein.","Association"
"The sequence variant <e1>c.465G>T</e1> encodes a conservative amino acid substitution, p.Glu155Asp, located in EF-hand 4, the <e2>calcium</e2> binding site of GCAP2 protein.","Association"
"The sequence variant c.465G>T encodes a conservative amino acid substitution, <e1>p.Glu155Asp</e1>, located in EF-hand 4, the <e2>calcium</e2> binding site of GCAP2 protein.","Association"
"Background: Heterozygous mutations in <e2>GUCA1A</e2> (MIM # 600364) have been identified to cause autosomal dominantly inherited <e1>cone dystrophy</e1>, cone rod dystrophy and macular dystrophy.","Association"
"Background: Heterozygous mutations in <e2>GUCA1A</e2> (MIM # 600364) have been identified to cause autosomal dominantly inherited <e1>cone dystrophy</e1>, cone rod dystrophy and macular dystrophy.","Association"
"Background: Heterozygous mutations in <e2>GUCA1A</e2> (MIM # 600364) have been identified to cause autosomal dominantly inherited <e1>cone dystrophy</e1>, cone rod dystrophy and macular dystrophy.","Association"
"Background: Heterozygous mutations in <e2>GUCA1A</e2> (MIM # 600364) have been identified to cause autosomal dominantly inherited cone dystrophy, <e1>cone rod dystrophy</e1> and macular dystrophy.","Association"
"Background: Heterozygous mutations in <e2>GUCA1A</e2> (MIM # 600364) have been identified to cause autosomal dominantly inherited cone dystrophy, <e1>cone rod dystrophy</e1> and macular dystrophy.","Association"
"Background: Heterozygous mutations in <e2>GUCA1A</e2> (MIM # 600364) have been identified to cause autosomal dominantly inherited cone dystrophy, <e1>cone rod dystrophy</e1> and macular dystrophy.","Association"
"However, the role of <e1>GUCA1B</e1> gene mutations in inherited <e2>retinal disease</e2> has been controversial.","Association"
"However, the role of <e1>GUCA1B</e1> gene mutations in inherited <e2>retinal disease</e2> has been controversial.","Association"
"However, the role of <e1>GUCA1B</e1> gene mutations in inherited <e2>retinal disease</e2> has been controversial.","Association"
"However, the role of <e1>GUCA1B</e1> gene mutations in inherited <e2>retinal disease</e2> has been controversial.","Association"
"Conclusion: The absence of clearly pathogenic mutations in the selected patient group suggests that the <e1>GUCA1B</e1> gene is a minor cause for <e2>retinal degenerations</e2> in Europeans or North-Americans.","Association"
"Conclusion: The absence of clearly pathogenic mutations in the selected patient group suggests that the <e1>GUCA1B</e1> gene is a minor cause for <e2>retinal degenerations</e2> in Europeans or North-Americans.","Association"
"Conclusion: The absence of clearly pathogenic mutations in the selected patient group suggests that the <e1>GUCA1B</e1> gene is a minor cause for <e2>retinal degenerations</e2> in Europeans or North-Americans.","Association"
"Conclusion: The absence of clearly pathogenic mutations in the selected patient group suggests that the <e1>GUCA1B</e1> gene is a minor cause for <e2>retinal degenerations</e2> in Europeans or North-Americans.","Association"
"We therefore performed a mutation analysis of the <e1>GUCA1B</e1> gene in a clinically well characterized group of patients of European and North-American geographical origin with autosomal dominantly inherited <e2>cone dystrophy</e2> and cone rod dystrophy.","Association"
"We therefore performed a mutation analysis of the <e1>GUCA1B</e1> gene in a clinically well characterized group of patients of European and North-American geographical origin with autosomal dominantly inherited <e2>cone dystrophy</e2> and cone rod dystrophy.","Association"
"We therefore performed a mutation analysis of the <e1>GUCA1B</e1> gene in a clinically well characterized group of patients of European and North-American geographical origin with autosomal dominantly inherited <e2>cone dystrophy</e2> and cone rod dystrophy.","Association"
"We therefore performed a mutation analysis of the <e1>GUCA1B</e1> gene in a clinically well characterized group of patients of European and North-American geographical origin with autosomal dominantly inherited <e2>cone dystrophy</e2> and cone rod dystrophy.","Association"
"We therefore performed a mutation analysis of the <e1>GUCA1B</e1> gene in a clinically well characterized group of patients of European and North-American geographical origin with autosomal dominantly inherited cone dystrophy and <e2>cone rod dystrophy</e2>.","Association"
"We therefore performed a mutation analysis of the <e1>GUCA1B</e1> gene in a clinically well characterized group of patients of European and North-American geographical origin with autosomal dominantly inherited cone dystrophy and <e2>cone rod dystrophy</e2>.","Association"
"We therefore performed a mutation analysis of the <e1>GUCA1B</e1> gene in a clinically well characterized group of patients of European and North-American geographical origin with autosomal dominantly inherited cone dystrophy and <e2>cone rod dystrophy</e2>.","Association"
"We therefore performed a mutation analysis of the <e1>GUCA1B</e1> gene in a clinically well characterized group of patients of European and North-American geographical origin with autosomal dominantly inherited cone dystrophy and <e2>cone rod dystrophy</e2>.","Association"
"Cardioprotective effect of tincture of Crataegus on <e1>isoproterenol</e1>-induced <e2>myocardial infarction</e2> in rats.","Positive_Correlation"
"Cardioprotective effect of <e1>tincture of Crataegus</e1> on <e2>isoproterenol</e2>-induced myocardial infarction in rats.","Negative_Correlation"
"Cardioprotective effect of <e1>tincture of Crataegus</e1> on isoproterenol-induced <e2>myocardial infarction</e2> in rats.","Negative_Correlation"
"TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of <e1>ADP</e1>-stimulated <e2>oxygen</e2> uptake and respiratory coupling ratio.","Positive_Correlation"
"<e1>TCR</e1> prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated <e2>oxygen</e2> uptake and respiratory coupling ratio.","Positive_Correlation"
"<e1>TCR</e1> prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated <e2>oxygen</e2> uptake and respiratory coupling ratio.","Positive_Correlation"
"<e1>TCR</e1> prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated <e2>oxygen</e2> uptake and respiratory coupling ratio.","Positive_Correlation"
"<e1>TCR</e1> prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated <e2>oxygen</e2> uptake and respiratory coupling ratio.","Positive_Correlation"
"<e1>TCR</e1> prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated <e2>oxygen</e2> uptake and respiratory coupling ratio.","Positive_Correlation"
"<e1>TCR</e1> prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated <e2>oxygen</e2> uptake and respiratory coupling ratio.","Positive_Correlation"
"<e1>TCR</e1> prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of <e2>ADP</e2>-stimulated oxygen uptake and respiratory coupling ratio.","Positive_Correlation"
"<e1>TCR</e1> prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of <e2>ADP</e2>-stimulated oxygen uptake and respiratory coupling ratio.","Positive_Correlation"
"<e1>TCR</e1> prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of <e2>ADP</e2>-stimulated oxygen uptake and respiratory coupling ratio.","Positive_Correlation"
"<e1>TCR</e1> prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of <e2>ADP</e2>-stimulated oxygen uptake and respiratory coupling ratio.","Positive_Correlation"
"<e1>TCR</e1> prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of <e2>ADP</e2>-stimulated oxygen uptake and respiratory coupling ratio.","Positive_Correlation"
"<e1>TCR</e1> prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of <e2>ADP</e2>-stimulated oxygen uptake and respiratory coupling ratio.","Positive_Correlation"
"Pretreatment of <e1>TCR</e1>, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in <e2>lipid</e2> peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).","Association"
"Pretreatment of <e1>TCR</e1>, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in <e2>lipid</e2> peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).","Association"
"Pretreatment of <e1>TCR</e1>, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in <e2>lipid</e2> peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).","Association"
"Pretreatment of <e1>TCR</e1>, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in <e2>lipid</e2> peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).","Association"
"Pretreatment of <e1>TCR</e1>, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in <e2>lipid</e2> peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).","Association"
"Pretreatment of <e1>TCR</e1>, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in <e2>lipid</e2> peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).","Association"
"Pretreatment of <e1>TCR</e1>, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in <e2>isoproterenol</e2>-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).","Negative_Correlation"
"Pretreatment of <e1>TCR</e1>, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in <e2>isoproterenol</e2>-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).","Negative_Correlation"
"Pretreatment of <e1>TCR</e1>, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in <e2>isoproterenol</e2>-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).","Negative_Correlation"
"Pretreatment of <e1>TCR</e1>, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in <e2>isoproterenol</e2>-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).","Negative_Correlation"
"Pretreatment of <e1>TCR</e1>, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in <e2>isoproterenol</e2>-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).","Negative_Correlation"
"Pretreatment of <e1>TCR</e1>, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in <e2>isoproterenol</e2>-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).","Negative_Correlation"
"The present study was done to investigate the protective effect of <e1>TCR</e1> on experimentally induced <e2>myocardial infarction</e2> in rats.","Negative_Correlation"
"The present study was done to investigate the protective effect of <e1>TCR</e1> on experimentally induced <e2>myocardial infarction</e2> in rats.","Negative_Correlation"
"The present study was done to investigate the protective effect of <e1>TCR</e1> on experimentally induced <e2>myocardial infarction</e2> in rats.","Negative_Correlation"
"The present study was done to investigate the protective effect of <e1>TCR</e1> on experimentally induced <e2>myocardial infarction</e2> in rats.","Negative_Correlation"
"The present study was done to investigate the protective effect of <e1>TCR</e1> on experimentally induced <e2>myocardial infarction</e2> in rats.","Negative_Correlation"
"The present study was done to investigate the protective effect of <e1>TCR</e1> on experimentally induced <e2>myocardial infarction</e2> in rats.","Negative_Correlation"
"A novel splicing mutation in <e1>SLC12A3</e1> associated with Gitelman syndrome and <e2>idiopathic intracranial hypertension</e2>.","Association"
"A novel splicing mutation in <e1>SLC12A3</e1> associated with <e2>Gitelman syndrome</e2> and idiopathic intracranial hypertension.","Association"
"Supplementation with <e1>potassium</e1> and <e2>magnesium</e2> improved clinical symptoms and resulted in catch-up growth, but vision remained impaired.","Cotreatment"
"However, mutation analysis showed that the proband is a compound heterozygote for 2 mutations in SLC12A3: a substitution of serine by leucine at amino acid position 555 (p.Ser555Leu) and a novel guanine to cytosine transition at the 5' splice site of intron 22 (<e1>c.2633+1G>C</e1>), providing the molecular diagnosis of <e2>GS</e2>.","Association"
"However, mutation analysis showed that the proband is a compound heterozygote for 2 mutations in SLC12A3: a substitution of serine by leucine at amino acid position 555 (p.Ser555Leu) and a novel guanine to cytosine transition at the 5' splice site of intron 22 (<e1>c.2633+1G>C</e1>), providing the molecular diagnosis of <e2>GS</e2>.","Association"
"However, mutation analysis showed that the proband is a compound heterozygote for 2 mutations in SLC12A3: a substitution of serine by leucine at amino acid position 555 (p.Ser555Leu) and a novel <e1>guanine to cytosine</e1> transition at the 5' splice site of intron 22 (c.2633+1G>C), providing the molecular diagnosis of <e2>GS</e2>.","Association"
"However, mutation analysis showed that the proband is a compound heterozygote for 2 mutations in SLC12A3: a substitution of <e1>serine by leucine at amino acid position 555</e1> (p.Ser555Leu) and a novel guanine to cytosine transition at the 5' splice site of intron 22 (c.2633+1G>C), providing the molecular diagnosis of <e2>GS</e2>.","Association"
"However, mutation analysis showed that the proband is a compound heterozygote for 2 mutations in SLC12A3: a substitution of serine by leucine at amino acid position 555 (<e1>p.Ser555Leu</e1>) and a novel guanine to cytosine transition at the 5' splice site of intron 22 (c.2633+1G>C), providing the molecular diagnosis of <e2>GS</e2>.","Association"
"However, mutation analysis showed that the proband is a compound heterozygote for 2 mutations in <e1>SLC12A3</e1>: a substitution of serine by leucine at amino acid position 555 (p.Ser555Leu) and a novel guanine to cytosine transition at the 5' splice site of intron 22 (c.2633+1G>C), providing the molecular diagnosis of <e2>GS</e2>.","Association"
"Association between polymorphisms in <e2>SLC30A8</e2>, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and <e1>type 2 diabetes</e1> in the Korean population.","Association"
"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, <e2>KCNQ1</e2> and <e1>type 2 diabetes</e1> in the Korean population.","Association"
"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, <e2>CDKAL1</e2>, KCNQ1 and <e1>type 2 diabetes</e1> in the Korean population.","Association"
"Association between polymorphisms in SLC30A8, <e2>HHEX</e2>, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and <e1>type 2 diabetes</e1> in the Korean population.","Association"
"<e1>Rs13266634</e1> (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of <e2>T2DM</e2>, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated.","Positive_Correlation"
"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of <e1>rs2237892</e1> (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with <e2>T2DM</e2>.","Positive_Correlation"
"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of <e1>rs2237892</e1> (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with <e2>T2DM</e2>.","Positive_Correlation"
"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of <e1>rs10811661</e1> (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with <e2>T2DM</e2>.","Positive_Correlation"
"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of <e1>rs10811661</e1> (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with <e2>T2DM</e2>.","Positive_Correlation"
"The G allele of <e1>rs1111875</e1> (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with <e2>T2DM</e2>.","Positive_Correlation"
"The G allele of <e1>rs1111875</e1> (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with <e2>T2DM</e2>.","Positive_Correlation"
"The aim of the present study was to investigate the association among the polymorphisms of <e2>SLC30A8</e2>, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of <e2>SLC30A8</e2>, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of <e2>SLC30A8</e2>, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of <e2>SLC30A8</e2>, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of <e2>SLC30A8</e2>, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of <e2>SLC30A8</e2>, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and <e2>KCNQ1</e2> and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and <e2>KCNQ1</e2> and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and <e2>KCNQ1</e2> and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and <e2>KCNQ1</e2> and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and <e2>KCNQ1</e2> and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and <e2>KCNQ1</e2> and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, <e2>CDKAL1</e2> and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, <e2>CDKAL1</e2> and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, <e2>CDKAL1</e2> and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, <e2>CDKAL1</e2> and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, <e2>CDKAL1</e2> and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, <e2>CDKAL1</e2> and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, <e2>HHEX</e2>, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, <e2>HHEX</e2>, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, <e2>HHEX</e2>, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, <e2>HHEX</e2>, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, <e2>HHEX</e2>, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, <e2>HHEX</e2>, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of <e1>T2DM</e1> in the Korean population.","Association"
"<e1>Serotonin 6 receptor</e1> gene is associated with methamphetamine-induced <e2>psychosis</e2> in a Japanese population.","Association"
"<e1>Serotonin 6 receptor</e1> gene is associated with <e2>methamphetamine</e2>-induced psychosis in a Japanese population.","Association"
"Serotonin 6 receptor gene is associated with <e1>methamphetamine</e1>-induced <e2>psychosis</e2> in a Japanese population.","Positive_Correlation"
"METHOD: Using five tagging SNPs (rs6693503, rs1805054, <e1>rs4912138</e1>, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced <e2>psychosis</e2> patients and 337 controls) in the Japanese population.","Association"
"METHOD: Using five tagging SNPs (rs6693503, rs1805054, <e1>rs4912138</e1>, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced <e2>psychosis</e2> patients and 337 controls) in the Japanese population.","Association"
"<e2>METH</e2>OD: Using five tagging SNPs (rs6693503, rs1805054, <e1>rs4912138</e1>, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.","Association"
"<e2>METH</e2>OD: Using five tagging SNPs (rs6693503, rs1805054, <e1>rs4912138</e1>, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.","Association"
"METHOD: Using five tagging SNPs (rs6693503, <e1>rs1805054</e1>, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced <e2>psychosis</e2> patients and 337 controls) in the Japanese population.","Association"
"METHOD: Using five tagging SNPs (rs6693503, <e1>rs1805054</e1>, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced <e2>psychosis</e2> patients and 337 controls) in the Japanese population.","Association"
"METHOD: Using five tagging SNPs (rs6693503, <e1>rs1805054</e1>, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced <e2>psychosis</e2> patients and 337 controls) in the Japanese population.","Association"
"<e2>METH</e2>OD: Using five tagging SNPs (rs6693503, <e1>rs1805054</e1>, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.","Association"
"<e2>METH</e2>OD: Using five tagging SNPs (rs6693503, <e1>rs1805054</e1>, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.","Association"
"<e2>METH</e2>OD: Using five tagging SNPs (rs6693503, <e1>rs1805054</e1>, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.","Association"
"METHOD: Using five tagging SNPs (<e1>rs6693503</e1>, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced <e2>psychosis</e2> patients and 337 controls) in the Japanese population.","Association"
"METHOD: Using five tagging SNPs (<e1>rs6693503</e1>, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced <e2>psychosis</e2> patients and 337 controls) in the Japanese population.","Association"
"METHOD: Using five tagging SNPs (<e1>rs6693503</e1>, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced <e2>psychosis</e2> patients and 337 controls) in the Japanese population.","Association"
"METHOD: Using five tagging SNPs (<e1>rs6693503</e1>, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced <e2>psychosis</e2> patients and 337 controls) in the Japanese population.","Association"
"<e2>METH</e2>OD: Using five tagging SNPs (<e1>rs6693503</e1>, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.","Association"
"<e2>METH</e2>OD: Using five tagging SNPs (<e1>rs6693503</e1>, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.","Association"
"<e2>METH</e2>OD: Using five tagging SNPs (<e1>rs6693503</e1>, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.","Association"
"<e2>METH</e2>OD: Using five tagging SNPs (<e1>rs6693503</e1>, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.","Association"
"In addition, the disrupted prepulse inhibition induced by d-amphetamine or <e1>phencyclidine</e1> was restored by <e2>5-HT6 receptor antagonist</e2> in an animal study using rats.","Association"
"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and <e1>d-amphetamine</e1>-induced hyperactivity in rats is corrected with the use of a selective <e2>5-HT6 receptor antagonist</e2>.","Association"
"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and <e1>d-amphetamine</e1>-induced hyperactivity in rats is corrected with the use of a selective <e2>5-HT6 receptor antagonist</e2>.","Association"
"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and <e1>d-amphetamine</e1>-induced <e2>hyperactivity</e2> in rats is corrected with the use of a selective 5-HT6 receptor antagonist.","Positive_Correlation"
"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and <e1>d-amphetamine</e1>-induced <e2>hyperactivity</e2> in rats is corrected with the use of a selective 5-HT6 receptor antagonist.","Positive_Correlation"
"The <e1>serotonin 6 (5-HT6) receptor</e1> is therapeutically targeted by several second generation antipsychotics, such as clozapine and <e2>olanzapine</e2>, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.","Association"
"The serotonin 6 (<e1>5-HT6</e1>) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and <e2>olanzapine</e2>, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.","Association"
"The <e1>serotonin 6 (5-HT6) receptor</e1> is therapeutically targeted by several second generation antipsychotics, such as <e2>clozapine</e2> and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.","Association"
"The serotonin 6 (<e1>5-HT6</e1>) receptor is therapeutically targeted by several second generation antipsychotics, such as <e2>clozapine</e2> and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.","Association"
"The <e1>serotonin 6 (5-HT6) receptor</e1> is therapeutically targeted by several second generation <e2>antipsychotics</e2>, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.","Association"
"The serotonin 6 (<e1>5-HT6</e1>) receptor is therapeutically targeted by several second generation <e2>antipsychotics</e2>, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.","Association"
"The <e1>serotonin 6 (5-HT6) receptor</e1> is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced <e2>hyperactivity</e2> in rats is corrected with the use of a selective 5-HT6 receptor antagonist.","Association"
"The serotonin 6 (<e1>5-HT6</e1>) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced <e2>hyperactivity</e2> in rats is corrected with the use of a selective 5-HT6 receptor antagonist.","Association"
"These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered <e1>5-HT6 receptors</e1> are involved in the pathophysiology of <e2>psychotic disorders</e2>.","Association"
"These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered <e1>5-HT6</e1> receptors are involved in the pathophysiology of <e2>psychotic disorders</e2>.","Association"
"Therefore, we conducted an analysis of the association of the 5-HT6 gene (<e1>HTR6</e1>) with METH-induced <e2>psychosis</e2>.","Association"
"Therefore, we conducted an analysis of the association of the 5-HT6 gene (<e1>HTR6</e1>) with METH-induced <e2>psychosis</e2>.","Association"
"Therefore, we conducted an analysis of the association of the 5-HT6 gene (<e1>HTR6</e1>) with METH-induced <e2>psychosis</e2>.","Association"
"Therefore, we conducted an analysis of the association of the <e1>5-HT6</e1> gene (HTR6) with <e2>METH</e2>-induced psychosis.","Association"
"Therefore, we conducted an analysis of the association of the 5-HT6 gene (<e1>HTR6</e1>) with <e2>METH</e2>-induced psychosis.","Association"
"Therefore, we conducted an analysis of the association of the 5-HT6 gene (<e1>HTR6</e1>) with <e2>METH</e2>-induced psychosis.","Association"
"Therefore, we conducted an analysis of the association of the 5-HT6 gene (<e1>HTR6</e1>) with <e2>METH</e2>-induced psychosis.","Association"
"The symptoms of <e1>methamphetamine</e1> (METH)-induced <e2>psychosis</e2> are similar to those of paranoid type schizophrenia.","Positive_Correlation"
"The symptoms of methamphetamine (<e1>METH</e1>)-induced <e2>psychosis</e2> are similar to those of paranoid type schizophrenia.","Positive_Correlation"
"The symptoms of methamphetamine (<e1>METH</e1>)-induced <e2>psychosis</e2> are similar to those of paranoid type schizophrenia.","Positive_Correlation"
"The symptoms of methamphetamine (<e1>METH</e1>)-induced <e2>psychosis</e2> are similar to those of paranoid type schizophrenia.","Positive_Correlation"
"The symptoms of <e1>methamphetamine</e1> (METH)-induced <e2>psychosis</e2> are similar to those of paranoid type schizophrenia.","Positive_Correlation"
"The symptoms of methamphetamine (<e1>METH</e1>)-induced <e2>psychosis</e2> are similar to those of paranoid type schizophrenia.","Positive_Correlation"
"The symptoms of methamphetamine (<e1>METH</e1>)-induced <e2>psychosis</e2> are similar to those of paranoid type schizophrenia.","Positive_Correlation"
"The symptoms of methamphetamine (<e1>METH</e1>)-induced <e2>psychosis</e2> are similar to those of paranoid type schizophrenia.","Positive_Correlation"
"Reciprocal effects of <e1>NNK</e1> and <e2>SLURP-1</e2> on oncogene expression in target epithelial cells.","Negative_Correlation"
"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as <e2>tumor</e2> suppressors CDKN3 and FOXD3 in BEP2D cells and <e1>SERPINB5</e1> in Het-1A cells.","Association"
"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as <e2>tumor</e2> suppressors CDKN3 and <e1>FOXD3</e1> in BEP2D cells and SERPINB5 in Het-1A cells.","Association"
"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as <e2>tumor</e2> suppressors <e1>CDKN3</e1> and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Association"
"Other <e1>cancer</e1>-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and <e2>STAT3</e2> (Het-1A only).","Association"
"Other <e1>cancer</e1>-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors <e2>CDKN2A</e2> and STAT3 (Het-1A only).","Association"
"Other <e1>cancer</e1>-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and <e2>HGF</e2> in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Association"
"Other <e1>cancer</e1>-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors <e2>EGF</e2> in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Association"
"KEY FINDINGS: <e2>NNK</e2> stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and <e1>RB1</e1> in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e2>NNK</e2> stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, <e1>KIT</e1> and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e2>NNK</e2> stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and <e1>AKT1</e1>, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e2>NNK</e2> stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and <e1>SRC</e1> in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e2>NNK</e2> stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, <e1>NRAS</e1> and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e2>NNK</e2> stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, <e1>ETS1</e1>, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"These pro-oncogenic effects of NNK were abolished by r<e1>SLURP-1</e1> that also upregulated <e2>RUNX3</e2>.","Positive_Correlation"
"These pro-oncogenic effects of NNK were abolished by r<e1>SLURP-1</e1> that also upregulated <e2>RUNX3</e2>.","Positive_Correlation"
"These pro-oncogenic effects of NNK were abolished by <e1>rSLURP-1</e1> that also upregulated <e2>RUNX3</e2>.","Positive_Correlation"
"These pro-oncogenic effects of NNK were abolished by <e1>rSLURP-1</e1> that also upregulated <e2>RUNX3</e2>.","Positive_Correlation"
"These pro-oncogenic effects of NNK were abolished by <e1>rSLURP-1</e1> that also upregulated <e2>RUNX3</e2>.","Positive_Correlation"
"These pro-oncogenic effects of NNK were abolished by <e1>rSLURP-1</e1> that also upregulated <e2>RUNX3</e2>.","Positive_Correlation"
"These pro-oncogenic effects of NNK were abolished by r<e1>SLURP-1</e1> that also upregulated <e2>RUNX3</e2>.","Positive_Correlation"
"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian <e1>Ly-6/urokinase plasminogen activator receptor related protein-1</e1> (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to <e2>tumorigenesis</e2> in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively.","Association"
"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (<e1>SLURP-1</e1>), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to <e2>tumorigenesis</e2> in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively.","Association"
"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (<e1>SLURP-1</e1>), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to <e2>tumorigenesis</e2> in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively.","Association"
"Other <e2>cancer</e2>-related genes whose upregulation by NNK was abolishable by <e1>rSLURP-1</e1> were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Association"
"Other <e2>cancer</e2>-related genes whose upregulation by NNK was abolishable by <e1>rSLURP-1</e1> were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Association"
"Other <e2>cancer</e2>-related genes whose upregulation by NNK was abolishable by <e1>rSLURP-1</e1> were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Association"
"Other <e2>cancer</e2>-related genes whose upregulation by NNK was abolishable by <e1>rSLURP-1</e1> were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Association"
"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (<e1>SLURP-1</e1>), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to <e2>tumorigenesis</e2> in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively.","Association"
"These pro-oncogenic effects of <e1>NNK</e1> were abolished by rSLURP-1 that also upregulated <e2>RUNX3</e2>.","Positive_Correlation"
"These pro-oncogenic effects of <e1>NNK</e1> were abolished by rSLURP-1 that also upregulated <e2>RUNX3</e2>.","Positive_Correlation"
"These pro-oncogenic effects of <e1>NNK</e1> were abolished by rSLURP-1 that also upregulated <e2>RUNX3</e2>.","Positive_Correlation"
"These pro-oncogenic effects of <e1>NNK</e1> were abolished by rSLURP-1 that also upregulated <e2>RUNX3</e2>.","Positive_Correlation"
"These pro-oncogenic effects of <e1>NNK</e1> were abolished by rSLURP-1 that also upregulated <e2>RUNX3</e2>.","Positive_Correlation"
"These pro-oncogenic effects of <e1>NNK</e1> were abolished by rSLURP-1 that also upregulated <e2>RUNX3</e2>.","Positive_Correlation"
"These pro-oncogenic effects of <e1>NNK</e1> were abolished by rSLURP-1 that also upregulated <e2>RUNX3</e2>.","Positive_Correlation"
"These pro-oncogenic effects of <e1>NNK</e1> were abolished by rSLURP-1 that also upregulated <e2>RUNX3</e2>.","Positive_Correlation"
"These pro-oncogenic effects of <e1>NNK</e1> were abolished by rSLURP-1 that also upregulated <e2>RUNX3</e2>.","Positive_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and <e2>SERPINB5</e2> in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and <e2>SERPINB5</e2> in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and <e2>SERPINB5</e2> in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and <e2>SERPINB5</e2> in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and <e2>SERPINB5</e2> in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and <e2>SERPINB5</e2> in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and <e2>SERPINB5</e2> in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and <e2>SERPINB5</e2> in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and <e2>SERPINB5</e2> in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and <e2>FOXD3</e2> in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and <e2>FOXD3</e2> in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and <e2>FOXD3</e2> in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and <e2>FOXD3</e2> in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and <e2>FOXD3</e2> in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and <e2>FOXD3</e2> in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and <e2>FOXD3</e2> in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and <e2>FOXD3</e2> in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and <e2>FOXD3</e2> in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors <e2>CDKN3</e2> and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors <e2>CDKN3</e2> and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors <e2>CDKN3</e2> and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors <e2>CDKN3</e2> and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors <e2>CDKN3</e2> and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors <e2>CDKN3</e2> and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors <e2>CDKN3</e2> and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors <e2>CDKN3</e2> and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors <e2>CDKN3</e2> and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the <e2>CTNNB1</e2> gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the <e2>CTNNB1</e2> gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the <e2>CTNNB1</e2> gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the <e2>CTNNB1</e2> gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the <e2>CTNNB1</e2> gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the <e2>CTNNB1</e2> gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the <e2>CTNNB1</e2> gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the <e2>CTNNB1</e2> gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> decreased expression of the <e2>CTNNB1</e2> gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and <e2>CASP8</e2> (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and <e2>CASP8</e2> (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and <e2>CASP8</e2> (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and <e2>CASP8</e2> (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and <e2>CASP8</e2> (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and <e2>CASP8</e2> (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and <e2>CASP8</e2> (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and <e2>CASP8</e2> (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and <e2>CASP8</e2> (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), <e2>BAX</e2> and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), <e2>BAX</e2> and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), <e2>BAX</e2> and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), <e2>BAX</e2> and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), <e2>BAX</e2> and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), <e2>BAX</e2> and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), <e2>BAX</e2> and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), <e2>BAX</e2> and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), <e2>BAX</e2> and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic <e2>TNF</e2> (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic <e2>TNF</e2> (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic <e2>TNF</e2> (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic <e2>TNF</e2> (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic <e2>TNF</e2> (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic <e2>TNF</e2> (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic <e2>TNF</e2> (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic <e2>TNF</e2> (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic <e2>TNF</e2> (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Negative_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic <e2>BCL2</e2> (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Positive_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic <e2>BCL2</e2> (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Positive_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic <e2>BCL2</e2> (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Positive_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic <e2>BCL2</e2> (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Positive_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic <e2>BCL2</e2> (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Positive_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic <e2>BCL2</e2> (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Positive_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic <e2>BCL2</e2> (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Positive_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic <e2>BCL2</e2> (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Positive_Correlation"
"<e1>NNK</e1> also upregulated the anti-apoptotic <e2>BCL2</e2> (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1.","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and <e2>STAT3</e2> (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and <e2>STAT3</e2> (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and <e2>STAT3</e2> (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and <e2>STAT3</e2> (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and <e2>STAT3</e2> (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and <e2>STAT3</e2> (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and <e2>STAT3</e2> (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and <e2>STAT3</e2> (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and <e2>STAT3</e2> (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors <e2>CDKN2A</e2> and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors <e2>CDKN2A</e2> and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors <e2>CDKN2A</e2> and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors <e2>CDKN2A</e2> and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors <e2>CDKN2A</e2> and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors <e2>CDKN2A</e2> and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors <e2>CDKN2A</e2> and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors <e2>CDKN2A</e2> and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors <e2>CDKN2A</e2> and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and <e2>HGF</e2> in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and <e2>HGF</e2> in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and <e2>HGF</e2> in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and <e2>HGF</e2> in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and <e2>HGF</e2> in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and <e2>HGF</e2> in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and <e2>HGF</e2> in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and <e2>HGF</e2> in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and <e2>HGF</e2> in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors <e2>EGF</e2> in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors <e2>EGF</e2> in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors <e2>EGF</e2> in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors <e2>EGF</e2> in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors <e2>EGF</e2> in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors <e2>EGF</e2> in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors <e2>EGF</e2> in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors <e2>EGF</e2> in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"Other cancer-related genes whose upregulation by <e1>NNK</e1> was abolishable by rSLURP-1 were the growth factors <e2>EGF</e2> in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only).","Positive_Correlation"
"AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (<e1>4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone</e1>) (NNK) facilitate <e2>carcinogenic</e2> transformation.","Association"
"AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (<e1>NNK</e1>) facilitate <e2>carcinogenic</e2> transformation.","Association"
"AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (<e1>NNK</e1>) facilitate <e2>carcinogenic</e2> transformation.","Association"
"AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (<e1>NNK</e1>) facilitate <e2>carcinogenic</e2> transformation.","Association"
"AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (<e1>NNK</e1>) facilitate <e2>carcinogenic</e2> transformation.","Association"
"AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (<e1>NNK</e1>) facilitate <e2>carcinogenic</e2> transformation.","Association"
"AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (<e1>NNK</e1>) facilitate <e2>carcinogenic</e2> transformation.","Association"
"AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (<e1>NNK</e1>) facilitate <e2>carcinogenic</e2> transformation.","Association"
"AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (<e1>NNK</e1>) facilitate <e2>carcinogenic</e2> transformation.","Association"
"AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (<e1>NNK</e1>) facilitate <e2>carcinogenic</e2> transformation.","Association"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including MYB and <e2>PIK3CA</e2> in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including MYB and <e2>PIK3CA</e2> in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including MYB and <e2>PIK3CA</e2> in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including MYB and <e2>PIK3CA</e2> in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including MYB and <e2>PIK3CA</e2> in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including MYB and <e2>PIK3CA</e2> in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including MYB and <e2>PIK3CA</e2> in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including MYB and <e2>PIK3CA</e2> in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including MYB and <e2>PIK3CA</e2> in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including <e2>MYB</e2> and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including <e2>MYB</e2> and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including <e2>MYB</e2> and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including <e2>MYB</e2> and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including <e2>MYB</e2> and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including <e2>MYB</e2> and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including <e2>MYB</e2> and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including <e2>MYB</e2> and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"KEY FINDINGS: <e1>NNK</e1> stimulated expression of oncogenic genes, including <e2>MYB</e2> and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1.","Positive_Correlation"
"MAIN METHODS: Since <e1>NNK</e1>-dependent transformation can be abolished by the nicotinergic secreted mammalian <e2>Ly-6/urokinase plasminogen activator receptor related protein-1</e2> (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively.","Negative_Correlation"
"MAIN METHODS: Since <e1>NNK</e1>-dependent transformation can be abolished by the nicotinergic secreted mammalian <e2>Ly-6/urokinase plasminogen activator receptor related protein-1</e2> (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively.","Negative_Correlation"
"MAIN METHODS: Since <e1>NNK</e1>-dependent transformation can be abolished by the nicotinergic secreted mammalian <e2>Ly-6/urokinase plasminogen activator receptor related protein-1</e2> (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively.","Negative_Correlation"
"MAIN METHODS: Since <e1>NNK</e1>-dependent transformation can be abolished by the nicotinergic secreted mammalian <e2>Ly-6/urokinase plasminogen activator receptor related protein-1</e2> (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively.","Negative_Correlation"
"MAIN METHODS: Since <e1>NNK</e1>-dependent transformation can be abolished by the nicotinergic secreted mammalian <e2>Ly-6/urokinase plasminogen activator receptor related protein-1</e2> (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively.","Negative_Correlation"
"MAIN METHODS: Since <e1>NNK</e1>-dependent transformation can be abolished by the nicotinergic secreted mammalian <e2>Ly-6/urokinase plasminogen activator receptor related protein-1</e2> (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively.","Negative_Correlation"
"MAIN METHODS: Since <e1>NNK</e1>-dependent transformation can be abolished by the nicotinergic secreted mammalian <e2>Ly-6/urokinase plasminogen activator receptor related protein-1</e2> (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively.","Negative_Correlation"
"MAIN METHODS: Since <e1>NNK</e1>-dependent transformation can be abolished by the nicotinergic secreted mammalian <e2>Ly-6/urokinase plasminogen activator receptor related protein-1</e2> (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively.","Negative_Correlation"
"MAIN METHODS: Since <e1>NNK</e1>-dependent transformation can be abolished by the nicotinergic secreted mammalian <e2>Ly-6/urokinase plasminogen activator receptor related protein-1</e2> (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively.","Negative_Correlation"
"Long-term exposure of MCF-7 <e2>breast cancer</e2> cells to <e1>ethanol</e1> stimulates oncogenic features.","Positive_Correlation"
"Long-term exposure upregulated expression of some <e2>malignancy</e2> related genes (STEAP4, SERPINA3, SAMD9, GDF15, KRT15, ITGB6, TP63, and PGR, as well as the CEACAM, interferon related, and <e1>HLA</e1> gene families).","Association"
"Long-term exposure upregulated expression of some <e2>malignancy</e2> related genes (STEAP4, SERPINA3, SAMD9, GDF15, KRT15, ITGB6, TP63, and PGR, as well as the CEACAM, <e1>interferon</e1> related, and HLA gene families).","Association"
"Long-term exposure upregulated expression of some <e2>malignancy</e2> related genes (STEAP4, SERPINA3, SAMD9, GDF15, KRT15, ITGB6, TP63, and <e1>PGR</e1>, as well as the CEACAM, interferon related, and HLA gene families).","Association"
"Long-term exposure upregulated expression of some <e2>malignancy</e2> related genes (STEAP4, SERPINA3, SAMD9, GDF15, KRT15, ITGB6, <e1>TP63</e1>, and PGR, as well as the CEACAM, interferon related, and HLA gene families).","Association"
"Long-term exposure upregulated expression of some <e2>malignancy</e2> related genes (STEAP4, SERPINA3, SAMD9, GDF15, KRT15, <e1>ITGB6</e1>, TP63, and PGR, as well as the CEACAM, interferon related, and HLA gene families).","Association"
"Long-term exposure upregulated expression of some <e2>malignancy</e2> related genes (STEAP4, SERPINA3, SAMD9, GDF15, <e1>KRT15</e1>, ITGB6, TP63, and PGR, as well as the CEACAM, interferon related, and HLA gene families).","Association"
"Long-term exposure upregulated expression of some <e2>malignancy</e2> related genes (STEAP4, SERPINA3, SAMD9, <e1>GDF15</e1>, KRT15, ITGB6, TP63, and PGR, as well as the CEACAM, interferon related, and HLA gene families).","Association"
"Long-term exposure upregulated expression of some <e2>malignancy</e2> related genes (STEAP4, SERPINA3, <e1>SAMD9</e1>, GDF15, KRT15, ITGB6, TP63, and PGR, as well as the CEACAM, interferon related, and HLA gene families).","Association"
"Long-term exposure upregulated expression of some <e2>malignancy</e2> related genes (STEAP4, <e1>SERPINA3</e1>, SAMD9, GDF15, KRT15, ITGB6, TP63, and PGR, as well as the CEACAM, interferon related, and HLA gene families).","Association"
"Long-term exposure upregulated expression of some <e2>malignancy</e2> related genes (<e1>STEAP4</e1>, SERPINA3, SAMD9, GDF15, KRT15, ITGB6, TP63, and PGR, as well as the CEACAM, interferon related, and HLA gene families).","Association"
"Long-term (4-week) exposure to 25 mM ethanol upregulated the Oct4 and Nanog proteins, as well as the <e1>malignancy</e1> marker <e2>Ceacam6</e2>.","Association"
"Long-term (4-week) exposure to 25 mM ethanol upregulated the Oct4 and Nanog proteins, as well as the <e1>malignancy</e1> marker <e2>Ceacam6</e2>.","Association"
"Long-term (4-week) exposure to 25 mM ethanol upregulated the Oct4 and Nanog proteins, as well as the <e1>malignancy</e1> marker <e2>Ceacam6</e2>.","Association"
"Short-term (1-week) incubation to ethanol at as low as 1-5 mM (corresponding to blood <e2>alcohol</e2> concentration of ~0.0048-0.024%) upregulated the stem cell related proteins Oct4 and <e1>Nanog</e1>, but they were reduced after exposure at 25 mM.","Positive_Correlation"
"Short-term (1-week) incubation to ethanol at as low as 1-5 mM (corresponding to blood <e2>alcohol</e2> concentration of ~0.0048-0.024%) upregulated the stem cell related proteins Oct4 and <e1>Nanog</e1>, but they were reduced after exposure at 25 mM.","Positive_Correlation"
"Short-term (1-week) incubation to ethanol at as low as 1-5 mM (corresponding to blood <e2>alcohol</e2> concentration of ~0.0048-0.024%) upregulated the stem cell related proteins <e1>Oct4</e1> and Nanog, but they were reduced after exposure at 25 mM.","Positive_Correlation"
"Short-term (1-week) incubation to ethanol at as low as 1-5 mM (corresponding to blood <e2>alcohol</e2> concentration of ~0.0048-0.024%) upregulated the stem cell related proteins <e1>Oct4</e1> and Nanog, but they were reduced after exposure at 25 mM.","Positive_Correlation"
"Short-term (1-week) incubation to ethanol at as low as 1-5 mM (corresponding to blood <e2>alcohol</e2> concentration of ~0.0048-0.024%) upregulated the stem cell related proteins <e1>Oct4</e1> and Nanog, but they were reduced after exposure at 25 mM.","Positive_Correlation"
"<e1>Alcohol</e1> consumption is a risk factor for <e2>breast cancer</e2>.","Positive_Correlation"
"The previously shown <e1>alcohol</e1> induction of oncogenic transformation of normal breast cells is now complemented by the current results suggesting alcohol's potential involvement in malignant progression of <e2>breast cancer</e2>.","Positive_Correlation"
"The previously shown <e1>alcohol</e1> induction of oncogenic transformation of normal breast cells is now complemented by the current results suggesting alcohol's potential involvement in malignant progression of <e2>breast cancer</e2>.","Positive_Correlation"
"The previously shown <e1>alcohol</e1> induction of oncogenic transformation of normal breast cells is now complemented by the current results suggesting alcohol's potential involvement in malignant progression of <e2>breast cancer</e2>.","Positive_Correlation"
"The previously shown <e1>alcohol</e1> induction of oncogenic transformation of normal breast cells is now complemented by the current results suggesting alcohol's potential involvement in malignant progression of <e2>breast cancer</e2>.","Positive_Correlation"
"We previously showed that long-term exposure to 2.5 mM <e2>ethanol</e2> (blood <e1>alcohol</e1> ~0.012%) of MCF-12A, a human normal epithelial breast cell line, induced epithelial mesenchymal transition (EMT) and oncogenic transformation.","Positive_Correlation"
"We previously showed that long-term exposure to 2.5 mM <e2>ethanol</e2> (blood <e1>alcohol</e1> ~0.012%) of MCF-12A, a human normal epithelial breast cell line, induced epithelial mesenchymal transition (EMT) and oncogenic transformation.","Positive_Correlation"
"We previously showed that long-term exposure to 2.5 mM <e2>ethanol</e2> (blood <e1>alcohol</e1> ~0.012%) of MCF-12A, a human normal epithelial breast cell line, induced epithelial mesenchymal transition (EMT) and oncogenic transformation.","Positive_Correlation"
"We previously showed that long-term exposure to 2.5 mM <e2>ethanol</e2> (blood <e1>alcohol</e1> ~0.012%) of MCF-12A, a human normal epithelial breast cell line, induced epithelial mesenchymal transition (EMT) and oncogenic transformation.","Positive_Correlation"
"Long-term (4-week) exposure to 25 mM <e1>ethanol</e1> upregulated the Oct4 and Nanog proteins, as well as the <e2>malignancy</e2> marker Ceacam6.","Association"
"Long-term (4-week) exposure to 25 mM <e1>ethanol</e1> upregulated the Oct4 and Nanog proteins, as well as the <e2>malignancy</e2> marker Ceacam6.","Association"
"Long-term (4-week) exposure to 25 mM <e1>ethanol</e1> upregulated the Oct4 and Nanog proteins, as well as the <e2>malignancy</e2> marker Ceacam6.","Association"
"Long-term (4-week) exposure to 25 mM <e1>ethanol</e1> upregulated the Oct4 and Nanog proteins, as well as the <e2>malignancy</e2> marker Ceacam6.","Association"
"Long-term (4-week) exposure to 25 mM <e1>ethanol</e1> upregulated the Oct4 and Nanog proteins, as well as the <e2>malignancy</e2> marker Ceacam6.","Association"
"Long-term (4-week) exposure to 25 mM <e1>ethanol</e1> upregulated the Oct4 and Nanog proteins, as well as the <e2>malignancy</e2> marker Ceacam6.","Association"
"Long-term (4-week) exposure to 25 mM <e1>ethanol</e1> upregulated the Oct4 and Nanog proteins, as well as the malignancy marker <e2>Ceacam6</e2>.","Positive_Correlation"
"Long-term (4-week) exposure to 25 mM <e1>ethanol</e1> upregulated the Oct4 and Nanog proteins, as well as the malignancy marker <e2>Ceacam6</e2>.","Positive_Correlation"
"Long-term (4-week) exposure to 25 mM <e1>ethanol</e1> upregulated the Oct4 and Nanog proteins, as well as the malignancy marker <e2>Ceacam6</e2>.","Positive_Correlation"
"Long-term (4-week) exposure to 25 mM <e1>ethanol</e1> upregulated the Oct4 and Nanog proteins, as well as the malignancy marker <e2>Ceacam6</e2>.","Positive_Correlation"
"Long-term (4-week) exposure to 25 mM <e1>ethanol</e1> upregulated the Oct4 and Nanog proteins, as well as the malignancy marker <e2>Ceacam6</e2>.","Positive_Correlation"
"Long-term (4-week) exposure to 25 mM <e1>ethanol</e1> upregulated the Oct4 and Nanog proteins, as well as the malignancy marker <e2>Ceacam6</e2>.","Positive_Correlation"
"Short-term (1-week) incubation to <e1>ethanol</e1> at as low as 1-5 mM (corresponding to blood alcohol concentration of ~0.0048-0.024%) upregulated the stem cell related proteins Oct4 and <e2>Nanog</e2>, but they were reduced after exposure at 25 mM.","Positive_Correlation"
"Short-term (1-week) incubation to <e1>ethanol</e1> at as low as 1-5 mM (corresponding to blood alcohol concentration of ~0.0048-0.024%) upregulated the stem cell related proteins Oct4 and <e2>Nanog</e2>, but they were reduced after exposure at 25 mM.","Positive_Correlation"
"Short-term (1-week) incubation to <e1>ethanol</e1> at as low as 1-5 mM (corresponding to blood alcohol concentration of ~0.0048-0.024%) upregulated the stem cell related proteins Oct4 and <e2>Nanog</e2>, but they were reduced after exposure at 25 mM.","Positive_Correlation"
"Short-term (1-week) incubation to <e1>ethanol</e1> at as low as 1-5 mM (corresponding to blood alcohol concentration of ~0.0048-0.024%) upregulated the stem cell related proteins Oct4 and <e2>Nanog</e2>, but they were reduced after exposure at 25 mM.","Positive_Correlation"
"Short-term (1-week) incubation to <e1>ethanol</e1> at as low as 1-5 mM (corresponding to blood alcohol concentration of ~0.0048-0.024%) upregulated the stem cell related proteins Oct4 and <e2>Nanog</e2>, but they were reduced after exposure at 25 mM.","Positive_Correlation"
"Short-term (1-week) incubation to <e1>ethanol</e1> at as low as 1-5 mM (corresponding to blood alcohol concentration of ~0.0048-0.024%) upregulated the stem cell related proteins Oct4 and <e2>Nanog</e2>, but they were reduced after exposure at 25 mM.","Positive_Correlation"
"Short-term (1-week) incubation to <e1>ethanol</e1> at as low as 1-5 mM (corresponding to blood alcohol concentration of ~0.0048-0.024%) upregulated the stem cell related proteins <e2>Oct4</e2> and Nanog, but they were reduced after exposure at 25 mM.","Positive_Correlation"
"Short-term (1-week) incubation to <e1>ethanol</e1> at as low as 1-5 mM (corresponding to blood alcohol concentration of ~0.0048-0.024%) upregulated the stem cell related proteins <e2>Oct4</e2> and Nanog, but they were reduced after exposure at 25 mM.","Positive_Correlation"
"Short-term (1-week) incubation to <e1>ethanol</e1> at as low as 1-5 mM (corresponding to blood alcohol concentration of ~0.0048-0.024%) upregulated the stem cell related proteins <e2>Oct4</e2> and Nanog, but they were reduced after exposure at 25 mM.","Positive_Correlation"
"Short-term (1-week) incubation to <e1>ethanol</e1> at as low as 1-5 mM (corresponding to blood alcohol concentration of ~0.0048-0.024%) upregulated the stem cell related proteins <e2>Oct4</e2> and Nanog, but they were reduced after exposure at 25 mM.","Positive_Correlation"
"Short-term (1-week) incubation to <e1>ethanol</e1> at as low as 1-5 mM (corresponding to blood alcohol concentration of ~0.0048-0.024%) upregulated the stem cell related proteins <e2>Oct4</e2> and Nanog, but they were reduced after exposure at 25 mM.","Positive_Correlation"
"Short-term (1-week) incubation to <e1>ethanol</e1> at as low as 1-5 mM (corresponding to blood alcohol concentration of ~0.0048-0.024%) upregulated the stem cell related proteins <e2>Oct4</e2> and Nanog, but they were reduced after exposure at 25 mM.","Positive_Correlation"
"In this study, we investigated in the human <e2>breast cancer</e2> cell line MCF-7, whether a similar exposure to <e1>ethanol</e1> at concentrations ranging up to peak blood levels in heavy drinkers would increase malignant progression.","Positive_Correlation"
"In this study, we investigated in the human <e2>breast cancer</e2> cell line MCF-7, whether a similar exposure to <e1>ethanol</e1> at concentrations ranging up to peak blood levels in heavy drinkers would increase malignant progression.","Positive_Correlation"
"In this study, we investigated in the human <e2>breast cancer</e2> cell line MCF-7, whether a similar exposure to <e1>ethanol</e1> at concentrations ranging up to peak blood levels in heavy drinkers would increase malignant progression.","Positive_Correlation"
"In this study, we investigated in the human <e2>breast cancer</e2> cell line MCF-7, whether a similar exposure to <e1>ethanol</e1> at concentrations ranging up to peak blood levels in heavy drinkers would increase malignant progression.","Positive_Correlation"
"In this study, we investigated in the human <e2>breast cancer</e2> cell line MCF-7, whether a similar exposure to <e1>ethanol</e1> at concentrations ranging up to peak blood levels in heavy drinkers would increase malignant progression.","Positive_Correlation"
"In this study, we investigated in the human <e2>breast cancer</e2> cell line MCF-7, whether a similar exposure to <e1>ethanol</e1> at concentrations ranging up to peak blood levels in heavy drinkers would increase malignant progression.","Positive_Correlation"
"A 24-year-old <e2>SLS</e2> female was homozygous for a 352-kb deletion involving ALDH3A2 and 4 contiguous genes including <e1>ALDH3A1</e1>, which codes for the major soluble protein in cornea.","Association"
"A 24-year-old <e2>SLS</e2> female was homozygous for a <e1>352-kb deletion</e1> involving ALDH3A2 and 4 contiguous genes including ALDH3A1, which codes for the major soluble protein in cornea.","Association"
"<e1>Sjogren-Larsson syndrome</e1> (SLS) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the <e2>ALDH3A2</e2> gene for fatty aldehyde dehydrogenase, an enzyme that catalyzes the oxidation of fatty aldehyde to fatty acid.","Association"
"Sjogren-Larsson syndrome (<e1>SLS</e1>) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the <e2>ALDH3A2</e2> gene for fatty aldehyde dehydrogenase, an enzyme that catalyzes the oxidation of fatty aldehyde to fatty acid.","Association"
"Sjogren-Larsson syndrome (<e1>SLS</e1>) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the <e2>ALDH3A2</e2> gene for fatty aldehyde dehydrogenase, an enzyme that catalyzes the oxidation of fatty aldehyde to fatty acid.","Association"
"Sjogren-Larsson syndrome (<e1>SLS</e1>) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the <e2>ALDH3A2</e2> gene for fatty aldehyde dehydrogenase, an enzyme that catalyzes the oxidation of fatty aldehyde to fatty acid.","Association"
"Sjogren-Larsson syndrome (<e1>SLS</e1>) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the <e2>ALDH3A2</e2> gene for fatty aldehyde dehydrogenase, an enzyme that catalyzes the oxidation of fatty aldehyde to fatty acid.","Association"
"Sjogren-Larsson syndrome (<e1>SLS</e1>) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the <e2>ALDH3A2</e2> gene for fatty aldehyde dehydrogenase, an enzyme that catalyzes the oxidation of fatty aldehyde to fatty acid.","Association"
"Sjogren-Larsson syndrome (<e1>SLS</e1>) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the <e2>ALDH3A2</e2> gene for fatty aldehyde dehydrogenase, an enzyme that catalyzes the oxidation of fatty aldehyde to fatty acid.","Association"
"Sjogren-Larsson syndrome (<e1>SLS</e1>) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the <e2>ALDH3A2</e2> gene for fatty aldehyde dehydrogenase, an enzyme that catalyzes the oxidation of fatty aldehyde to fatty acid.","Association"
"Sjogren-Larsson syndrome (SLS) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the <e1>ALDH3A2</e1> gene for <e2>fatty aldehyde</e2> dehydrogenase, an enzyme that catalyzes the oxidation of fatty aldehyde to fatty acid.","Association"
"Sjogren-Larsson syndrome (SLS) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the ALDH3A2 gene for <e1><e2>fatty aldehyde</e2> dehydrogenase</e1>, an enzyme that catalyzes the oxidation of fatty aldehyde to fatty acid.","Association"
"Sjogren-Larsson syndrome (SLS) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the <e1>ALDH3A2</e1> gene for <e2>fatty aldehyde</e2> dehydrogenase, an enzyme that catalyzes the oxidation of fatty aldehyde to fatty acid.","Association"
"Sjogren-Larsson syndrome (SLS) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the <e1>ALDH3A2</e1> gene for <e2>fatty aldehyde</e2> dehydrogenase, an enzyme that catalyzes the oxidation of fatty aldehyde to fatty acid.","Association"
"Sjogren-Larsson syndrome (SLS) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the <e1>ALDH3A2</e1> gene for fatty aldehyde dehydrogenase, an enzyme that catalyzes the oxidation of fatty aldehyde to <e2>fatty acid</e2>.","Association"
"Sjogren-Larsson syndrome (SLS) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the ALDH3A2 gene for <e1>fatty aldehyde dehydrogenase</e1>, an enzyme that catalyzes the oxidation of fatty aldehyde to <e2>fatty acid</e2>.","Association"
"Sjogren-Larsson syndrome (SLS) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the <e1>ALDH3A2</e1> gene for fatty aldehyde dehydrogenase, an enzyme that catalyzes the oxidation of fatty aldehyde to <e2>fatty acid</e2>.","Association"
"Sjogren-Larsson syndrome (SLS) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, spasticity and mutations in the <e1>ALDH3A2</e1> gene for fatty aldehyde dehydrogenase, an enzyme that catalyzes the oxidation of fatty aldehyde to <e2>fatty acid</e2>.","Association"
"In two models of <e2>hepatic fibrogenesis</e2>, <e1>CCl4</e1> treatment and bile duct ligation, hepatic mRNA levels of SAA1 and SAA3 were strongly increased.","Association"
"In two models of hepatic fibrogenesis, <e1>CCl4</e1> treatment and bile duct ligation, hepatic mRNA levels of SAA1 and <e2>SAA3</e2> were strongly increased.","Positive_Correlation"
"In two models of hepatic fibrogenesis, <e1>CCl4</e1> treatment and bile duct ligation, hepatic mRNA levels of <e2>SAA1</e2> and SAA3 were strongly increased.","Positive_Correlation"
"In two models of <e1>hepatic fibrogenesis</e1>, CCl4 treatment and bile duct ligation, hepatic mRNA levels of SAA1 and <e2>SAA3</e2> were strongly increased.","Association"
"In two models of <e1>hepatic fibrogenesis</e1>, CCl4 treatment and bile duct ligation, hepatic mRNA levels of <e2>SAA1</e2> and SAA3 were strongly increased.","Association"
"However, HCV genotype 1-infected patients with high baseline <e1>viremia</e1> carrying the IL12B 3'-UTR <e2>1188-C</e2>-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).","Association"
"However, HCV genotype 1-infected patients with high baseline <e1>viremia</e1> carrying the <e2>IL12B</e2> 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).","Association"
"No Evidence for <e2>BRAF</e2> as a <e1>melanoma</e1>/nevus susceptibility gene.","Association"
"Somatic mutations of <e2>BRAF</e2> have been identified in both <e1>melanoma tumors</e1> and benign nevi.","Association"
"Somatic mutations of <e2>BRAF</e2> have been identified in both <e1>melanoma</e1> tumors and benign nevi.","Association"
"However, a recent study suggested that a <e2>BRAF</e2> haplotype was associated with risk of <e1>sporadic melanoma</e1> in men.","Association"
"Somatic mutations of <e2>BRAF</e2> have been identified in both <e1>melanoma</e1> tumors and benign nevi.","Association"
"Using denaturing high-pressure liquid chromatography and sequencing, we screened peripheral blood DNA from 184 <e1>familial melanoma</e1> cases for <e2>BRAF</e2> promoter variants.","Association"
"Somatic mutations of <e2>BRAF</e2> have been identified in both <e1>melanoma</e1> tumors and benign nevi.","Association"
"Somatic mutations of <e2>BRAF</e2> have been identified in both <e1>melanoma</e1> tumors and benign nevi.","Association"
"Somatic mutations of <e2>BRAF</e2> have been identified in both <e1>melanoma</e1> tumors and benign nevi.","Association"
"CFI-<e1>rs7356506</e1> polymorphisms associated with <e2>Vogt-Koyanagi-Harada syndrome</e2>.","Association"
"<e1>CFI</e1>-rs7356506 polymorphisms associated with <e2>Vogt-Koyanagi-Harada syndrome</e2>.","Association"
"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in CFI-<e1>rs7356506</e1> in patients with VKH syndrome with complicated <e2>cataract</e2> compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).","Association"
"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in CFI-<e1>rs7356506</e1> in patients with VKH syndrome with complicated <e2>cataract</e2> compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).","Association"
"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in CFI-<e1>rs7356506</e1> in patients with VKH syndrome with complicated <e2>cataract</e2> compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).","Association"
"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in CFI-<e1>rs7356506</e1> in patients with VKH syndrome with complicated <e2>cataract</e2> compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).","Association"
"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in CFI-<e1>rs7356506</e1> in patients with VKH syndrome with complicated <e2>cataract</e2> compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).","Association"
"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in CFI-rs<e1>7356506</e1> in patients with VKH syndrome with complicated <e2>cataract</e2> compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).","Association"
"RESULTS: No significant association was found between CFI-<e1>rs7356506</e1> polymorphisms and <e2>VKH syndrome</e2>.","Association"
"RESULTS: No significant association was found between CFI-<e1>rs7356506</e1> polymorphisms and <e2>VKH syndrome</e2>.","Association"
"RESULTS: No significant association was found between CFI-<e1>rs7356506</e1> polymorphisms and <e2>VKH syndrome</e2>.","Association"
"RESULTS: No significant association was found between CFI-<e1>rs7356506</e1> polymorphisms and <e2>VKH syndrome</e2>.","Association"
"RESULTS: No significant association was found between CFI-<e1>rs7356506</e1> polymorphisms and <e2>VKH syndrome</e2>.","Association"
"RESULTS: No significant association was found between CFI-rs<e1>7356506</e1> polymorphisms and <e2>VKH syndrome</e2>.","Association"
"PURPOSE: <e1>Complement factor I</e1> (CFI) plays an important role in complement activation pathways and is known to affect the development of <e2>uveitis</e2>.","Association"
"PURPOSE: Complement factor I (<e1>CFI</e1>) plays an important role in complement activation pathways and is known to affect the development of <e2>uveitis</e2>.","Association"
"PURPOSE: Complement factor I (<e1>CFI</e1>) plays an important role in complement activation pathways and is known to affect the development of <e2>uveitis</e2>.","Association"
"PURPOSE: Complement factor I (<e1>CFI</e1>) plays an important role in complement activation pathways and is known to affect the development of <e2>uveitis</e2>.","Association"
"PURPOSE: Complement factor I (<e1>CFI</e1>) plays an important role in complement activation pathways and is known to affect the development of <e2>uveitis</e2>.","Association"
"PURPOSE: Complement factor I (<e1>CFI</e1>) plays an important role in complement activation pathways and is known to affect the development of <e2>uveitis</e2>.","Association"
"PURPOSE: Complement factor I (<e1>CFI</e1>) plays an important role in complement activation pathways and is known to affect the development of <e2>uveitis</e2>.","Association"
"PURPOSE: Complement factor I (<e1>CFI</e1>) plays an important role in complement activation pathways and is known to affect the development of <e2>uveitis</e2>.","Association"
"PURPOSE: Complement factor I (<e1>CFI</e1>) plays an important role in complement activation pathways and is known to affect the development of <e2>uveitis</e2>.","Association"
"PURPOSE: Complement factor I (<e1>CFI</e1>) plays an important role in complement activation pathways and is known to affect the development of <e2>uveitis</e2>.","Association"
"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in <e1>CFI</e1>-rs7356506 in patients with VKH syndrome with complicated <e2>cataract</e2> compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).","Association"
"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in <e1>CFI</e1>-rs7356506 in patients with VKH syndrome with complicated <e2>cataract</e2> compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).","Association"
"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in <e1>CFI</e1>-rs7356506 in patients with VKH syndrome with complicated <e2>cataract</e2> compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).","Association"
"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in <e1>CFI</e1>-rs7356506 in patients with VKH syndrome with complicated <e2>cataract</e2> compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).","Association"
"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in <e1>CFI</e1>-rs7356506 in patients with VKH syndrome with complicated <e2>cataract</e2> compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).","Association"
"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in <e1>CFI</e1>-rs7356506 in patients with VKH syndrome with complicated <e2>cataract</e2> compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).","Association"
"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in <e1>CFI</e1>-rs7356506 in patients with VKH syndrome with complicated <e2>cataract</e2> compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).","Association"
"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in <e1>CFI</e1>-rs7356506 in patients with VKH syndrome with complicated <e2>cataract</e2> compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).","Association"
"Furthermore, there were significant decreases in the frequencies of the G allele and GG homozygosity in <e1>CFI</e1>-rs7356506 in patients with VKH syndrome with complicated <e2>cataract</e2> compared to the controls (p<0.001, OR=0.357, 95% CI=0.197-0.648; p<0.001, OR=0.273, 95% CI=0.135-0.551, respectively).","Association"
"The present study was performed to investigate the existence of an association between <e1>CFI</e1> genetic polymorphisms and <e2>Vogt-Koyanagi-Harada (VKH) syndrome</e2>.","Association"
"The present study was performed to investigate the existence of an association between <e1>CFI</e1> genetic polymorphisms and <e2>Vogt-Koyanagi-Harada (VKH) syndrome</e2>.","Association"
"The present study was performed to investigate the existence of an association between <e1>CFI</e1> genetic polymorphisms and <e2>Vogt-Koyanagi-Harada (VKH) syndrome</e2>.","Association"
"The present study was performed to investigate the existence of an association between <e1>CFI</e1> genetic polymorphisms and <e2>Vogt-Koyanagi-Harada (VKH) syndrome</e2>.","Association"
"The present study was performed to investigate the existence of an association between <e1>CFI</e1> genetic polymorphisms and <e2>Vogt-Koyanagi-Harada (VKH) syndrome</e2>.","Association"
"The present study was performed to investigate the existence of an association between <e1>CFI</e1> genetic polymorphisms and <e2>Vogt-Koyanagi-Harada (VKH) syndrome</e2>.","Association"
"The present study was performed to investigate the existence of an association between <e1>CFI</e1> genetic polymorphisms and <e2>Vogt-Koyanagi-Harada (VKH) syndrome</e2>.","Association"
"The present study was performed to investigate the existence of an association between <e1>CFI</e1> genetic polymorphisms and <e2>Vogt-Koyanagi-Harada (VKH) syndrome</e2>.","Association"
"The present study was performed to investigate the existence of an association between <e1>CFI</e1> genetic polymorphisms and <e2>Vogt-Koyanagi-Harada (VKH) syndrome</e2>.","Association"
"Two novel mutations in the <e1>MEN1</e1> gene in subjects with <e2>multiple endocrine neoplasia-1</e2>.","Association"
"The Turkish patient and her affected relatives all had a heterozygous A to G transition at codon 557 (AAG-->GAG) of exon 10 of <e1>MEN1</e1> that results in a replacement of <e2>lysine by glutamic acid</e2>.","Association"
"The Turkish patient and her affected relatives all had a heterozygous <e2>A to G transition at codon 557 (AAG-->GAG)</e2> of exon 10 of <e1>MEN1</e1> that results in a replacement of lysine by glutamic acid.","Association"
"<e2>Multiple endocrine neoplasia type 1</e2> (<e1>MEN1</e1>) is characterized by parathyroid, enteropancreatic endocrine and pituitary adenomas as well as germline mutation of the MEN1 gene.","Association"
"<e2>Multiple endocrine neoplasia type 1</e2> (<e1>MEN1</e1>) is characterized by parathyroid, enteropancreatic endocrine and pituitary adenomas as well as germline mutation of the MEN1 gene.","Association"
"<e2>Multiple endocrine neoplasia type 1</e2> (<e1>MEN1</e1>) is characterized by parathyroid, enteropancreatic endocrine and pituitary adenomas as well as germline mutation of the MEN1 gene.","Association"
"<e2>Multiple endocrine neoplasia type 1</e2> (<e1>MEN1</e1>) is characterized by parathyroid, enteropancreatic endocrine and pituitary adenomas as well as germline mutation of the MEN1 gene.","Association"
"<e2>Multiple endocrine neoplasia type 1</e2> (<e1>MEN1</e1>) is characterized by parathyroid, enteropancreatic endocrine and pituitary adenomas as well as germline mutation of the MEN1 gene.","Association"
"<e2>Multiple endocrine neoplasia type 1</e2> (<e1>MEN1</e1>) is characterized by parathyroid, enteropancreatic endocrine and pituitary adenomas as well as germline mutation of the MEN1 gene.","Association"
"The HH genotype of the nonconservative amino acid substitution polymorphism <e1>N372H</e1> in the BRCA2 gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both breast and <e2>ovarian cancer</e2>.","Positive_Correlation"
"The HH genotype of the nonconservative amino acid substitution polymorphism <e1>N372H</e1> in the BRCA2 gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both breast and <e2>ovarian cancer</e2>.","Positive_Correlation"
"The HH genotype of the nonconservative amino acid substitution polymorphism <e1>N372H</e1> in the BRCA2 gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both breast and <e2>ovarian cancer</e2>.","Positive_Correlation"
"The HH genotype of the nonconservative amino acid substitution polymorphism <e1>N372H</e1> in the BRCA2 gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both breast and <e2>ovarian cancer</e2>.","Positive_Correlation"
"The HH genotype of the nonconservative amino acid substitution polymorphism <e1>N372H</e1> in the BRCA2 gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both breast and <e2>ovarian cancer</e2>.","Positive_Correlation"
"As these studies concerned sporadic cancer cases, we investigated whether N372H and another common variant located in the 5'-untranslated region (203G > A) of the BRCA2 gene modify breast or <e2>ovarian cancer</e2> risk in <e1>BRCA1</e1> mutation carriers.","Association"
"As these studies concerned sporadic cancer cases, we investigated whether N372H and another common variant located in the 5'-untranslated region (203G > A) of the BRCA2 gene modify breast or <e2>ovarian cancer</e2> risk in <e1>BRCA1</e1> mutation carriers.","Association"
"As these studies concerned sporadic cancer cases, we investigated whether N372H and another common variant located in the 5'-untranslated region (203G > A) of the BRCA2 gene modify breast or <e2>ovarian cancer</e2> risk in <e1>BRCA1</e1> mutation carriers.","Association"
"As these studies concerned sporadic cancer cases, we investigated whether N372H and another common variant located in the 5'-untranslated region (203G > A) of the BRCA2 gene modify breast or <e2>ovarian cancer</e2> risk in <e1>BRCA1</e1> mutation carriers.","Association"
"As these studies concerned sporadic cancer cases, we investigated whether N372H and another common variant located in the 5'-untranslated region (203G > A) of the BRCA2 gene modify breast or <e2>ovarian cancer</e2> risk in <e1>BRCA1</e1> mutation carriers.","Association"
"We found no evidence of a significant modification of <e2>breast cancer</e2> penetrance in <e1>BRCA1</e1> mutation carriers by either polymorphism.","Association"
"We found no evidence of a significant modification of <e2>breast cancer</e2> penetrance in <e1>BRCA1</e1> mutation carriers by either polymorphism.","Association"
"We found no evidence of a significant modification of <e2>breast cancer</e2> penetrance in <e1>BRCA1</e1> mutation carriers by either polymorphism.","Association"
"We found no evidence of a significant modification of <e2>breast cancer</e2> penetrance in <e1>BRCA1</e1> mutation carriers by either polymorphism.","Association"
"We found no evidence of a significant modification of <e2>breast cancer</e2> penetrance in <e1>BRCA1</e1> mutation carriers by either polymorphism.","Association"
"In respect of <e1>ovarian cancer</e1> risk, we also saw no effect with the N372H variant but we did observe a borderline association with the 5'-untranslated region <e2>203A</e2> allele (hazard ratio, 1.43; CI, 1.01-2.00).","Association"
"The HH genotype of the nonconservative amino acid substitution polymorphism N372H in the <e1>BRCA2</e1> gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both breast and <e2>ovarian cancer</e2>.","Association"
"The HH genotype of the nonconservative amino acid substitution polymorphism N372H in the <e1>BRCA2</e1> gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both breast and <e2>ovarian cancer</e2>.","Association"
"The HH genotype of the nonconservative amino acid substitution polymorphism N372H in the <e1>BRCA2</e1> gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both breast and <e2>ovarian cancer</e2>.","Association"
"<e1>Transgelin</e1> increases metastatic potential of <e2>colorectal cancer</e2> cells in vivo and alters expression of genes involved in cell motility.","Association"
"Although the role of <e1>transgelin</e1> in <e2>cancer</e2> is controversial, a number of studies have shown that elevated levels correlate with aggressive tumor behavior, advanced stage, and poor prognosis.","Association"
"Although the role of <e1>transgelin</e1> in <e2>cancer</e2> is controversial, a number of studies have shown that elevated levels correlate with aggressive tumor behavior, advanced stage, and poor prognosis.","Association"
"Although the role of <e1>transgelin</e1> in <e2>cancer</e2> is controversial, a number of studies have shown that elevated levels correlate with aggressive tumor behavior, advanced stage, and poor prognosis.","Association"
"Although the role of <e1>transgelin</e1> in <e2>cancer</e2> is controversial, a number of studies have shown that elevated levels correlate with aggressive tumor behavior, advanced stage, and poor prognosis.","Association"
"Although the role of <e1>transgelin</e1> in <e2>cancer</e2> is controversial, a number of studies have shown that elevated levels correlate with aggressive tumor behavior, advanced stage, and poor prognosis.","Association"
"Although the role of <e1>transgelin</e1> in <e2>cancer</e2> is controversial, a number of studies have shown that elevated levels correlate with aggressive tumor behavior, advanced stage, and poor prognosis.","Association"
"Although the role of <e1>transgelin</e1> in <e2>cancer</e2> is controversial, a number of studies have shown that elevated levels correlate with aggressive tumor behavior, advanced stage, and poor prognosis.","Association"
"Although the role of <e1>transgelin</e1> in <e2>cancer</e2> is controversial, a number of studies have shown that elevated levels correlate with aggressive tumor behavior, advanced stage, and poor prognosis.","Association"
"Although the role of <e1>transgelin</e1> in <e2>cancer</e2> is controversial, a number of studies have shown that elevated levels correlate with aggressive tumor behavior, advanced stage, and poor prognosis.","Association"
"BACKGROUND: <e1>Transgelin</e1> is an <e2>actin</e2>-binding protein that promotes motility in normal cells.","Association"
"Investigation of mRNA expression patterns showed that <e1>transgelin</e1> overexpression altered the levels of approximately 250 other transcripts, with over-representation of genes that affect function of <e2>actin</e2> or other cytoskeletal proteins.","Association"
"Investigation of mRNA expression patterns showed that <e1>transgelin</e1> overexpression altered the levels of approximately 250 other transcripts, with over-representation of genes that affect function of <e2>actin</e2> or other cytoskeletal proteins.","Association"
"Investigation of mRNA expression patterns showed that <e1>transgelin</e1> overexpression altered the levels of approximately 250 other transcripts, with over-representation of genes that affect function of <e2>actin</e2> or other cytoskeletal proteins.","Association"
"Investigation of mRNA expression patterns showed that <e1>transgelin</e1> overexpression altered the levels of approximately 250 other transcripts, with over-representation of genes that affect function of <e2>actin</e2> or other cytoskeletal proteins.","Association"
"Investigation of mRNA expression patterns showed that <e1>transgelin</e1> overexpression altered the levels of approximately 250 other transcripts, with over-representation of genes that affect function of <e2>actin</e2> or other cytoskeletal proteins.","Association"
"Investigation of mRNA expression patterns showed that <e1>transgelin</e1> overexpression altered the levels of approximately 250 other transcripts, with over-representation of genes that affect function of <e2>actin</e2> or other cytoskeletal proteins.","Association"
"Investigation of mRNA expression patterns showed that <e1>transgelin</e1> overexpression altered the levels of approximately 250 other transcripts, with over-representation of genes that affect function of <e2>actin</e2> or other cytoskeletal proteins.","Association"
"Investigation of mRNA expression patterns showed that <e1>transgelin</e1> overexpression altered the levels of approximately 250 other transcripts, with over-representation of genes that affect function of <e2>actin</e2> or other cytoskeletal proteins.","Association"
"Investigation of mRNA expression patterns showed that <e1>transgelin</e1> overexpression altered the levels of approximately 250 other transcripts, with over-representation of genes that affect function of <e2>actin</e2> or other cytoskeletal proteins.","Association"
"Here we sought to determine the role of <e1>transgelin</e1> more directly by determining whether experimental manipulation of transgelin levels in <e2>colorectal cancer</e2> (CRC) cells led to changes in metastatic potential in vivo.","Association"
"Here we sought to determine the role of <e1>transgelin</e1> more directly by determining whether experimental manipulation of transgelin levels in <e2>colorectal cancer</e2> (CRC) cells led to changes in metastatic potential in vivo.","Association"
"Here we sought to determine the role of <e1>transgelin</e1> more directly by determining whether experimental manipulation of transgelin levels in <e2>colorectal cancer</e2> (CRC) cells led to changes in metastatic potential in vivo.","Association"
"Here we sought to determine the role of <e1>transgelin</e1> more directly by determining whether experimental manipulation of transgelin levels in <e2>colorectal cancer</e2> (CRC) cells led to changes in metastatic potential in vivo.","Association"
"Here we sought to determine the role of <e1>transgelin</e1> more directly by determining whether experimental manipulation of transgelin levels in <e2>colorectal cancer</e2> (CRC) cells led to changes in metastatic potential in vivo.","Association"
"Here we sought to determine the role of <e1>transgelin</e1> more directly by determining whether experimental manipulation of transgelin levels in <e2>colorectal cancer</e2> (CRC) cells led to changes in metastatic potential in vivo.","Association"
"Here we sought to determine the role of <e1>transgelin</e1> more directly by determining whether experimental manipulation of transgelin levels in <e2>colorectal cancer</e2> (CRC) cells led to changes in metastatic potential in vivo.","Association"
"Here we sought to determine the role of <e1>transgelin</e1> more directly by determining whether experimental manipulation of transgelin levels in <e2>colorectal cancer</e2> (CRC) cells led to changes in metastatic potential in vivo.","Association"
"Here we sought to determine the role of <e1>transgelin</e1> more directly by determining whether experimental manipulation of transgelin levels in <e2>colorectal cancer</e2> (CRC) cells led to changes in metastatic potential in vivo.","Association"
"Association of sporadic chondrocalcinosis with a <e1>-4-basepair G-to-A</e1> transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular <e2>inorganic pyrophosphate</e2>.","Positive_Correlation"
"Association of <e1>sporadic chondrocalcinosis</e1> with a <e2>-4-basepair G-to-A</e2> transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate.","Positive_Correlation"
"Association of <e1>sporadic chondrocalcinosis</e1> with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular <e2>inorganic pyrophosphate</e2>.","Association"
"Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of <e1>ANKH</e1> that promotes enhanced expression of ANKH protein and excess generation of extracellular <e2>inorganic pyrophosphate</e2>.","Association"
"Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of <e1>ANKH</e1> that promotes enhanced expression of ANKH protein and excess generation of extracellular <e2>inorganic pyrophosphate</e2>.","Association"
"Association of <e2>sporadic chondrocalcinosis</e2> with a -4-basepair G-to-A transition in the 5'-untranslated region of <e1>ANKH</e1> that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate.","Association"
"Association of <e2>sporadic chondrocalcinosis</e2> with a -4-basepair G-to-A transition in the 5'-untranslated region of <e1>ANKH</e1> that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate.","Association"
"CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a <e1>-4-bp G-to-A</e1> ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular <e2>PPi</e2> in chondrocyte cells.","Positive_Correlation"
"CONCLUSION: A subset of sporadic <e1>chondrocalcinosis</e1> appears to be heritable via a <e2>-4-bp G-to-A</e2> ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells.","Positive_Correlation"
"CONCLUSION: A subset of sporadic <e1>chondrocalcinosis</e1> appears to be heritable via a <e2>-4-bp G-to-A</e2> ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells.","Positive_Correlation"
"CONCLUSION: A subset of sporadic <e1>chondrocalcinosis</e1> appears to be heritable via a <e2>-4-bp G-to-A</e2> ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells.","Positive_Correlation"
"CONCLUSION: A subset of <e1>sporadic chondrocalcinosis</e1> appears to be heritable via a <e2>-4-bp G-to-A</e2> ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells.","Positive_Correlation"
"CONCLUSION: A subset of sporadic <e1>chondrocalcinosis</e1> appears to be heritable via a <e2>-4-bp G-to-A</e2> ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells.","Positive_Correlation"
"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to <e1>autosomal-dominant familial chondrocalcinosis</e1>.","Association"
"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to autosomal-dominant familial <e1>chondrocalcinosis</e1>.","Association"
"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to autosomal-dominant familial <e1>chondrocalcinosis</e1>.","Association"
"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to autosomal-dominant familial <e1>chondrocalcinosis</e1>.","Association"
"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to autosomal-dominant <e1>familial chondrocalcinosis</e1>.","Association"
"CONCLUSION: A subset of <e1>sporadic chondrocalcinosis</e1> appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular <e2>PPi</e2> in chondrocyte cells.","Association"
"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to autosomal-dominant familial <e1>chondrocalcinosis</e1>.","Association"
"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic <e1>chondrocalcinosis</e1> (+14 bp C-to-T and C-terminal <e2>GAG deletion</e2>, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro.","Association"
"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic <e1>chondrocalcinosis</e1> (+14 bp C-to-T and C-terminal <e2>GAG deletion</e2>, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro.","Association"
"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic <e1>chondrocalcinosis</e1> (+14 bp C-to-T and C-terminal <e2>GAG deletion</e2>, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro.","Association"
"This -4-bp transition, as well as 2 mutations previously linked with <e1>familial and sporadic chondrocalcinosis</e1> (+14 bp C-to-T and C-terminal <e2>GAG deletion</e2>, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro.","Association"
"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal <e2>GAG deletion</e2>, respectively), but not the French <e1>familial chondrocalcinosis</e1> kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro.","Association"
"This -4-bp transition, as well as 2 mutations previously linked with familial and <e1>sporadic chondrocalcinosis</e1> (+14 bp C-to-T and C-terminal <e2>GAG deletion</e2>, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro.","Association"
"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic <e1>chondrocalcinosis</e1> (+14 bp C-to-T and C-terminal <e2>GAG deletion</e2>, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro.","Association"
"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic <e1>chondrocalcinosis</e1> (<e2>+14 bp C-to-T</e2> and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro.","Association"
"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic <e1>chondrocalcinosis</e1> (<e2>+14 bp C-to-T</e2> and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro.","Association"
"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic <e1>chondrocalcinosis</e1> (<e2>+14 bp C-to-T</e2> and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro.","Association"
"This -4-bp transition, as well as 2 mutations previously linked with <e1>familial and sporadic chondrocalcinosis</e1> (<e2>+14 bp C-to-T</e2> and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro.","Association"
"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (<e2>+14 bp C-to-T</e2> and C-terminal GAG deletion, respectively), but not the French <e1>familial chondrocalcinosis</e1> kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro.","Association"
"This -4-bp transition, as well as 2 mutations previously linked with familial and <e1>sporadic chondrocalcinosis</e1> (<e2>+14 bp C-to-T</e2> and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro.","Association"
"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic <e1>chondrocalcinosis</e1> (<e2>+14 bp C-to-T</e2> and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro.","Association"
"RESULTS: Sporadic <e1>chondrocalcinosis</e1> was associated with a <e2>G-to-A</e2> transition in the ANKH 5'-untranslated region (5'-UTR) at 4 bp upstream of the start codon (in homozygotes of the minor allele, genotype relative risk 6.0, P = 0.0006; overall genotype association P = 0.02).","Association"
"RESULTS: Sporadic <e1>chondrocalcinosis</e1> was associated with a <e2>G-to-A</e2> transition in the ANKH 5'-untranslated region (5'-UTR) at 4 bp upstream of the start codon (in homozygotes of the minor allele, genotype relative risk 6.0, P = 0.0006; overall genotype association P = 0.02).","Association"
"RESULTS: Sporadic <e1>chondrocalcinosis</e1> was associated with a <e2>G-to-A</e2> transition in the ANKH 5'-untranslated region (5'-UTR) at 4 bp upstream of the start codon (in homozygotes of the minor allele, genotype relative risk 6.0, P = 0.0006; overall genotype association P = 0.02).","Association"
"RESULTS: <e1>Sporadic chondrocalcinosis</e1> was associated with a <e2>G-to-A</e2> transition in the ANKH 5'-untranslated region (5'-UTR) at 4 bp upstream of the start codon (in homozygotes of the minor allele, genotype relative risk 6.0, P = 0.0006; overall genotype association P = 0.02).","Association"
"CONCLUSION: A subset of <e1>sporadic chondrocalcinosis</e1> appears to be heritable via a -4-bp <e2>G-to-A</e2> ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells.","Association"
"RESULTS: Sporadic <e1>chondrocalcinosis</e1> was associated with a <e2>G-to-A</e2> transition in the ANKH 5'-untranslated region (5'-UTR) at 4 bp upstream of the start codon (in homozygotes of the minor allele, genotype relative risk 6.0, P = 0.0006; overall genotype association P = 0.02).","Association"
"Transfection of complementary DNA for both the wild-type <e1>ANKH</e1> and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte <e2>hypertrophy</e2> marker, type X collagen.","Association"
"Transfection of complementary DNA for both the wild-type <e1>ANKH</e1> and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte <e2>hypertrophy</e2> marker, type X collagen.","Association"
"Transfection of complementary DNA for both the wild-type <e1>ANKH</e1> and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte <e2>hypertrophy</e2> marker, type X collagen.","Association"
"Transfection of complementary DNA for both the wild-type <e1>ANKH</e1> and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte <e2>hypertrophy</e2> marker, type X collagen.","Association"
"Transfection of complementary DNA for both the wild-type <e1>ANKH</e1> and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte <e2>hypertrophy</e2> marker, type X collagen.","Association"
"Transfection of complementary DNA for both the wild-type <e1>ANKH</e1> and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte <e2>hypertrophy</e2> marker, type X collagen.","Association"
"Transfection of complementary DNA for both the wild-type <e1>ANKH</e1> and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte <e2>hypertrophy</e2> marker, type X collagen.","Association"
"Transfection of complementary DNA for both the wild-type <e1>ANKH</e1> and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte <e2>hypertrophy</e2> marker, type X collagen.","Association"
"Transfection of complementary DNA for both the wild-type <e1>ANKH</e1> and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte <e2>hypertrophy</e2> marker, type X collagen.","Association"
"Transfection of complementary DNA for both the wild-type <e1>ANKH</e1> and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte <e2>hypertrophy</e2> marker, type X collagen.","Association"
"Transfection of complementary DNA for both the wild-type <e1>ANKH</e1> and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte <e2>hypertrophy</e2> marker, type X collagen.","Association"
"Transfection of complementary DNA for both the wild-type <e1>ANKH</e1> and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte <e2>hypertrophy</e2> marker, type X collagen.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates <e2>inorganic pyrophosphate</e2> (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to <e2>autosomal-dominant familial chondrocalcinosis</e2>.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to <e2>autosomal-dominant familial chondrocalcinosis</e2>.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to <e2>autosomal-dominant familial chondrocalcinosis</e2>.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to <e2>autosomal-dominant familial chondrocalcinosis</e2>.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to <e2>autosomal-dominant familial chondrocalcinosis</e2>.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to <e2>autosomal-dominant familial chondrocalcinosis</e2>.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to <e2>autosomal-dominant familial chondrocalcinosis</e2>.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to <e2>autosomal-dominant familial chondrocalcinosis</e2>.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to <e2>autosomal-dominant familial chondrocalcinosis</e2>.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to <e2>autosomal-dominant familial chondrocalcinosis</e2>.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to <e2>autosomal-dominant familial chondrocalcinosis</e2>.","Association"
"OBJECTIVE: Certain mutations in <e1>ANKH</e1>, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to <e2>autosomal-dominant familial chondrocalcinosis</e2>.","Association"
"Contribution of <e2>STAT4</e2> gene single-nucleotide polymorphism to <e1>systemic lupus erythematosus</e1> in the Polish population.","Association"
"Moreover, we found a contribution of <e2>STAT4</e2> C/C and C/G genotypes to the presence of the anti-snRNP Ab OR = 3.237 (1.667-6.288, p = 0.0003), (p (corr) = 0.0051) and the presence of the anti-<e1>Scl-70</e1> Ab OR = 2.665 (1.380-5.147, p = 0.0028), (p (corr) = 0.0476).","Association"
"Moreover, we found a contribution of <e1>STAT4</e1> C/C and C/G genotypes to the presence of the anti-<e2>snRNP</e2> Ab OR = 3.237 (1.667-6.288, p = 0.0003), (p (corr) = 0.0051) and the presence of the anti-Scl-70 Ab OR = 2.665 (1.380-5.147, p = 0.0028), (p (corr) = 0.0476).","Association"
"Moreover, we found a contribution of <e1>STAT4</e1> C/C and C/G genotypes to the presence of the anti-<e2>snRNP</e2> Ab OR = 3.237 (1.667-6.288, p = 0.0003), (p (corr) = 0.0051) and the presence of the anti-Scl-70 Ab OR = 2.665 (1.380-5.147, p = 0.0028), (p (corr) = 0.0476).","Association"
"Moreover, we found a contribution of <e1>STAT4</e1> C/C and C/G genotypes to the presence of the anti-<e2>snRNP</e2> Ab OR = 3.237 (1.667-6.288, p = 0.0003), (p (corr) = 0.0051) and the presence of the anti-Scl-70 Ab OR = 2.665 (1.380-5.147, p = 0.0028), (p (corr) = 0.0476).","Association"
"Moreover, we found a contribution of <e1>STAT4</e1> C/C and C/G genotypes to the presence of the anti-<e2>snRNP</e2> Ab OR = 3.237 (1.667-6.288, p = 0.0003), (p (corr) = 0.0051) and the presence of the anti-Scl-70 Ab OR = 2.665 (1.380-5.147, p = 0.0028), (p (corr) = 0.0476).","Association"
"Moreover, we found a contribution of <e1>STAT4</e1> C/C and C/G genotypes to the presence of the anti-<e2>snRNP</e2> Ab OR = 3.237 (1.667-6.288, p = 0.0003), (p (corr) = 0.0051) and the presence of the anti-Scl-70 Ab OR = 2.665 (1.380-5.147, p = 0.0028), (p (corr) = 0.0476).","Association"
"Moreover, we found a contribution of <e1>STAT4</e1> C/C and C/G genotypes to the presence of the anti-<e2>snRNP</e2> Ab OR = 3.237 (1.667-6.288, p = 0.0003), (p (corr) = 0.0051) and the presence of the anti-Scl-70 Ab OR = 2.665 (1.380-5.147, p = 0.0028), (p (corr) = 0.0476).","Association"
"Moreover, we found a contribution of <e1>STAT4</e1> C/C and C/G genotypes to the presence of the anti-<e2>snRNP</e2> Ab OR = 3.237 (1.667-6.288, p = 0.0003), (p (corr) = 0.0051) and the presence of the anti-Scl-70 Ab OR = 2.665 (1.380-5.147, p = 0.0028), (p (corr) = 0.0476).","Association"
"We also observed an increased frequency of <e1>STAT4</e1> C/C and C/G genotypes in SLE patients with <e2>renal symptoms</e2> OR = 2.259 (1.365-3.738, p = 0.0014), (p (corr) = 0.0238) and in SLE patients with neurologic manifestations OR = 2.867 (1.467-5.604, p = 0.0016), (p (corr) = 0.0272).","Association"
"We also observed an increased frequency of <e1>STAT4</e1> C/C and C/G genotypes in SLE patients with <e2>renal symptoms</e2> OR = 2.259 (1.365-3.738, p = 0.0014), (p (corr) = 0.0238) and in SLE patients with neurologic manifestations OR = 2.867 (1.467-5.604, p = 0.0016), (p (corr) = 0.0272).","Association"
"We also observed an increased frequency of <e1>STAT4</e1> C/C and C/G genotypes in SLE patients with <e2>renal symptoms</e2> OR = 2.259 (1.365-3.738, p = 0.0014), (p (corr) = 0.0238) and in SLE patients with neurologic manifestations OR = 2.867 (1.467-5.604, p = 0.0016), (p (corr) = 0.0272).","Association"
"We also observed an increased frequency of <e1>STAT4</e1> C/C and C/G genotypes in SLE patients with <e2>renal symptoms</e2> OR = 2.259 (1.365-3.738, p = 0.0014), (p (corr) = 0.0238) and in SLE patients with neurologic manifestations OR = 2.867 (1.467-5.604, p = 0.0016), (p (corr) = 0.0272).","Association"
"We also observed an increased frequency of <e1>STAT4</e1> C/C and C/G genotypes in SLE patients with <e2>renal symptoms</e2> OR = 2.259 (1.365-3.738, p = 0.0014), (p (corr) = 0.0238) and in SLE patients with neurologic manifestations OR = 2.867 (1.467-5.604, p = 0.0016), (p (corr) = 0.0272).","Association"
"We also observed an increased frequency of <e1>STAT4</e1> C/C and C/G genotypes in SLE patients with <e2>renal symptoms</e2> OR = 2.259 (1.365-3.738, p = 0.0014), (p (corr) = 0.0238) and in SLE patients with neurologic manifestations OR = 2.867 (1.467-5.604, p = 0.0016), (p (corr) = 0.0272).","Association"
"We also observed an increased frequency of <e1>STAT4</e1> C/C and C/G genotypes in SLE patients with <e2>renal symptoms</e2> OR = 2.259 (1.365-3.738, p = 0.0014), (p (corr) = 0.0238) and in SLE patients with neurologic manifestations OR = 2.867 (1.467-5.604, p = 0.0016), (p (corr) = 0.0272).","Association"
"The <e2>STAT4</e2> has been found to be a susceptible gene in the development of <e1>systemic lupus erythematosus</e1> (SLE) in various populations.","Association"
"The <e2>STAT4</e2> has been found to be a susceptible gene in the development of systemic lupus erythematosus (<e1>SLE</e1>) in various populations.","Association"
"The <e2>STAT4</e2> has been found to be a susceptible gene in the development of systemic lupus erythematosus (<e1>SLE</e1>) in various populations.","Association"
"The <e2>STAT4</e2> has been found to be a susceptible gene in the development of systemic lupus erythematosus (<e1>SLE</e1>) in various populations.","Association"
"The <e2>STAT4</e2> has been found to be a susceptible gene in the development of systemic lupus erythematosus (<e1>SLE</e1>) in various populations.","Association"
"The <e2>STAT4</e2> has been found to be a susceptible gene in the development of systemic lupus erythematosus (<e1>SLE</e1>) in various populations.","Association"
"The <e2>STAT4</e2> has been found to be a susceptible gene in the development of systemic lupus erythematosus (<e1>SLE</e1>) in various populations.","Association"
"The <e2>STAT4</e2> has been found to be a susceptible gene in the development of systemic lupus erythematosus (<e1>SLE</e1>) in various populations.","Association"
"The <e2>STAT4</e2> has been found to be a susceptible gene in the development of systemic lupus erythematosus (<e1>SLE</e1>) in various populations.","Association"
"There are evident population differences in the context of clinical manifestations of <e1>SLE</e1>, therefore we investigated the prevalence of the STAT4 <e2>G > C</e2> (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population.","Positive_Correlation"
"There are evident population differences in the context of clinical manifestations of <e1>SLE</e1>, therefore we investigated the prevalence of the STAT4 <e2>G > C</e2> (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population.","Positive_Correlation"
"There are evident population differences in the context of clinical manifestations of <e1>SLE</e1>, therefore we investigated the prevalence of the STAT4 <e2>G > C</e2> (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population.","Positive_Correlation"
"There are evident population differences in the context of clinical manifestations of <e1>SLE</e1>, therefore we investigated the prevalence of the STAT4 <e2>G > C</e2> (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population.","Positive_Correlation"
"There are evident population differences in the context of clinical manifestations of <e1>SLE</e1>, therefore we investigated the prevalence of the STAT4 <e2>G > C</e2> (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population.","Positive_Correlation"
"There are evident population differences in the context of clinical manifestations of <e1>SLE</e1>, therefore we investigated the prevalence of the STAT4 <e2>G > C</e2> (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population.","Positive_Correlation"
"There are evident population differences in the context of clinical manifestations of <e1>SLE</e1>, therefore we investigated the prevalence of the STAT4 <e2>G > C</e2> (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population.","Positive_Correlation"
"There are evident population differences in the context of clinical manifestations of <e1>SLE</e1>, therefore we investigated the prevalence of the STAT4 <e2>G > C</e2> (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population.","Positive_Correlation"
"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and <e1>MIF</e1> were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and <e1>MIF</e1> were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, <e1>MIG</e1>/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/<e1>CXCL9</e1> and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, <e1>IL-22</e1>, MIG/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, <e1>IP-10</e1>/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/<e1>CXCL10</e1>, IL-22, MIG/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, <e1>CXCL1</e1>, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, <e1>CCL3</e1>, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, <e1>CCL5</e1>, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, <e1>CCL2</e1>, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), <e1>IFN-g</e1>, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), <e1>IFN-g</e1>, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, <e1>IL-12</e1>(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(<e1>p40</e1>), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, IL-4, IL-5, <e1>IL-6</e1>, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, IL-4, <e1>IL-5</e1>, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, IL-4, <e1>IL-5</e1>, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway IL-1b, <e1>IL-4</e1>, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway <e1>IL-1b</e1>, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"In vivo induction of airway <e1>IL-1b</e1>, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on <e2>Mavs</e2> expression in mice.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of IL-1b, IL-5, <e2>CXCL12</e2>, MIF, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of IL-1b, IL-5, <e2>CXCL12</e2>, MIF, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of IL-1b, IL-5, <e2>CXCL12</e2>, MIF, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, <e2>MIF</e2>, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, <e2>MIF</e2>, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, <e2>MIF</e2>, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, MIF, LIF, CXCL12 and <e2>IFN-g</e2>. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, MIF, LIF, CXCL12 and <e2>IFN-g</e2>. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, MIF, LIF, CXCL12 and <e2>IFN-g</e2>. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of IL-1b, <e2>IL-5</e2>, CXCL12, MIF, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of IL-1b, <e2>IL-5</e2>, CXCL12, MIF, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of IL-1b, <e2>IL-5</e2>, CXCL12, MIF, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of <e2>IL-1b</e2>, IL-5, CXCL12, MIF, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of <e2>IL-1b</e2>, IL-5, CXCL12, MIF, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of <e2>IL-1b</e2>, IL-5, CXCL12, MIF, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, MIF, <e2>LIF</e2>, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, MIF, <e2>LIF</e2>, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of <e1>Trif</e1> expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, MIF, <e2>LIF</e2>, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of Trif expression in mice altered the RSV induction of IL-1b, IL-5, <e2>CXCL12</e2>, MIF, LIF, CXCL12 and IFN-g. Silencing of <e1>retinoic acid-inducible gene-1</e1> (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of Trif expression in mice altered the RSV induction of IL-1b, IL-5, <e2>CXCL12</e2>, MIF, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (<e1>RIG-I</e1>) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of Trif expression in mice altered the RSV induction of IL-1b, IL-5, <e2>CXCL12</e2>, MIF, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (<e1>RIG-I</e1>) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of Trif expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, <e2>MIF</e2>, LIF, CXCL12 and IFN-g. Silencing of <e1>retinoic acid-inducible gene-1</e1> (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of Trif expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, <e2>MIF</e2>, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (<e1>RIG-I</e1>) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of Trif expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, <e2>MIF</e2>, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (<e1>RIG-I</e1>) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"CONCLUSIONS: RSV <e2>infection</e2> in the epithelium induces a network of immune factors to counter infection, primarily in a <e1>RIG-I</e1> dependent manner.","Association"
"CONCLUSIONS: RSV <e2>infection</e2> in the epithelium induces a network of immune factors to counter infection, primarily in a <e1>RIG-I</e1> dependent manner.","Association"
"Loss of Trif expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, MIF, <e2>LIF</e2>, CXCL12 and IFN-g. Silencing of <e1>retinoic acid-inducible gene-1</e1> (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of Trif expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, MIF, <e2>LIF</e2>, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (<e1>RIG-I</e1>) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Loss of Trif expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, MIF, <e2>LIF</e2>, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (<e1>RIG-I</e1>) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.","Association"
"Expression of <e1>LIF</e1> protects the lung from <e2>lung injury</e2> and enhanced pathology during RSV infection.","Negative_Correlation"
"Expression of <e1>LIF</e1> protects the lung from <e2>lung injury</e2> and enhanced pathology during RSV infection.","Negative_Correlation"
"Neutralizing anti-<e1>leukemia inhibitory factor</e1> (LIF) IgG or control IgG was administered to a group of wild-type animals prior to RSV <e2>infection</e2>.","Association"
"Neutralizing anti-leukemia inhibitory factor (<e1>LIF</e1>) IgG or control IgG was administered to a group of wild-type animals prior to RSV <e2>infection</e2>.","Association"
"Neutralizing anti-leukemia inhibitory factor (<e1>LIF</e1>) IgG or control IgG was administered to a group of wild-type animals prior to RSV <e2>infection</e2>.","Association"
"Neutralizing anti-<e1>leukemia inhibitory factor</e1> (LIF) IgG or control IgG was administered to a group of wild-type animals prior to <e2>RSV infection</e2>.","Positive_Correlation"
"Neutralizing anti-leukemia inhibitory factor (<e1>LIF</e1>) IgG or control IgG was administered to a group of wild-type animals prior to <e2>RSV infection</e2>.","Positive_Correlation"
"Neutralizing anti-leukemia inhibitory factor (<e1>LIF</e1>) IgG or control IgG was administered to a group of wild-type animals prior to <e2>RSV infection</e2>.","Positive_Correlation"
"RESULTS AND DISCUSSION: <e1>RSV-infected</e1> A549 and SAE cells release a network of cytokines, including newly identified RSV-inducible cytokines LIF, migration inhibitory factor (MIF), stem cell factor (SCF), CCL27, CXCL12 and <e2>stem cell growth factor beta</e2> (SCGF-b).","Positive_Correlation"
"RESULTS AND DISCUSSION: <e1>RSV-infected</e1> A549 and SAE cells release a network of cytokines, including newly identified RSV-inducible cytokines LIF, migration inhibitory factor (MIF), stem cell factor (SCF), CCL27, <e2>CXCL12</e2> and stem cell growth factor beta (SCGF-b).","Positive_Correlation"
"RESULTS AND DISCUSSION: <e1>RSV-infected</e1> A549 and SAE cells release a network of cytokines, including newly identified RSV-inducible cytokines LIF, migration inhibitory factor (MIF), stem cell factor (SCF), <e2>CCL27</e2>, CXCL12 and stem cell growth factor beta (SCGF-b).","Positive_Correlation"
"RESULTS AND DISCUSSION: <e1>RSV-infected</e1> A549 and SAE cells release a network of cytokines, including newly identified RSV-inducible cytokines LIF, migration inhibitory factor (MIF), <e2>stem cell factor</e2> (SCF), CCL27, CXCL12 and stem cell growth factor beta (SCGF-b).","Positive_Correlation"
"RESULTS AND DISCUSSION: <e1>RSV-infected</e1> A549 and SAE cells release a network of cytokines, including newly identified RSV-inducible cytokines LIF, <e2>migration inhibitory factor</e2> (MIF), stem cell factor (SCF), CCL27, CXCL12 and stem cell growth factor beta (SCGF-b).","Positive_Correlation"
"CONCLUSIONS: <e1>RSV infection</e1> in the epithelium induces a network of immune factors to counter infection, primarily in a <e2>RIG-I</e2> dependent manner.","Association"
"CONCLUSIONS: <e1>RSV infection</e1> in the epithelium induces a network of immune factors to counter infection, primarily in a <e2>RIG-I</e2> dependent manner.","Association"
"CONCLUSIONS: <e1>RSV infection</e1> in the epithelium induces a network of immune factors to counter infection, primarily in a <e2>RIG-I</e2> dependent manner.","Association"
"CONCLUSIONS: <e1>RSV infection</e1> in the epithelium induces a network of immune factors to counter infection, primarily in a <e2>RIG-I</e2> dependent manner.","Association"
"CONCLUSIONS: <e1>RSV infection</e1> in the epithelium induces a network of immune factors to counter infection, primarily in a <e2>RIG-I</e2> dependent manner.","Association"
"Expression of <e1>LIF</e1> protects the lung from <e2>lung injury</e2> and enhanced pathology during RSV infection.","Negative_Correlation"
"Expression of <e1>LIF</e1> protects the lung from <e2>lung injury</e2> and enhanced pathology during RSV infection.","Negative_Correlation"
"Expression of <e1>LIF</e1> protects the lung from <e2>lung injury</e2> and enhanced pathology during RSV infection.","Negative_Correlation"
"Neutralizing anti-leukemia inhibitory factor (<e1>LIF</e1>) IgG or control IgG was administered to a group of wild-type animals prior to <e2>RSV infection</e2>.","Association"
"Neutralizing anti-leukemia inhibitory factor (<e1>LIF</e1>) IgG or control IgG was administered to a group of wild-type animals prior to <e2>RSV infection</e2>.","Association"
"Neutralizing anti-leukemia inhibitory factor (<e1>LIF</e1>) IgG or control IgG was administered to a group of wild-type animals prior to <e2>RSV infection</e2>.","Association"
"Urinary bladder cancer in <e2>Wegener's granulomatosis</e2>: risks and relation to <e1>cyclophosphamide</e1>.","Association"
"<e2>Urinary bladder cancer</e2> in Wegener's granulomatosis: risks and relation to <e1>cyclophosphamide</e1>.","Positive_Correlation"
"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to <e1>cyclophosphamide</e1>, in patients with <e2>Wegener's granulomatosis</e2>.","Association"
"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to <e1>cyclophosphamide</e1>, in patients with <e2>Wegener's granulomatosis</e2>.","Association"
"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to <e1>cyclophosphamide</e1>, in patients with <e2>Wegener's granulomatosis</e2>.","Association"
"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to <e1>cyclophosphamide</e1>, in patients with <e2>Wegener's granulomatosis</e2>.","Association"
"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to <e1>cyclophosphamide</e1>, in patients with <e2>Wegener's granulomatosis</e2>.","Association"
"OBJECTIVE: To assess and characterise the risk of <e2>bladder cancer</e2>, and its relation to <e1>cyclophosphamide</e1>, in patients with Wegener's granulomatosis.","Positive_Correlation"
"OBJECTIVE: To assess and characterise the risk of <e2>bladder cancer</e2>, and its relation to <e1>cyclophosphamide</e1>, in patients with Wegener's granulomatosis.","Positive_Correlation"
"OBJECTIVE: To assess and characterise the risk of <e2>bladder cancer</e2>, and its relation to <e1>cyclophosphamide</e1>, in patients with Wegener's granulomatosis.","Positive_Correlation"
"OBJECTIVE: To assess and characterise the risk of <e2>bladder cancer</e2>, and its relation to <e1>cyclophosphamide</e1>, in patients with Wegener's granulomatosis.","Positive_Correlation"
"OBJECTIVE: To assess and characterise the risk of <e2>bladder cancer</e2>, and its relation to <e1>cyclophosphamide</e1>, in patients with Wegener's granulomatosis.","Positive_Correlation"
"Co-inheritance of a PKD1 mutation and homozygous <e2>PKD2</e2> variant: a potential modifier in <e1>autosomal dominant polycystic kidney disease</e1>.","Association"
"Co-inheritance of a <e2>PKD1</e2> mutation and homozygous PKD2 variant: a potential modifier in <e1>autosomal dominant polycystic kidney disease</e1>.","Association"
"BACKGROUND: <e1>Autosomal dominant polycystic kidney disease</e1> (ADPKD), which is caused by mutations in polycystins 1 (PC1) and 2 (<e2>PC2</e2>), is one of the most commonly inherited renal diseases, affecting ~1 : 1000 Caucasians.","Association"
"BACKGROUND: Autosomal dominant polycystic kidney disease (<e1>ADPKD</e1>), which is caused by mutations in polycystins 1 (PC1) and 2 (<e2>PC2</e2>), is one of the most commonly inherited renal diseases, affecting ~1 : 1000 Caucasians.","Association"
"BACKGROUND: Autosomal dominant polycystic kidney disease (<e1>ADPKD</e1>), which is caused by mutations in polycystins 1 (PC1) and 2 (<e2>PC2</e2>), is one of the most commonly inherited renal diseases, affecting ~1 : 1000 Caucasians.","Association"
"BACKGROUND: Autosomal dominant polycystic kidney disease (<e1>ADPKD</e1>), which is caused by mutations in polycystins 1 (PC1) and 2 (<e2>PC2</e2>), is one of the most commonly inherited renal diseases, affecting ~1 : 1000 Caucasians.","Association"
"BACKGROUND: <e1>Autosomal dominant polycystic kidney disease</e1> (ADPKD), which is caused by mutations in <e2>polycystins 1</e2> (PC1) and 2 (PC2), is one of the most commonly inherited renal diseases, affecting ~1 : 1000 Caucasians.","Association"
"BACKGROUND: Autosomal dominant polycystic kidney disease (<e1>ADPKD</e1>), which is caused by mutations in <e2>polycystins 1</e2> (PC1) and 2 (PC2), is one of the most commonly inherited renal diseases, affecting ~1 : 1000 Caucasians.","Association"
"BACKGROUND: Autosomal dominant polycystic kidney disease (<e1>ADPKD</e1>), which is caused by mutations in <e2>polycystins 1</e2> (PC1) and 2 (PC2), is one of the most commonly inherited renal diseases, affecting ~1 : 1000 Caucasians.","Association"
"BACKGROUND: Autosomal dominant polycystic kidney disease (<e1>ADPKD</e1>), which is caused by mutations in <e2>polycystins 1</e2> (PC1) and 2 (PC2), is one of the most commonly inherited renal diseases, affecting ~1 : 1000 Caucasians.","Association"
"Two novel mutations of the <e2>TSH-beta</e2> subunit gene underlying <e1>congenital central hypothyroidism</e1> undetectable in neonatal TSH screening.","Association"
"CONTEXT: Patients with <e2>TSH-beta</e2> subunit defects and <e1>congenital hypothyroidism</e1> are missed by TSH-based neonatal screening.","Association"
"OBJECTIVE: Our objective was to report the molecular consequences of a novel splice-junction mutation and a novel missense mutation in the <e2>TSH-beta</e2> subunit gene found in two patients with <e1>congenital central hypothyroidism</e1> and conventional treatment-resistant anemia.","Association"
"OBJECTIVE: Our objective was to report the molecular consequences of a novel splice-junction mutation and a novel missense mutation in the <e1>TSH-beta</e1> subunit gene found in two patients with congenital central hypothyroidism and conventional treatment-resistant <e2>anemia</e2>.","Association"
"OBJECTIVE: Our objective was to report the molecular consequences of a novel splice-junction mutation and a novel missense mutation in the <e1>TSH</e1>-beta subunit gene found in two patients with congenital central hypothyroidism and conventional treatment-resistant <e2>anemia</e2>.","Association"
"OBJECTIVE: Our objective was to report the molecular consequences of a novel splice-junction mutation and a novel missense mutation in the <e1>TSH-beta</e1> subunit gene found in two patients with congenital central hypothyroidism and conventional treatment-resistant <e2>anemia</e2>.","Association"
"Mutations in the <e1>NDP</e1> gene: contribution to Norrie disease, familial exudative vitreoretinopathy and <e2>retinopathy of prematurity</e2>.","Association"
"Mutations in the <e1>NDP</e1> gene: contribution to Norrie disease, <e2>familial exudative vitreoretinopathy</e2> and retinopathy of prematurity.","Association"
"Mutations in the <e1>NDP</e1> gene: contribution to <e2>Norrie disease</e2>, familial exudative vitreoretinopathy and retinopathy of prematurity.","Association"
"Furthermore, a previously described <e1>14-bp deletion</e1> located in the 5' unstranslated region of the NDP gene was detected in three cases of regressed <e2>ROP</e2>.","Association"
"Furthermore, a previously described <e1>14-bp deletion</e1> located in the 5' unstranslated region of the NDP gene was detected in three cases of regressed <e2>ROP</e2>.","Association"
"RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and <e1>His43Arg</e1> in monozygotic twin <e2>Norrie disease</e2> patients.","Association"
"RESULTS: Evidence for two novel mutations in the NDP gene was presented: <e1>Leu103Val</e1> in one <e2>FEVR</e2> patient and His43Arg in monozygotic twin Norrie disease patients.","Association"
"BACKGROUND: To examine the contribution of mutations within the Norrie disease (<e1>NDP</e1>) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and <e2>retinopathy of prematurity</e2> (ROP).","Association"
"BACKGROUND: To examine the contribution of mutations within the Norrie disease (<e1>NDP</e1>) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and <e2>retinopathy of prematurity</e2> (ROP).","Association"
"BACKGROUND: To examine the contribution of mutations within the Norrie disease (<e1>NDP</e1>) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and <e2>retinopathy of prematurity</e2> (ROP).","Association"
"BACKGROUND: To examine the contribution of mutations within the Norrie disease (<e1>NDP</e1>) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and <e2>retinopathy of prematurity</e2> (ROP).","Association"
"BACKGROUND: To examine the contribution of mutations within the Norrie disease (<e1>NDP</e1>) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and <e2>retinopathy of prematurity</e2> (ROP).","Association"
"BACKGROUND: To examine the contribution of mutations within the Norrie disease (<e1>NDP</e1>) gene to the clinically similar retinal diseases Norrie disease, <e2>X-linked familial exudative vitreoretinopathy</e2> (FEVR), Coat's disease and retinopathy of prematurity (ROP).","Association"
"BACKGROUND: To examine the contribution of mutations within the Norrie disease (<e1>NDP</e1>) gene to the clinically similar retinal diseases Norrie disease, <e2>X-linked familial exudative vitreoretinopathy</e2> (FEVR), Coat's disease and retinopathy of prematurity (ROP).","Association"
"BACKGROUND: To examine the contribution of mutations within the Norrie disease (<e1>NDP</e1>) gene to the clinically similar retinal diseases Norrie disease, <e2>X-linked familial exudative vitreoretinopathy</e2> (FEVR), Coat's disease and retinopathy of prematurity (ROP).","Association"
"BACKGROUND: To examine the contribution of mutations within the Norrie disease (<e1>NDP</e1>) gene to the clinically similar retinal diseases Norrie disease, <e2>X-linked familial exudative vitreoretinopathy</e2> (FEVR), Coat's disease and retinopathy of prematurity (ROP).","Association"
"BACKGROUND: To examine the contribution of mutations within the Norrie disease (<e1>NDP</e1>) gene to the clinically similar retinal diseases Norrie disease, <e2>X-linked familial exudative vitreoretinopathy</e2> (FEVR), Coat's disease and retinopathy of prematurity (ROP).","Association"
"BACKGROUND: To examine the contribution of mutations within the <e2>Norrie disease</e2> (<e1>NDP</e1>) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP).","Association"
"BACKGROUND: To examine the contribution of mutations within the <e2>Norrie disease</e2> (<e1>NDP</e1>) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP).","Association"
"BACKGROUND: To examine the contribution of mutations within the <e2>Norrie disease</e2> (<e1>NDP</e1>) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP).","Association"
"BACKGROUND: To examine the contribution of mutations within the <e2>Norrie disease</e2> (<e1>NDP</e1>) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP).","Association"
"BACKGROUND: To examine the contribution of mutations within the <e2>Norrie disease</e2> (<e1>NDP</e1>) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP).","Association"
"<e2>Growth hormone</e2> dose in growth hormone-deficient adults is not associated with <e1>IGF-1</e1> gene polymorphisms.","Association"
"<e1>Growth hormone</e1> dose in <e2>growth hormone-deficient</e2> adults is not associated with IGF-1 gene polymorphisms.","Negative_Correlation"
"Variance in <e1>IGF-1</e1> concentrations due to genetic variations may affect different response to <e2>growth hormone</e2> (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients.","Association"
"Variance in <e1>IGF-1</e1> concentrations due to genetic variations may affect different response to <e2>growth hormone</e2> (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients.","Association"
"Variance in <e1>IGF-1</e1> concentrations due to genetic variations may affect different response to <e2>growth hormone</e2> (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients.","Association"
"Variance in <e1>IGF-1</e1> concentrations due to genetic variations may affect different response to <e2>growth hormone</e2> (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients.","Association"
"Variance in <e1>IGF-1</e1> concentrations due to genetic variations may affect different response to <e2>growth hormone</e2> (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients.","Association"
"Variance in <e1>IGF-1</e1> concentrations due to genetic variations may affect different response to <e2>growth hormone</e2> (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients.","Association"
"Variance in <e1>IGF-1</e1> concentrations due to genetic variations may affect different response to <e2>growth hormone</e2> (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients.","Association"
"Variance in <e1>IGF-1</e1> concentrations due to genetic variations may affect different response to <e2>growth hormone</e2> (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients.","Association"
"Variance in <e1>IGF-1</e1> concentrations due to genetic variations may affect different response to <e2>growth hormone</e2> (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients.","Association"
"Variance in <e1>IGF-1</e1> concentrations due to genetic variations may affect different response to <e2>growth hormone</e2> (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients.","Association"
"Variance in <e1>IGF-1</e1> concentrations due to genetic variations may affect different response to <e2>growth hormone</e2> (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients.","Association"
"Variance in <e1>IGF-1</e1> concentrations due to genetic variations may affect different response to <e2>growth hormone</e2> (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients.","Association"
"Variance in <e1>IGF-1</e1> concentrations due to genetic variations may affect different response to <e2>growth hormone</e2> (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients.","Association"
"Variance in <e1>IGF-1</e1> concentrations due to genetic variations may affect different response to <e2>growth hormone</e2> (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients.","Association"
"Variance in <e1>IGF</e1>-1 concentrations due to genetic variations may affect different response to <e2>growth hormone</e2> (GH) treatment, resulting in different individually required GH-doses in GH-deficient patients.","Association"
"Variance in IGF-1 concentrations due to genetic variations may affect different response to <e1>growth hormone</e1> (GH) treatment, resulting in different individually required GH-doses in <e2>GH-deficient</e2> patients.","Negative_Correlation"
"Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (<e1>GH</e1>) treatment, resulting in different individually required GH-doses in <e2>GH-deficient</e2> patients.","Negative_Correlation"
"Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (<e1>GH</e1>) treatment, resulting in different individually required GH-doses in <e2>GH-deficient</e2> patients.","Negative_Correlation"
"Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (<e1>GH</e1>) treatment, resulting in different individually required GH-doses in <e2>GH-deficient</e2> patients.","Negative_Correlation"
"Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (<e1>GH</e1>) treatment, resulting in different individually required GH-doses in <e2>GH-deficient</e2> patients.","Negative_Correlation"
"Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (<e1>GH</e1>) treatment, resulting in different individually required GH-doses in <e2>GH-deficient</e2> patients.","Negative_Correlation"
"Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (<e1>GH</e1>) treatment, resulting in different individually required GH-doses in <e2>GH-deficient</e2> patients.","Negative_Correlation"
"Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (<e1>GH</e1>) treatment, resulting in different individually required GH-doses in <e2>GH-deficient</e2> patients.","Negative_Correlation"
"Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (<e1>GH</e1>) treatment, resulting in different individually required GH-doses in <e2>GH-deficient</e2> patients.","Negative_Correlation"
"Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (<e1>GH</e1>) treatment, resulting in different individually required GH-doses in <e2>GH-deficient</e2> patients.","Negative_Correlation"
"Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (<e1>GH</e1>) treatment, resulting in different individually required GH-doses in <e2>GH-deficient</e2> patients.","Negative_Correlation"
"Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (<e1>GH</e1>) treatment, resulting in different individually required GH-doses in <e2>GH-deficient</e2> patients.","Negative_Correlation"
"Variance in IGF-1 concentrations due to genetic variations may affect different response to growth hormone (<e1>GH</e1>) treatment, resulting in different individually required GH-doses in <e2>GH-deficient</e2> patients.","Negative_Correlation"
"Mutation analysis of <e2>FOXF2</e2> in patients with <e1>disorders of sex development</e1> (DSD) in combination with cleft palate.","Association"
"Mutation analysis of <e2>FOXF2</e2> in patients with disorders of sex development (<e1>DSD</e1>) in combination with cleft palate.","Association"
"Mutation analysis of <e2>FOXF2</e2> in patients with disorders of sex development (DSD) in combination with <e1>cleft palate</e1>.","Association"
"We hypothesized that humans with <e1>disorders of sex development</e1> (DSD) in combination with cleft palate could have mutations in the <e2>FOXF2</e2> gene.","Association"
"We hypothesized that humans with disorders of sex development (<e1>DSD</e1>) in combination with cleft palate could have mutations in the <e2>FOXF2</e2> gene.","Association"
"We hypothesized that humans with disorders of sex development (<e1>DSD</e1>) in combination with cleft palate could have mutations in the <e2>FOXF2</e2> gene.","Association"
"We hypothesized that humans with disorders of sex development (<e1>DSD</e1>) in combination with cleft palate could have mutations in the <e2>FOXF2</e2> gene.","Association"
"In contrast to <e1>disorders of sexual differentiation</e1> caused by lack of <e2>androgen</e2> production or inhibited androgen action, defects affecting development of the bipotent genital anlagen have rarely been investigated in humans.","Negative_Correlation"
"We hypothesized that humans with disorders of sex development (DSD) in combination with <e1>cleft palate</e1> could have mutations in the <e2>FOXF2</e2> gene.","Association"
"We hypothesized that humans with disorders of sex development (DSD) in combination with <e1>cleft palate</e1> could have mutations in the <e2>FOXF2</e2> gene.","Association"
"We hypothesized that humans with disorders of sex development (DSD) in combination with <e1>cleft palate</e1> could have mutations in the <e2>FOXF2</e2> gene.","Association"
"Moreover, <e1>Foxf2</e1> knockout mice present with cleft palate in combination with <e2>hypoplasia of the genital tubercle</e2>.","Association"
"Moreover, <e1>Foxf2</e1> knockout mice present with <e2>cleft palate</e2> in combination with hypoplasia of the genital tubercle.","Association"
"<e1>Ehlers-Danlos syndrome, vascular type</e1> (vEDS) (MIM #130050) is an autosomal dominant disorder caused by <e2>type III procollagen</e2> gene (COL3A1) mutations.","Association"
"Ehlers-Danlos syndrome, vascular type (<e1>vEDS</e1>) (MIM #130050) is an autosomal dominant disorder caused by <e2>type III procollagen</e2> gene (COL3A1) mutations.","Association"
"Ehlers-Danlos syndrome, vascular type (vEDS) (<e1>MIM #130050</e1>) is an autosomal dominant disorder caused by <e2>type III procollagen</e2> gene (COL3A1) mutations.","Association"
"Ehlers-Danlos syndrome, vascular type (<e1>vEDS</e1>) (MIM #130050) is an autosomal dominant disorder caused by <e2>type III procollagen</e2> gene (COL3A1) mutations.","Association"
"Critical role of <e1>neuronal pentraxin 1</e1> in mitochondria-mediated <e2>hypoxic-ischemic neuronal injury</e2>.","Association"
"Previously, we have reported induction of <e1>neuronal pentraxin 1</e1> (NP1), a novel neuronal protein of long-pentraxin family, following <e2>HI neuronal injury</e2>.","Association"
"Previously, we have reported induction of neuronal pentraxin 1 (<e1>NP1</e1>), a novel neuronal protein of long-pentraxin family, following <e2>HI neuronal injury</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and <e1>caspase-3</e1> activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and <e1>caspase-3</e1> activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and <e1>caspase-3</e1> activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and <e1>caspase-3</e1> activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased <e1>Cyt C</e1> release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased <e1>Cyt C</e1> release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased <e1>Cyt C</e1> release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased <e1>Cyt C</e1> release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of Bad and <e1>Bax</e1> proteins from cytoplasm following OGD (4 h) and simultaneously increased release of Cyt C from mitochondria followed by activation of <e2>caspase-3</e2>.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of Bad and <e1>Bax</e1> proteins from cytoplasm following OGD (4 h) and simultaneously increased release of Cyt C from mitochondria followed by activation of <e2>caspase-3</e2>.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of Bad and <e1>Bax</e1> proteins from cytoplasm following OGD (4 h) and simultaneously increased release of Cyt C from mitochondria followed by activation of <e2>caspase-3</e2>.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of Bad and <e1>Bax</e1> proteins from cytoplasm following OGD (4 h) and simultaneously increased release of Cyt C from mitochondria followed by activation of <e2>caspase-3</e2>.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of Bad and <e1>Bax</e1> proteins from cytoplasm following OGD (4 h) and simultaneously increased release of Cyt C from mitochondria followed by activation of <e2>caspase-3</e2>.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of Bad and <e1>Bax</e1> proteins from cytoplasm following OGD (4 h) and simultaneously increased release of Cyt C from mitochondria followed by activation of <e2>caspase-3</e2>.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of Bad and <e1>Bax</e1> proteins from cytoplasm following OGD (4 h) and simultaneously increased release of <e2>Cyt C</e2> from mitochondria followed by activation of caspase-3.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of Bad and <e1>Bax</e1> proteins from cytoplasm following OGD (4 h) and simultaneously increased release of <e2>Cyt C</e2> from mitochondria followed by activation of caspase-3.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of Bad and <e1>Bax</e1> proteins from cytoplasm following OGD (4 h) and simultaneously increased release of <e2>Cyt C</e2> from mitochondria followed by activation of caspase-3.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of Bad and <e1>Bax</e1> proteins from cytoplasm following OGD (4 h) and simultaneously increased release of <e2>Cyt C</e2> from mitochondria followed by activation of caspase-3.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of Bad and <e1>Bax</e1> proteins from cytoplasm following OGD (4 h) and simultaneously increased release of <e2>Cyt C</e2> from mitochondria followed by activation of caspase-3.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of Bad and <e1>Bax</e1> proteins from cytoplasm following OGD (4 h) and simultaneously increased release of <e2>Cyt C</e2> from mitochondria followed by activation of caspase-3.","Association"
"In contrast, in NP1-KO neurons there was no translocation of Bad and <e1>Bax</e1> from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of Bad and <e1>Bax</e1> from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of Bad and <e1>Bax</e1> from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of Bad and <e1>Bax</e1> from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of Bad and <e1>Bax</e1> from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of Bad and <e1>Bax</e1> from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of <e1>Bad</e1> and Bax proteins from cytoplasm following OGD (4 h) and simultaneously increased release of Cyt C from mitochondria followed by activation of <e2>caspase-3</e2>.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of <e1>Bad</e1> and Bax proteins from cytoplasm following OGD (4 h) and simultaneously increased release of Cyt C from mitochondria followed by activation of <e2>caspase-3</e2>.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of <e1>Bad</e1> and Bax proteins from cytoplasm following OGD (4 h) and simultaneously increased release of Cyt C from mitochondria followed by activation of <e2>caspase-3</e2>.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of <e1>Bad</e1> and Bax proteins from cytoplasm following OGD (4 h) and simultaneously increased release of Cyt C from mitochondria followed by activation of <e2>caspase-3</e2>.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of <e1>Bad</e1> and Bax proteins from cytoplasm following OGD (4 h) and simultaneously increased release of Cyt C from mitochondria followed by activation of <e2>caspase-3</e2>.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of <e1>Bad</e1> and Bax proteins from cytoplasm following OGD (4 h) and simultaneously increased release of Cyt C from mitochondria followed by activation of <e2>caspase-3</e2>.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of <e1>Bad</e1> and Bax proteins from cytoplasm following OGD (4 h) and simultaneously increased release of <e2>Cyt C</e2> from mitochondria followed by activation of caspase-3.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of <e1>Bad</e1> and Bax proteins from cytoplasm following OGD (4 h) and simultaneously increased release of <e2>Cyt C</e2> from mitochondria followed by activation of caspase-3.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of <e1>Bad</e1> and Bax proteins from cytoplasm following OGD (4 h) and simultaneously increased release of <e2>Cyt C</e2> from mitochondria followed by activation of caspase-3.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of <e1>Bad</e1> and Bax proteins from cytoplasm following OGD (4 h) and simultaneously increased release of <e2>Cyt C</e2> from mitochondria followed by activation of caspase-3.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of <e1>Bad</e1> and Bax proteins from cytoplasm following OGD (4 h) and simultaneously increased release of <e2>Cyt C</e2> from mitochondria followed by activation of caspase-3.","Association"
"Immunofluorescence staining and subcellular fractionation analyses revealed increased mitochondrial translocation of <e1>Bad</e1> and Bax proteins from cytoplasm following OGD (4 h) and simultaneously increased release of <e2>Cyt C</e2> from mitochondria followed by activation of caspase-3.","Association"
"In contrast, in NP1-KO neurons there was no translocation of <e1>Bad</e1> and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of <e1>Bad</e1> and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of <e1>Bad</e1> and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of <e1>Bad</e1> and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of <e1>Bad</e1> and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in NP1-KO neurons there was no translocation of <e1>Bad</e1> and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"We also found increased <e1>PTEN</e1> activity concurrent with OGD time-dependent (4-8 h) dephosphorylation of Akt (Ser473) and <e2>GSK-3b</e2> (Ser9).","Association"
"We also found increased <e1>PTEN</e1> activity concurrent with OGD time-dependent (4-8 h) dephosphorylation of <e2>Akt</e2> (Ser473) and GSK-3b (Ser9).","Association"
"In contrast, in <e1>NP1</e1>-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in <e1>NP1</e1>-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in <e1>NP1</e1>-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in <e1>NP1</e1>-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in <e1>NP1</e1>-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in <e1>NP1</e1>-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in <e1>NP1</e1>-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in <e1>NP1</e1>-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in <e1>NP1</e1>-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"In contrast, in <e1>NP1</e1>-KO neurons there was no translocation of Bad and Bax from cytosol to the mitochondria, and no evidence of D (m) loss, increased Cyt C release and caspase-3 activation following OGD; which resulted in significantly reduced <e2>neuronal death</e2>.","Association"
"<e1>NP1</e1> protein was immunoprecipitated with Bad and <e2>Bax</e2> proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with Bad and <e2>Bax</e2> proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with Bad and <e2>Bax</e2> proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with Bad and <e2>Bax</e2> proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with Bad and <e2>Bax</e2> proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with Bad and <e2>Bax</e2> proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with Bad and <e2>Bax</e2> proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with Bad and <e2>Bax</e2> proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with Bad and <e2>Bax</e2> proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with Bad and <e2>Bax</e2> proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with <e2>Bad</e2> and Bax proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with <e2>Bad</e2> and Bax proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with <e2>Bad</e2> and Bax proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with <e2>Bad</e2> and Bax proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with <e2>Bad</e2> and Bax proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with <e2>Bad</e2> and Bax proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with <e2>Bad</e2> and Bax proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with <e2>Bad</e2> and Bax proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with <e2>Bad</e2> and Bax proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"<e1>NP1</e1> protein was immunoprecipitated with <e2>Bad</e2> and Bax proteins; OGD caused increased interactions of NP1 with Bad and Bax, thereby, facilitating their mitochondrial translocation and dissipation of mitochondrial membrane potential (D (m)).","Association"
"Previously, we have reported induction of neuronal pentraxin 1 (<e1>NP1</e1>), a novel neuronal protein of long-pentraxin family, following <e2>HI neuronal injury</e2>.","Association"
"Previously, we have reported induction of neuronal pentraxin 1 (<e1>NP1</e1>), a novel neuronal protein of long-pentraxin family, following <e2>HI neuronal injury</e2>.","Association"
"Previously, we have reported induction of neuronal pentraxin 1 (<e1>NP1</e1>), a novel neuronal protein of long-pentraxin family, following <e2>HI neuronal injury</e2>.","Association"
"Previously, we have reported induction of neuronal pentraxin 1 (<e1>NP1</e1>), a novel neuronal protein of long-pentraxin family, following <e2>HI neuronal injury</e2>.","Association"
"Previously, we have reported induction of neuronal pentraxin 1 (<e1>NP1</e1>), a novel neuronal protein of long-pentraxin family, following <e2>HI neuronal injury</e2>.","Association"
"Previously, we have reported induction of neuronal pentraxin 1 (<e1>NP1</e1>), a novel neuronal protein of long-pentraxin family, following <e2>HI neuronal injury</e2>.","Association"
"Previously, we have reported induction of neuronal pentraxin 1 (<e1>NP1</e1>), a novel neuronal protein of long-pentraxin family, following <e2>HI neuronal injury</e2>.","Association"
"Previously, we have reported induction of neuronal pentraxin 1 (<e1>NP1</e1>), a novel neuronal protein of long-pentraxin family, following <e2>HI neuronal injury</e2>.","Association"
"Previously, we have reported induction of neuronal pentraxin 1 (<e1>NP1</e1>), a novel neuronal protein of long-pentraxin family, following <e2>HI neuronal injury</e2>.","Association"
"Previously, we have reported induction of neuronal pentraxin 1 (<e1>NP1</e1>), a novel neuronal protein of long-pentraxin family, following <e2>HI neuronal injury</e2>.","Association"
"Neuroserpin (<e2>NSP</e2>) reportedly exerts neuroprotective effects in <e1>cerebral ischemic</e1> animal models and patients; however, the mechanism of protection is poorly understood.","Negative_Correlation"
"To verify the cause-and-effect relationship between neuroprotection and the NF-kappaB pathway, a NF-kappaB pathway inhibitor <e1>sc3060</e1> was employed to observe the effects of <e2>NSP</e2>-induced neuroprotection.","Positive_Correlation"
"To verify the cause-and-effect relationship between neuroprotection and the NF-kappaB pathway, a NF-kappaB pathway inhibitor <e1>sc3060</e1> was employed to observe the effects of <e2>NSP</e2>-induced neuroprotection.","Positive_Correlation"
"To verify the cause-and-effect relationship between neuroprotection and the <e1>NF-kappaB</e1> pathway, a NF-kappaB pathway inhibitor <e2>sc3060</e2> was employed to observe the effects of NSP-induced neuroprotection.","Negative_Correlation"
"To verify the cause-and-effect relationship between neuroprotection and the <e1>NF-kappaB</e1> pathway, a NF-kappaB pathway inhibitor <e2>sc3060</e2> was employed to observe the effects of NSP-induced neuroprotection.","Negative_Correlation"
"To verify the cause-and-effect relationship between neuroprotection and the <e1>NF-kappaB</e1> pathway, a NF-kappaB pathway inhibitor <e2>sc3060</e2> was employed to observe the effects of NSP-induced neuroprotection.","Negative_Correlation"
"To verify the cause-and-effect relationship between neuroprotection and the <e1>NF-kappaB</e1> pathway, a NF-kappaB pathway inhibitor <e2>sc3060</e2> was employed to observe the effects of NSP-induced neuroprotection.","Negative_Correlation"
"To verify the cause-and-effect relationship between neuroprotection and the <e1>NF-kappaB</e1> pathway, a NF-kappaB pathway inhibitor <e2>sc3060</e2> was employed to observe the effects of NSP-induced neuroprotection.","Negative_Correlation"
"To explore the potential mechanisms of <e2>NSP</e2>, the release of <e1>nitric oxide</e1> (NO) and TNF-alpha related to NSP administration were measured by enzyme-linked immunosorbent assay.","Negative_Correlation"
"To explore the potential mechanisms of <e2>NSP</e2>, the release of nitric oxide (<e1>NO</e1>) and TNF-alpha related to NSP administration were measured by enzyme-linked immunosorbent assay.","Negative_Correlation"
"To explore the potential mechanisms of <e2>NSP</e2>, the release of nitric oxide (<e1>NO</e1>) and TNF-alpha related to NSP administration were measured by enzyme-linked immunosorbent assay.","Negative_Correlation"
"To explore the potential mechanisms of <e2>NSP</e2>, the release of nitric oxide (<e1>NO</e1>) and TNF-alpha related to NSP administration were measured by enzyme-linked immunosorbent assay.","Negative_Correlation"
"Neuroserpin (<e1>NSP</e1>) reportedly exerts neuroprotective effects in cerebral <e2>ischemic</e2> animal models and patients; however, the mechanism of protection is poorly understood.","Negative_Correlation"
"Neuroserpin (<e1>NSP</e1>) reportedly exerts neuroprotective effects in cerebral <e2>ischemic</e2> animal models and patients; however, the mechanism of protection is poorly understood.","Negative_Correlation"
"Neuroserpin (<e1>NSP</e1>) reportedly exerts neuroprotective effects in cerebral <e2>ischemic</e2> animal models and patients; however, the mechanism of protection is poorly understood.","Negative_Correlation"
"Neuroserpin (<e1>NSP</e1>) reportedly exerts neuroprotective effects in cerebral <e2>ischemic</e2> animal models and patients; however, the mechanism of protection is poorly understood.","Negative_Correlation"
"Neuroserpin (<e1>NSP</e1>) reportedly exerts neuroprotective effects in cerebral <e2>ischemic</e2> animal models and patients; however, the mechanism of protection is poorly understood.","Negative_Correlation"
"Neuroserpin (<e1>NSP</e1>) reportedly exerts neuroprotective effects in cerebral <e2>ischemic</e2> animal models and patients; however, the mechanism of protection is poorly understood.","Negative_Correlation"
"Neuroserpin (<e1>NSP</e1>) reportedly exerts neuroprotective effects in cerebral <e2>ischemic</e2> animal models and patients; however, the mechanism of protection is poorly understood.","Negative_Correlation"
"Neuroserpin (<e1>NSP</e1>) reportedly exerts neuroprotective effects in cerebral <e2>ischemic</e2> animal models and patients; however, the mechanism of protection is poorly understood.","Negative_Correlation"
"Neuroserpin (<e1>NSP</e1>) reportedly exerts neuroprotective effects in cerebral <e2>ischemic</e2> animal models and patients; however, the mechanism of protection is poorly understood.","Negative_Correlation"
"Neuroserpin (<e1>NSP</e1>) reportedly exerts neuroprotective effects in cerebral <e2>ischemic</e2> animal models and patients; however, the mechanism of protection is poorly understood.","Negative_Correlation"
"Neuroserpin (<e1>NSP</e1>) reportedly exerts neuroprotective effects in cerebral <e2>ischemic</e2> animal models and patients; however, the mechanism of protection is poorly understood.","Negative_Correlation"
"To confirm the neuroprotective effects of <e1>NSP</e1>, we measured the cell survival rate, relative <e2>lactate dehydrogenase</e2> (LDH) release; we also performed morphological methods, namely Hoechst 33342 staining and Annexin V assay.","Negative_Correlation"
"To confirm the neuroprotective effects of <e1>NSP</e1>, we measured the cell survival rate, relative <e2>lactate dehydrogenase</e2> (LDH) release; we also performed morphological methods, namely Hoechst 33342 staining and Annexin V assay.","Negative_Correlation"
"To confirm the neuroprotective effects of <e1>NSP</e1>, we measured the cell survival rate, relative <e2>lactate dehydrogenase</e2> (LDH) release; we also performed morphological methods, namely Hoechst 33342 staining and Annexin V assay.","Negative_Correlation"
"To confirm the neuroprotective effects of <e1>NSP</e1>, we measured the cell survival rate, relative <e2>lactate dehydrogenase</e2> (LDH) release; we also performed morphological methods, namely Hoechst 33342 staining and Annexin V assay.","Negative_Correlation"
"To confirm the neuroprotective effects of <e1>NSP</e1>, we measured the cell survival rate, relative <e2>lactate dehydrogenase</e2> (LDH) release; we also performed morphological methods, namely Hoechst 33342 staining and Annexin V assay.","Negative_Correlation"
"To confirm the neuroprotective effects of <e1>NSP</e1>, we measured the cell survival rate, relative <e2>lactate dehydrogenase</e2> (LDH) release; we also performed morphological methods, namely Hoechst 33342 staining and Annexin V assay.","Negative_Correlation"
"To confirm the neuroprotective effects of <e1>NSP</e1>, we measured the cell survival rate, relative <e2>lactate dehydrogenase</e2> (LDH) release; we also performed morphological methods, namely Hoechst 33342 staining and Annexin V assay.","Negative_Correlation"
"To confirm the neuroprotective effects of <e1>NSP</e1>, we measured the cell survival rate, relative <e2>lactate dehydrogenase</e2> (LDH) release; we also performed morphological methods, namely Hoechst 33342 staining and Annexin V assay.","Negative_Correlation"
"To confirm the neuroprotective effects of <e1>NSP</e1>, we measured the cell survival rate, relative <e2>lactate dehydrogenase</e2> (LDH) release; we also performed morphological methods, namely Hoechst 33342 staining and Annexin V assay.","Negative_Correlation"
"To confirm the neuroprotective effects of <e1>NSP</e1>, we measured the cell survival rate, relative <e2>lactate dehydrogenase</e2> (LDH) release; we also performed morphological methods, namely Hoechst 33342 staining and Annexin V assay.","Negative_Correlation"
"To confirm the neuroprotective effects of <e1>NSP</e1>, we measured the cell survival rate, relative <e2>lactate dehydrogenase</e2> (LDH) release; we also performed morphological methods, namely Hoechst 33342 staining and Annexin V assay.","Negative_Correlation"
"To explore the potential mechanisms of <e2>NSP</e2>, the release of nitric oxide (NO) and <e1>TNF-alpha</e1> related to NSP administration were measured by enzyme-linked immunosorbent assay.","Negative_Correlation"
"To explore the potential mechanisms of <e2>NSP</e2>, the release of nitric oxide (NO) and <e1>TNF-alpha</e1> related to NSP administration were measured by enzyme-linked immunosorbent assay.","Negative_Correlation"
"To explore the potential mechanisms of <e2>NSP</e2>, the release of nitric oxide (NO) and <e1>TNF-alpha</e1> related to NSP administration were measured by enzyme-linked immunosorbent assay.","Negative_Correlation"
"<e1>Interleukin 6</e1> (IL-6) and Tumor Necrosis Factor alpha (TNF-alpha) Single Nucleotide Polymorphisms (SNPs), Inflammation and Metabolism in <e2>Gestational Diabetes Mellitus</e2> in Inner Mongolia.","Association"
"Interleukin 6 (<e1>IL-6</e1>) and Tumor Necrosis Factor alpha (TNF-alpha) Single Nucleotide Polymorphisms (SNPs), Inflammation and Metabolism in <e2>Gestational Diabetes Mellitus</e2> in Inner Mongolia.","Association"
"<e2>Interleukin 6</e2> (IL-6) and Tumor Necrosis Factor alpha (TNF-alpha) Single Nucleotide Polymorphisms (SNPs), <e1>Inflammation</e1> and Metabolism in Gestational Diabetes Mellitus in Inner Mongolia.","Association"
"Interleukin 6 (IL-6) and <e2>Tumor Necrosis Factor alpha</e2> (TNF-alpha) Single Nucleotide Polymorphisms (SNPs), <e1>Inflammation</e1> and Metabolism in Gestational Diabetes Mellitus in Inner Mongolia.","Association"
"Interleukin 6 (IL-6) and <e1>Tumor Necrosis Factor alpha</e1> (TNF-alpha) Single Nucleotide Polymorphisms (SNPs), Inflammation and Metabolism in <e2>Gestational Diabetes Mellitus</e2> in Inner Mongolia.","Association"
"Interleukin 6 (IL-6) and Tumor Necrosis Factor alpha (<e1>TNF-alpha</e1>) Single Nucleotide Polymorphisms (SNPs), Inflammation and Metabolism in <e2>Gestational Diabetes Mellitus</e2> in Inner Mongolia.","Association"
"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (<e1>NF-kappaB</e1>, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with <e2>GDM</e2> and women with healthy pregnancies.","Association"
"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/<e1>IL-10</e1> ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with <e2>GDM</e2> and women with healthy pregnancies.","Association"
"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/<e1>IL-10</e1> ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with <e2>GDM</e2> and women with healthy pregnancies.","Association"
"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/<e1>IL-10</e1> ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with <e2>GDM</e2> and women with healthy pregnancies.","Association"
"Inflammatory biomarkers in serum (hs-CRP, IL-6, <e1>IL-8</e1>, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with <e2>GDM</e2> and women with healthy pregnancies.","Association"
"Inflammatory biomarkers in serum (hs-CRP, IL-6, <e1>IL-8</e1>, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with <e2>GDM</e2> and women with healthy pregnancies.","Association"
"Inflammatory biomarkers in serum (hs-CRP, IL-6, <e1>IL-8</e1>, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with <e2>GDM</e2> and women with healthy pregnancies.","Association"
"However, few studies have focused on the association of <e1>IL-65</e1>-72C/G and TNF-alpha -857C/T single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of <e1>IL-65</e1>-72C/G and TNF-alpha -857C/T single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of <e1>IL-65</e1>-72C/G and TNF-alpha -857C/T single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of <e1>IL-6</e1>5-72C/G and TNF-alpha -857C/T single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of <e1>IL-6</e1>5-72C/G and TNF-alpha -857C/T single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of <e1>IL-6</e1>5-72C/G and TNF-alpha -857C/T single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of <e1>IL-6</e1>5-72C/G and TNF-alpha -857C/T single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of <e1>IL-6</e1>5-72C/G and TNF-alpha -857C/T single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of <e1>IL-6</e1>5-72C/G and TNF-alpha -857C/T single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Association"
"Inflammatory biomarkers in serum (hs-<e1>CRP</e1>, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with <e2>GDM</e2> and women with healthy pregnancies.","Association"
"Inflammatory biomarkers in serum (hs-<e1>CRP</e1>, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with <e2>GDM</e2> and women with healthy pregnancies.","Association"
"<e1>Inflammatory</e1> biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, <e2>IL-1b</e2>, TNF-alpha) were significantly different (p   <0.05) between women with GDM and women with healthy pregnancies.","Association"
"<e1>Inflammatory</e1> biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (<e2>NF-kappaB</e2>, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with GDM and women with healthy pregnancies.","Association"
"CONCLUSIONS TNF-alpha -857C/T SNP, hs-CRP, IL-6, IL-8, and IL-6/<e2>IL-10</e2> were associated with GDM in women from Inner Mongolia, as was serious <e1>inflammation</e1> and disordered lipid and glucose metabolisms.","Association"
"<e1>Inflammatory</e1> biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/<e2>IL-10</e2> ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with GDM and women with healthy pregnancies.","Association"
"CONCLUSIONS TNF-alpha -857C/T SNP, hs-CRP, IL-6, IL-8, and IL-6/<e2>IL-10</e2> were associated with GDM in women from Inner Mongolia, as was serious <e1>inflammation</e1> and disordered lipid and glucose metabolisms.","Association"
"CONCLUSIONS TNF-alpha -857C/T SNP, hs-CRP, IL-6, <e2>IL-8</e2>, and IL-6/IL-10 were associated with GDM in women from Inner Mongolia, as was serious <e1>inflammation</e1> and disordered lipid and glucose metabolisms.","Association"
"<e1>Inflammatory</e1> biomarkers in serum (hs-CRP, IL-6, <e2>IL-8</e2>, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with GDM and women with healthy pregnancies.","Association"
"CONCLUSIONS TNF-alpha -857C/T SNP, hs-CRP, IL-6, <e2>IL-8</e2>, and IL-6/IL-10 were associated with GDM in women from Inner Mongolia, as was serious <e1>inflammation</e1> and disordered lipid and glucose metabolisms.","Association"
"However, few studies have focused on the association of <e2>IL-65</e2>-72C/G and TNF-alpha -857C/T single nucleotide polymorphisms (SNPs), <e1>inflammatory</e1> biomarkers, and metabolic indexes in women with GDM, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of <e2>IL-65</e2>-72C/G and TNF-alpha -857C/T single nucleotide polymorphisms (SNPs), <e1>inflammatory</e1> biomarkers, and metabolic indexes in women with GDM, especially in the Inner Mongolia population.","Association"
"The aim of this study was to investigate the associations of <e2>IL-65</e2>-72C/G and TNF-alpha -857C/T SNPs, and <e1>inflammation</e1> and metabolic biomarkers in women with GDM pregnancies.","Association"
"However, few studies have focused on the association of <e2>IL-65</e2>-72C/G and TNF-alpha -857C/T single nucleotide polymorphisms (SNPs), <e1>inflammatory</e1> biomarkers, and metabolic indexes in women with GDM, especially in the Inner Mongolia population.","Association"
"<e1>Inflammatory</e1> biomarkers in serum (hs-CRP, <e2>IL-6</e2>, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with GDM and women with healthy pregnancies.","Association"
"The aim of this study was to investigate the associations of <e2>IL-65</e2>-72C/G and TNF-alpha -857C/T SNPs, and <e1>inflammation</e1> and metabolic biomarkers in women with GDM pregnancies.","Association"
"CONCLUSIONS TNF-alpha -857C/T SNP, hs-<e2>CRP</e2>, IL-6, IL-8, and IL-6/IL-10 were associated with GDM in women from Inner Mongolia, as was serious <e1>inflammation</e1> and disordered lipid and glucose metabolisms.","Association"
"<e1>Inflammatory</e1> biomarkers in serum (hs-<e2>CRP</e2>, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, TNF-alpha) were significantly different (p   <0.05) between women with GDM and women with healthy pregnancies.","Association"
"CONCLUSIONS TNF-alpha -857C/T SNP, hs-<e2>CRP</e2>, IL-6, IL-8, and IL-6/IL-10 were associated with GDM in women from Inner Mongolia, as was serious <e1>inflammation</e1> and disordered lipid and glucose metabolisms.","Association"
"However, few studies have focused on the association of IL-65-72C/G and <e2>TNF-alpha</e2> -857C/T single nucleotide polymorphisms (SNPs), <e1>inflammatory</e1> biomarkers, and metabolic indexes in women with GDM, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of IL-65-72C/G and <e2>TNF-alpha</e2> -857C/T single nucleotide polymorphisms (SNPs), <e1>inflammatory</e1> biomarkers, and metabolic indexes in women with GDM, especially in the Inner Mongolia population.","Association"
"The aim of this study was to investigate the associations of IL-65-72C/G and <e2>TNF-alpha</e2> -857C/T SNPs, and <e1>inflammation</e1> and metabolic biomarkers in women with GDM pregnancies.","Association"
"However, few studies have focused on the association of IL-65-72C/G and <e2>TNF-alpha</e2> -857C/T single nucleotide polymorphisms (SNPs), <e1>inflammatory</e1> biomarkers, and metabolic indexes in women with GDM, especially in the Inner Mongolia population.","Association"
"<e1>Inflammatory</e1> biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, IL-1b, <e2>TNF-alpha</e2>) were significantly different (p   <0.05) between women with GDM and women with healthy pregnancies.","Association"
"The aim of this study was to investigate the associations of IL-65-72C/G and <e2>TNF-alpha</e2> -857C/T SNPs, and <e1>inflammation</e1> and metabolic biomarkers in women with GDM pregnancies.","Association"
"However, few studies have focused on the association of IL-65-72C/G and TNF-alpha <e1>-857C/T</e1> single nucleotide polymorphisms (SNPs), <e2>inflammatory</e2> biomarkers, and metabolic indexes in women with GDM, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of IL-65-72C/G and TNF-alpha <e1>-857C/T</e1> single nucleotide polymorphisms (SNPs), <e2>inflammatory</e2> biomarkers, and metabolic indexes in women with GDM, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of IL-65-72C/G and TNF-alpha <e1>-857C/T</e1> single nucleotide polymorphisms (SNPs), <e2>inflammatory</e2> biomarkers, and metabolic indexes in women with GDM, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of IL-65-72C/G and TNF-alpha <e1>-857C/T</e1> single nucleotide polymorphisms (SNPs), <e2>inflammatory</e2> biomarkers, and metabolic indexes in women with GDM, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of IL-65-72C/G and TNF-alpha <e1>-857C/T</e1> single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Positive_Correlation"
"However, few studies have focused on the association of IL-65-72C/G and TNF-alpha <e1>-857C/T</e1> single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Positive_Correlation"
"However, few studies have focused on the association of IL-65-72C/G and TNF-alpha <e1>-857C/T</e1> single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Positive_Correlation"
"RESULTS Distribution frequency of TNF-alpha <e1>-857CT</e1> (OR=3.316, 95% CI=1.092-8.304, p=0.025) in women with <e2>GDM</e2> pregnancies were obviously higher than that in women with healthy pregnancies.","Positive_Correlation"
"However, few studies have focused on the association of IL-65-72C/G and TNF-alpha <e1>-857C/T</e1> single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Positive_Correlation"
"However, few studies have focused on the association of IL-65-72C/G and <e1>TNF-alpha</e1> -857C/T single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of IL-65-72C/G and <e1>TNF-alpha</e1> -857C/T single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of IL-65-72C/G and <e1>TNF-alpha</e1> -857C/T single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of IL-65-72C/G and <e1>TNF-alpha</e1> -857C/T single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of IL-65-72C/G and <e1>TNF-alpha</e1> -857C/T single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Association"
"However, few studies have focused on the association of IL-65-72C/G and <e1>TNF-alpha</e1> -857C/T single nucleotide polymorphisms (SNPs), inflammatory biomarkers, and metabolic indexes in women with <e2>GDM</e2>, especially in the Inner Mongolia population.","Association"
"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, <e2>IL-1b</e2>, TNF-alpha) were significantly different (p   <0.05) between women with <e1>GDM</e1> and women with healthy pregnancies.","Association"
"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, <e2>IL-1b</e2>, TNF-alpha) were significantly different (p   <0.05) between women with <e1>GDM</e1> and women with healthy pregnancies.","Association"
"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, <e2>IL-1b</e2>, TNF-alpha) were significantly different (p   <0.05) between women with <e1>GDM</e1> and women with healthy pregnancies.","Association"
"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, <e2>IL-1b</e2>, TNF-alpha) were significantly different (p   <0.05) between women with <e1>GDM</e1> and women with healthy pregnancies.","Association"
"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, <e2>IL-1b</e2>, TNF-alpha) were significantly different (p   <0.05) between women with <e1>GDM</e1> and women with healthy pregnancies.","Association"
"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, <e2>IL-1b</e2>, TNF-alpha) were significantly different (p   <0.05) between women with <e1>GDM</e1> and women with healthy pregnancies.","Association"
"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, <e2>IL-1b</e2>, TNF-alpha) were significantly different (p   <0.05) between women with <e1>GDM</e1> and women with healthy pregnancies.","Association"
"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, <e2>IL-1b</e2>, TNF-alpha) were significantly different (p   <0.05) between women with <e1>GDM</e1> and women with healthy pregnancies.","Association"
"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, <e2>IL-1b</e2>, TNF-alpha) were significantly different (p   <0.05) between women with <e1>GDM</e1> and women with healthy pregnancies.","Association"
"Inflammatory biomarkers in serum (hs-CRP, IL-6, IL-8, IL-6/IL-10 ratio) and placental (NF-kappaB, IL-6, IL-8, IL-6/IL-10 ratio, <e2>IL-1b</e2>, TNF-alpha) were significantly different (p   <0.05) between women with <e1>GDM</e1> and women with healthy pregnancies.","Association"
"Fine mapping and identification of a candidate gene <e1>SSH1</e1> in <e2>disseminated superficial actinic porokeratosis</e2>.","Association"
"Upon screening 30 candidate genes, we identified a missense mutation, p.Ser63Asn in <e1>SSH1</e1> in one family, a frameshift mutation, p.Ser19CysfsX24 in an alternative variant (isoform f) of SSH1 in another family, and a frameshift mutation, p.Pro27ProfsX54 in the same alternative variant in one non-familial case with <e2>DSAP</e2>.","Association"
"Upon screening 30 candidate genes, we identified a missense mutation, p.Ser63Asn in <e1>SSH1</e1> in one family, a frameshift mutation, p.Ser19CysfsX24 in an alternative variant (isoform f) of SSH1 in another family, and a frameshift mutation, p.Pro27ProfsX54 in the same alternative variant in one non-familial case with <e2>DSAP</e2>.","Association"
"Upon screening 30 candidate genes, we identified a missense mutation, p.Ser63Asn in <e1>SSH1</e1> in one family, a frameshift mutation, p.Ser19CysfsX24 in an alternative variant (isoform f) of SSH1 in another family, and a frameshift mutation, p.Pro27ProfsX54 in the same alternative variant in one non-familial case with <e2>DSAP</e2>.","Association"
"Upon screening 30 candidate genes, we identified a missense mutation, <e1>p.Ser63Asn</e1> in SSH1 in one family, a frameshift mutation, p.Ser19CysfsX24 in an alternative variant (isoform f) of SSH1 in another family, and a frameshift mutation, p.Pro27ProfsX54 in the same alternative variant in one non-familial case with <e2>DSAP</e2>.","Association"
"Upon screening 30 candidate genes, we identified a missense mutation, p.Ser63Asn in SSH1 in one family, a frameshift mutation, p.Ser19CysfsX24 in an alternative variant (isoform f) of SSH1 in another family, and a frameshift mutation, <e1>p.Pro27ProfsX54</e1> in the same alternative variant in one non-familial case with <e2>DSAP</e2>.","Association"
"Upon screening 30 candidate genes, we identified a missense mutation, p.Ser63Asn in SSH1 in one family, a frameshift mutation, <e1>p.Ser19CysfsX24</e1> in an alternative variant (isoform f) of SSH1 in another family, and a frameshift mutation, p.Pro27ProfsX54 in the same alternative variant in one non-familial case with <e2>DSAP</e2>.","Association"
"Seven of seven PCLBCL, leg type, patients with deletion of 9p21.3 and/or complete methylation of <e1>CDKN2A</e1> died as a result of their <e2>lymphoma</e2>.","Association"
"Seven of seven PCLBCL, leg type, patients with deletion of 9p21.3 and/or complete methylation of <e1>CDKN2A</e1> died as a result of their <e2>lymphoma</e2>.","Association"
"Seven of seven PCLBCL, leg type, patients with deletion of 9p21.3 and/or complete methylation of <e1>CDKN2A</e1> died as a result of their <e2>lymphoma</e2>.","Association"
"Seven of seven PCLBCL, leg type, patients with deletion of 9p21.3 and/or complete methylation of <e1>CDKN2A</e1> died as a result of their <e2>lymphoma</e2>.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and <e2>NSG-x</e2> genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and <e2>NSG-x</e2> genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and <e2>NSG-x</e2> genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and <e2>NSG-x</e2> genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and <e2>NSG-x</e2> genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and <e2>NSG-x</e2> genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and <e2>NSG-x</e2> genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and <e2>NSG-x</e2> genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and <e2>NSG-x</e2> genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, <e2>CDKN2B</e2>, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, <e2>CDKN2B</e2>, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, <e2>CDKN2B</e2>, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, <e2>CDKN2B</e2>, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, <e2>CDKN2B</e2>, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, <e2>CDKN2B</e2>, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, <e2>CDKN2B</e2>, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, <e2>CDKN2B</e2>, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, <e2>CDKN2B</e2>, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the <e2>CDKN2A</e2>, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the <e2>CDKN2A</e2>, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the <e2>CDKN2A</e2>, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the <e2>CDKN2A</e2>, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the <e2>CDKN2A</e2>, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the <e2>CDKN2A</e2>, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the <e2>CDKN2A</e2>, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the <e2>CDKN2A</e2>, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the <e2>CDKN2A</e2>, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and <e2>MALT1</e2> genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and <e2>MALT1</e2> genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and <e2>MALT1</e2> genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and <e2>MALT1</e2> genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and <e2>MALT1</e2> genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and <e2>MALT1</e2> genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and <e2>MALT1</e2> genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and <e2>MALT1</e2> genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and <e2>MALT1</e2> genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the <e2>BCL-2</e2> and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the <e2>BCL-2</e2> and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the <e2>BCL-2</e2> and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the <e2>BCL-2</e2> and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the <e2>BCL-2</e2> and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the <e2>BCL-2</e2> and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the <e2>BCL-2</e2> and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the <e2>BCL-2</e2> and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"In <e1>PCLBCL</e1>, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the <e2>BCL-2</e2> and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes.","Association"
"Osteogenesis imperfecta type III with <e2>intracranial hemorrhage</e2> and brachydactyly associated with mutations in exon 49 of <e1>COL1A2</e1>.","Association"
"<e2>Osteogenesis imperfecta type III</e2> with intracranial hemorrhage and brachydactyly associated with mutations in exon 49 of <e1>COL1A2</e1>.","Association"
"Osteogenesis imperfecta type III with intracranial hemorrhage and <e1>brachydactyly</e1> associated with mutations in exon 49 of <e2>COL1A2</e2>.","Association"
"These observations suggest that mutations in this region of the <e1>collagen type I alpha 2</e1> chain carry a high risk of <e2>abnormal limb development</e2> and intracranial bleeding.","Association"
"These observations suggest that mutations in this region of the <e1>collagen type I alpha 2</e1> chain carry a high risk of <e2>abnormal limb development</e2> and intracranial bleeding.","Association"
"These observations suggest that mutations in this region of the <e1>collagen type I alpha 2</e1> chain carry a high risk of abnormal limb development and <e2>intracranial bleeding</e2>.","Association"
"These observations suggest that mutations in this region of the <e1>collagen type I alpha 2</e1> chain carry a high risk of abnormal limb development and <e2>intracranial bleeding</e2>.","Association"
"In all of these patients, <e2>OI</e2> was caused by glycine mutations affecting exon 49 of the <e1>COL1A2</e1> gene, which codes for the most carboxy-terminal part of the triple-helical domain of the collagen type I alpha 2 chain.","Association"
"In all of these patients, <e2>OI</e2> was caused by glycine mutations affecting exon 49 of the COL1A2 gene, which codes for the most carboxy-terminal part of the triple-helical domain of the <e1>collagen type I alpha 2</e1> chain.","Association"
"In all of these patients, <e2>OI</e2> was caused by glycine mutations affecting exon 49 of the COL1A2 gene, which codes for the most carboxy-terminal part of the triple-helical domain of the <e1>collagen type I alpha 2</e1> chain.","Association"
"We present the case of a 31-year-old man with bilateral <e2>ischemia of the globus pallidus</e2> after excessive <e1>alcohol</e1> and intranasal cocaine use.","Positive_Correlation"
"In our patient, transient cardiac arrhythmia or respiratory dysfunction related to cocaine and/or <e1>ethanol</e1> use were the most likely causes of <e2>cerebral hypoperfusion</e2>.","Positive_Correlation"
"In our patient, transient cardiac arrhythmia or <e2>respiratory dysfunction</e2> related to cocaine and/or <e1>ethanol</e1> use were the most likely causes of cerebral hypoperfusion.","Positive_Correlation"
"In our patient, transient <e2>cardiac arrhythmia</e2> or respiratory dysfunction related to cocaine and/or <e1>ethanol</e1> use were the most likely causes of cerebral hypoperfusion.","Positive_Correlation"
"Drug-related <e1>globus pallidus infarctions</e1> are most often associated with <e2>heroin</e2>.","Positive_Correlation"
"Bilateral <e1>basal ganglia infarcts</e1> after the use of cocaine, without concurrent <e2>heroin</e2> use, have never been reported.","Positive_Correlation"
"We present the case of a 31-year-old man with bilateral <e2>ischemia of the globus pallidus</e2> after excessive alcohol and intranasal <e1>cocaine</e1> use.","Positive_Correlation"
"We present the case of a 31-year-old man with bilateral <e2>ischemia of the globus pallidus</e2> after excessive alcohol and intranasal <e1>cocaine</e1> use.","Positive_Correlation"
"We present the case of a 31-year-old man with bilateral <e2>ischemia of the globus pallidus</e2> after excessive alcohol and intranasal <e1>cocaine</e1> use.","Positive_Correlation"
"In our patient, transient cardiac arrhythmia or <e2>respiratory dysfunction</e2> related to <e1>cocaine</e1> and/or ethanol use were the most likely causes of cerebral hypoperfusion.","Positive_Correlation"
"In our patient, transient cardiac arrhythmia or <e2>respiratory dysfunction</e2> related to <e1>cocaine</e1> and/or ethanol use were the most likely causes of cerebral hypoperfusion.","Positive_Correlation"
"In our patient, transient cardiac arrhythmia or <e2>respiratory dysfunction</e2> related to <e1>cocaine</e1> and/or ethanol use were the most likely causes of cerebral hypoperfusion.","Positive_Correlation"
"In our patient, transient <e2>cardiac arrhythmia</e2> or respiratory dysfunction related to <e1>cocaine</e1> and/or ethanol use were the most likely causes of cerebral hypoperfusion.","Positive_Correlation"
"In our patient, transient <e2>cardiac arrhythmia</e2> or respiratory dysfunction related to <e1>cocaine</e1> and/or ethanol use were the most likely causes of cerebral hypoperfusion.","Positive_Correlation"
"In our patient, transient <e2>cardiac arrhythmia</e2> or respiratory dysfunction related to <e1>cocaine</e1> and/or ethanol use were the most likely causes of cerebral hypoperfusion.","Positive_Correlation"
"Bilateral <e2>basal ganglia infarcts</e2> after the use of <e1>cocaine</e1>, without concurrent heroin use, have never been reported.","Positive_Correlation"
"Bilateral <e2>basal ganglia infarcts</e2> after the use of <e1>cocaine</e1>, without concurrent heroin use, have never been reported.","Positive_Correlation"
"Bilateral <e2>basal ganglia infarcts</e2> after the use of <e1>cocaine</e1>, without concurrent heroin use, have never been reported.","Positive_Correlation"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the FGG gene (FGG <e1>10034C>T</e1>, rs2066865) has been associated with deep venous thrombosis and <e2>myocardial infarction</e2>.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the FGG gene (FGG 10034C>T, <e1>rs2066865</e1>) has been associated with deep venous thrombosis and <e2>myocardial infarction</e2>.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the FGG gene (FGG <e1>10034C>T</e1>, rs2066865) has been associated with deep venous thrombosis and <e2>myocardial infarction</e2>.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the FGG gene (FGG <e1>10034C>T</e1>, rs2066865) has been associated with <e2>deep venous thrombosis</e2> and myocardial infarction.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the FGG gene (FGG 10034C>T, <e1>rs2066865</e1>) has been associated with <e2>deep venous thrombosis</e2> and myocardial infarction.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the FGG gene (FGG <e1>10034C>T</e1>, rs2066865) has been associated with <e2>deep venous thrombosis</e2> and myocardial infarction.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <e1>FGG</e1> gene (FGG 10034C>T, rs2066865) has been associated with deep venous thrombosis and <e2>myocardial infarction</e2>.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <e1>FGG</e1> gene (FGG 10034C>T, rs2066865) has been associated with deep venous thrombosis and <e2>myocardial infarction</e2>.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <e1>FGG</e1> gene (FGG 10034C>T, rs2066865) has been associated with deep venous thrombosis and <e2>myocardial infarction</e2>.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <e1>FGG</e1> gene (FGG 10034C>T, rs2066865) has been associated with deep venous thrombosis and <e2>myocardial infarction</e2>.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <e1>FGG</e1> gene (FGG 10034C>T, rs2066865) has been associated with deep venous thrombosis and <e2>myocardial infarction</e2>.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <e1>FGG</e1> gene (FGG 10034C>T, rs2066865) has been associated with deep venous thrombosis and <e2>myocardial infarction</e2>.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <e1>FGG</e1> gene (FGG 10034C>T, rs2066865) has been associated with deep venous thrombosis and <e2>myocardial infarction</e2>.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <e1>FGG</e1> gene (FGG 10034C>T, rs2066865) has been associated with deep venous thrombosis and <e2>myocardial infarction</e2>.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <e1>FGG</e1> gene (FGG 10034C>T, rs2066865) has been associated with <e2>deep venous thrombosis</e2> and myocardial infarction.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <e1>FGG</e1> gene (FGG 10034C>T, rs2066865) has been associated with <e2>deep venous thrombosis</e2> and myocardial infarction.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <e1>FGG</e1> gene (FGG 10034C>T, rs2066865) has been associated with <e2>deep venous thrombosis</e2> and myocardial infarction.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <e1>FGG</e1> gene (FGG 10034C>T, rs2066865) has been associated with <e2>deep venous thrombosis</e2> and myocardial infarction.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <e1>FGG</e1> gene (FGG 10034C>T, rs2066865) has been associated with <e2>deep venous thrombosis</e2> and myocardial infarction.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <e1>FGG</e1> gene (FGG 10034C>T, rs2066865) has been associated with <e2>deep venous thrombosis</e2> and myocardial infarction.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <e1>FGG</e1> gene (FGG 10034C>T, rs2066865) has been associated with <e2>deep venous thrombosis</e2> and myocardial infarction.","Association"
"A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <e1>FGG</e1> gene (FGG 10034C>T, rs2066865) has been associated with <e2>deep venous thrombosis</e2> and myocardial infarction.","Association"
"Genotype rs8099917 near the <e1>IL28B</e1> gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum <e2>apolipoprotein B-100</e2> concentration in chronic hepatitis C.","Association"
"Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum <e2>apolipoprotein B-100</e2> concentration in <e1>chronic hepatitis C</e1>.","Association"
"Genotype rs8099917 near the <e2>IL28B</e2> gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in <e1>chronic hepatitis C</e1>.","Association"
"Genotype <e2>rs8099917</e2> near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in <e1>chronic hepatitis C</e1>.","Association"
"Serum levels of <e1>lipid</e1> are associated with the response to pegylated interferon plus <e2>ribavirin</e2> (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.","Association"
"Serum levels of <e1>lipid</e1> are associated with the response to pegylated interferon plus <e2>ribavirin</e2> (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.","Association"
"Serum levels of <e1>lipid</e1> are associated with the response to <e2>pegylated interferon</e2> plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.","Association"
"Serum levels of <e1>lipid</e1> are associated with the response to <e2>pegylated interferon</e2> plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.","Association"
"The aim of this study was to elucidate the relationship between serum lipid and factors that are able to predict the efficacy of PEG-IFN/RB therapy, with specific focus on <e2>apolipoprotein B-100</e2> (apoB-100) in 148 subjects with chronic <e1>HCV G1b infection</e1>.","Association"
"Our results suggest that <e2>apoB-100</e2> and LDL cholesterol are markers of impaired cellular lipoprotein pathways and/or host endogenous interferon response to HCV in chronic <e1>HCV infection</e1>.","Association"
"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human <e2>interleukin 28B</e2> (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with <e1>HCV genotype 1b infection</e1>.","Association"
"A significant association was noted between higher levels of apoB-100 (P = 1.1 10(-3)) and <e1>LDL cholesterol</e1> (P = 0.02) and the subjects having <e2>Arg70</e2>.","Positive_Correlation"
"A significant association was noted between higher levels of apoB-100 (P = 1.1 10(-3)) and <e1>LDL cholesterol</e1> (P = 0.02) and the subjects having <e2>Arg70</e2>.","Positive_Correlation"
"A significant association was noted between higher levels of apoB-100 (P = 1.1 10(-3)) and <e1>LDL cholesterol</e1> (P = 0.02) and the subjects having <e2>Arg70</e2>.","Positive_Correlation"
"Our results suggest that apoB-100 and <e1>LDL cholesterol</e1> are markers of impaired cellular lipoprotein pathways and/or host endogenous interferon response to HCV in chronic <e2>HCV infection</e2>.","Association"
"Our results suggest that apoB-100 and <e1>LDL cholesterol</e1> are markers of impaired cellular lipoprotein pathways and/or host endogenous interferon response to HCV in chronic <e2>HCV infection</e2>.","Association"
"Our results suggest that apoB-100 and <e1>LDL cholesterol</e1> are markers of impaired cellular lipoprotein pathways and/or host endogenous interferon response to HCV in chronic <e2>HCV infection</e2>.","Association"
"Serum levels of lipid are associated with the response to pegylated interferon plus <e1>ribavirin</e1> (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with <e2>HCV genotype 1b infection</e2>.","Negative_Correlation"
"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/<e1>RBV</e1>) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with <e2>HCV genotype 1b infection</e2>.","Negative_Correlation"
"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/<e1>RBV</e1>) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with <e2>HCV genotype 1b infection</e2>.","Negative_Correlation"
"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/<e1>RB</e1>V) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with <e2>HCV genotype 1b infection</e2>.","Negative_Correlation"
"Serum levels of lipid are associated with the response to pegylated interferon plus <e1>ribavirin</e1> (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in <e2>chronic hepatitis</e2> with HCV genotype 1b infection.","Negative_Correlation"
"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/<e1>RBV</e1>) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in <e2>chronic hepatitis</e2> with HCV genotype 1b infection.","Negative_Correlation"
"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/<e1>RBV</e1>) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in <e2>chronic hepatitis</e2> with HCV genotype 1b infection.","Negative_Correlation"
"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/<e1>RB</e1>V) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in <e2>chronic hepatitis</e2> with HCV genotype 1b infection.","Negative_Correlation"
"Serum levels of lipid are associated with the response to <e1>pegylated interferon</e1> plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with <e2>HCV genotype 1b infection</e2>.","Negative_Correlation"
"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (<e1>PEG-IFN</e1>/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with <e2>HCV genotype 1b infection</e2>.","Negative_Correlation"
"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (<e1>PEG-IFN</e1>/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with <e2>HCV genotype 1b infection</e2>.","Negative_Correlation"
"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (<e1>PEG-IFN</e1>/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with <e2>HCV genotype 1b infection</e2>.","Negative_Correlation"
"Serum levels of lipid are associated with the response to <e1>pegylated interferon</e1> plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in <e2>chronic hepatitis</e2> with HCV genotype 1b infection.","Negative_Correlation"
"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (<e1>PEG-IFN</e1>/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in <e2>chronic hepatitis</e2> with HCV genotype 1b infection.","Negative_Correlation"
"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (<e1>PEG-IFN</e1>/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in <e2>chronic hepatitis</e2> with HCV genotype 1b infection.","Negative_Correlation"
"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (<e1>PEG-IFN</e1>/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in <e2>chronic hepatitis</e2> with HCV genotype 1b infection.","Negative_Correlation"
"Serum levels of lipid are associated with the response to <e1>pegylated interferon</e1> plus <e2>ribavirin</e2> (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.","Cotreatment"
"Serum levels of lipid are associated with the response to pegylated interferon plus <e2>ribavirin</e2> (<e1>PEG-IFN</e1>/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.","Cotreatment"
"Serum levels of lipid are associated with the response to pegylated interferon plus <e2>ribavirin</e2> (<e1>PEG-IFN</e1>/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.","Cotreatment"
"Serum levels of lipid are associated with the response to pegylated interferon plus <e2>ribavirin</e2> (<e1>PEG-IFN</e1>/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.","Cotreatment"
"Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the rs8099917 SNP located proximal to the IL28B were independent factors in determining serum <e1>apoB-100</e1> and <e2>low-density lipoprotein (LDL) cholesterol</e2> levels.","Association"
"Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the rs8099917 SNP located proximal to the IL28B were independent factors in determining serum <e1>apoB-100</e1> and <e2>low-density lipoprotein (LDL) cholesterol</e2> levels.","Association"
"Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the rs8099917 SNP located proximal to the IL28B were independent factors in determining serum <e1>apoB-100</e1> and <e2>low-density lipoprotein (LDL) cholesterol</e2> levels.","Association"
"Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the rs8099917 SNP located proximal to the IL28B were independent factors in determining serum <e1>apoB-100</e1> and <e2>low-density lipoprotein (LDL) cholesterol</e2> levels.","Association"
"Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the rs8099917 SNP located proximal to the IL28B were independent factors in determining serum <e1>apoB-100</e1> and <e2>low-density lipoprotein (LDL) cholesterol</e2> levels.","Association"
"Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the rs8099917 SNP located proximal to the IL28B were independent factors in determining serum <e1>apoB-100</e1> and <e2>low-density lipoprotein (LDL) cholesterol</e2> levels.","Association"
"Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the rs8099917 SNP located proximal to the <e1>IL28B</e1> were independent factors in determining serum apoB-100 and <e2>low-density lipoprotein (LDL) cholesterol</e2> levels.","Association"
"Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the rs8099917 SNP located proximal to the <e1>IL28B</e1> were independent factors in determining serum apoB-100 and <e2>low-density lipoprotein (LDL) cholesterol</e2> levels.","Association"
"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human <e1>interleukin 28B</e1> (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in <e2>chronic hepatitis</e2> with HCV genotype 1b infection.","Association"
"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (<e1>IL28B</e1>) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in <e2>chronic hepatitis</e2> with HCV genotype 1b infection.","Association"
"Serum levels of lipid are associated with the response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (<e1>IL28B</e1>) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in <e2>chronic hepatitis</e2> with HCV genotype 1b infection.","Association"
"Serum levels of lipid are associated with the response to pegylated interferon plus <e2>ribavirin</e2> (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human <e1>interleukin 28B</e1> (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.","Association"
"Serum levels of lipid are associated with the response to pegylated interferon plus <e2>ribavirin</e2> (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (<e1>IL28B</e1>) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.","Association"
"Serum levels of lipid are associated with the response to pegylated interferon plus <e2>ribavirin</e2> (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (<e1>IL28B</e1>) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.","Association"
"Serum levels of lipid are associated with the response to <e2>pegylated interferon</e2> plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human <e1>interleukin 28B</e1> (IL28B) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.","Association"
"Serum levels of lipid are associated with the response to <e2>pegylated interferon</e2> plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (<e1>IL28B</e1>) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.","Association"
"Serum levels of lipid are associated with the response to <e2>pegylated interferon</e2> plus ribavirin (PEG-IFN/RBV) therapy, while single nucleotide polymorphisms (SNPs) around the human interleukin 28B (<e1>IL28B</e1>) gene locus and amino acid substitutions in the core region of the HCV have been reported to affect the efficacy of PEG-IFN/RBV therapy in chronic hepatitis with HCV genotype 1b infection.","Association"
"Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the rs8099917 SNP located proximal to the <e1>IL28B</e1> were independent factors in determining serum <e2>apoB-100</e2> and low-density lipoprotein (LDL) cholesterol levels.","Association"
"Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the rs8099917 SNP located proximal to the <e1>IL28B</e1> were independent factors in determining serum <e2>apoB-100</e2> and low-density lipoprotein (LDL) cholesterol levels.","Association"
"Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the <e1>rs8099917</e1> SNP located proximal to the IL28B were independent factors in determining serum apoB-100 and <e2>low-density lipoprotein (LDL) cholesterol</e2> levels.","Positive_Correlation"
"Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the <e1>rs8099917</e1> SNP located proximal to the IL28B were independent factors in determining serum apoB-100 and <e2>low-density lipoprotein (LDL) cholesterol</e2> levels.","Positive_Correlation"
"Our results demonstrated that both the aa 70 substitution in the core region of the HCV and the <e1>rs8099917</e1> SNP located proximal to the IL28B were independent factors in determining serum apoB-100 and <e2>low-density lipoprotein (LDL) cholesterol</e2> levels.","Positive_Correlation"
"We found that depletion of <e1>PI4KIIa</e1> and PI4KIIb using small interfering RNA led to <e2>actin</e2> remodeling.","Association"
"We propose that PI4KIIb synthesizes a pool of <e1>PI(4)P</e1> that maintains <e2>MT1-MMP</e2> traffic in the degradative pathway and suppresses the formation of invadopodia.","Association"
"We propose that PI4KIIb synthesizes a pool of <e1>PI(4)P</e1> that maintains <e2>MT1-MMP</e2> traffic in the degradative pathway and suppresses the formation of invadopodia.","Association"
"We propose that PI4KIIb synthesizes a pool of <e1>PI(4)P</e1> that maintains <e2>MT1-MMP</e2> traffic in the degradative pathway and suppresses the formation of invadopodia.","Association"
"PI4KIIb depletion caused increased <e1>MT1-MMP</e1> trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers Rab5 and <e2>Rab7</e2> but increased localization with the exocytic Rab8.","Association"
"PI4KIIb depletion caused increased <e1>MT1-MMP</e1> trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers Rab5 and <e2>Rab7</e2> but increased localization with the exocytic Rab8.","Association"
"PI4KIIb depletion caused increased <e1>MT1-MMP</e1> trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers Rab5 and <e2>Rab7</e2> but increased localization with the exocytic Rab8.","Association"
"PI4KIIb depletion caused increased <e1>MT1-MMP</e1> trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers Rab5 and <e2>Rab7</e2> but increased localization with the exocytic Rab8.","Association"
"PI4KIIb depletion caused increased <e1>MT1-MMP</e1> trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers <e2>Rab5</e2> and Rab7 but increased localization with the exocytic Rab8.","Association"
"PI4KIIb depletion caused increased <e1>MT1-MMP</e1> trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers <e2>Rab5</e2> and Rab7 but increased localization with the exocytic Rab8.","Association"
"PI4KIIb depletion caused increased <e1>MT1-MMP</e1> trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers <e2>Rab5</e2> and Rab7 but increased localization with the exocytic Rab8.","Association"
"PI4KIIb depletion caused increased <e1>MT1-MMP</e1> trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers <e2>Rab5</e2> and Rab7 but increased localization with the exocytic Rab8.","Association"
"PI4KIIb depletion caused increased <e1>MT1-MMP</e1> trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers Rab5 and Rab7 but increased localization with the exocytic <e2>Rab8</e2>.","Association"
"PI4KIIb depletion caused increased <e1>MT1-MMP</e1> trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers Rab5 and Rab7 but increased localization with the exocytic <e2>Rab8</e2>.","Association"
"PI4KIIb depletion caused increased <e1>MT1-MMP</e1> trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers Rab5 and Rab7 but increased localization with the exocytic <e2>Rab8</e2>.","Association"
"PI4KIIb depletion caused increased <e1>MT1-MMP</e1> trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers Rab5 and Rab7 but increased localization with the exocytic <e2>Rab8</e2>.","Association"
"We found that depletion of PI4KIIa and <e1>PI4KIIb</e1> using small interfering RNA led to <e2>actin</e2> remodeling.","Association"
"We found that depletion of PI4KIIa and <e1>PI4KIIb</e1> using small interfering RNA led to <e2>actin</e2> remodeling.","Association"
"We found that depletion of PI4KIIa and <e1>PI4KIIb</e1> using small interfering RNA led to <e2>actin</e2> remodeling.","Association"
"We found that depletion of PI4KIIa and <e1>PI4KIIb</e1> using small interfering RNA led to <e2>actin</e2> remodeling.","Association"
"We found that depletion of PI4KIIa and <e1>PI4KIIb</e1> using small interfering RNA led to <e2>actin</e2> remodeling.","Association"
"We found that depletion of PI4KIIa and <e1>PI4KIIb</e1> using small interfering RNA led to <e2>actin</e2> remodeling.","Association"
"We found that depletion of PI4KIIa and <e1>PI4KIIb</e1> using small interfering RNA led to <e2>actin</e2> remodeling.","Association"
"Mining oncogenomic databases revealed that loss of the PI4K2B allele and underexpression of <e1>PI4KIIb</e1> mRNA are associated with human <e2>cancers</e2>.","Negative_Correlation"
"Mining oncogenomic databases revealed that loss of the PI4K2B allele and underexpression of <e1>PI4KIIb</e1> mRNA are associated with human <e2>cancers</e2>.","Negative_Correlation"
"Mining oncogenomic databases revealed that loss of the PI4K2B allele and underexpression of <e1>PI4KIIb</e1> mRNA are associated with human <e2>cancers</e2>.","Negative_Correlation"
"Mining oncogenomic databases revealed that loss of the PI4K2B allele and underexpression of <e1>PI4KIIb</e1> mRNA are associated with human <e2>cancers</e2>.","Negative_Correlation"
"Mining oncogenomic databases revealed that loss of the <e1>PI4K2B</e1> allele and underexpression of PI4KIIb mRNA are associated with human <e2>cancers</e2>.","Negative_Correlation"
"Mining oncogenomic databases revealed that loss of the PI4K2B allele and underexpression of <e1>PI4KIIb</e1> mRNA are associated with human <e2>cancers</e2>.","Negative_Correlation"
"Mining oncogenomic databases revealed that loss of the PI4K2B allele and underexpression of <e1>PI4KIIb</e1> mRNA are associated with human <e2>cancers</e2>.","Negative_Correlation"
"Mining oncogenomic databases revealed that loss of the PI4K2B allele and underexpression of <e1>PI4KIIb</e1> mRNA are associated with human <e2>cancers</e2>.","Negative_Correlation"
"<e1>PI4KIIb</e1> depletion caused increased MT1-MMP trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers Rab5 and Rab7 but increased localization with the exocytic <e2>Rab8</e2>.","Association"
"<e1>PI4KIIb</e1> depletion caused increased MT1-MMP trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers Rab5 and Rab7 but increased localization with the exocytic <e2>Rab8</e2>.","Association"
"<e1>PI4KIIb</e1> depletion caused increased MT1-MMP trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers Rab5 and Rab7 but increased localization with the exocytic <e2>Rab8</e2>.","Association"
"<e1>PI4KIIb</e1> depletion caused increased MT1-MMP trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers Rab5 and Rab7 but increased localization with the exocytic <e2>Rab8</e2>.","Association"
"<e1>PI4KIIb</e1> depletion caused increased MT1-MMP trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers Rab5 and Rab7 but increased localization with the exocytic <e2>Rab8</e2>.","Association"
"<e1>PI4KIIb</e1> depletion caused increased MT1-MMP trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers Rab5 and Rab7 but increased localization with the exocytic <e2>Rab8</e2>.","Association"
"<e1>PI4KIIb</e1> depletion caused increased MT1-MMP trafficking to invasive structures at the plasma membrane and was accompanied by reduced colocalization of MT1-MMP with membranes containing the endosomal markers Rab5 and Rab7 but increased localization with the exocytic <e2>Rab8</e2>.","Association"
"We propose that <e1>PI4KIIb</e1> synthesizes a pool of <e2>PI(4)P</e2> that maintains MT1-MMP traffic in the degradative pathway and suppresses the formation of invadopodia.","Association"
"We propose that <e1>PI4KIIb</e1> synthesizes a pool of <e2>PI(4)P</e2> that maintains MT1-MMP traffic in the degradative pathway and suppresses the formation of invadopodia.","Association"
"We propose that <e1>PI4KIIb</e1> synthesizes a pool of <e2>PI(4)P</e2> that maintains MT1-MMP traffic in the degradative pathway and suppresses the formation of invadopodia.","Association"
"We propose that <e1>PI4KIIb</e1> synthesizes a pool of <e2>PI(4)P</e2> that maintains MT1-MMP traffic in the degradative pathway and suppresses the formation of invadopodia.","Association"
"We propose that <e1>PI4KIIb</e1> synthesizes a pool of <e2>PI(4)P</e2> that maintains MT1-MMP traffic in the degradative pathway and suppresses the formation of invadopodia.","Association"
"We propose that <e1>PI4KIIb</e1> synthesizes a pool of <e2>PI(4)P</e2> that maintains MT1-MMP traffic in the degradative pathway and suppresses the formation of invadopodia.","Association"
"We propose that <e1>PI4KIIb</e1> synthesizes a pool of <e2>PI(4)P</e2> that maintains MT1-MMP traffic in the degradative pathway and suppresses the formation of invadopodia.","Association"
"Depletion of <e1>PI4KIIb</e1> also induced the formation of invadopodia containing <e2>membrane type I matrix metalloproteinase</e2> (MT1-MMP).","Association"
"Depletion of <e1>PI4KIIb</e1> also induced the formation of invadopodia containing <e2>membrane type I matrix metalloproteinase</e2> (MT1-MMP).","Association"
"Depletion of <e1>PI4KIIb</e1> also induced the formation of invadopodia containing <e2>membrane type I matrix metalloproteinase</e2> (MT1-MMP).","Association"
"Depletion of <e1>PI4KIIb</e1> also induced the formation of invadopodia containing <e2>membrane type I matrix metalloproteinase</e2> (MT1-MMP).","Association"
"Depletion of <e1>PI4KIIb</e1> also induced the formation of invadopodia containing <e2>membrane type I matrix metalloproteinase</e2> (MT1-MMP).","Association"
"Depletion of <e1>PI4KIIb</e1> also induced the formation of invadopodia containing <e2>membrane type I matrix metalloproteinase</e2> (MT1-MMP).","Association"
"Depletion of <e1>PI4KIIb</e1> also induced the formation of invadopodia containing <e2>membrane type I matrix metalloproteinase</e2> (MT1-MMP).","Association"
"CenpH regulates meiotic G2/M transition by modulating the <e2>APC/CCdh1</e2>-<e1>cyclin B1</e1> pathway in oocytes.","Association"
"<e1>CenpH</e1> regulates meiotic G2/M transition by modulating the <e2>APC/CCdh1</e2>-cyclin B1 pathway in oocytes.","Association"
"<e1>CenpH</e1> regulates meiotic G2/M transition by modulating the APC/CCdh1-<e2>cyclin B1</e2> pathway in oocytes.","Positive_Correlation"
"Depletion of CenpH by <e1>morpholino</e1> injection decreased <e2>cyclin B1</e2> levels, resulting in attenuation of maturation-promoting factor (MPF) activation, and severely compromised meiotic resumption.","Negative_Correlation"
"CenpH protects <e1>cyclin B1</e1> from destruction by competing with the action of <e2>APC/C</e2>(Cdh1) Impaired G2/M transition after CenpH depletion could be rescued by expression of exogenous cyclin B1.","Association"
"CenpH protects <e1>cyclin B1</e1> from destruction by competing with the action of <e2>APC/C</e2>(Cdh1) Impaired G2/M transition after CenpH depletion could be rescued by expression of exogenous cyclin B1.","Association"
"CenpH protects <e1>cyclin B1</e1> from destruction by competing with the action of <e2>APC/C</e2>(Cdh1) Impaired G2/M transition after CenpH depletion could be rescued by expression of exogenous cyclin B1.","Association"
"CenpH protects <e1>cyclin B1</e1> from destruction by competing with the action of <e2>APC/C</e2>(Cdh1) Impaired G2/M transition after CenpH depletion could be rescued by expression of exogenous cyclin B1.","Association"
"<e1>CenpH</e1> protects cyclin B1 from destruction by competing with the action of <e2>APC/C</e2>(Cdh1) Impaired G2/M transition after CenpH depletion could be rescued by expression of exogenous cyclin B1.","Association"
"<e1>CenpH</e1> protects cyclin B1 from destruction by competing with the action of <e2>APC/C</e2>(Cdh1) Impaired G2/M transition after CenpH depletion could be rescued by expression of exogenous cyclin B1.","Association"
"<e1>CenpH</e1> protects cyclin B1 from destruction by competing with the action of <e2>APC/C</e2>(Cdh1) Impaired G2/M transition after CenpH depletion could be rescued by expression of exogenous cyclin B1.","Association"
"<e1>CenpH</e1> protects cyclin B1 from destruction by competing with the action of <e2>APC/C</e2>(Cdh1) Impaired G2/M transition after CenpH depletion could be rescued by expression of exogenous cyclin B1.","Association"
"<e1>CenpH</e1> protects cyclin B1 from destruction by competing with the action of <e2>APC/C</e2>(Cdh1) Impaired G2/M transition after CenpH depletion could be rescued by expression of exogenous cyclin B1.","Association"
"<e1>CenpH</e1> protects cyclin B1 from destruction by competing with the action of <e2>APC/C</e2>(Cdh1) Impaired G2/M transition after CenpH depletion could be rescued by expression of exogenous cyclin B1.","Association"
"Depletion of <e1>CenpH</e1> by <e2>morpholino</e2> injection decreased cyclin B1 levels, resulting in attenuation of maturation-promoting factor (MPF) activation, and severely compromised meiotic resumption.","Negative_Correlation"
"Depletion of <e1>CenpH</e1> by <e2>morpholino</e2> injection decreased cyclin B1 levels, resulting in attenuation of maturation-promoting factor (MPF) activation, and severely compromised meiotic resumption.","Negative_Correlation"
"Depletion of <e1>CenpH</e1> by <e2>morpholino</e2> injection decreased cyclin B1 levels, resulting in attenuation of maturation-promoting factor (MPF) activation, and severely compromised meiotic resumption.","Negative_Correlation"
"Depletion of <e1>CenpH</e1> by <e2>morpholino</e2> injection decreased cyclin B1 levels, resulting in attenuation of maturation-promoting factor (MPF) activation, and severely compromised meiotic resumption.","Negative_Correlation"
"Depletion of <e1>CenpH</e1> by <e2>morpholino</e2> injection decreased cyclin B1 levels, resulting in attenuation of maturation-promoting factor (MPF) activation, and severely compromised meiotic resumption.","Negative_Correlation"
"Depletion of <e1>CenpH</e1> by <e2>morpholino</e2> injection decreased cyclin B1 levels, resulting in attenuation of maturation-promoting factor (MPF) activation, and severely compromised meiotic resumption.","Negative_Correlation"
"Depletion of <e1>CenpH</e1> by morpholino injection decreased <e2>cyclin B1</e2> levels, resulting in attenuation of maturation-promoting factor (MPF) activation, and severely compromised meiotic resumption.","Positive_Correlation"
"Depletion of <e1>CenpH</e1> by morpholino injection decreased <e2>cyclin B1</e2> levels, resulting in attenuation of maturation-promoting factor (MPF) activation, and severely compromised meiotic resumption.","Positive_Correlation"
"Depletion of <e1>CenpH</e1> by morpholino injection decreased <e2>cyclin B1</e2> levels, resulting in attenuation of maturation-promoting factor (MPF) activation, and severely compromised meiotic resumption.","Positive_Correlation"
"Depletion of <e1>CenpH</e1> by morpholino injection decreased <e2>cyclin B1</e2> levels, resulting in attenuation of maturation-promoting factor (MPF) activation, and severely compromised meiotic resumption.","Positive_Correlation"
"Depletion of <e1>CenpH</e1> by morpholino injection decreased <e2>cyclin B1</e2> levels, resulting in attenuation of maturation-promoting factor (MPF) activation, and severely compromised meiotic resumption.","Positive_Correlation"
"Depletion of <e1>CenpH</e1> by morpholino injection decreased <e2>cyclin B1</e2> levels, resulting in attenuation of maturation-promoting factor (MPF) activation, and severely compromised meiotic resumption.","Positive_Correlation"
"<e1>CRYBA3/A1</e1> gene mutation associated with suture-sparing <e2>autosomal dominant congenital nuclear cataract</e2>: a novel phenotype.","Association"
"CONCLUSIONS: The <e1>DeltaG91</e1> mutation in CRYBA3/A1 is associated with an autosomal dominant <e2>congenital nuclear lactescent cataract</e2>.","Association"
"A splice mutation (<e1>IVS3+1G/A</e1>) in this gene has been reported in a <e2>zonular cataract</e2> with sutural opacities.","Association"
"CONCLUSIONS: The DeltaG91 mutation in <e1>CRYBA3/A1</e1> is associated with an autosomal dominant <e2>congenital nuclear lactescent cataract</e2>.","Association"
"CONCLUSIONS: The DeltaG91 mutation in <e1>CRYBA3/A1</e1> is associated with an autosomal dominant <e2>congenital nuclear lactescent cataract</e2>.","Association"
"Vitamin D-binding protein gene polymorphism association with <e1>IA-2</e1> autoantibodies in <e2>type 1 diabetes</e2>.","Association"
"<e1>Vitamin D-binding protein</e1> gene polymorphism association with IA-2 autoantibodies in <e2>type 1 diabetes</e2>.","Association"
"<e1>Vitamin D-binding protein</e1> gene polymorphism association with <e2>IA-2</e2> autoantibodies in type 1 diabetes.","Association"
"These finding supports a role of the <e1>vitamin D</e1> endocrine system in the autoimmune process of <e2>type 1 diabetes</e2>.","Association"
"RESULTS: The frequencies of the Asp/Glu and Glu/Glu were significantly increased in <e2>diabetic</e2> subjects with detectable <e1>IA-2</e1> antibodies (P < 0.01).","Association"
"BACKGROUND: <e1>Vitamin D-binding protein</e1> (DBP) is the main systemic transporter of <e2>1.25(OH)2D3</e2> and is essential for its cellular endocytosis.","Association"
"BACKGROUND: Vitamin D-binding protein (<e1>DBP</e1>) is the main systemic transporter of <e2>1.25(OH)2D3</e2> and is essential for its cellular endocytosis.","Association"
"BACKGROUND: Vitamin D-binding protein (<e1>DBP</e1>) is the main systemic transporter of <e2>1.25(OH)2D3</e2> and is essential for its cellular endocytosis.","Association"
"BACKGROUND: Vitamin D-binding protein (<e1>DBP</e1>) is the main systemic transporter of <e2>1.25(OH)2D3</e2> and is essential for its cellular endocytosis.","Association"
"BACKGROUND: Vitamin D-binding protein (<e1>DBP</e1>) is the main systemic transporter of <e2>1.25(OH)2D3</e2> and is essential for its cellular endocytosis.","Association"
"BACKGROUND: Vitamin D-binding protein (<e1>DBP</e1>) is the main systemic transporter of <e2>1.25(OH)2D3</e2> and is essential for its cellular endocytosis.","Association"
"BACKGROUND: Vitamin D-binding protein (<e1>DBP</e1>) is the main systemic transporter of <e2>1.25(OH)2D3</e2> and is essential for its cellular endocytosis.","Association"
"BACKGROUND: Vitamin D-binding protein (<e1>DBP</e1>) is the main systemic transporter of <e2>1.25(OH)2D3</e2> and is essential for its cellular endocytosis.","Association"
"BACKGROUND: Vitamin D-binding protein (<e1>DBP</e1>) is the main systemic transporter of <e2>1.25(OH)2D3</e2> and is essential for its cellular endocytosis.","Association"
"Correlations between <e1>DBP</e1> alleles and <e2>type 1 diabetes</e2> have been described in different populations.","Association"
"Correlations between <e1>DBP</e1> alleles and <e2>type 1 diabetes</e2> have been described in different populations.","Association"
"Correlations between <e1>DBP</e1> alleles and <e2>type 1 diabetes</e2> have been described in different populations.","Association"
"Correlations between <e1>DBP</e1> alleles and <e2>type 1 diabetes</e2> have been described in different populations.","Association"
"Correlations between <e1>DBP</e1> alleles and <e2>type 1 diabetes</e2> have been described in different populations.","Association"
"Correlations between <e1>DBP</e1> alleles and <e2>type 1 diabetes</e2> have been described in different populations.","Association"
"Correlations between <e1>DBP</e1> alleles and <e2>type 1 diabetes</e2> have been described in different populations.","Association"
"Correlations between <e1>DBP</e1> alleles and <e2>type 1 diabetes</e2> have been described in different populations.","Association"
"Characterization of <e1>Bietti crystalline dystrophy</e1> patients with <e2>CYP4V2</e2> mutations.","Association"
"PURPOSE: Mutations of the <e2>CYP4V2</e2> gene, a novel family member of the cytochrome P450 genes on chromosome 4q35, have recently been identified in patients with <e1>Bietti crystalline dystrophy</e1> (BCD).","Association"
"PURPOSE: Mutations of the <e2>CYP4V2</e2> gene, a novel family member of the cytochrome P450 genes on chromosome 4q35, have recently been identified in patients with Bietti crystalline dystrophy (<e1>BCD</e1>).","Association"
"PURPOSE: Mutations of the <e2>CYP4V2</e2> gene, a novel family member of the cytochrome P450 genes on chromosome 4q35, have recently been identified in patients with Bietti crystalline dystrophy (<e1>BCD</e1>).","Association"
"PURPOSE: Mutations of the <e2>CYP4V2</e2> gene, a novel family member of the cytochrome P450 genes on chromosome 4q35, have recently been identified in patients with Bietti crystalline dystrophy (<e1>BCD</e1>).","Association"
"PURPOSE: Mutations of the <e2>CYP4V2</e2> gene, a novel family member of the cytochrome P450 genes on chromosome 4q35, have recently been identified in patients with Bietti crystalline dystrophy (<e1>BCD</e1>).","Association"
"An extremely rare case of delusional parasitosis in a <e1>chronic hepatitis C</e1> patient during pegylated interferon alpha-2b and <e2>ribavirin</e2> treatment.","Negative_Correlation"
"An extremely rare case of delusional parasitosis in a <e1>chronic hepatitis C</e1> patient during <e2>pegylated interferon alpha-2b</e2> and ribavirin treatment.","Negative_Correlation"
"An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during <e1>pegylated interferon alpha-2b</e1> and <e2>ribavirin</e2> treatment.","Cotreatment"
"An extremely rare case of <e1>delusional parasitosis</e1> in a chronic hepatitis C patient during <e2>pegylated interferon alpha-2b</e2> and ribavirin treatment.","Positive_Correlation"
"During treatment of <e1>chronic hepatitis C</e1> patients with interferon and <e2>ribavirin</e2>, a lot of side effects are described.","Negative_Correlation"
"During treatment of <e1>chronic hepatitis C</e1> patients with <e2>interferon</e2> and ribavirin, a lot of side effects are described.","Negative_Correlation"
"During treatment of chronic hepatitis C patients with <e1>interferon</e1> and <e2>ribavirin</e2>, a lot of side effects are described.","Cotreatment"
"During treatment of chronic hepatitis C patients with <e1>interferon</e1> and <e2>ribavirin</e2>, a lot of side effects are described.","Cotreatment"
"We present a 49-year-old woman who developed a delusional parasitosis during treatment with <e1>pegylated interferon alpha-2b</e1> weekly and <e2>ribavirin</e2>.","Cotreatment"
"We present a 49-year-old woman who developed a delusional parasitosis during treatment with <e1>pegylated interferon alpha-2b</e1> weekly and <e2>ribavirin</e2>.","Cotreatment"
"To the best of our knowledge, no cases of <e1>psychogenic parasitosis</e1> occurring during <e2>interferon</e2> therapy have been described in the literature.","Positive_Correlation"
"We present a 49-year-old woman who developed a <e1>delusional parasitosis</e1> during treatment with pegylated <e2>interferon</e2> alpha-2b weekly and ribavirin.","Positive_Correlation"
"Protein-<e1>Trap</e1> Insertional Mutagenesis Uncovers New Genes Involved in Zebrafish Skin Development, Including a <e2>Neuregulin 2a</e2>-Based ErbB Signaling Pathway Required during Median Fin Fold Morphogenesis.","Association"
"Moreover, knockdown of the epithelial polarity regulator and tumor suppressor <e1>lgl2</e1> ameliorated the <e2>nrg2a</e2> mutant phenotype.","Negative_Correlation"
"Identifying <e1>Lgl2</e1> as an antagonist of <e2>Nrg2a</e2>-ErbB signaling revealed a significantly earlier role for Lgl2 during epidermal morphogenesis than has been described to date.","Negative_Correlation"
"Identifying <e1>Lgl2</e1> as an antagonist of <e2>Nrg2a</e2>-ErbB signaling revealed a significantly earlier role for Lgl2 during epidermal morphogenesis than has been described to date.","Negative_Correlation"
"Moreover, knockdown of the epithelial polarity regulator and <e1>tumor</e1> suppressor <e2>lgl2</e2> ameliorated the nrg2a mutant phenotype.","Negative_Correlation"
"Embryos homozygous for a GBT insertion within neuregulin 2a (<e1>nrg2a</e1>) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-<e2>AKT</e2> signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis.","Association"
"Embryos homozygous for a GBT insertion within <e1>neuregulin 2a</e1> (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-<e2>AKT</e2> signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis.","Association"
"Embryos homozygous for a GBT insertion within neuregulin 2a (<e1>nrg2a</e1>) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-<e2>AKT</e2> signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis.","Association"
"Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a <e1>Neuregulin 2a</e1> (Nrg2a)-ErbB2/3-<e2>AKT</e2> signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis.","Association"
"Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (<e1>Nrg2a</e1>)-ErbB2/3-<e2>AKT</e2> signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis.","Association"
"Embryos homozygous for a GBT insertion within neuregulin 2a (<e1>nrg2a</e1>) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-<e2>AKT</e2> signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis.","Association"
"Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (<e1>Nrg2a</e1>)-ErbB2/3-<e2>AKT</e2> signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis.","Association"
"Embryos homozygous for a GBT insertion within neuregulin 2a (<e1>nrg2a</e1>) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-<e2>AKT</e2> signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis.","Association"
"Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (<e1>Nrg2a</e1>)-ErbB2/3-<e2>AKT</e2> signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis.","Association"
"Mutation analysis of CHRNA1, CHRNB1, CHRND, and <e1>RAPSN</e1> genes in multiple pterygium syndrome/<e2>fetal akinesia</e2> patients.","Negative_Correlation"
"No CHRNA1, CHRNB1, or CHRND mutations were detected, but a homozygous RAPSN frameshift mutation, <e1>c.1177-1178delAA</e1>, was identified in a family with three children affected with lethal <e2>fetal akinesia</e2> sequence.","Positive_Correlation"
"Functional studies were consistent with the hypothesis that whereas incomplete loss of <e1>rapsyn</e1> function may cause <e2>congenital myasthenia</e2>, more severe loss of function can result in a lethal fetal akinesia phenotype.","Negative_Correlation"
"Previously, <e1>RAPSN</e1> mutations have been reported in <e2>congenital myasthenia</e2>.","Negative_Correlation"
"Previously, <e1>RAPSN</e1> mutations have been reported in <e2>congenital myasthenia</e2>.","Negative_Correlation"
"Previously, <e1>RAPSN</e1> mutations have been reported in <e2>congenital myasthenia</e2>.","Negative_Correlation"
"Functional studies were consistent with the hypothesis that whereas incomplete loss of <e1>rapsyn</e1> function may cause <e2>congenital myasthenia</e2>, more severe loss of function can result in a lethal fetal akinesia phenotype.","Negative_Correlation"
"We hypothesized that mutations in acetylcholine receptor-related genes might also result in a MPS/<e2>fetal akinesia</e2> phenotype and so we analyzed 15 cases of lethal MPS/fetal akinesia without CHRNG mutations for mutations in the CHRNA1, CHRNB1, CHRND, and <e1>rapsyn</e1> (RAPSN) genes.","Negative_Correlation"
"We hypothesized that mutations in acetylcholine receptor-related genes might also result in a MPS/<e2>fetal akinesia</e2> phenotype and so we analyzed 15 cases of lethal MPS/fetal akinesia without CHRNG mutations for mutations in the CHRNA1, CHRNB1, CHRND, and rapsyn (<e1>RAPSN</e1>) genes.","Negative_Correlation"
"We hypothesized that mutations in acetylcholine receptor-related genes might also result in a MPS/<e2>fetal akinesia</e2> phenotype and so we analyzed 15 cases of lethal MPS/fetal akinesia without CHRNG mutations for mutations in the CHRNA1, CHRNB1, CHRND, and rapsyn (<e1>RAPSN</e1>) genes.","Negative_Correlation"
"We hypothesized that mutations in acetylcholine receptor-related genes might also result in a MPS/<e2>fetal akinesia</e2> phenotype and so we analyzed 15 cases of lethal MPS/fetal akinesia without CHRNG mutations for mutations in the CHRNA1, CHRNB1, CHRND, and rapsyn (<e1>RAPSN</e1>) genes.","Negative_Correlation"
"We hypothesized that mutations in acetylcholine receptor-related genes might also result in a MPS/<e2>fetal akinesia</e2> phenotype and so we analyzed 15 cases of lethal MPS/fetal akinesia without CHRNG mutations for mutations in the CHRNA1, CHRNB1, CHRND, and <e1>rapsyn</e1> (RAPSN) genes.","Negative_Correlation"
"Previously, we and others reported that recessive mutations in the <e1>embryonal acetylcholine receptor g subunit</e1> (CHRNG) can cause both lethal and nonlethal <e2>MPS</e2>, thus demonstrating that pterygia resulted from fetal akinesia.","Association"
"Previously, we and others reported that recessive mutations in the embryonal acetylcholine receptor g subunit (<e1>CHRNG</e1>) can cause both lethal and nonlethal <e2>MPS</e2>, thus demonstrating that pterygia resulted from fetal akinesia.","Association"
"Previously, we and others reported that recessive mutations in the embryonal acetylcholine receptor g subunit (<e1>CHRNG</e1>) can cause both lethal and nonlethal <e2>MPS</e2>, thus demonstrating that pterygia resulted from fetal akinesia.","Association"
"Pure monosomy and pure trisomy of 13q21.2-31.1 consequent to a familial insertional translocation: exclusion of <e2>PCDH9</e2> as the responsible gene for <e1>autosomal dominant auditory neuropathy</e1> (AUNA1).","Association"
"Pure monosomy and pure trisomy of 13q21.2-31.1 consequent to a familial insertional translocation: exclusion of <e2>PCDH9</e2> as the responsible gene for autosomal dominant auditory neuropathy (<e1>AUNA1</e1>).","Association"
"As the <e1>AUNA1</e1> deafness locus on 13q14-21 overlaps the IT in the <e2>PCDH9</e2> (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families.","Association"
"As the <e1>AUNA1</e1> deafness locus on 13q14-21 overlaps the IT in the <e2>PCDH9</e2> (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families.","Association"
"As the <e1>AUNA1</e1> deafness locus on 13q14-21 overlaps the IT in the <e2>PCDH9</e2> (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families.","Association"
"As the <e1>AUNA1</e1> deafness locus on 13q14-21 overlaps the IT in the <e2>PCDH9</e2> (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families.","Association"
"As the AUNA1 <e1>deafness</e1> locus on 13q14-21 overlaps the IT in the <e2>PCDH9</e2> (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families.","Association"
"As the AUNA1 <e1>deafness</e1> locus on 13q14-21 overlaps the IT in the <e2>PCDH9</e2> (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families.","Association"
"As the AUNA1 <e1>deafness</e1> locus on 13q14-21 overlaps the IT in the <e2>PCDH9</e2> (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families.","Association"
"As the AUNA1 <e1>deafness</e1> locus on 13q14-21 overlaps the IT in the <e2>PCDH9</e2> (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families.","Association"
"As the AUNA1 <e1>deafness</e1> locus on 13q14-21 overlaps the IT in the <e2>PCDH9</e2> (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families.","Association"
"As the AUNA1 <e1>deafness</e1> locus on 13q14-21 overlaps the IT in the <e2>PCDH9</e2> (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families.","Association"
"A Taiwanese boy with <e1>congenital generalized lipodystrophy</e1> caused by homozygous Ile262fs mutation in the <e2>BSCL2</e2> gene.","Association"
"A Taiwanese boy with <e1>congenital generalized lipodystrophy</e1> caused by homozygous <e2>Ile262fs</e2> mutation in the BSCL2 gene.","Positive_Correlation"
"Mutations in the <e1>BSCL2</e1> gene are known to result in CGL2, a more severe phenotype than CGL1, with earlier onset, more extensive fat loss and biochemical changes, more severe <e2>intellectual impairment</e2>, and more severe cardiomyopathy.","Association"
"Mutations in the <e1>BSCL2</e1> gene are known to result in CGL2, a more severe phenotype than CGL1, with earlier onset, more extensive fat loss and biochemical changes, more severe <e2>intellectual impairment</e2>, and more severe cardiomyopathy.","Association"
"Mutations in the <e1>BSCL2</e1> gene are known to result in CGL2, a more severe phenotype than CGL1, with earlier onset, more extensive fat loss and biochemical changes, more severe <e2>intellectual impairment</e2>, and more severe cardiomyopathy.","Association"
"Mutations in the <e1>BSCL2</e1> gene are known to result in CGL2, a more severe phenotype than CGL1, with earlier onset, more extensive fat loss and biochemical changes, more severe intellectual impairment, and more severe <e2>cardiomyopathy</e2>.","Association"
"Mutations in the <e1>BSCL2</e1> gene are known to result in CGL2, a more severe phenotype than CGL1, with earlier onset, more extensive fat loss and biochemical changes, more severe intellectual impairment, and more severe <e2>cardiomyopathy</e2>.","Association"
"Mutations in the <e1>BSCL2</e1> gene are known to result in CGL2, a more severe phenotype than CGL1, with earlier onset, more extensive fat loss and biochemical changes, more severe intellectual impairment, and more severe <e2>cardiomyopathy</e2>.","Association"
"Mutations in the <e2>BSCL2</e2> gene are known to result in <e1>CGL</e1>2, a more severe phenotype than CGL1, with earlier onset, more extensive fat loss and biochemical changes, more severe intellectual impairment, and more severe cardiomyopathy.","Association"
"Mutations in the <e2>BSCL2</e2> gene are known to result in <e1>CGL2</e1>, a more severe phenotype than CGL1, with earlier onset, more extensive fat loss and biochemical changes, more severe intellectual impairment, and more severe cardiomyopathy.","Association"
"Mutations in the <e2>BSCL2</e2> gene are known to result in CGL2, a more severe phenotype than <e1>CGL1</e1>, with earlier onset, more extensive fat loss and biochemical changes, more severe intellectual impairment, and more severe cardiomyopathy.","Association"
"Mutations in the <e2>BSCL2</e2> gene are known to result in <e1>CGL</e1>2, a more severe phenotype than CGL1, with earlier onset, more extensive fat loss and biochemical changes, more severe intellectual impairment, and more severe cardiomyopathy.","Association"
"Mutations in the <e2>BSCL2</e2> gene are known to result in <e1>CGL</e1>2, a more severe phenotype than CGL1, with earlier onset, more extensive fat loss and biochemical changes, more severe intellectual impairment, and more severe cardiomyopathy.","Association"
"Concordance between <e1>PIK3CA</e1> mutations in endoscopic biopsy and surgically resected specimens of <e2>esophageal squamous cell carcinoma</e2>.","Association"
"METHODS: We examined five hotspot mutations in the PIK3CA gene (E542K, E545K, <e1>E546K</e1>, H1047R, and H1047L) in formalin-fixed and paraffin-embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 patients undergoing curative resection for <e2>ESCC</e2> between 2000 and 2011 using a Luminex technology-based multiplex gene mutation detection kit.","Association"
"METHODS: We examined five hotspot mutations in the PIK3CA gene (E542K, <e1>E545K</e1>, E546K, H1047R, and H1047L) in formalin-fixed and paraffin-embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 patients undergoing curative resection for <e2>ESCC</e2> between 2000 and 2011 using a Luminex technology-based multiplex gene mutation detection kit.","Association"
"METHODS: We examined five hotspot mutations in the PIK3CA gene (<e1>E542K</e1>, E545K, E546K, H1047R, and H1047L) in formalin-fixed and paraffin-embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 patients undergoing curative resection for <e2>ESCC</e2> between 2000 and 2011 using a Luminex technology-based multiplex gene mutation detection kit.","Association"
"METHODS: We examined five hotspot mutations in the PIK3CA gene (E542K, E545K, E546K, <e1>H1047R</e1>, and H1047L) in formalin-fixed and paraffin-embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 patients undergoing curative resection for <e2>ESCC</e2> between 2000 and 2011 using a Luminex technology-based multiplex gene mutation detection kit.","Association"
"METHODS: We examined five hotspot mutations in the PIK3CA gene (E542K, E545K, E546K, H1047R, and <e1>H1047L</e1>) in formalin-fixed and paraffin-embedded tissue sections of paired endoscopic biopsy and surgically resected specimens from 181 patients undergoing curative resection for <e2>ESCC</e2> between 2000 and 2011 using a Luminex technology-based multiplex gene mutation detection kit.","Association"
"BACKGROUND: <e1>PIK3CA</e1> mutations are expected to be potential therapeutic targets for <e2>esophageal squamous cell carcinoma</e2> (ESCC).","Association"
"BACKGROUND: <e1>PIK3CA</e1> mutations are expected to be potential therapeutic targets for <e2>esophageal squamous cell carcinoma</e2> (ESCC).","Association"
"BACKGROUND: <e1>PIK3CA</e1> mutations are expected to be potential therapeutic targets for <e2>esophageal squamous cell carcinoma</e2> (ESCC).","Association"
"BACKGROUND: <e1>PIK3CA</e1> mutations are expected to be potential therapeutic targets for <e2>esophageal squamous cell carcinoma</e2> (ESCC).","Association"
"BACKGROUND: <e1>PIK3CA</e1> mutations are expected to be potential therapeutic targets for <e2>esophageal squamous cell carcinoma</e2> (ESCC).","Association"
"BACKGROUND: <e1>PIK3CA</e1> mutations are expected to be potential therapeutic targets for <e2>esophageal squamous cell carcinoma</e2> (ESCC).","Association"
"BACKGROUND: <e1>PIK3CA</e1> mutations are expected to be potential therapeutic targets for <e2>esophageal squamous cell carcinoma</e2> (ESCC).","Association"
"BACKGROUND: <e1>PIK3CA</e1> mutations are expected to be potential therapeutic targets for <e2>esophageal squamous cell carcinoma</e2> (ESCC).","Association"
"BACKGROUND: <e1>PIK3CA</e1> mutations are expected to be potential therapeutic targets for <e2>esophageal squamous cell carcinoma</e2> (ESCC).","Association"
"BACKGROUND: <e1>PIK3CA</e1> mutations are expected to be potential therapeutic targets for <e2>esophageal squamous cell carcinoma</e2> (ESCC).","Association"
"Polymorphisms of the DNA <e1>mismatch repair</e1> gene HMSH2 in <e2>breast cancer</e2> occurence and progression.","Association"
"Polymorphisms of the DNA mismatch repair gene <e1>HMSH2</e1> in <e2>breast cancer</e2> occurence and progression.","Association"
"We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a <e2>G --> A transition at 1032 position</e2> resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and <e1>breast cancer</e1> risk and cancer progression.","Association"
"We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a <e2>G --> A transition at 1032 position</e2> resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and <e1>breast cancer</e1> risk and cancer progression.","Association"
"We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a <e2>G --> A transition at 1032 position</e2> resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and <e1>breast cancer</e1> risk and cancer progression.","Association"
"We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a <e2>G --> A transition at 1032 position</e2> resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and <e1>breast cancer</e1> risk and cancer progression.","Association"
"We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a <e2>G --> A transition at 1032 position</e2> resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and <e1>breast cancer</e1> risk and cancer progression.","Association"
"Therefore, MMR may play a role in the <e1>breast carcinogenesis</e1> and the <e2>Gly322Asp</e2> polymorphism of the hMSH2 gene may be considered as a potential marker in breast cancer.","Association"
"We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a <e2>G --> A transition at 1032 position</e2> resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and <e1>breast cancer</e1> risk and cancer progression.","Association"
"We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an <e1>A --> G transition at 127 position</e1> producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and <e2>breast cancer</e2> risk and cancer progression.","Association"
"We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an A --> G transition at 127 position producing an <e1>Asn --> Ser substitution at codon 127</e1> (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and <e2>breast cancer</e2> risk and cancer progression.","Association"
"We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the <e1>Asn127Ser</e1> polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and <e2>breast cancer</e2> risk and cancer progression.","Association"
"We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an <e1>A --> G transition at 127 position</e1> producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and breast <e2>cancer</e2> risk and cancer progression.","Association"
"We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an A --> G transition at 127 position producing an <e1>Asn --> Ser substitution at codon 127</e1> (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and breast <e2>cancer</e2> risk and cancer progression.","Association"
"We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the <e1>Asn127Ser</e1> polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and breast <e2>cancer</e2> risk and cancer progression.","Association"
"The importance of genetic variability of the components of <e1>mismatch repair</e1> (MMR) genes is well documented in <e2>colorectal cancer</e2>, but little is known about its role in breast cancer.","Association"
"The importance of genetic variability of the components of mismatch repair (<e1>MMR</e1>) genes is well documented in <e2>colorectal cancer</e2>, but little is known about its role in breast cancer.","Association"
"The importance of genetic variability of the components of mismatch repair (<e1>MMR</e1>) genes is well documented in <e2>colorectal cancer</e2>, but little is known about its role in breast cancer.","Association"
"The importance of genetic variability of the components of mismatch repair (<e1>MMR</e1>) genes is well documented in <e2>colorectal cancer</e2>, but little is known about its role in breast cancer.","Association"
"The importance of genetic variability of the components of <e1>mismatch repair</e1> (MMR) genes is well documented in colorectal cancer, but little is known about its role in <e2>breast cancer</e2>.","Association"
"The importance of genetic variability of the components of mismatch repair (<e1>MMR</e1>) genes is well documented in colorectal cancer, but little is known about its role in <e2>breast cancer</e2>.","Association"
"We performed a case-control study to test the association between two polymorphisms in the <e1>hMSH2</e1> gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and <e2>breast cancer</e2> risk and cancer progression.","Association"
"The importance of genetic variability of the components of mismatch repair (<e1>MMR</e1>) genes is well documented in colorectal cancer, but little is known about its role in <e2>breast cancer</e2>.","Association"
"We performed a case-control study to test the association between two polymorphisms in the <e1>hMSH2</e1> gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and <e2>breast cancer</e2> risk and cancer progression.","Association"
"The importance of genetic variability of the components of mismatch repair (<e1>MMR</e1>) genes is well documented in colorectal cancer, but little is known about its role in <e2>breast cancer</e2>.","Association"
"We performed a case-control study to test the association between two polymorphisms in the <e1>hMSH2</e1> gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and <e2>breast cancer</e2> risk and cancer progression.","Association"
"The importance of genetic variability of the components of <e1>mismatch repair</e1> (MMR) genes is well documented in colorectal <e2>cancer</e2>, but little is known about its role in breast cancer.","Association"
"The importance of genetic variability of the components of mismatch repair (<e1>MMR</e1>) genes is well documented in colorectal <e2>cancer</e2>, but little is known about its role in breast cancer.","Association"
"We performed a case-control study to test the association between two polymorphisms in the <e1>hMSH2</e1> gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and breast <e2>cancer</e2> risk and cancer progression.","Association"
"The importance of genetic variability of the components of mismatch repair (<e1>MMR</e1>) genes is well documented in colorectal <e2>cancer</e2>, but little is known about its role in breast cancer.","Association"
"We performed a case-control study to test the association between two polymorphisms in the <e1>hMSH2</e1> gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and breast <e2>cancer</e2> risk and cancer progression.","Association"
"The importance of genetic variability of the components of mismatch repair (<e1>MMR</e1>) genes is well documented in colorectal <e2>cancer</e2>, but little is known about its role in breast cancer.","Association"
"We performed a case-control study to test the association between two polymorphisms in the <e1>hMSH2</e1> gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and breast <e2>cancer</e2> risk and cancer progression.","Association"
"Atorvastatin prevented and reversed <e1>dexamethasone</e1>-induced <e2>hypertension</e2> in the rat.","Positive_Correlation"
"<e1>Atorvastatin</e1> prevented and reversed dexamethasone-induced <e2>hypertension</e2> in the rat.","Negative_Correlation"
"<e1>Atorvastatin</e1> prevented and reversed <e2>dexamethasone</e2>-induced hypertension in the rat.","Negative_Correlation"
"Plasma nitrate/nitrite (<e1>NOx</e1>) was decreased in <e2>dex</e2>-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).","Negative_Correlation"
"Plasma nitrate/nitrite (<e1>NOx</e1>) was decreased in <e2>dex</e2>-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).","Negative_Correlation"
"Plasma nitrate/<e1>nitrite</e1> (NOx) was decreased in <e2>dex</e2>-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).","Negative_Correlation"
"Plasma <e1>nitrate</e1>/nitrite (NOx) was decreased in <e2>dex</e2>-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).","Negative_Correlation"
"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma <e2>superoxide</e2> (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml <e1>dex</e1>, P < 0.001).","Positive_Correlation"
"<e1>Dex</e1> increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma <e2>superoxide</e2> (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).","Positive_Correlation"
"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma <e2>superoxide</e2> (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml <e1>dex</e1>, P < 0.001).","Positive_Correlation"
"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma <e2>superoxide</e2> (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml <e1>dex</e1>, P < 0.001).","Positive_Correlation"
"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma <e2>superoxide</e2> (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml <e1>dex</e1>, P < 0.001).","Positive_Correlation"
"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma <e2>superoxide</e2> (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml <e1>dex</e1>, P < 0.001).","Positive_Correlation"
"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma <e2>superoxide</e2> (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml <e1>dex</e1>, P < 0.001).","Positive_Correlation"
"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma <e2>superoxide</e2> (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml <e1>dex</e1>, P < 0.001).","Positive_Correlation"
"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma <e2>superoxide</e2> (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml <e1>dex</e1>, P < 0.001).","Positive_Correlation"
"To assess the antioxidant effects of atorvastatin (atorva) on <e1>dexamethasone</e1> (dex)-induced <e2>hypertension</e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Positive_Correlation"
"To assess the antioxidant effects of atorvastatin (atorva) on <e1>dex</e1>amethasone (dex)-induced <e2>hypertension</e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Positive_Correlation"
"To assess the antioxidant effects of atorvastatin (atorva) on <e1>dex</e1>amethasone (dex)-induced <e2>hypertension</e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Positive_Correlation"
"To assess the antioxidant effects of atorvastatin (atorva) on <e1>dex</e1>amethasone (dex)-induced <e2>hypertension</e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Positive_Correlation"
"To assess the antioxidant effects of atorvastatin (atorva) on <e1>dex</e1>amethasone (dex)-induced <e2>hypertension</e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Positive_Correlation"
"To assess the antioxidant effects of atorvastatin (atorva) on <e1>dex</e1>amethasone (dex)-induced <e2>hypertension</e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Positive_Correlation"
"To assess the antioxidant effects of atorvastatin (atorva) on <e1>dex</e1>amethasone (dex)-induced <e2>hypertension</e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Positive_Correlation"
"To assess the antioxidant effects of atorvastatin (atorva) on <e1>dex</e1>amethasone (dex)-induced <e2>hypertension</e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Positive_Correlation"
"To assess the antioxidant effects of atorvastatin (atorva) on <e1>dex</e1>amethasone (dex)-induced <e2>hypertension</e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Positive_Correlation"
"To assess the antioxidant effects of atorvastatin (atorva) on <e1>dexamethasone</e1> (dex)-induced <e2>hypertension</e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Positive_Correlation"
"To assess the antioxidant effects of <e1>atorvastatin</e1> (atorva) on dexamethasone (dex)-induced <e2>hypertension</e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Negative_Correlation"
"To assess the antioxidant effects of <e1>atorva</e1>statin (atorva) on dexamethasone (dex)-induced <e2>hypertension</e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Negative_Correlation"
"To assess the antioxidant effects of <e1>atorva</e1>statin (atorva) on dexamethasone (dex)-induced <e2>hypertension</e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Negative_Correlation"
"To assess the antioxidant effects of <e1>atorva</e1>statin (atorva) on dexamethasone (dex)-induced <e2>hypertension</e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Negative_Correlation"
"<e1>Atorva</e1> reversed dex-induced <e2>hypertension</e2> (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).","Negative_Correlation"
"To assess the antioxidant effects of <e1>atorva</e1>statin (atorva) on dexamethasone (dex)-induced <e2>hypertension</e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Negative_Correlation"
"<e1>Atorva</e1> reversed dex-induced <e2>hypertension</e2> (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).","Negative_Correlation"
"To assess the antioxidant effects of <e1>atorvastatin</e1> (atorva) on dexamethasone (dex)-induced <e2>hypertension</e2>, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Negative_Correlation"
"To assess the antioxidant effects of <e1>atorvastatin</e1> (atorva) on <e2>dexamethasone</e2> (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Negative_Correlation"
"To assess the antioxidant effects of <e1>atorva</e1>statin (atorva) on <e2>dexamethasone</e2> (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Negative_Correlation"
"To assess the antioxidant effects of <e1>atorva</e1>statin (atorva) on <e2>dexamethasone</e2> (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Negative_Correlation"
"To assess the antioxidant effects of <e1>atorva</e1>statin (atorva) on <e2>dexamethasone</e2> (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Negative_Correlation"
"<e1>Atorva</e1> reversed <e2>dex</e2>-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).","Negative_Correlation"
"To assess the antioxidant effects of <e1>atorva</e1>statin (atorva) on <e2>dexamethasone</e2> (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Negative_Correlation"
"<e1>Atorva</e1> reversed <e2>dex</e2>-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).","Negative_Correlation"
"To assess the antioxidant effects of <e1>atorvastatin</e1> (atorva) on <e2>dexamethasone</e2> (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.","Negative_Correlation"
"Variants of coagulation factors [factor V 1691G>A (factor V Leiden), factor V 4070A>G (factor V HR2 haplotype), factor VII Arg353Gln, factor XIII Val34Leu, beta-fibrinogen -455G>A, prothrombin 20210G>A], coagulation inhibitors [tissue factor pathway inhibitor 536C>T, thrombomodulin 127G>A], fibrinolytic factors [angiotensin converting enzyme intron 16 insertion/deletion, factor VII-activating protease 1601G>A (FSAP Marburg I), plasminogen activator inhibitor 1-675 insertion/deletion (5G/4G), tissue plasminogen activator intron h deletion/insertion], and other factors implicated in influencing susceptibility to <e2>thromboembolic diseases</e2> [apolipoprotein E2/E3/E4, glycoprotein Ia 807C>T, methylenetetrahydrofolate reductase <e1>677C>T</e1>] were included.","Association"
"Variants of coagulation factors [factor V 1691G>A (factor V Leiden), factor V 4070A>G (factor V HR2 haplotype), factor VII Arg353Gln, factor XIII Val34Leu, beta-fibrinogen -455G>A, prothrombin 20210G>A], coagulation inhibitors [tissue factor pathway inhibitor 536C>T, thrombomodulin 127G>A], fibrinolytic factors [angiotensin converting enzyme intron 16 insertion/deletion, factor VII-activating protease 1601G>A (FSAP Marburg I), plasminogen activator inhibitor 1-675 insertion/deletion (5G/4G), tissue plasminogen activator intron h deletion/insertion], and other factors implicated in influencing susceptibility to <e2>thromboembolic diseases</e2> [apolipoprotein E2/E3/E4, glycoprotein Ia 807C>T, <e1>methylenetetrahydrofolate reductase</e1> 677C>T] were included.","Association"
"Variants of coagulation factors [factor V 1691G>A (factor V Leiden), factor V 4070A>G (factor V HR2 haplotype), factor VII Arg353Gln, factor XIII Val34Leu, beta-fibrinogen -455G>A, prothrombin 20210G>A], coagulation inhibitors [tissue factor pathway inhibitor 536C>T, thrombomodulin 127G>A], fibrinolytic factors [angiotensin converting enzyme intron 16 insertion/deletion, factor VII-activating protease 1601G>A (FSAP Marburg I), plasminogen activator inhibitor 1-675 insertion/deletion (5G/4G), tissue plasminogen activator intron h deletion/insertion], and other factors implicated in influencing susceptibility to <e2>thromboembolic diseases</e2> [apolipoprotein E2/E3/E4, glycoprotein Ia <e1>807C>T</e1>, methylenetetrahydrofolate reductase 677C>T] were included.","Association"
"Variants of coagulation factors [factor V 1691G>A (factor V Leiden), factor V 4070A>G (factor V HR2 haplotype), factor VII Arg353Gln, factor XIII Val34Leu, beta-fibrinogen -455G>A, prothrombin 20210G>A], coagulation inhibitors [tissue factor pathway inhibitor 536C>T, thrombomodulin 127G>A], fibrinolytic factors [angiotensin converting enzyme intron 16 insertion/deletion, factor VII-activating protease 1601G>A (FSAP Marburg I), plasminogen activator inhibitor 1-675 insertion/deletion (5G/4G), tissue plasminogen activator intron h deletion/insertion], and other factors implicated in influencing susceptibility to <e2>thromboembolic diseases</e2> [apolipoprotein E2/E3/E4, glycoprotein Ia <e1>807C>T</e1>, methylenetetrahydrofolate reductase 677C>T] were included.","Association"
"Variants of coagulation factors [factor V 1691G>A (factor V Leiden), factor V 4070A>G (factor V HR2 haplotype), factor VII Arg353Gln, factor XIII Val34Leu, beta-fibrinogen -455G>A, prothrombin 20210G>A], coagulation inhibitors [tissue factor pathway inhibitor 536C>T, thrombomodulin 127G>A], fibrinolytic factors [angiotensin converting enzyme intron 16 insertion/deletion, factor VII-activating protease 1601G>A (FSAP Marburg I), plasminogen activator inhibitor 1-675 insertion/deletion (5G/4G), tissue plasminogen activator intron h deletion/insertion], and other factors implicated in influencing susceptibility to <e2>thromboembolic diseases</e2> [<e1>apolipoprotein E2/E3/E4, glycoprotein Ia</e1> 807C>T, methylenetetrahydrofolate reductase 677C>T] were included.","Association"
"Variants of coagulation factors [factor V 1691G>A (factor V Leiden), factor V 4070A>G (factor V HR2 haplotype), factor VII Arg353Gln, factor XIII Val34Leu, beta-fibrinogen -455G>A, prothrombin 20210G>A], coagulation inhibitors [tissue factor pathway inhibitor 536C>T, thrombomodulin 127G>A], fibrinolytic factors [angiotensin converting enzyme intron 16 insertion/deletion, factor VII-activating protease 1601G>A (FSAP Marburg I), plasminogen activator inhibitor 1-675 insertion/deletion (5G/4G), tissue plasminogen activator intron h deletion/insertion], and other factors implicated in influencing susceptibility to <e2>thromboembolic diseases</e2> [apolipoprotein E2/E3/E4, <e1>glycoprotein Ia</e1> 807C>T, methylenetetrahydrofolate reductase 677C>T] were included.","Association"
"Necrotising fasciitis after bortezomib and <e1>dexamethasone</e1>-containing regimen in an elderly patient of <e2>Waldenstrom macroglobulinaemia</e2>.","Negative_Correlation"
"Necrotising fasciitis after <e1>bortezomib</e1> and dexamethasone-containing regimen in an elderly patient of <e2>Waldenstrom macroglobulinaemia</e2>.","Negative_Correlation"
"Necrotising fasciitis after <e1>bortezomib</e1> and <e2>dexamethasone</e2>-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.","Cotreatment"
"<e1>Necrotising fasciitis</e1> after bortezomib and <e2>dexamethasone</e2>-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.","Positive_Correlation"
"<e1>Necrotising fasciitis</e1> after <e2>bortezomib</e2> and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.","Positive_Correlation"
"Bortezomib and high-dose <e2>dexamethasone</e2>-containing regimens are considered to be generally tolerable with few severe <e1>bacterial infections</e1> in patients with B-cell malignancies.","Positive_Correlation"
"Bortezomib and high-dose <e2>dexamethasone</e2>-containing regimens are considered to be generally tolerable with few severe <e1>bacterial infections</e1> in patients with B-cell malignancies.","Positive_Correlation"
"<e2>Bortezomib</e2> and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe <e1>bacterial infections</e1> in patients with B-cell malignancies.","Positive_Correlation"
"<e2>Bortezomib</e2> and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe <e1>bacterial infections</e1> in patients with B-cell malignancies.","Positive_Correlation"
"We report a case of a 76-year-old man with <e2>Waldenstrom macroglobulinaemia</e2> who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and <e1>rituximab</e1>.","Negative_Correlation"
"Bortezomib and high-dose <e1>dexamethasone</e1>-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell <e2>malignancies</e2>.","Negative_Correlation"
"Bortezomib and high-dose <e1>dexamethasone</e1>-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell <e2>malignancies</e2>.","Negative_Correlation"
"Bortezomib and high-dose <e1>dexamethasone</e1>-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell <e2>malignancies</e2>.","Negative_Correlation"
"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose <e1>dexamethasone</e1> and <e2>rituximab</e2>.","Cotreatment"
"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose <e1>dexamethasone</e1> and <e2>rituximab</e2>.","Cotreatment"
"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose <e1>dexamethasone</e1> and <e2>rituximab</e2>.","Cotreatment"
"We report a case of a 76-year-old man with <e2>Waldenstrom macroglobulinaemia</e2> who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose <e1>dexamethasone</e1> and rituximab.","Negative_Correlation"
"We report a case of a 76-year-old man with <e2>Waldenstrom macroglobulinaemia</e2> who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose <e1>dexamethasone</e1> and rituximab.","Negative_Correlation"
"We report a case of a 76-year-old man with <e2>Waldenstrom macroglobulinaemia</e2> who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose <e1>dexamethasone</e1> and rituximab.","Negative_Correlation"
"<e1>Bortezomib</e1> and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell <e2>malignancies</e2>.","Negative_Correlation"
"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with <e1>bortezomib</e1>, high-dose dexamethasone and <e2>rituximab</e2>.","Cotreatment"
"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with <e1>bortezomib</e1>, high-dose dexamethasone and <e2>rituximab</e2>.","Cotreatment"
"We report a case of a 76-year-old man with <e2>Waldenstrom macroglobulinaemia</e2> who suffered necrotising fasciitis without neutropenia after the combination treatment with <e1>bortezomib</e1>, high-dose dexamethasone and rituximab.","Negative_Correlation"
"We report a case of a 76-year-old man with <e2>Waldenstrom macroglobulinaemia</e2> who suffered necrotising fasciitis without neutropenia after the combination treatment with <e1>bortezomib</e1>, high-dose dexamethasone and rituximab.","Negative_Correlation"
"<e1>Bortezomib</e1> and high-dose <e2>dexamethasone</e2>-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies.","Cotreatment"
"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with <e1>bortezomib</e1>, high-dose <e2>dexamethasone</e2> and rituximab.","Cotreatment"
"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with <e1>bortezomib</e1>, high-dose <e2>dexamethasone</e2> and rituximab.","Cotreatment"
"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered <e1>necrotising fasciitis</e1> without neutropenia after the combination treatment with bortezomib, high-dose <e2>dexamethasone</e2> and rituximab.","Positive_Correlation"
"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered <e1>necrotising fasciitis</e1> without neutropenia after the combination treatment with <e2>bortezomib</e2>, high-dose dexamethasone and rituximab.","Positive_Correlation"
"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a <e2>dyskinetic</e2> state induced by continuous <e1>apomorphine</e1> infusion.","Positive_Correlation"
"The neural mechanisms and circuitry involved in <e1>levodopa</e1>-induced <e2>dyskinesia</e2> are unclear.","Positive_Correlation"
"<e2>Angiotensin converting enzyme</e2> gene polymorphism in Turkish <e1>asthmatic</e1> patients.","Association"
"<e1>Asthma</e1>tics with the ID <e2>ACE</e2> genotype showed a higher frequency of drug allergies, although this was not statistically significant (p = 0.08).","Association"
"Several candidate genes have been identified with a potential role in the pathogenesis of <e1>asthma</e1>, including the <e2>angiotensin converting enzyme</e2> (ACE) gene.","Association"
"We aimed to investigate the frequency of an <e2>ACE</e2> gene polymorphism in Turkish <e1>asthmatic</e1> patients and to determine its impact on clinical parameters and disease severity.","Association"
"We aimed to investigate the frequency of an <e2>ACE</e2> gene polymorphism in Turkish <e1>asthmatic</e1> patients and to determine its impact on clinical parameters and disease severity.","Association"
"Several candidate genes have been identified with a potential role in the pathogenesis of <e1>asthma</e1>, including the <e2>angiotensin converting enzyme</e2> (ACE) gene.","Association"
"The frequency of the <e2>ACE</e2> genotypes (I = insertion and D = deletion) among <e1>asthmatics</e1> and controls were compared: asthmatics showed a 40.2% prevalence of the DD genotype (n = 39), ID was 45.4% (n = 44), and II was 14.4% (n = 14.4).","Association"
"The frequency of the <e2>ACE</e2> genotypes (I = insertion and D = deletion) among <e1>asthmatics</e1> and controls were compared: asthmatics showed a 40.2% prevalence of the DD genotype (n = 39), ID was 45.4% (n = 44), and II was 14.4% (n = 14.4).","Association"
"The frequency of the <e2>ACE</e2> genotypes (I = insertion and D = deletion) among <e1>asthmatics</e1> and controls were compared: asthmatics showed a 40.2% prevalence of the DD genotype (n = 39), ID was 45.4% (n = 44), and II was 14.4% (n = 14.4).","Association"
"<e1>Asthmatics</e1> with the ID <e2>ACE</e2> genotype showed a higher frequency of drug allergies, although this was not statistically significant (p = 0.08).","Association"
"<e1>Asthmatics</e1> with the ID <e2>ACE</e2> genotype showed a higher frequency of drug allergies, although this was not statistically significant (p = 0.08).","Association"
"We aimed to investigate the frequency of an <e2>ACE</e2> gene polymorphism in Turkish <e1>asthmatic</e1> patients and to determine its impact on clinical parameters and disease severity.","Association"
"Several candidate genes have been identified with a potential role in the pathogenesis of <e1>asthma</e1>, including the <e2>angiotensin converting enzyme</e2> (ACE) gene.","Association"
"We aimed to investigate the frequency of an <e2>ACE</e2> gene polymorphism in Turkish <e1>asthmatic</e1> patients and to determine its impact on clinical parameters and disease severity.","Association"
"The frequency of the <e2>ACE</e2> genotypes (I = insertion and D = deletion) among <e1>asthmatics</e1> and controls were compared: asthmatics showed a 40.2% prevalence of the DD genotype (n = 39), ID was 45.4% (n = 44), and II was 14.4% (n = 14.4).","Association"
"Several candidate genes have been identified with a potential role in the pathogenesis of <e1>asthma</e1>, including the <e2>angiotensin converting enzyme</e2> (ACE) gene.","Association"
"Our data underscore the major role of <e2>PPARa</e2> in regulation of hepatic lipid and xenobiotic metabolism in human liver and reveal a marked immuno-suppressive/anti-inflammatory effect of PPARa in human liver slices that may be therapeutically relevant for <e1>non-alcoholic fatty liver disease</e1>.","Association"
"BACKGROUND: Studies in mice have shown that <e1>PPARa</e1> is an important regulator of <e2>lipid</e2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.","Association"
"Many genes induced by PPARa activation were involved in <e1>lipid</e1> metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Association"
"Many genes induced by PPARa activation were involved in <e1>lipid</e1> metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Association"
"Many genes induced by PPARa activation were involved in <e1>lipid</e1> metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Association"
"Many genes induced by PPARa activation were involved in <e1>lipid</e1> metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Association"
"Many genes induced by PPARa activation were involved in <e1>lipid</e1> metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Association"
"Many genes induced by PPARa activation were involved in <e1>lipid</e1> metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Association"
"Many genes induced by PPARa activation were involved in <e1>lipid</e1> metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Association"
"Many genes induced by PPARa activation were involved in <e1>lipid</e1> metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Association"
"Many genes induced by PPARa activation were involved in <e1>lipid</e1> metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Association"
"Many genes induced by PPARa activation were involved in <e1>lipid</e1> metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Association"
"Many genes induced by PPARa activation were involved in <e1>lipid</e1> metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Association"
"Many genes induced by PPARa activation were involved in <e1>lipid</e1> metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Association"
"RESULTS: Quantitative PCR indicated that <e2>PPARa</e2> is well expressed in human liver and human liver slices and that the classical PPARa targets PLIN2, VLDLR, ANGPTL4, CPT1A and <e1>PDK4</e1> are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e2>PPARa</e2> is well expressed in human liver and human liver slices and that the classical PPARa targets PLIN2, VLDLR, ANGPTL4, <e1>CPT1A</e1> and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e2>PPARa</e2> is well expressed in human liver and human liver slices and that the classical PPARa targets PLIN2, VLDLR, <e1>ANGPTL4</e1>, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e2>PPARa</e2> is well expressed in human liver and human liver slices and that the classical PPARa targets PLIN2, <e1>VLDLR</e1>, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"In particular, <e1>PPARa</e1> activation markedly suppressed immunity/<e2>inflammation</e2>-related genes in human liver slices but not in primary hepatocytes.","Association"
"In particular, <e1>PPARa</e1> activation markedly suppressed immunity/<e2>inflammation</e2>-related genes in human liver slices but not in primary hepatocytes.","Association"
"In particular, <e1>PPARa</e1> activation markedly suppressed immunity/<e2>inflammation</e2>-related genes in human liver slices but not in primary hepatocytes.","Association"
"In particular, <e1>PPARa</e1> activation markedly suppressed immunity/<e2>inflammation</e2>-related genes in human liver slices but not in primary hepatocytes.","Association"
"In particular, <e1>PPARa</e1> activation markedly suppressed immunity/<e2>inflammation</e2>-related genes in human liver slices but not in primary hepatocytes.","Association"
"In particular, <e1>PPARa</e1> activation markedly suppressed immunity/<e2>inflammation</e2>-related genes in human liver slices but not in primary hepatocytes.","Association"
"In particular, <e1>PPARa</e1> activation markedly suppressed immunity/<e2>inflammation</e2>-related genes in human liver slices but not in primary hepatocytes.","Association"
"In particular, <e1>PPARa</e1> activation markedly suppressed immunity/<e2>inflammation</e2>-related genes in human liver slices but not in primary hepatocytes.","Association"
"In particular, <e1>PPARa</e1> activation markedly suppressed immunity/<e2>inflammation</e2>-related genes in human liver slices but not in primary hepatocytes.","Association"
"In particular, <e1>PPARa</e1> activation markedly suppressed immunity/<e2>inflammation</e2>-related genes in human liver slices but not in primary hepatocytes.","Association"
"In particular, <e1>PPARa</e1> activation markedly suppressed immunity/<e2>inflammation</e2>-related genes in human liver slices but not in primary hepatocytes.","Association"
"In particular, <e1>PPARa</e1> activation markedly suppressed immunity/<e2>inflammation</e2>-related genes in human liver slices but not in primary hepatocytes.","Association"
"In particular, <e1>PPARa</e1> activation markedly suppressed immunity/<e2>inflammation</e2>-related genes in human liver slices but not in primary hepatocytes.","Association"
"In particular, <e1>PPARa</e1> activation markedly suppressed immunity/<e2>inflammation</e2>-related genes in human liver slices but not in primary hepatocytes.","Association"
"In particular, <e1>PPARa</e1> activation markedly suppressed immunity/<e2>inflammation</e2>-related genes in human liver slices but not in primary hepatocytes.","Association"
"In particular, <e1>PPARa</e1> activation markedly suppressed immunity/<e2>inflammation</e2>-related genes in human liver slices but not in primary hepatocytes.","Association"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, CA12 and <e2>VSIG10L</e2>.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, CA12 and <e2>VSIG10L</e2>.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, CA12 and <e2>VSIG10L</e2>.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, CA12 and <e2>VSIG10L</e2>.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, CA12 and <e2>VSIG10L</e2>.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, CA12 and <e2>VSIG10L</e2>.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, CA12 and <e2>VSIG10L</e2>.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, CA12 and <e2>VSIG10L</e2>.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, CA12 and <e2>VSIG10L</e2>.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, CA12 and <e2>VSIG10L</e2>.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, CA12 and <e2>VSIG10L</e2>.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, CA12 and <e2>VSIG10L</e2>.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, CA12 and <e2>VSIG10L</e2>.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, CA12 and <e2>VSIG10L</e2>.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, CA12 and <e2>VSIG10L</e2>.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, CA12 and <e2>VSIG10L</e2>.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, <e2>CA12</e2> and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, <e2>CA12</e2> and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, <e2>CA12</e2> and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, <e2>CA12</e2> and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, <e2>CA12</e2> and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, <e2>CA12</e2> and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, <e2>CA12</e2> and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, <e2>CA12</e2> and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, <e2>CA12</e2> and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, <e2>CA12</e2> and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, <e2>CA12</e2> and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, <e2>CA12</e2> and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, <e2>CA12</e2> and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, <e2>CA12</e2> and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, <e2>CA12</e2> and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, <e2>CA12</e2> and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, <e2>RHOF</e2>, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, <e2>RHOF</e2>, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, <e2>RHOF</e2>, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, <e2>RHOF</e2>, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, <e2>RHOF</e2>, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, <e2>RHOF</e2>, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, <e2>RHOF</e2>, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, <e2>RHOF</e2>, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, <e2>RHOF</e2>, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, <e2>RHOF</e2>, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, <e2>RHOF</e2>, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, <e2>RHOF</e2>, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, <e2>RHOF</e2>, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, <e2>RHOF</e2>, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, <e2>RHOF</e2>, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, <e2>RHOF</e2>, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including <e2>TSKU</e2>, RHOF, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including <e2>TSKU</e2>, RHOF, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including <e2>TSKU</e2>, RHOF, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including <e2>TSKU</e2>, RHOF, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including <e2>TSKU</e2>, RHOF, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including <e2>TSKU</e2>, RHOF, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including <e2>TSKU</e2>, RHOF, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including <e2>TSKU</e2>, RHOF, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including <e2>TSKU</e2>, RHOF, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including <e2>TSKU</e2>, RHOF, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including <e2>TSKU</e2>, RHOF, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including <e2>TSKU</e2>, RHOF, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including <e2>TSKU</e2>, RHOF, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including <e2>TSKU</e2>, RHOF, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including <e2>TSKU</e2>, RHOF, CA12 and VSIG10L.","Positive_Correlation"
"Finally, several putative new target genes of <e1>PPARa</e1> were identified that were commonly induced by PPARa activation in the two human liver model systems, including <e2>TSKU</e2>, RHOF, CA12 and VSIG10L.","Positive_Correlation"
"BACKGROUND: Studies in mice have shown that <e1>PPARa</e1> is an important regulator of <e2>lipid</e2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.","Association"
"BACKGROUND: Studies in mice have shown that <e1>PPARa</e1> is an important regulator of <e2>lipid</e2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.","Association"
"BACKGROUND: Studies in mice have shown that <e1>PPARa</e1> is an important regulator of <e2>lipid</e2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.","Association"
"BACKGROUND: Studies in mice have shown that <e1>PPARa</e1> is an important regulator of <e2>lipid</e2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.","Association"
"BACKGROUND: Studies in mice have shown that <e1>PPARa</e1> is an important regulator of <e2>lipid</e2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.","Association"
"BACKGROUND: Studies in mice have shown that <e1>PPARa</e1> is an important regulator of <e2>lipid</e2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.","Association"
"BACKGROUND: Studies in mice have shown that <e1>PPARa</e1> is an important regulator of <e2>lipid</e2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.","Association"
"BACKGROUND: Studies in mice have shown that <e1>PPARa</e1> is an important regulator of <e2>lipid</e2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.","Association"
"BACKGROUND: Studies in mice have shown that <e1>PPARa</e1> is an important regulator of <e2>lipid</e2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.","Association"
"BACKGROUND: Studies in mice have shown that <e1>PPARa</e1> is an important regulator of <e2>lipid</e2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.","Association"
"BACKGROUND: Studies in mice have shown that <e1>PPARa</e1> is an important regulator of <e2>lipid</e2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.","Association"
"BACKGROUND: Studies in mice have shown that <e1>PPARa</e1> is an important regulator of <e2>lipid</e2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.","Association"
"BACKGROUND: Studies in mice have shown that <e1>PPARa</e1> is an important regulator of <e2>lipid</e2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.","Association"
"BACKGROUND: Studies in mice have shown that <e1>PPARa</e1> is an important regulator of <e2>lipid</e2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.","Association"
"BACKGROUND: Studies in mice have shown that <e1>PPARa</e1> is an important regulator of <e2>lipid</e2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.","Association"
"BACKGROUND: Studies in mice have shown that <e1>PPARa</e1> is an important regulator of <e2>lipid</e2> metabolism in liver and key transcription factor involved in the adaptive response to fasting.","Association"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, <e2>CYP3A5</e2>) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, <e2>CYP3A5</e2>) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, <e2>CYP3A5</e2>) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, <e2>CYP3A5</e2>) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, <e2>CYP3A5</e2>) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, <e2>CYP3A5</e2>) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, <e2>CYP3A5</e2>) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, <e2>CYP3A5</e2>) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, <e2>CYP3A5</e2>) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, <e2>CYP3A5</e2>) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, <e2>CYP3A5</e2>) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, <e2>CYP3A5</e2>) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, <e2>CYP3A5</e2>) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, <e2>CYP3A5</e2>) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, <e2>CYP3A5</e2>) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, <e2>CYP3A5</e2>) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, <e2>ABCC2</e2>, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, <e2>ABCC2</e2>, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, <e2>ABCC2</e2>, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, <e2>ABCC2</e2>, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, <e2>ABCC2</e2>, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, <e2>ABCC2</e2>, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, <e2>ABCC2</e2>, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, <e2>ABCC2</e2>, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, <e2>ABCC2</e2>, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, <e2>ABCC2</e2>, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, <e2>ABCC2</e2>, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, <e2>ABCC2</e2>, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, <e2>ABCC2</e2>, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, <e2>ABCC2</e2>, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, <e2>ABCC2</e2>, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, <e2>ABCC2</e2>, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (<e2>POR</e2>, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (<e2>POR</e2>, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (<e2>POR</e2>, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (<e2>POR</e2>, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (<e2>POR</e2>, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (<e2>POR</e2>, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (<e2>POR</e2>, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (<e2>POR</e2>, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (<e2>POR</e2>, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (<e2>POR</e2>, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (<e2>POR</e2>, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (<e2>POR</e2>, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (<e2>POR</e2>, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (<e2>POR</e2>, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (<e2>POR</e2>, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (<e2>POR</e2>, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, <e2>SLC27A4</e2>), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, AGPAT9, <e2>FADS1</e2>, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (ACSL5, <e2>AGPAT9</e2>, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"Many genes induced by <e1>PPARa</e1> activation were involved in lipid metabolism (<e2>ACSL5</e2>, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e1>PPARa</e1> is well expressed in human liver and human liver slices and that the classical PPARa targets <e2>PLIN2</e2>, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e1>PPARa</e1> is well expressed in human liver and human liver slices and that the classical PPARa targets <e2>PLIN2</e2>, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e1>PPARa</e1> is well expressed in human liver and human liver slices and that the classical PPARa targets <e2>PLIN2</e2>, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e1>PPARa</e1> is well expressed in human liver and human liver slices and that the classical PPARa targets <e2>PLIN2</e2>, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e1>PPARa</e1> is well expressed in human liver and human liver slices and that the classical PPARa targets <e2>PLIN2</e2>, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e1>PPARa</e1> is well expressed in human liver and human liver slices and that the classical PPARa targets <e2>PLIN2</e2>, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e1>PPARa</e1> is well expressed in human liver and human liver slices and that the classical PPARa targets <e2>PLIN2</e2>, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e1>PPARa</e1> is well expressed in human liver and human liver slices and that the classical PPARa targets <e2>PLIN2</e2>, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e1>PPARa</e1> is well expressed in human liver and human liver slices and that the classical PPARa targets <e2>PLIN2</e2>, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e1>PPARa</e1> is well expressed in human liver and human liver slices and that the classical PPARa targets <e2>PLIN2</e2>, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e1>PPARa</e1> is well expressed in human liver and human liver slices and that the classical PPARa targets <e2>PLIN2</e2>, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e1>PPARa</e1> is well expressed in human liver and human liver slices and that the classical PPARa targets <e2>PLIN2</e2>, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e1>PPARa</e1> is well expressed in human liver and human liver slices and that the classical PPARa targets <e2>PLIN2</e2>, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e1>PPARa</e1> is well expressed in human liver and human liver slices and that the classical PPARa targets <e2>PLIN2</e2>, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e1>PPARa</e1> is well expressed in human liver and human liver slices and that the classical PPARa targets <e2>PLIN2</e2>, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"RESULTS: Quantitative PCR indicated that <e1>PPARa</e1> is well expressed in human liver and human liver slices and that the classical PPARa targets <e2>PLIN2</e2>, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation.","Positive_Correlation"
"METHODS: Here we set out to study the function of <e1>PPARa</e1> in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist <e2>Wy14643</e2>.","Positive_Correlation"
"METHODS: Here we set out to study the function of <e1>PPARa</e1> in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist <e2>Wy14643</e2>.","Positive_Correlation"
"METHODS: Here we set out to study the function of <e1>PPARa</e1> in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist <e2>Wy14643</e2>.","Positive_Correlation"
"METHODS: Here we set out to study the function of <e1>PPARa</e1> in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist <e2>Wy14643</e2>.","Positive_Correlation"
"METHODS: Here we set out to study the function of <e1>PPARa</e1> in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist <e2>Wy14643</e2>.","Positive_Correlation"
"METHODS: Here we set out to study the function of <e1>PPARa</e1> in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist <e2>Wy14643</e2>.","Positive_Correlation"
"METHODS: Here we set out to study the function of <e1>PPARa</e1> in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist <e2>Wy14643</e2>.","Positive_Correlation"
"METHODS: Here we set out to study the function of <e1>PPARa</e1> in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist <e2>Wy14643</e2>.","Positive_Correlation"
"METHODS: Here we set out to study the function of <e1>PPARa</e1> in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist <e2>Wy14643</e2>.","Positive_Correlation"
"METHODS: Here we set out to study the function of <e1>PPARa</e1> in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist <e2>Wy14643</e2>.","Positive_Correlation"
"METHODS: Here we set out to study the function of <e1>PPARa</e1> in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist <e2>Wy14643</e2>.","Positive_Correlation"
"METHODS: Here we set out to study the function of <e1>PPARa</e1> in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist <e2>Wy14643</e2>.","Positive_Correlation"
"METHODS: Here we set out to study the function of <e1>PPARa</e1> in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist <e2>Wy14643</e2>.","Positive_Correlation"
"METHODS: Here we set out to study the function of <e1>PPARa</e1> in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist <e2>Wy14643</e2>.","Positive_Correlation"
"METHODS: Here we set out to study the function of <e1>PPARa</e1> in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist <e2>Wy14643</e2>.","Positive_Correlation"
"METHODS: Here we set out to study the function of <e1>PPARa</e1> in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist <e2>Wy14643</e2>.","Positive_Correlation"
"Oncogenic activity of amplified <e1>miniature chromosome maintenance 8</e1> in human <e2>malignancies</e2>.","Association"
"MCM8 bound cyclin D1 and activated <e1>Rb</e1> protein phosphorylation by <e2>cyclin-dependent kinase 4</e2> in vitro and in vivo.","Association"
"MCM8 bound cyclin D1 and activated <e1>Rb</e1> protein phosphorylation by <e2>cyclin-dependent kinase 4</e2> in vitro and in vivo.","Association"
"MCM8 bound <e1>cyclin D1</e1> and activated <e2>Rb</e2> protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Association"
"MCM8 bound <e1>cyclin D1</e1> and activated <e2>Rb</e2> protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Association"
"<e1>MCM</e1>8 bound cyclin D1 and activated Rb protein phosphorylation by <e2>cyclin-dependent kinase 4</e2> in vitro and in vivo.","Association"
"<e1>MCM8</e1> bound cyclin D1 and activated Rb protein phosphorylation by <e2>cyclin-dependent kinase 4</e2> in vitro and in vivo.","Association"
"<e1>MCM</e1>8 bound cyclin D1 and activated Rb protein phosphorylation by <e2>cyclin-dependent kinase 4</e2> in vitro and in vivo.","Association"
"<e1>MCM8</e1> bound cyclin D1 and activated Rb protein phosphorylation by <e2>cyclin-dependent kinase 4</e2> in vitro and in vivo.","Association"
"<e1>MCM8</e1> bound cyclin D1 and activated Rb protein phosphorylation by <e2>cyclin-dependent kinase 4</e2> in vitro and in vivo.","Association"
"<e1>MCM8</e1> bound cyclin D1 and activated Rb protein phosphorylation by <e2>cyclin-dependent kinase 4</e2> in vitro and in vivo.","Association"
"<e1>MCM8</e1> bound cyclin D1 and activated Rb protein phosphorylation by <e2>cyclin-dependent kinase 4</e2> in vitro and in vivo.","Association"
"<e1>MCM8</e1> bound cyclin D1 and activated Rb protein phosphorylation by <e2>cyclin-dependent kinase 4</e2> in vitro and in vivo.","Association"
"<e1>MCM8</e1> bound cyclin D1 and activated Rb protein phosphorylation by <e2>cyclin-dependent kinase 4</e2> in vitro and in vivo.","Association"
"<e1>MCM8</e1> bound cyclin D1 and activated Rb protein phosphorylation by <e2>cyclin-dependent kinase 4</e2> in vitro and in vivo.","Association"
"<e1>MCM</e1>8 bound cyclin D1 and activated <e2>Rb</e2> protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Association"
"<e1>MCM8</e1> bound cyclin D1 and activated <e2>Rb</e2> protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Association"
"<e1>MCM</e1>8 bound cyclin D1 and activated <e2>Rb</e2> protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Association"
"<e1>MCM8</e1> bound cyclin D1 and activated <e2>Rb</e2> protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Association"
"<e1>MCM8</e1> bound cyclin D1 and activated <e2>Rb</e2> protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Association"
"<e1>MCM8</e1> bound cyclin D1 and activated <e2>Rb</e2> protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Association"
"<e1>MCM8</e1> bound cyclin D1 and activated <e2>Rb</e2> protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Association"
"<e1>MCM8</e1> bound cyclin D1 and activated <e2>Rb</e2> protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Association"
"<e1>MCM8</e1> bound cyclin D1 and activated <e2>Rb</e2> protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Association"
"<e1>MCM8</e1> bound cyclin D1 and activated <e2>Rb</e2> protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Association"
"<e1>MCM</e1>8 bound <e2>cyclin D1</e2> and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Bind"
"<e1>MCM8</e1> bound <e2>cyclin D1</e2> and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Bind"
"<e1>MCM</e1>8 bound <e2>cyclin D1</e2> and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Bind"
"<e1>MCM8</e1> bound <e2>cyclin D1</e2> and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Bind"
"<e1>MCM8</e1> bound <e2>cyclin D1</e2> and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Bind"
"<e1>MCM8</e1> bound <e2>cyclin D1</e2> and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Bind"
"<e1>MCM8</e1> bound <e2>cyclin D1</e2> and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Bind"
"<e1>MCM8</e1> bound <e2>cyclin D1</e2> and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Bind"
"<e1>MCM8</e1> bound <e2>cyclin D1</e2> and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Bind"
"<e1>MCM8</e1> bound <e2>cyclin D1</e2> and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.","Bind"
"Forced expression of <e1>MCM</e1>8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined <e2>immunodeficiency</e2> mice xenografted with PC3 and DU145 cells.","Association"
"Forced expression of <e1>MCM8</e1> in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined <e2>immunodeficiency</e2> mice xenografted with PC3 and DU145 cells.","Association"
"Forced expression of <e1>MCM</e1>8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined <e2>immunodeficiency</e2> mice xenografted with PC3 and DU145 cells.","Association"
"Forced expression of <e1>MCM8</e1> in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined <e2>immunodeficiency</e2> mice xenografted with PC3 and DU145 cells.","Association"
"Forced expression of <e1>MCM8</e1> in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined <e2>immunodeficiency</e2> mice xenografted with PC3 and DU145 cells.","Association"
"Forced expression of <e1>MCM8</e1> in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined <e2>immunodeficiency</e2> mice xenografted with PC3 and DU145 cells.","Association"
"Forced expression of <e1>MCM8</e1> in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined <e2>immunodeficiency</e2> mice xenografted with PC3 and DU145 cells.","Association"
"Forced expression of <e1>MCM8</e1> in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined <e2>immunodeficiency</e2> mice xenografted with PC3 and DU145 cells.","Association"
"Forced expression of <e1>MCM8</e1> in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined <e2>immunodeficiency</e2> mice xenografted with PC3 and DU145 cells.","Association"
"Forced expression of <e1>MCM8</e1> in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined <e2>immunodeficiency</e2> mice xenografted with PC3 and DU145 cells.","Association"
"Increased expression of <e1>MCM</e1>8 in <e2>prostate cancer</e2> is associated with cancer recurrence.","Association"
"Increased expression of <e1>MCM8</e1> in <e2>prostate cancer</e2> is associated with cancer recurrence.","Association"
"Increased expression of <e1>MCM</e1>8 in <e2>prostate cancer</e2> is associated with cancer recurrence.","Association"
"Increased expression of <e1>MCM8</e1> in <e2>prostate cancer</e2> is associated with cancer recurrence.","Association"
"Increased expression of <e1>MCM8</e1> in <e2>prostate cancer</e2> is associated with cancer recurrence.","Association"
"Increased expression of <e1>MCM8</e1> in <e2>prostate cancer</e2> is associated with cancer recurrence.","Association"
"Increased expression of <e1>MCM8</e1> in <e2>prostate cancer</e2> is associated with cancer recurrence.","Association"
"Increased expression of <e1>MCM8</e1> in <e2>prostate cancer</e2> is associated with cancer recurrence.","Association"
"Increased expression of <e1>MCM8</e1> in <e2>prostate cancer</e2> is associated with cancer recurrence.","Association"
"Increased expression of <e1>MCM8</e1> in <e2>prostate cancer</e2> is associated with cancer recurrence.","Association"
"<e1>MCM</e1>8, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human <e2>malignancies</e2>.","Association"
"<e1>MCM8</e1>, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human <e2>malignancies</e2>.","Association"
"<e1>MCM</e1>8, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human <e2>malignancies</e2>.","Association"
"<e1>MCM8</e1>, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human <e2>malignancies</e2>.","Association"
"<e1>MCM8</e1>, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human <e2>malignancies</e2>.","Association"
"<e1>MCM8</e1>, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human <e2>malignancies</e2>.","Association"
"<e1>MCM8</e1>, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human <e2>malignancies</e2>.","Association"
"<e1>MCM8</e1>, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human <e2>malignancies</e2>.","Association"
"<e1>MCM8</e1>, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human <e2>malignancies</e2>.","Association"
"<e1>MCM8</e1>, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human <e2>malignancies</e2>.","Association"
"Enhanced isoproterenol-induced <e2>cardiac hypertrophy</e2> in transgenic rats with low brain <e1>angiotensinogen</e1>.","Association"
"Enhanced <e2>isoproterenol</e2>-induced cardiac hypertrophy in transgenic rats with low brain <e1>angiotensinogen</e1>.","Association"
"Enhanced <e1>isoproterenol</e1>-induced <e2>cardiac hypertrophy</e2> in transgenic rats with low brain angiotensinogen.","Positive_Correlation"
"We have previously shown that a permanent deficiency in the brain <e1>renin</e1>-<e2>angiotensin</e2> system (RAS) may increase the sensitivity of the baroreflex control of heart rate.","Association"
"The greater LV <e2>hypertrophy</e2> in TGR rats was associated with more pronounced downregulation of <e1>beta-AR</e1> and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats.","Association"
"The greater LV <e2>hypertrophy</e2> in TGR rats was associated with more pronounced downregulation of <e1>beta-AR</e1> and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats.","Association"
"The greater LV <e2>hypertrophy</e2> in TGR rats was associated with more pronounced downregulation of <e1>beta-AR</e1> and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats.","Association"
"The greater LV <e2>hypertrophy</e2> in TGR rats was associated with more pronounced downregulation of <e1>beta-AR</e1> and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats.","Association"
"The decrease in the heart rate (HR) induced by the <e1>beta-AR</e1> antagonist <e2>metoprolol</e2> in conscious rats was significantly attenuated in TGR compared with SD rats (-9.9 +/- 1.7% vs. -18.1 +/- 1.5%), whereas the effect of parasympathetic blockade by atropine on HR was similar in both strains.","Negative_Correlation"
"The decrease in the heart rate (HR) induced by the <e1>beta-AR</e1> antagonist <e2>metoprolol</e2> in conscious rats was significantly attenuated in TGR compared with SD rats (-9.9 +/- 1.7% vs. -18.1 +/- 1.5%), whereas the effect of parasympathetic blockade by atropine on HR was similar in both strains.","Negative_Correlation"
"The decrease in the heart rate (HR) induced by the <e1>beta-AR</e1> antagonist <e2>metoprolol</e2> in conscious rats was significantly attenuated in TGR compared with SD rats (-9.9 +/- 1.7% vs. -18.1 +/- 1.5%), whereas the effect of parasympathetic blockade by atropine on HR was similar in both strains.","Negative_Correlation"
"The decrease in the heart rate (HR) induced by the <e1>beta-AR</e1> antagonist <e2>metoprolol</e2> in conscious rats was significantly attenuated in TGR compared with SD rats (-9.9 +/- 1.7% vs. -18.1 +/- 1.5%), whereas the effect of parasympathetic blockade by atropine on HR was similar in both strains.","Negative_Correlation"
"In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the <e1>beta-adrenoceptor</e1> (beta-AR) agonist <e2>isoproterenol</e2> (Iso).","Positive_Correlation"
"In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta-adrenoceptor (<e1>beta-AR</e1>) agonist <e2>isoproterenol</e2> (Iso).","Positive_Correlation"
"In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta-adrenoceptor (<e1>beta-AR</e1>) agonist <e2>isoproterenol</e2> (Iso).","Positive_Correlation"
"In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta-adrenoceptor (<e1>beta-AR</e1>) agonist <e2>isoproterenol</e2> (Iso).","Positive_Correlation"
"In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta-adrenoceptor (<e1>beta-AR</e1>) agonist <e2>isoproterenol</e2> (Iso).","Positive_Correlation"
"The greater <e1>LV hypertrophy</e1> in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV <e2>beta-AR kinase-1</e2> mRNA levels compared with those in SD rats.","Association"
"The greater <e1>LV hypertrophy</e1> in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV <e2>beta-AR kinase-1</e2> mRNA levels compared with those in SD rats.","Association"
"The greater <e1>LV hypertrophy</e1> in TGR rats was associated with more pronounced downregulation of <e2>beta-AR</e2> and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats.","Association"
"The greater <e1>LV hypertrophy</e1> in TGR rats was associated with more pronounced downregulation of <e2>beta-AR</e2> and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats.","Association"
"<e2>LV hypertrophy</e2> induced by <e1>Iso</e1> treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/- 0.004 vs. 0.24 +/- 0.004, respectively).","Positive_Correlation"
"<e2>LV hypertrophy</e2> induced by <e1>Iso</e1> treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/- 0.004 vs. 0.24 +/- 0.004, respectively).","Positive_Correlation"
"<e2>LV hypertrophy</e2> induced by <e1>Iso</e1> treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/- 0.004 vs. 0.24 +/- 0.004, respectively).","Positive_Correlation"
"Intronic deletions in the <e1>SLC34A3</e1> gene cause <e2>hereditary hypophosphatemic rickets with hypercalciuria</e2>.","Association"
"CONTEXT: Hereditary hypophosphatemic rickets with <e2>hypercalciuria</e2> (HHRH) is a rare metabolic disorder, characterized by hypophosphatemia and rickets/osteomalacia with increased serum <e1>1,25-dihydroxyvitamin D</e1> [1,25-(OH)(2)D] resulting in hypercalciuria.","Positive_Correlation"
"CONTEXT: Hereditary hypophosphatemic rickets with <e2>hypercalciuria</e2> (HHRH) is a rare metabolic disorder, characterized by hypophosphatemia and rickets/osteomalacia with increased serum 1,25-dihydroxyvitamin D [<e1>1,25-(OH)(2)D</e1>] resulting in hypercalciuria.","Positive_Correlation"
"CONTEXT: <e1>Hereditary hypophosphatemic rickets with hypercalciuria</e1> (HHRH) is a rare metabolic disorder, characterized by hypophosphatemia and rickets/osteomalacia with increased serum <e2>1,25-dihydroxyvitamin D</e2> [1,25-(OH)(2)D] resulting in hypercalciuria.","Positive_Correlation"
"CONTEXT: Hereditary hypophosphatemic rickets with hypercalciuria (<e1>HHRH</e1>) is a rare metabolic disorder, characterized by hypophosphatemia and rickets/osteomalacia with increased serum <e2>1,25-dihydroxyvitamin D</e2> [1,25-(OH)(2)D] resulting in hypercalciuria.","Positive_Correlation"
"CONTEXT: Hereditary hypophosphatemic rickets with hypercalciuria (<e1>HHRH</e1>) is a rare metabolic disorder, characterized by hypophosphatemia and rickets/osteomalacia with increased serum <e2>1,25-dihydroxyvitamin D</e2> [1,25-(OH)(2)D] resulting in hypercalciuria.","Positive_Correlation"
"CONTEXT: Hereditary hypophosphatemic rickets with hypercalciuria (<e1>HHRH</e1>) is a rare metabolic disorder, characterized by hypophosphatemia and rickets/osteomalacia with increased serum <e2>1,25-dihydroxyvitamin D</e2> [1,25-(OH)(2)D] resulting in hypercalciuria.","Positive_Correlation"
"CONTEXT: Hereditary hypophosphatemic rickets with hypercalciuria (<e1>HHRH</e1>) is a rare metabolic disorder, characterized by hypophosphatemia and rickets/osteomalacia with increased serum <e2>1,25-dihydroxyvitamin D</e2> [1,25-(OH)(2)D] resulting in hypercalciuria.","Positive_Correlation"
"CONTEXT: Hereditary hypophosphatemic rickets with hypercalciuria (<e1>HHRH</e1>) is a rare metabolic disorder, characterized by hypophosphatemia and rickets/osteomalacia with increased serum <e2>1,25-dihydroxyvitamin D</e2> [1,25-(OH)(2)D] resulting in hypercalciuria.","Positive_Correlation"
"An unrelated individual with <e1>HHRH</e1> was a compound heterozygote for an 85-bp deletion in intron 10 and a <e2>G-to-A</e2> substitution at the last nucleotide in exon 7.","Association"
"An unrelated individual with <e1>HHRH</e1> was a compound heterozygote for an 85-bp deletion in intron 10 and a <e2>G-to-A</e2> substitution at the last nucleotide in exon 7.","Association"
"An unrelated individual with <e1>HHRH</e1> was a compound heterozygote for an 85-bp deletion in intron 10 and a <e2>G-to-A</e2> substitution at the last nucleotide in exon 7.","Association"
"An unrelated individual with <e1>HHRH</e1> was a compound heterozygote for an 85-bp deletion in intron 10 and a <e2>G-to-A</e2> substitution at the last nucleotide in exon 7.","Association"
"An unrelated individual with <e1>HHRH</e1> was a compound heterozygote for an 85-bp deletion in intron 10 and a <e2>G-to-A</e2> substitution at the last nucleotide in exon 7.","Association"
"An unrelated individual with <e1>HHRH</e1> was a compound heterozygote for an <e2>85-bp deletion</e2> in intron 10 and a G-to-A substitution at the last nucleotide in exon 7.","Positive_Correlation"
"An unrelated individual with <e1>HHRH</e1> was a compound heterozygote for an <e2>85-bp deletion</e2> in intron 10 and a G-to-A substitution at the last nucleotide in exon 7.","Positive_Correlation"
"An unrelated individual with <e1>HHRH</e1> was a compound heterozygote for an <e2>85-bp deletion</e2> in intron 10 and a G-to-A substitution at the last nucleotide in exon 7.","Positive_Correlation"
"An unrelated individual with <e1>HHRH</e1> was a compound heterozygote for an <e2>85-bp deletion</e2> in intron 10 and a G-to-A substitution at the last nucleotide in exon 7.","Positive_Correlation"
"An unrelated individual with <e1>HHRH</e1> was a compound heterozygote for an <e2>85-bp deletion</e2> in intron 10 and a G-to-A substitution at the last nucleotide in exon 7.","Positive_Correlation"
"OBJECTIVE: Our objective was to determine whether mutations in the <e1>SLC34A3</e1> gene, which encodes sodium-phosphate cotransporter type IIc, are responsible for the occurrence of <e2>HHRH</e2>.","Association"
"OBJECTIVE: Our objective was to determine whether mutations in the SLC34A3 gene, which encodes <e1>sodium-phosphate cotransporter type IIc</e1>, are responsible for the occurrence of <e2>HHRH</e2>.","Association"
"OBJECTIVE: Our objective was to determine whether mutations in the <e1>SLC34A3</e1> gene, which encodes sodium-phosphate cotransporter type IIc, are responsible for the occurrence of <e2>HHRH</e2>.","Association"
"OBJECTIVE: Our objective was to determine whether mutations in the <e1>SLC34A3</e1> gene, which encodes sodium-phosphate cotransporter type IIc, are responsible for the occurrence of <e2>HHRH</e2>.","Association"
"OBJECTIVE: Our objective was to determine whether mutations in the <e1>SLC34A3</e1> gene, which encodes sodium-phosphate cotransporter type IIc, are responsible for the occurrence of <e2>HHRH</e2>.","Association"
"OBJECTIVE: Our objective was to determine whether mutations in the <e1>SLC34A3</e1> gene, which encodes sodium-phosphate cotransporter type IIc, are responsible for the occurrence of <e2>HHRH</e2>.","Association"
"Vitamin D receptor expression is associated with PIK3CA and <e1>KRAS</e1> mutations in <e2>colorectal cancer</e2>.","Association"
"Vitamin D receptor expression is associated with <e1>PIK3CA</e1> and KRAS mutations in <e2>colorectal cancer</e2>.","Association"
"<e1>Vitamin D receptor</e1> expression is associated with PIK3CA and KRAS mutations in <e2>colorectal cancer</e2>.","Positive_Correlation"
"<e1>Vitamin D receptor</e1> expression is associated with PIK3CA and <e2>KRAS</e2> mutations in colorectal cancer.","Association"
"<e1>Vitamin D receptor</e1> expression is associated with <e2>PIK3CA</e2> and KRAS mutations in colorectal cancer.","Association"
"<e1>Vitamin D</e1> is associated with decreased risks of various cancers, including <e2>colon cancer</e2>.","Negative_Correlation"
"<e1>Vitamin D</e1> is associated with decreased risks of various <e2>cancers</e2>, including colon cancer.","Negative_Correlation"
"Among 619 colorectal <e1>cancers</e1> in two prospective cohort studies, 233 (38%) tumors showed <e2>VDR</e2> overexpression by immunohistochemistry.","Positive_Correlation"
"Among 619 colorectal cancers in two prospective cohort studies, 233 (38%) <e1>tumors</e1> showed <e2>VDR</e2> overexpression by immunohistochemistry.","Positive_Correlation"
"Among 619 colorectal cancers in two prospective cohort studies, 233 (38%) <e1>tumor</e1>s showed <e2>VDR</e2> overexpression by immunohistochemistry.","Positive_Correlation"
"Among 619 colorectal cancers in two prospective cohort studies, 233 (38%) <e1>tumor</e1>s showed <e2>VDR</e2> overexpression by immunohistochemistry.","Positive_Correlation"
"In conclusion, VDR overexpression in <e2>colorectal cancer</e2> is independently associated with PIK3CA and K<e1>RAS</e1> mutations.","Association"
"In conclusion, VDR overexpression in <e2>colorectal cancer</e2> is independently associated with PIK3CA and <e1>KRAS</e1> mutations.","Association"
"In conclusion, VDR overexpression in <e2>colorectal cancer</e2> is independently associated with PIK3CA and <e1>KRAS</e1> mutations.","Association"
"In conclusion, VDR overexpression in <e2>colorectal cancer</e2> is independently associated with PIK3CA and <e1>KRAS</e1> mutations.","Association"
"In conclusion, VDR overexpression in <e2>colorectal cancer</e2> is independently associated with PIK3CA and <e1>KRAS</e1> mutations.","Association"
"In conclusion, VDR overexpression in <e2>colorectal cancer</e2> is independently associated with PIK3CA and K<e1>RAS</e1> mutations.","Association"
"In conclusion, VDR overexpression in <e2>colorectal cancer</e2> is independently associated with PIK3CA and <e1>KRAS</e1> mutations.","Association"
"A link between VDR and the <e1>RAS</e1>-<e2>mitogen-activated protein kinase</e2> (MAPK) or phosphatidylinositol 3-kinase (PI3K)-AKT pathway has been suggested.","Association"
"Our data support potential interactions between the VDR, RAS-<e2>MAPK</e2> and PI3K-AKT pathways, and possible influence by <e1>KRAS</e1> or PIK3CA mutation on therapy or chemoprevention targeting VDR.","Association"
"Our data support potential interactions between the VDR, RAS-<e2>MAPK</e2> and PI3K-AKT pathways, and possible influence by <e1>KRAS</e1> or PIK3CA mutation on therapy or chemoprevention targeting VDR.","Association"
"Our data support potential interactions between the VDR, RAS-<e2>MAPK</e2> and PI3K-AKT pathways, and possible influence by <e1>KRAS</e1> or PIK3CA mutation on therapy or chemoprevention targeting VDR.","Association"
"Our data support potential interactions between the VDR, RAS-<e2>MAPK</e2> and PI3K-AKT pathways, and possible influence by <e1>KRAS</e1> or PIK3CA mutation on therapy or chemoprevention targeting VDR.","Association"
"A link between VDR and the <e1>RAS</e1>-<e2>mitogen-activated protein kinase</e2> (MAPK) or phosphatidylinositol 3-kinase (PI3K)-AKT pathway has been suggested.","Association"
"Our data support potential interactions between the VDR, RAS-<e2>MAPK</e2> and PI3K-AKT pathways, and possible influence by <e1>KRAS</e1> or PIK3CA mutation on therapy or chemoprevention targeting VDR.","Association"
"In conclusion, VDR overexpression in <e2>colorectal cancer</e2> is independently associated with <e1>PIK3CA</e1> and KRAS mutations.","Association"
"In conclusion, VDR overexpression in <e2>colorectal cancer</e2> is independently associated with <e1>PIK3CA</e1> and KRAS mutations.","Association"
"In conclusion, VDR overexpression in <e2>colorectal cancer</e2> is independently associated with <e1>PIK3CA</e1> and KRAS mutations.","Association"
"In conclusion, VDR overexpression in <e2>colorectal cancer</e2> is independently associated with <e1>PIK3CA</e1> and KRAS mutations.","Association"
"In conclusion, VDR overexpression in <e2>colorectal cancer</e2> is independently associated with <e1>PIK3CA</e1> and KRAS mutations.","Association"
"A link between VDR and the RAS-mitogen-activated protein kinase (MAPK) or <e1>phosphatidylinositol 3-kinase</e1> (PI3K)-<e2>AKT</e2> pathway has been suggested.","Association"
"A link between VDR and the RAS-mitogen-activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (<e1>PI3K</e1>)-<e2>AKT</e2> pathway has been suggested.","Association"
"Our data support potential interactions between the VDR, RAS-MAPK and PI3K-<e2>AKT</e2> pathways, and possible influence by KRAS or <e1>PIK3CA</e1> mutation on therapy or chemoprevention targeting VDR.","Association"
"Our data support potential interactions between the VDR, RAS-MAPK and PI3K-<e2>AKT</e2> pathways, and possible influence by KRAS or <e1>PIK3CA</e1> mutation on therapy or chemoprevention targeting VDR.","Association"
"Our data support potential interactions between the VDR, RAS-MAPK and PI3K-<e2>AKT</e2> pathways, and possible influence by KRAS or <e1>PIK3CA</e1> mutation on therapy or chemoprevention targeting VDR.","Association"
"Our data support potential interactions between the VDR, RAS-MAPK and PI3K-<e2>AKT</e2> pathways, and possible influence by KRAS or <e1>PIK3CA</e1> mutation on therapy or chemoprevention targeting VDR.","Association"
"A link between VDR and the RAS-mitogen-activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (<e1>PI3K</e1>)-<e2>AKT</e2> pathway has been suggested.","Association"
"Our data support potential interactions between the VDR, RAS-MAPK and PI3K-<e2>AKT</e2> pathways, and possible influence by KRAS or <e1>PIK3CA</e1> mutation on therapy or chemoprevention targeting VDR.","Association"
"Among 619 <e2>colorectal cancers</e2> in two prospective cohort studies, 233 (38%) tumors showed <e1>VDR</e1> overexpression by immunohistochemistry.","Positive_Correlation"
"Among 619 <e2>colorectal cancers</e2> in two prospective cohort studies, 233 (38%) tumors showed <e1>VDR</e1> overexpression by immunohistochemistry.","Positive_Correlation"
"Among 619 <e2>colorectal cancers</e2> in two prospective cohort studies, 233 (38%) tumors showed <e1>VDR</e1> overexpression by immunohistochemistry.","Positive_Correlation"
"Among 619 <e2>colorectal cancers</e2> in two prospective cohort studies, 233 (38%) tumors showed <e1>VDR</e1> overexpression by immunohistochemistry.","Positive_Correlation"
"Among 619 <e2>colorectal cancers</e2> in two prospective cohort studies, 233 (38%) tumors showed <e1>VDR</e1> overexpression by immunohistochemistry.","Positive_Correlation"
"Among 619 <e2>colorectal cancers</e2> in two prospective cohort studies, 233 (38%) tumors showed <e1>VDR</e1> overexpression by immunohistochemistry.","Positive_Correlation"
"Among 619 <e2>colorectal cancers</e2> in two prospective cohort studies, 233 (38%) tumors showed <e1>VDR</e1> overexpression by immunohistochemistry.","Positive_Correlation"
"Among 619 <e2>colorectal cancers</e2> in two prospective cohort studies, 233 (38%) tumors showed <e1>VDR</e1> overexpression by immunohistochemistry.","Positive_Correlation"
"Among 619 <e2>colorectal cancers</e2> in two prospective cohort studies, 233 (38%) tumors showed <e1>VDR</e1> overexpression by immunohistochemistry.","Positive_Correlation"
"Among 619 <e2>colorectal cancers</e2> in two prospective cohort studies, 233 (38%) tumors showed <e1>VDR</e1> overexpression by immunohistochemistry.","Positive_Correlation"
"A link between <e1>VDR</e1> and the <e2>RAS</e2>-mitogen-activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the <e2>RAS</e2>-mitogen-activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the <e2>RAS</e2>-mitogen-activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the <e2>RAS</e2>-mitogen-activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the <e2>RAS</e2>-mitogen-activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the <e2>RAS</e2>-mitogen-activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the <e2>RAS</e2>-mitogen-activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the <e2>RAS</e2>-mitogen-activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the <e2>RAS</e2>-mitogen-activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the <e2>RAS</e2>-mitogen-activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the RAS-mitogen-activated protein kinase (MAPK) or <e2>phosphatidylinositol 3-kinase</e2> (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the RAS-mitogen-activated protein kinase (MAPK) or <e2>phosphatidylinositol 3-kinase</e2> (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the RAS-mitogen-activated protein kinase (MAPK) or <e2>phosphatidylinositol 3-kinase</e2> (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the RAS-mitogen-activated protein kinase (MAPK) or <e2>phosphatidylinositol 3-kinase</e2> (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the RAS-mitogen-activated protein kinase (MAPK) or <e2>phosphatidylinositol 3-kinase</e2> (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the RAS-mitogen-activated protein kinase (MAPK) or <e2>phosphatidylinositol 3-kinase</e2> (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the RAS-mitogen-activated protein kinase (MAPK) or <e2>phosphatidylinositol 3-kinase</e2> (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the RAS-mitogen-activated protein kinase (MAPK) or <e2>phosphatidylinositol 3-kinase</e2> (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the RAS-mitogen-activated protein kinase (MAPK) or <e2>phosphatidylinositol 3-kinase</e2> (PI3K)-AKT pathway has been suggested.","Association"
"A link between <e1>VDR</e1> and the RAS-mitogen-activated protein kinase (MAPK) or <e2>phosphatidylinositol 3-kinase</e2> (PI3K)-AKT pathway has been suggested.","Association"
"Compared with the model group, CMCS and 1,10-phenanthroline significantly improved serum ALT/<e1>AST</e1>, attenuated <e2>hepatic inflammation</e2> and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.","Association"
"Compared with the model group, CMCS and 1,10-phenanthroline significantly improved serum ALT/<e1>AST</e1>, attenuated <e2>hepatic inflammation</e2> and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.","Association"
"Compared with the model group, CMCS and 1,10-phenanthroline significantly improved serum ALT/<e1>AST</e1>, attenuated <e2>hepatic inflammation</e2> and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.","Association"
"Compared with the model group, CMCS and 1,10-phenanthroline significantly improved serum <e1>ALT</e1>/AST, attenuated <e2>hepatic inflammation</e2> and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.","Association"
"Compared with the model group, CMCS and 1,10-phenanthroline significantly improved serum <e1>ALT</e1>/AST, attenuated <e2>hepatic inflammation</e2> and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.","Association"
"Compared with the model group, CMCS and 1,10-phenanthroline significantly improved serum <e1>ALT</e1>/AST, attenuated <e2>hepatic inflammation</e2> and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.","Association"
"Compared with the model group, CMCS and <e1>1,10-phenanthroline</e1> significantly improved serum ALT/<e2>AST</e2>, attenuated hepatic inflammation and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.","Positive_Correlation"
"Compared with the model group, CMCS and <e1>1,10-phenanthroline</e1> significantly improved serum ALT/<e2>AST</e2>, attenuated hepatic inflammation and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.","Positive_Correlation"
"Compared with the model group, CMCS and <e1>1,10-phenanthroline</e1> significantly improved serum <e2>ALT</e2>/AST, attenuated hepatic inflammation and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.","Positive_Correlation"
"Compared with the model group, CMCS and <e1>1,10-phenanthroline</e1> significantly improved serum <e2>ALT</e2>/AST, attenuated hepatic inflammation and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.","Positive_Correlation"
"Compared with the model group, CMCS and <e1>1,10-phenanthroline</e1> significantly improved serum ALT/AST, attenuated hepatic inflammation and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and <e2>ICAM-1</e2>.","Negative_Correlation"
"Compared with the model group, CMCS and <e1>1,10-phenanthroline</e1> significantly improved serum ALT/AST, attenuated hepatic inflammation and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and <e2>ICAM-1</e2>.","Negative_Correlation"
"Compared with the model group, CMCS and <e1>1,10-phenanthroline</e1> significantly improved serum ALT/AST, attenuated hepatic inflammation and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of <e2>VCAM-1</e2> and ICAM-1.","Negative_Correlation"
"Compared with the model group, CMCS and <e1>1,10-phenanthroline</e1> significantly improved serum ALT/AST, attenuated hepatic inflammation and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of <e2>VCAM-1</e2> and ICAM-1.","Negative_Correlation"
"Compared with the model group, CMCS and <e1>1,10-phenanthroline</e1> significantly improved serum ALT/AST, attenuated <e2>hepatic inflammation</e2> and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.","Negative_Correlation"
"Compared with the model group, CMCS and <e1>1,10-phenanthroline</e1> significantly improved serum ALT/AST, attenuated <e2>hepatic inflammation</e2> and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and ICAM-1.","Negative_Correlation"
"CMCS could protect <e1>LSECs from injury</e1> and maintain the microvasculature integration in acute injured liver of mice induced by <e2>LPS</e2>/D-GalN.","Positive_Correlation"
"CMCS could protect LSECs from injury and maintain the microvasculature integration in acute <e1>injured liver</e1> of mice induced by <e2>LPS</e2>/D-GalN.","Positive_Correlation"
"CMCS could protect LSECs from injury and maintain the microvasculature integration in acute <e1>injured liver</e1> of mice induced by <e2>LPS</e2>/D-GalN.","Positive_Correlation"
"Compared to that in the normal control, more severe <e1>liver inflammation</e1> and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and <e2>MDA</e2>, but decreased SOD and GST, increased MMP-2/9 activities and VCAM-1, ICAM-1 and vWF expressions, which revealed obvious LSEC injury and scaffold structure broken, were shown in the model control.","Positive_Correlation"
"Compared to that in the normal control, more severe liver inflammation and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and <e2>MDA</e2>, but decreased SOD and GST, increased MMP-2/9 activities and VCAM-1, ICAM-1 and vWF expressions, which revealed obvious <e1>LSEC injury</e1> and scaffold structure broken, were shown in the model control.","Positive_Correlation"
"Compared to that in the normal control, more severe <e1>liver inflammation</e1> and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, <e2>.OH</e2> and MDA, but decreased SOD and GST, increased MMP-2/9 activities and VCAM-1, ICAM-1 and vWF expressions, which revealed obvious LSEC injury and scaffold structure broken, were shown in the model control.","Positive_Correlation"
"Compared to that in the normal control, more severe liver inflammation and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, <e2>.OH</e2> and MDA, but decreased SOD and GST, increased MMP-2/9 activities and VCAM-1, ICAM-1 and vWF expressions, which revealed obvious <e1>LSEC injury</e1> and scaffold structure broken, were shown in the model control.","Positive_Correlation"
"Compared to that in the normal control, more severe <e1>liver inflammation</e1> and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased SOD and GST, increased MMP-2/9 activities and VCAM-1, ICAM-1 and <e2>vWF</e2> expressions, which revealed obvious LSEC injury and scaffold structure broken, were shown in the model control.","Association"
"Compared to that in the normal control, more severe liver inflammation and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased SOD and GST, increased MMP-2/9 activities and VCAM-1, ICAM-1 and <e2>vWF</e2> expressions, which revealed obvious <e1>LSEC injury</e1> and scaffold structure broken, were shown in the model control.","Association"
"Compared to that in the normal control, more severe <e1>liver inflammation</e1> and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased SOD and GST, increased MMP-2/9 activities and VCAM-1, <e2>ICAM-1</e2> and vWF expressions, which revealed obvious LSEC injury and scaffold structure broken, were shown in the model control.","Association"
"Compared to that in the normal control, more severe liver inflammation and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased SOD and GST, increased MMP-2/9 activities and VCAM-1, <e2>ICAM-1</e2> and vWF expressions, which revealed obvious <e1>LSEC injury</e1> and scaffold structure broken, were shown in the model control.","Association"
"Compared with the model group, CMCS and 1,10-phenanthroline significantly improved serum ALT/AST, attenuated <e1>hepatic inflammation</e1> and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and <e2>ICAM-1</e2>.","Association"
"Compared with the model group, CMCS and 1,10-phenanthroline significantly improved serum ALT/AST, attenuated hepatic inflammation and improved peroxidative <e1>injury in liver</e1>, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of VCAM-1 and <e2>ICAM-1</e2>.","Association"
"Compared to that in the normal control, more severe <e1>liver inflammation</e1> and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased SOD and GST, increased MMP-2/9 activities and <e2>VCAM-1</e2>, ICAM-1 and vWF expressions, which revealed obvious LSEC injury and scaffold structure broken, were shown in the model control.","Association"
"Compared to that in the normal control, more severe liver inflammation and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased SOD and GST, increased MMP-2/9 activities and <e2>VCAM-1</e2>, ICAM-1 and vWF expressions, which revealed obvious <e1>LSEC injury</e1> and scaffold structure broken, were shown in the model control.","Association"
"Compared with the model group, CMCS and 1,10-phenanthroline significantly improved serum ALT/AST, attenuated <e1>hepatic inflammation</e1> and improved peroxidative injury in liver, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of <e2>VCAM-1</e2> and ICAM-1.","Association"
"Compared with the model group, CMCS and 1,10-phenanthroline significantly improved serum ALT/AST, attenuated hepatic inflammation and improved peroxidative <e1>injury in liver</e1>, decreased MMP-2/9 activities in liver tissue, improved integration of scaffold structure, and decreased protein expression of <e2>VCAM-1</e2> and ICAM-1.","Association"
"Compared to that in the normal control, more severe <e1>liver inflammation</e1> and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased SOD and <e2>GST</e2>, increased MMP-2/9 activities and VCAM-1, ICAM-1 and vWF expressions, which revealed obvious LSEC injury and scaffold structure broken, were shown in the model control.","Association"
"Compared to that in the normal control, more severe liver inflammation and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased SOD and <e2>GST</e2>, increased MMP-2/9 activities and VCAM-1, ICAM-1 and vWF expressions, which revealed obvious <e1>LSEC injury</e1> and scaffold structure broken, were shown in the model control.","Association"
"Compared to that in the normal control, more severe <e1>liver inflammation</e1> and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased <e2>SOD</e2> and GST, increased MMP-2/9 activities and VCAM-1, ICAM-1 and vWF expressions, which revealed obvious LSEC injury and scaffold structure broken, were shown in the model control.","Association"
"Compared to that in the normal control, more severe liver inflammation and hepatocyte apoptosis, worse hepatic lipid peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased <e2>SOD</e2> and GST, increased MMP-2/9 activities and VCAM-1, ICAM-1 and vWF expressions, which revealed obvious <e1>LSEC injury</e1> and scaffold structure broken, were shown in the model control.","Association"
"Compared to that in the normal control, more severe <e1>liver inflammation</e1> and hepatocyte apoptosis, worse hepatic <e2>lipid</e2> peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased SOD and GST, increased MMP-2/9 activities and VCAM-1, ICAM-1 and vWF expressions, which revealed obvious LSEC injury and scaffold structure broken, were shown in the model control.","Association"
"Compared to that in the normal control, more severe liver inflammation and hepatocyte apoptosis, worse hepatic <e2>lipid</e2> peroxidation demonstrated by the increased ASAFR, .OH and MDA, but decreased SOD and GST, increased MMP-2/9 activities and VCAM-1, ICAM-1 and vWF expressions, which revealed obvious <e1>LSEC injury</e1> and scaffold structure broken, were shown in the model control.","Association"
"CMCS could protect <e2>LSECs from injury</e2> and maintain the microvasculature integration in acute injured liver of mice induced by LPS/<e1>D-GalN</e1>.","Positive_Correlation"
"CMCS could protect <e2>LSECs from injury</e2> and maintain the microvasculature integration in acute injured liver of mice induced by LPS/<e1>D-GalN</e1>.","Positive_Correlation"
"A <e1>Type 2 Diabetes</e1>-Associated Functional Regulatory Variant in a Pancreatic Islet Enhancer at the <e2>ADCY5</e2> Locus.","Negative_Correlation"
"Variants associated with type 2 diabetes and fasting <e1>glucose</e1> levels reside in introns of <e2>ADCY5</e2>, a gene that encodes adenylate cyclase 5.","Association"
"Together, these data suggest that <e1>rs11708067</e1>-A risk allele contributes to type 2 diabetes by disrupting an islet enhancer, which results in reduced ADCY5 expression and <e2>impaired insulin secretion</e2>.","Positive_Correlation"
"Together, these data suggest that <e1>rs11708067</e1>-A risk allele contributes to type 2 diabetes by disrupting an islet enhancer, which results in reduced ADCY5 expression and <e2>impaired insulin secretion</e2>.","Positive_Correlation"
"Together, these data suggest that <e1>rs11708067</e1>-A risk allele contributes to type 2 diabetes by disrupting an islet enhancer, which results in reduced ADCY5 expression and <e2>impaired insulin secretion</e2>.","Positive_Correlation"
"Together, these data suggest that <e1>rs11708067</e1>-A risk allele contributes to type 2 diabetes by disrupting an islet enhancer, which results in reduced ADCY5 expression and <e2>impaired insulin secretion</e2>.","Positive_Correlation"
"Adenylate cyclase 5 catalyzes the production of <e1>cyclic AMP</e1>, which is a second messenger molecule involved in cell signaling and pancreatic b-cell <e2>insulin</e2> secretion.","Association"
"Together, these data suggest that rs11708067-A risk allele contributes to type 2 diabetes by disrupting an islet enhancer, which results in reduced <e1>ADCY5</e1> expression and <e2>impaired insulin secretion</e2>.","Association"
"Together, these data suggest that rs11708067-A risk allele contributes to type 2 diabetes by disrupting an islet enhancer, which results in reduced <e1>ADCY5</e1> expression and <e2>impaired insulin secretion</e2>.","Association"
"Together, these data suggest that rs11708067-A risk allele contributes to type 2 diabetes by disrupting an islet enhancer, which results in reduced <e1>ADCY5</e1> expression and <e2>impaired insulin secretion</e2>.","Association"
"<e1>Adenylate cyclase 5</e1> catalyzes the production of <e2>cyclic AMP</e2>, which is a second messenger molecule involved in cell signaling and pancreatic b-cell insulin secretion.","Positive_Correlation"
"Variants associated with <e1>type 2 diabetes</e1> and fasting <e2>glucose</e2> levels reside in introns of ADCY5, a gene that encodes adenylate cyclase 5.","Association"
"Variants associated with <e1>type 2 diabetes</e1> and fasting <e2>glucose</e2> levels reside in introns of ADCY5, a gene that encodes adenylate cyclase 5.","Association"
"Variants associated with <e1>type 2 diabetes</e1> and fasting <e2>glucose</e2> levels reside in introns of ADCY5, a gene that encodes adenylate cyclase 5.","Association"
"Variants associated with <e1>type 2 diabetes</e1> and fasting <e2>glucose</e2> levels reside in introns of ADCY5, a gene that encodes adenylate cyclase 5.","Association"
"Variants associated with <e1>type 2 diabetes</e1> and fasting <e2>glucose</e2> levels reside in introns of ADCY5, a gene that encodes adenylate cyclase 5.","Association"
"The <e1>type 2 diabetes</e1> risk <e2>rs11708067</e2>-A allele showed fewer H3K27ac ChIP-seq reads in human islets, lower transcriptional activity in reporter assays in rodent b-cells (rat 832/13 and mouse MIN6), and increased nuclear protein binding compared with the rs11708067-G allele.","Positive_Correlation"
"The <e1>type 2 diabetes</e1> risk <e2>rs11708067</e2>-A allele showed fewer H3K27ac ChIP-seq reads in human islets, lower transcriptional activity in reporter assays in rodent b-cells (rat 832/13 and mouse MIN6), and increased nuclear protein binding compared with the rs11708067-G allele.","Positive_Correlation"
"The <e1>type 2 diabetes</e1> risk <e2>rs11708067</e2>-A allele showed fewer H3K27ac ChIP-seq reads in human islets, lower transcriptional activity in reporter assays in rodent b-cells (rat 832/13 and mouse MIN6), and increased nuclear protein binding compared with the rs11708067-G allele.","Positive_Correlation"
"The <e1>type 2 diabetes</e1> risk <e2>rs11708067</e2>-A allele showed fewer H3K27ac ChIP-seq reads in human islets, lower transcriptional activity in reporter assays in rodent b-cells (rat 832/13 and mouse MIN6), and increased nuclear protein binding compared with the rs11708067-G allele.","Positive_Correlation"
"The <e1>type 2 diabetes</e1> risk <e2>rs11708067</e2>-A allele showed fewer H3K27ac ChIP-seq reads in human islets, lower transcriptional activity in reporter assays in rodent b-cells (rat 832/13 and mouse MIN6), and increased nuclear protein binding compared with the rs11708067-G allele.","Positive_Correlation"
"Variants associated with <e1>type 2 diabetes</e1> and fasting glucose levels reside in introns of <e2>ADCY5</e2>, a gene that encodes adenylate cyclase 5.","Negative_Correlation"
"Variants associated with <e1>type 2 diabetes</e1> and fasting glucose levels reside in introns of <e2>ADCY5</e2>, a gene that encodes adenylate cyclase 5.","Negative_Correlation"
"Variants associated with <e1>type 2 diabetes</e1> and fasting glucose levels reside in introns of <e2>ADCY5</e2>, a gene that encodes adenylate cyclase 5.","Negative_Correlation"
"Variants associated with <e1>type 2 diabetes</e1> and fasting glucose levels reside in introns of <e2>ADCY5</e2>, a gene that encodes adenylate cyclase 5.","Negative_Correlation"
"Variants associated with <e1>type 2 diabetes</e1> and fasting glucose levels reside in introns of <e2>ADCY5</e2>, a gene that encodes adenylate cyclase 5.","Negative_Correlation"
"Homozygously deleted gene <e1>DACH1</e1> regulates tumor-initiating activity of <e2>glioma</e2> cells.","Association"
"Homozygously deleted gene <e1>DACH1</e1> regulates <e2>tumor</e2>-initiating activity of glioma cells.","Association"
"These results illustrate that DACH1 is a distinctive tumor suppressor, which does not only suppress growth of tumor cells but also regulates <e1>bFGF</e1>-mediated tumor-initiating activity of <e2>glioma</e2> cells.","Association"
"These results illustrate that DACH1 is a distinctive tumor suppressor, which does not only suppress growth of tumor cells but also regulates <e1>bFGF</e1>-mediated tumor-initiating activity of <e2>glioma</e2> cells.","Association"
"These results illustrate that DACH1 is a distinctive tumor suppressor, which does not only suppress growth of tumor cells but also regulates <e1>bFGF</e1>-mediated tumor-initiating activity of <e2>glioma</e2> cells.","Association"
"These results illustrate that DACH1 is a distinctive tumor suppressor, which does not only suppress growth of tumor cells but also regulates <e1>bFGF</e1>-mediated tumor-initiating activity of <e2>glioma</e2> cells.","Association"
"Exogenous <e1>bFGF</e1> rescues spheroid-forming activity and <e2>tumor</e2>igenicity of the U87-DACH1-high cells, suggesting that loss of DACH1 increases the number of tumor-initiating cells through transcriptional activation of bFGF.","Association"
"Exogenous <e1>bFGF</e1> rescues spheroid-forming activity and <e2>tumor</e2>igenicity of the U87-DACH1-high cells, suggesting that loss of DACH1 increases the number of tumor-initiating cells through transcriptional activation of bFGF.","Association"
"Exogenous <e1>bFGF</e1> rescues spheroid-forming activity and <e2>tumor</e2>igenicity of the U87-DACH1-high cells, suggesting that loss of DACH1 increases the number of tumor-initiating cells through transcriptional activation of bFGF.","Association"
"Exogenous <e1>bFGF</e1> rescues spheroid-forming activity and <e2>tumor</e2>igenicity of the U87-DACH1-high cells, suggesting that loss of DACH1 increases the number of tumor-initiating cells through transcriptional activation of bFGF.","Association"
"Gene expression analysis and chromatin immunoprecipitation assay reveal that <e1>fibroblast growth factor 2</e1> (FGF2/bFGF) is transcriptionally repressed by <e2>DACH1</e2>, especially in cells cultured in serum-free medium.","Negative_Correlation"
"Gene expression analysis and chromatin immunoprecipitation assay reveal that fibroblast growth factor 2 (<e1>FGF2</e1>/bFGF) is transcriptionally repressed by <e2>DACH1</e2>, especially in cells cultured in serum-free medium.","Negative_Correlation"
"Gene expression analysis and chromatin immunoprecipitation assay reveal that fibroblast growth factor 2 (FGF2/<e1>bFGF</e1>) is transcriptionally repressed by <e2>DACH1</e2>, especially in cells cultured in serum-free medium.","Negative_Correlation"
"Gene expression analysis and chromatin immunoprecipitation assay reveal that fibroblast growth factor 2 (FGF2/<e1>bFGF</e1>) is transcriptionally repressed by <e2>DACH1</e2>, especially in cells cultured in serum-free medium.","Negative_Correlation"
"Gene expression analysis and chromatin immunoprecipitation assay reveal that fibroblast growth factor 2 (FGF2/<e1>bFGF</e1>) is transcriptionally repressed by <e2>DACH1</e2>, especially in cells cultured in serum-free medium.","Negative_Correlation"
"Gene expression analysis and chromatin immunoprecipitation assay reveal that fibroblast growth factor 2 (FGF2/<e1>bFGF</e1>) is transcriptionally repressed by <e2>DACH1</e2>, especially in cells cultured in serum-free medium.","Negative_Correlation"
"We then generated U87TR-Da glioma cells, where <e2>DACH1</e2> expression could be activated by exposure of the cells to <e1>doxycycline</e1>.","Positive_Correlation"
"U87-<e1>DACH1</e1>-low cells form spheroids with CD133 and <e2>Nestin</e2> expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with CD133 and <e2>Nestin</e2> expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with CD133 and <e2>Nestin</e2> expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with CD133 and <e2>Nestin</e2> expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with CD133 and <e2>Nestin</e2> expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with CD133 and <e2>Nestin</e2> expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with CD133 and <e2>Nestin</e2> expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with CD133 and <e2>Nestin</e2> expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with CD133 and <e2>Nestin</e2> expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with CD133 and <e2>Nestin</e2> expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with CD133 and <e2>Nestin</e2> expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with CD133 and <e2>Nestin</e2> expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with CD133 and <e2>Nestin</e2> expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with CD133 and <e2>Nestin</e2> expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with CD133 and <e2>Nestin</e2> expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with CD133 and <e2>Nestin</e2> expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with <e2>CD133</e2> and Nestin expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with <e2>CD133</e2> and Nestin expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with <e2>CD133</e2> and Nestin expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with <e2>CD133</e2> and Nestin expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with <e2>CD133</e2> and Nestin expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with <e2>CD133</e2> and Nestin expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with <e2>CD133</e2> and Nestin expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with <e2>CD133</e2> and Nestin expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with <e2>CD133</e2> and Nestin expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with <e2>CD133</e2> and Nestin expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with <e2>CD133</e2> and Nestin expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with <e2>CD133</e2> and Nestin expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with <e2>CD133</e2> and Nestin expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with <e2>CD133</e2> and Nestin expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with <e2>CD133</e2> and Nestin expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"U87-<e1>DACH1</e1>-low cells form spheroids with <e2>CD133</e2> and Nestin expression in serum-free medium but U87-DACH1-high cells do not.","Association"
"We found decreased cell proliferation of a series of <e2>glioma</e2> cell lines by forced expression of <e1>DACH1</e1>.","Association"
"We found decreased cell proliferation of a series of <e2>glioma</e2> cell lines by forced expression of <e1>DACH1</e1>.","Association"
"We found decreased cell proliferation of a series of <e2>glioma</e2> cell lines by forced expression of <e1>DACH1</e1>.","Association"
"We found decreased cell proliferation of a series of <e2>glioma</e2> cell lines by forced expression of <e1>DACH1</e1>.","Association"
"We found decreased cell proliferation of a series of <e2>glioma</e2> cell lines by forced expression of <e1>DACH1</e1>.","Association"
"We found decreased cell proliferation of a series of <e2>glioma</e2> cell lines by forced expression of <e1>DACH1</e1>.","Association"
"We found decreased cell proliferation of a series of <e2>glioma</e2> cell lines by forced expression of <e1>DACH1</e1>.","Association"
"We found decreased cell proliferation of a series of <e2>glioma</e2> cell lines by forced expression of <e1>DACH1</e1>.","Association"
"We found decreased cell proliferation of a series of <e2>glioma</e2> cell lines by forced expression of <e1>DACH1</e1>.","Association"
"We found decreased cell proliferation of a series of <e2>glioma</e2> cell lines by forced expression of <e1>DACH1</e1>.","Association"
"We found decreased cell proliferation of a series of <e2>glioma</e2> cell lines by forced expression of <e1>DACH1</e1>.","Association"
"We found decreased cell proliferation of a series of <e2>glioma</e2> cell lines by forced expression of <e1>DACH1</e1>.","Association"
"We found decreased cell proliferation of a series of <e2>glioma</e2> cell lines by forced expression of <e1>DACH1</e1>.","Association"
"We found decreased cell proliferation of a series of <e2>glioma</e2> cell lines by forced expression of <e1>DACH1</e1>.","Association"
"We found decreased cell proliferation of a series of <e2>glioma</e2> cell lines by forced expression of <e1>DACH1</e1>.","Association"
"We found decreased cell proliferation of a series of <e2>glioma</e2> cell lines by forced expression of <e1>DACH1</e1>.","Association"
"Both ex vivo cellular proliferation and in vivo growth of s.c. transplanted <e2>tumor</e2>s in mice are reduced in U87TR-Da cells with <e1>DACH1</e1> expression (U87-DACH1-high), compared with DACH1-nonexpressing U87TR-Da cells (U87-DACH1-low).","Association"
"Both ex vivo cellular proliferation and in vivo growth of s.c. transplanted <e2>tumor</e2>s in mice are reduced in U87TR-Da cells with <e1>DACH1</e1> expression (U87-DACH1-high), compared with DACH1-nonexpressing U87TR-Da cells (U87-DACH1-low).","Association"
"Both ex vivo cellular proliferation and in vivo growth of s.c. transplanted <e2>tumor</e2>s in mice are reduced in U87TR-Da cells with <e1>DACH1</e1> expression (U87-DACH1-high), compared with DACH1-nonexpressing U87TR-Da cells (U87-DACH1-low).","Association"
"Both ex vivo cellular proliferation and in vivo growth of s.c. transplanted <e2>tumor</e2>s in mice are reduced in U87TR-Da cells with <e1>DACH1</e1> expression (U87-DACH1-high), compared with DACH1-nonexpressing U87TR-Da cells (U87-DACH1-low).","Association"
"Both ex vivo cellular proliferation and in vivo growth of s.c. transplanted <e2>tumor</e2>s in mice are reduced in U87TR-Da cells with <e1>DACH1</e1> expression (U87-DACH1-high), compared with DACH1-nonexpressing U87TR-Da cells (U87-DACH1-low).","Association"
"Both ex vivo cellular proliferation and in vivo growth of s.c. transplanted <e2>tumor</e2>s in mice are reduced in U87TR-Da cells with <e1>DACH1</e1> expression (U87-DACH1-high), compared with DACH1-nonexpressing U87TR-Da cells (U87-DACH1-low).","Association"
"Both ex vivo cellular proliferation and in vivo growth of s.c. transplanted <e2>tumor</e2>s in mice are reduced in U87TR-Da cells with <e1>DACH1</e1> expression (U87-DACH1-high), compared with DACH1-nonexpressing U87TR-Da cells (U87-DACH1-low).","Association"
"Both ex vivo cellular proliferation and in vivo growth of s.c. transplanted <e2>tumor</e2>s in mice are reduced in U87TR-Da cells with <e1>DACH1</e1> expression (U87-DACH1-high), compared with DACH1-nonexpressing U87TR-Da cells (U87-DACH1-low).","Association"
"Both ex vivo cellular proliferation and in vivo growth of s.c. transplanted <e2>tumor</e2>s in mice are reduced in U87TR-Da cells with <e1>DACH1</e1> expression (U87-DACH1-high), compared with DACH1-nonexpressing U87TR-Da cells (U87-DACH1-low).","Association"
"Both ex vivo cellular proliferation and in vivo growth of s.c. transplanted <e2>tumor</e2>s in mice are reduced in U87TR-Da cells with <e1>DACH1</e1> expression (U87-DACH1-high), compared with DACH1-nonexpressing U87TR-Da cells (U87-DACH1-low).","Association"
"Both ex vivo cellular proliferation and in vivo growth of s.c. transplanted <e2>tumor</e2>s in mice are reduced in U87TR-Da cells with <e1>DACH1</e1> expression (U87-DACH1-high), compared with DACH1-nonexpressing U87TR-Da cells (U87-DACH1-low).","Association"
"Both ex vivo cellular proliferation and in vivo growth of s.c. transplanted <e2>tumor</e2>s in mice are reduced in U87TR-Da cells with <e1>DACH1</e1> expression (U87-DACH1-high), compared with DACH1-nonexpressing U87TR-Da cells (U87-DACH1-low).","Association"
"Both ex vivo cellular proliferation and in vivo growth of s.c. transplanted <e2>tumor</e2>s in mice are reduced in U87TR-Da cells with <e1>DACH1</e1> expression (U87-DACH1-high), compared with DACH1-nonexpressing U87TR-Da cells (U87-DACH1-low).","Association"
"Both ex vivo cellular proliferation and in vivo growth of s.c. transplanted <e2>tumor</e2>s in mice are reduced in U87TR-Da cells with <e1>DACH1</e1> expression (U87-DACH1-high), compared with DACH1-nonexpressing U87TR-Da cells (U87-DACH1-low).","Association"
"Both ex vivo cellular proliferation and in vivo growth of s.c. transplanted <e2>tumor</e2>s in mice are reduced in U87TR-Da cells with <e1>DACH1</e1> expression (U87-DACH1-high), compared with DACH1-nonexpressing U87TR-Da cells (U87-DACH1-low).","Association"
"Both ex vivo cellular proliferation and in vivo growth of s.c. transplanted <e2>tumor</e2>s in mice are reduced in U87TR-Da cells with <e1>DACH1</e1> expression (U87-DACH1-high), compared with DACH1-nonexpressing U87TR-Da cells (U87-DACH1-low).","Association"
"The current best treatment for HCV infection is combination therapy with <e1>pegylated interferon</e1> and <e2>ribavirin</e2>.","Cotreatment"
"The current best treatment for <e1>HCV infection</e1> is combination therapy with <e2>pegylated interferon</e2> and ribavirin.","Negative_Correlation"
"The current best treatment for <e1>HCV infection</e1> is combination therapy with <e2>pegylated interferon</e2> and ribavirin.","Negative_Correlation"
"The current best treatment for <e1>HCV infection</e1> is combination therapy with pegylated interferon and <e2>ribavirin</e2>.","Negative_Correlation"
"The current best treatment for <e1>HCV infection</e1> is combination therapy with pegylated interferon and <e2>ribavirin</e2>.","Negative_Correlation"
"<e1>Viramidine</e1>, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with <e2>chronic hepatitis C</e2>.","Association"
"<e1>Viramidine</e1>, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of <e2>hemolytic anemia</e2> in patients with chronic hepatitis C.","Negative_Correlation"
"<e1>Viramidine</e1>, a liver-targeting prodrug of <e2>ribavirin</e2>, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.","Association"
"Recombinant human <e1>erythropoietin</e1> has been used to manage ribavirin-associated <e2>anemia</e2> but has other potential disadvantages.","Association"
"Recombinant human <e1>erythropoietin</e1> has been used to manage <e2>ribavirin</e2>-associated anemia but has other potential disadvantages.","Association"
"<e1>Hemoglobin</e1> concentrations decrease mainly as a result of ribavirin-induced <e2>hemolysis</e2>, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.","Negative_Correlation"
"<e1>Hemoglobin</e1> concentrations decrease mainly as a result of <e2>ribavirin</e2>-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.","Negative_Correlation"
"Viramidine, a liver-targeting prodrug of <e1>ribavirin</e1>, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with <e2>chronic hepatitis C</e2>.","Association"
"Viramidine, a liver-targeting prodrug of <e1>ribavirin</e1>, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with <e2>chronic hepatitis C</e2>.","Association"
"Viramidine, a liver-targeting prodrug of <e1>ribavirin</e1>, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with <e2>chronic hepatitis C</e2>.","Association"
"Viramidine, a liver-targeting prodrug of <e1>ribavirin</e1>, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with <e2>chronic hepatitis C</e2>.","Association"
"Viramidine, a liver-targeting prodrug of <e1>ribavirin</e1>, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with <e2>chronic hepatitis C</e2>.","Association"
"Viramidine, a liver-targeting prodrug of <e1>ribavirin</e1>, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with <e2>chronic hepatitis C</e2>.","Association"
"Hemoglobin concentrations decrease mainly as a result of <e1>ribavirin</e1>-induced hemolysis, and this <e2>anemia</e2> can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.","Positive_Correlation"
"Hemoglobin concentrations decrease mainly as a result of <e1>ribavirin</e1>-induced hemolysis, and this <e2>anemia</e2> can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.","Positive_Correlation"
"Hemoglobin concentrations decrease mainly as a result of <e1>ribavirin</e1>-induced hemolysis, and this <e2>anemia</e2> can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.","Positive_Correlation"
"Hemoglobin concentrations decrease mainly as a result of <e1>ribavirin</e1>-induced hemolysis, and this <e2>anemia</e2> can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.","Positive_Correlation"
"Hemoglobin concentrations decrease mainly as a result of <e1>ribavirin</e1>-induced hemolysis, and this <e2>anemia</e2> can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.","Positive_Correlation"
"Hemoglobin concentrations decrease mainly as a result of <e1>ribavirin</e1>-induced hemolysis, and this <e2>anemia</e2> can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.","Positive_Correlation"
"Hemoglobin concentrations decrease mainly as a result of <e1>ribavirin</e1>-induced <e2>hemolysis</e2>, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.","Positive_Correlation"
"Hemoglobin concentrations decrease mainly as a result of <e1>ribavirin</e1>-induced <e2>hemolysis</e2>, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.","Positive_Correlation"
"Hemoglobin concentrations decrease mainly as a result of <e1>ribavirin</e1>-induced <e2>hemolysis</e2>, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.","Positive_Correlation"
"Hemoglobin concentrations decrease mainly as a result of <e1>ribavirin</e1>-induced <e2>hemolysis</e2>, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.","Positive_Correlation"
"Hemoglobin concentrations decrease mainly as a result of <e1>ribavirin</e1>-induced <e2>hemolysis</e2>, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.","Positive_Correlation"
"Hemoglobin concentrations decrease mainly as a result of <e1>ribavirin</e1>-induced <e2>hemolysis</e2>, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.","Positive_Correlation"
"Viramidine, a liver-targeting prodrug of <e1>ribavirin</e1>, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of <e2>hemolytic anemia</e2> in patients with chronic hepatitis C.","Positive_Correlation"
"Viramidine, a liver-targeting prodrug of <e1>ribavirin</e1>, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of <e2>hemolytic anemia</e2> in patients with chronic hepatitis C.","Positive_Correlation"
"Viramidine, a liver-targeting prodrug of <e1>ribavirin</e1>, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of <e2>hemolytic anemia</e2> in patients with chronic hepatitis C.","Positive_Correlation"
"Viramidine, a liver-targeting prodrug of <e1>ribavirin</e1>, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of <e2>hemolytic anemia</e2> in patients with chronic hepatitis C.","Positive_Correlation"
"Viramidine, a liver-targeting prodrug of <e1>ribavirin</e1>, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of <e2>hemolytic anemia</e2> in patients with chronic hepatitis C.","Positive_Correlation"
"Viramidine, a liver-targeting prodrug of <e1>ribavirin</e1>, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of <e2>hemolytic anemia</e2> in patients with chronic hepatitis C.","Positive_Correlation"
"Association between an <e2>endoglin</e2> gene polymorphism and systemic sclerosis-related <e1>pulmonary arterial hypertension</e1>.","Association"
"Association between an <e1>endoglin</e1> gene polymorphism and <e2>systemic sclerosis</e2>-related pulmonary arterial hypertension.","Association"
"CONCLUSIONS: Thus the frequency of 6bINS differs between SSc patients with or without <e1>PAH</e1>, suggesting the implication of <e2>ENG</e2> in this devastating vascular complication of SSc.","Association"
"CONCLUSIONS: Thus the frequency of 6bINS differs between SSc patients with or without <e1>PAH</e1>, suggesting the implication of <e2>ENG</e2> in this devastating vascular complication of SSc.","Association"
"CONCLUSIONS: Thus the frequency of 6bINS differs between SSc patients with or without <e1>PAH</e1>, suggesting the implication of <e2>ENG</e2> in this devastating vascular complication of SSc.","Association"
"CONCLUSIONS: Thus the frequency of 6bINS differs between SSc patients with or without <e1>PAH</e1>, suggesting the implication of <e2>ENG</e2> in this devastating vascular complication of SSc.","Association"
"CONCLUSIONS: Thus the frequency of 6bINS differs between SSc patients with or without <e1>PAH</e1>, suggesting the implication of <e2>ENG</e2> in this devastating vascular complication of SSc.","Association"
"CONCLUSIONS: Thus the frequency of 6bINS differs between SSc patients with or without <e1>PAH</e1>, suggesting the implication of <e2>ENG</e2> in this devastating vascular complication of SSc.","Association"
"OBJECTIVES: Our objective was to investigate the relationship between <e1>6bINS</e1> and the vascular complication <e2>pulmonary arterial hypertension</e2> (PAH) in SSc in a French Caucasian population.","Negative_Correlation"
"OBJECTIVES: Our objective was to investigate the relationship between <e1>6bINS</e1> and the vascular complication <e2>pulmonary arterial hypertension</e2> (PAH) in SSc in a French Caucasian population.","Negative_Correlation"
"OBJECTIVES: Our objective was to investigate the relationship between <e1>6bINS</e1> and the vascular complication <e2>pulmonary arterial hypertension</e2> (PAH) in SSc in a French Caucasian population.","Negative_Correlation"
"OBJECTIVES: Our objective was to investigate the relationship between <e1>6bINS</e1> and the vascular complication <e2>pulmonary arterial hypertension</e2> (PAH) in SSc in a French Caucasian population.","Negative_Correlation"
"OBJECTIVES: Our objective was to investigate the relationship between <e1>6bINS</e1> and the vascular complication <e2>pulmonary arterial hypertension</e2> (PAH) in SSc in a French Caucasian population.","Negative_Correlation"
"OBJECTIVES: Our objective was to investigate the relationship between <e1>6bINS</e1> and the vascular complication pulmonary arterial hypertension (PAH) in <e2>SSc</e2> in a French Caucasian population.","Association"
"OBJECTIVES: Our objective was to investigate the relationship between <e1>6bINS</e1> and the vascular complication pulmonary arterial hypertension (PAH) in <e2>SSc</e2> in a French Caucasian population.","Association"
"OBJECTIVES: Our objective was to investigate the relationship between <e1>6bINS</e1> and the vascular complication pulmonary arterial hypertension (PAH) in <e2>SSc</e2> in a French Caucasian population.","Association"
"OBJECTIVES: Our objective was to investigate the relationship between <e1>6bINS</e1> and the vascular complication pulmonary arterial hypertension (PAH) in <e2>SSc</e2> in a French Caucasian population.","Association"
"OBJECTIVES: Our objective was to investigate the relationship between <e1>6bINS</e1> and the vascular complication pulmonary arterial hypertension (PAH) in <e2>SSc</e2> in a French Caucasian population.","Association"
"OBJECTIVES: Our objective was to investigate the relationship between <e1>6bINS</e1> and the <e2>vascular complication</e2> pulmonary arterial hypertension (PAH) in SSc in a French Caucasian population.","Association"
"OBJECTIVES: Our objective was to investigate the relationship between <e1>6bINS</e1> and the <e2>vascular complication</e2> pulmonary arterial hypertension (PAH) in SSc in a French Caucasian population.","Association"
"OBJECTIVES: Our objective was to investigate the relationship between <e1>6bINS</e1> and the <e2>vascular complication</e2> pulmonary arterial hypertension (PAH) in SSc in a French Caucasian population.","Association"
"OBJECTIVES: Our objective was to investigate the relationship between <e1>6bINS</e1> and the <e2>vascular complication</e2> pulmonary arterial hypertension (PAH) in SSc in a French Caucasian population.","Association"
"OBJECTIVES: Our objective was to investigate the relationship between <e1>6bINS</e1> and the <e2>vascular complication</e2> pulmonary arterial hypertension (PAH) in SSc in a French Caucasian population.","Association"
"<e1>Endoglin</e1> gene (ENG) encodes a transmembrane glycoprotein which acts as an accessory receptor for the <e2>transforming growth factor-beta</e2> (TGF-beta) superfamily, and is crucial for maintaining vascular integrity.","Bind"
"Endoglin gene (<e1>ENG</e1>) encodes a transmembrane glycoprotein which acts as an accessory receptor for the <e2>transforming growth factor-beta</e2> (TGF-beta) superfamily, and is crucial for maintaining vascular integrity.","Bind"
"Endoglin gene (<e1>ENG</e1>) encodes a transmembrane glycoprotein which acts as an accessory receptor for the <e2>transforming growth factor-beta</e2> (TGF-beta) superfamily, and is crucial for maintaining vascular integrity.","Bind"
"Endoglin gene (<e1>ENG</e1>) encodes a transmembrane glycoprotein which acts as an accessory receptor for the <e2>transforming growth factor-beta</e2> (TGF-beta) superfamily, and is crucial for maintaining vascular integrity.","Bind"
"CONCLUSIONS: Thus the frequency of 6bINS differs between <e2>SSc</e2> patients with or without PAH, suggesting the implication of <e1>ENG</e1> in this devastating vascular complication of SSc.","Association"
"CONCLUSIONS: Thus the frequency of 6bINS differs between <e2>SSc</e2> patients with or without PAH, suggesting the implication of <e1>ENG</e1> in this devastating vascular complication of SSc.","Association"
"CONCLUSIONS: Thus the frequency of 6bINS differs between <e2>SSc</e2> patients with or without PAH, suggesting the implication of <e1>ENG</e1> in this devastating vascular complication of SSc.","Association"
"CONCLUSIONS: Thus the frequency of 6bINS differs between SSc patients with or without PAH, suggesting the implication of <e1>ENG</e1> in this devastating <e2>vascular complication</e2> of SSc.","Association"
"CONCLUSIONS: Thus the frequency of 6bINS differs between SSc patients with or without PAH, suggesting the implication of <e1>ENG</e1> in this devastating <e2>vascular complication</e2> of SSc.","Association"
"CONCLUSIONS: Thus the frequency of 6bINS differs between SSc patients with or without PAH, suggesting the implication of <e1>ENG</e1> in this devastating <e2>vascular complication</e2> of SSc.","Association"
"Assessment of a new non-invasive index of cardiac performance for detection of <e1>dobutamine</e1>-induced <e2>myocardial ischemia</e2>.","Positive_Correlation"
"BACKGROUND: Electrocardiography has a very low sensitivity in detecting <e1>dobutamine</e1>-induced myocardial <e2>ischemia</e2>.","Association"
"BACKGROUND: Electrocardiography has a very low sensitivity in detecting <e1>dobutamine</e1>-induced myocardial <e2>ischemia</e2>.","Association"
"BACKGROUND: Electrocardiography has a very low sensitivity in detecting <e1>dobutamine</e1>-induced myocardial <e2>ischemia</e2>.","Association"
"BACKGROUND: Electrocardiography has a very low sensitivity in detecting <e1>dobutamine</e1>-induced myocardial <e2>ischemia</e2>.","Association"
"BACKGROUND: Electrocardiography has a very low sensitivity in detecting <e1>dobutamine</e1>-induced myocardial <e2>ischemia</e2>.","Association"
"BACKGROUND: Electrocardiography has a very low sensitivity in detecting <e1>dobutamine</e1>-induced <e2>myocardial ischemia</e2>.","Positive_Correlation"
"BACKGROUND: Electrocardiography has a very low sensitivity in detecting <e1>dobutamine</e1>-induced <e2>myocardial ischemia</e2>.","Positive_Correlation"
"BACKGROUND: Electrocardiography has a very low sensitivity in detecting <e1>dobutamine</e1>-induced <e2>myocardial ischemia</e2>.","Positive_Correlation"
"BACKGROUND: Electrocardiography has a very low sensitivity in detecting <e1>dobutamine</e1>-induced <e2>myocardial ischemia</e2>.","Positive_Correlation"
"BACKGROUND: Electrocardiography has a very low sensitivity in detecting <e1>dobutamine</e1>-induced <e2>myocardial ischemia</e2>.","Positive_Correlation"
"Elevated expression of the <e1>C6orf49</e1> transcript was associated with <e2>breast cancer</e2> survival, adding biological interest to the finding.","Association"
"METHODS: We examined associations between common germline genetic variation in 13 genes involved in cell cycle control (CCND1, CCND2, <e1>CCND3</e1>, CCNE1, CDK2 [p33], CDK4, CDK6, CDKN1A [p21, Cip1], CDKN1B [p27, Kip1], CDKN2A [p16], CDKN2B [p15], CDKN2C [p18], and CDKN2D [p19]) and survival among women diagnosed with invasive <e2>breast cancer</e2> participating in the SEARCH (Studies of Epidemiology and Risk factors in Cancer Heredity) breast cancer study.","Association"
"METHODS: We examined associations between common germline genetic variation in 13 genes involved in cell cycle control (CCND1, CCND2, <e1>CCND3</e1>, CCNE1, CDK2 [p33], CDK4, CDK6, CDKN1A [p21, Cip1], CDKN1B [p27, Kip1], CDKN2A [p16], CDKN2B [p15], CDKN2C [p18], and CDKN2D [p19]) and survival among women diagnosed with invasive <e2>breast cancer</e2> participating in the SEARCH (Studies of Epidemiology and Risk factors in Cancer Heredity) breast cancer study.","Association"
"METHODS: We examined associations between common germline genetic variation in 13 genes involved in cell cycle control (CCND1, CCND2, <e1>CCND3</e1>, CCNE1, CDK2 [p33], CDK4, CDK6, CDKN1A [p21, Cip1], CDKN1B [p27, Kip1], CDKN2A [p16], CDKN2B [p15], CDKN2C [p18], and CDKN2D [p19]) and survival among women diagnosed with invasive <e2>breast cancer</e2> participating in the SEARCH (Studies of Epidemiology and Risk factors in Cancer Heredity) breast cancer study.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, BYSL, TRFP, USP49, C6ofr49, FRS3, and <e2>PGC</e2>.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, BYSL, TRFP, USP49, C6ofr49, FRS3, and <e2>PGC</e2>.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, BYSL, TRFP, USP49, C6ofr49, FRS3, and <e2>PGC</e2>.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, BYSL, TRFP, USP49, C6ofr49, <e2>FRS3</e2>, and PGC.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, BYSL, TRFP, USP49, C6ofr49, <e2>FRS3</e2>, and PGC.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, BYSL, TRFP, USP49, C6ofr49, <e2>FRS3</e2>, and PGC.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, BYSL, TRFP, USP49, <e2>C6ofr49</e2>, FRS3, and PGC.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, BYSL, TRFP, USP49, <e2>C6ofr49</e2>, FRS3, and PGC.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, BYSL, TRFP, USP49, <e2>C6ofr49</e2>, FRS3, and PGC.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, BYSL, TRFP, <e2>USP49</e2>, C6ofr49, FRS3, and PGC.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, BYSL, TRFP, <e2>USP49</e2>, C6ofr49, FRS3, and PGC.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, BYSL, TRFP, <e2>USP49</e2>, C6ofr49, FRS3, and PGC.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, BYSL, <e2>TRFP</e2>, USP49, C6ofr49, FRS3, and PGC.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, BYSL, <e2>TRFP</e2>, USP49, C6ofr49, FRS3, and PGC.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, BYSL, <e2>TRFP</e2>, USP49, C6ofr49, FRS3, and PGC.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, <e2>BYSL</e2>, TRFP, USP49, C6ofr49, FRS3, and PGC.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, <e2>BYSL</e2>, TRFP, USP49, C6ofr49, FRS3, and PGC.","Association"
"This SNP is part of a large linkage disequilibrium block, which contains <e1>CCND3</e1>, <e2>BYSL</e2>, TRFP, USP49, C6ofr49, FRS3, and PGC.","Association"
"CONCLUSION: It is possible that CCND3 <e1>rs2479717</e1>, or another variant it tags, is associated with prognosis after a diagnosis of <e2>breast cancer</e2>.","Association"
"CONCLUSION: It is possible that CCND3 <e1>rs2479717</e1>, or another variant it tags, is associated with prognosis after a diagnosis of <e2>breast cancer</e2>.","Association"
"RESULTS: The rare allele of the tagging single nucleotide polymorphism (SNP) <e1>rs2479717</e1> is associated with an increased risk of <e2>death</e2> (hazard ratio = 1.26 per rare allele carried, 95% confidence interval: 1.12 to 1.42; P = 0.0001), which was not attenuated after adjusting for tumour stage, grade, and treatment.","Positive_Correlation"
"RESULTS: The rare allele of the tagging single nucleotide polymorphism (SNP) <e1>rs2479717</e1> is associated with an increased risk of <e2>death</e2> (hazard ratio = 1.26 per rare allele carried, 95% confidence interval: 1.12 to 1.42; P = 0.0001), which was not attenuated after adjusting for tumour stage, grade, and treatment.","Positive_Correlation"
"Upregulation of <e1>centrosomal protein 55</e1> is associated with unfavorable prognosis and tumor invasion in <e2>epithelial ovarian carcinoma</e2>.","Association"
"Upregulation of <e1>centrosomal protein 55</e1> is associated with unfavorable prognosis and <e2>tumor</e2> invasion in epithelial ovarian carcinoma.","Positive_Correlation"
"However, characteristics of <e1>CEP55</e1> expression and its clinical/prognostic significance are unclear in human <e2>epithelial ovarian carcinoma</e2> (EOC).","Association"
"However, characteristics of <e1>CEP55</e1> expression and its clinical/prognostic significance are unclear in human <e2>epithelial ovarian carcinoma</e2> (EOC).","Association"
"However, characteristics of <e1>CEP55</e1> expression and its clinical/prognostic significance are unclear in human <e2>epithelial ovarian carcinoma</e2> (EOC).","Association"
"However, characteristics of <e1>CEP55</e1> expression and its clinical/prognostic significance are unclear in human <e2>epithelial ovarian carcinoma</e2> (EOC).","Association"
"However, characteristics of <e1>CEP55</e1> expression and its clinical/prognostic significance are unclear in human <e2>epithelial ovarian carcinoma</e2> (EOC).","Association"
"However, characteristics of <e1>CEP55</e1> expression and its clinical/prognostic significance are unclear in human <e2>epithelial ovarian carcinoma</e2> (EOC).","Association"
"However, characteristics of <e1>CEP55</e1> expression and its clinical/prognostic significance are unclear in human <e2>epithelial ovarian carcinoma</e2> (EOC).","Association"
"However, characteristics of <e1>CEP55</e1> expression and its clinical/prognostic significance are unclear in human <e2>epithelial ovarian carcinoma</e2> (EOC).","Association"
"However, characteristics of <e1>CEP55</e1> expression and its clinical/prognostic significance are unclear in human <e2>epithelial ovarian carcinoma</e2> (EOC).","Association"
"However, characteristics of <e1>CEP55</e1> expression and its clinical/prognostic significance are unclear in human <e2>epithelial ovarian carcinoma</e2> (EOC).","Association"
"However, characteristics of <e1>CEP55</e1> expression and its clinical/prognostic significance are unclear in human <e2>epithelial ovarian carcinoma</e2> (EOC).","Association"
"However, characteristics of <e1>CEP55</e1> expression and its clinical/prognostic significance are unclear in human <e2>epithelial ovarian carcinoma</e2> (EOC).","Association"
"However, characteristics of <e1>CEP55</e1> expression and its clinical/prognostic significance are unclear in human <e2>epithelial ovarian carcinoma</e2> (EOC).","Association"
"However, characteristics of <e1>CEP55</e1> expression and its clinical/prognostic significance are unclear in human <e2>epithelial ovarian carcinoma</e2> (EOC).","Association"
"However, characteristics of <e1>CEP55</e1> expression and its clinical/prognostic significance are unclear in human <e2>epithelial ovarian carcinoma</e2> (EOC).","Association"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), <e2>intraperitoneal metastasis</e2> (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), <e2>intraperitoneal metastasis</e2> (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), <e2>intraperitoneal metastasis</e2> (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), <e2>intraperitoneal metastasis</e2> (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), <e2>intraperitoneal metastasis</e2> (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), <e2>intraperitoneal metastasis</e2> (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), <e2>intraperitoneal metastasis</e2> (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), <e2>intraperitoneal metastasis</e2> (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), <e2>intraperitoneal metastasis</e2> (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), <e2>intraperitoneal metastasis</e2> (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), <e2>intraperitoneal metastasis</e2> (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), <e2>intraperitoneal metastasis</e2> (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), <e2>intraperitoneal metastasis</e2> (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), <e2>intraperitoneal metastasis</e2> (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), <e2>intraperitoneal metastasis</e2> (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), <e2>lymph node metastasis</e2> (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), <e2>lymph node metastasis</e2> (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), <e2>lymph node metastasis</e2> (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), <e2>lymph node metastasis</e2> (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), <e2>lymph node metastasis</e2> (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), <e2>lymph node metastasis</e2> (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), <e2>lymph node metastasis</e2> (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), <e2>lymph node metastasis</e2> (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), <e2>lymph node metastasis</e2> (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), <e2>lymph node metastasis</e2> (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), <e2>lymph node metastasis</e2> (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), <e2>lymph node metastasis</e2> (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), <e2>lymph node metastasis</e2> (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), <e2>lymph node metastasis</e2> (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), <e2>lymph node metastasis</e2> (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum <e2>CA153</e2> level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum <e2>CA153</e2> level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum <e2>CA153</e2> level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum <e2>CA153</e2> level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum <e2>CA153</e2> level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum <e2>CA153</e2> level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum <e2>CA153</e2> level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum <e2>CA153</e2> level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum <e2>CA153</e2> level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum <e2>CA153</e2> level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum <e2>CA153</e2> level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum <e2>CA153</e2> level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum <e2>CA153</e2> level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum <e2>CA153</e2> level (P < 0.001).","Positive_Correlation"
"In the 213 EOC samples, <e1>CEP55</e1> protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum <e2>CA153</e2> level (P < 0.001).","Positive_Correlation"
"<e1>Centrosomal protein 55</e1> (CEP55) is a cell cycle regulator implicated in development of certain <e2>cancers</e2>.","Positive_Correlation"
"Centrosomal protein 55 (<e1>CEP55</e1>) is a cell cycle regulator implicated in development of certain <e2>cancers</e2>.","Positive_Correlation"
"Centrosomal protein 55 (<e1>CEP55</e1>) is a cell cycle regulator implicated in development of certain <e2>cancers</e2>.","Positive_Correlation"
"Centrosomal protein 55 (<e1>CEP55</e1>) is a cell cycle regulator implicated in development of certain <e2>cancers</e2>.","Positive_Correlation"
"Centrosomal protein 55 (<e1>CEP55</e1>) is a cell cycle regulator implicated in development of certain <e2>cancers</e2>.","Positive_Correlation"
"Centrosomal protein 55 (<e1>CEP55</e1>) is a cell cycle regulator implicated in development of certain <e2>cancers</e2>.","Positive_Correlation"
"Centrosomal protein 55 (<e1>CEP55</e1>) is a cell cycle regulator implicated in development of certain <e2>cancers</e2>.","Positive_Correlation"
"Centrosomal protein 55 (<e1>CEP55</e1>) is a cell cycle regulator implicated in development of certain <e2>cancers</e2>.","Positive_Correlation"
"Centrosomal protein 55 (<e1>CEP55</e1>) is a cell cycle regulator implicated in development of certain <e2>cancers</e2>.","Positive_Correlation"
"Centrosomal protein 55 (<e1>CEP55</e1>) is a cell cycle regulator implicated in development of certain <e2>cancers</e2>.","Positive_Correlation"
"Centrosomal protein 55 (<e1>CEP55</e1>) is a cell cycle regulator implicated in development of certain <e2>cancers</e2>.","Positive_Correlation"
"Centrosomal protein 55 (<e1>CEP55</e1>) is a cell cycle regulator implicated in development of certain <e2>cancers</e2>.","Positive_Correlation"
"Centrosomal protein 55 (<e1>CEP55</e1>) is a cell cycle regulator implicated in development of certain <e2>cancers</e2>.","Positive_Correlation"
"Centrosomal protein 55 (<e1>CEP55</e1>) is a cell cycle regulator implicated in development of certain <e2>cancers</e2>.","Positive_Correlation"
"Centrosomal protein 55 (<e1>CEP55</e1>) is a cell cycle regulator implicated in development of certain <e2>cancers</e2>.","Positive_Correlation"
"Centrosomal protein 55 (<e1>CEP55</e1>) is a cell cycle regulator implicated in development of certain <e2>cancers</e2>.","Positive_Correlation"
"Therefore, we investigated the expression and clinicopathological significance of <e1>CEP55</e1> in patients with EOC and its role in regulating invasion and <e2>metastasis of ovarian</e2> cell lines.","Positive_Correlation"
"Therefore, we investigated the expression and clinicopathological significance of <e1>CEP55</e1> in patients with EOC and its role in regulating invasion and <e2>metastasis of ovarian</e2> cell lines.","Positive_Correlation"
"Therefore, we investigated the expression and clinicopathological significance of <e1>CEP55</e1> in patients with EOC and its role in regulating invasion and <e2>metastasis of ovarian</e2> cell lines.","Positive_Correlation"
"Therefore, we investigated the expression and clinicopathological significance of <e1>CEP55</e1> in patients with EOC and its role in regulating invasion and <e2>metastasis of ovarian</e2> cell lines.","Positive_Correlation"
"Therefore, we investigated the expression and clinicopathological significance of <e1>CEP55</e1> in patients with EOC and its role in regulating invasion and <e2>metastasis of ovarian</e2> cell lines.","Positive_Correlation"
"Therefore, we investigated the expression and clinicopathological significance of <e1>CEP55</e1> in patients with EOC and its role in regulating invasion and <e2>metastasis of ovarian</e2> cell lines.","Positive_Correlation"
"Therefore, we investigated the expression and clinicopathological significance of <e1>CEP55</e1> in patients with EOC and its role in regulating invasion and <e2>metastasis of ovarian</e2> cell lines.","Positive_Correlation"
"Therefore, we investigated the expression and clinicopathological significance of <e1>CEP55</e1> in patients with EOC and its role in regulating invasion and <e2>metastasis of ovarian</e2> cell lines.","Positive_Correlation"
"Therefore, we investigated the expression and clinicopathological significance of <e1>CEP55</e1> in patients with EOC and its role in regulating invasion and <e2>metastasis of ovarian</e2> cell lines.","Positive_Correlation"
"Therefore, we investigated the expression and clinicopathological significance of <e1>CEP55</e1> in patients with EOC and its role in regulating invasion and <e2>metastasis of ovarian</e2> cell lines.","Positive_Correlation"
"Therefore, we investigated the expression and clinicopathological significance of <e1>CEP55</e1> in patients with EOC and its role in regulating invasion and <e2>metastasis of ovarian</e2> cell lines.","Positive_Correlation"
"Therefore, we investigated the expression and clinicopathological significance of <e1>CEP55</e1> in patients with EOC and its role in regulating invasion and <e2>metastasis of ovarian</e2> cell lines.","Positive_Correlation"
"Therefore, we investigated the expression and clinicopathological significance of <e1>CEP55</e1> in patients with EOC and its role in regulating invasion and <e2>metastasis of ovarian</e2> cell lines.","Positive_Correlation"
"Therefore, we investigated the expression and clinicopathological significance of <e1>CEP55</e1> in patients with EOC and its role in regulating invasion and <e2>metastasis of ovarian</e2> cell lines.","Positive_Correlation"
"Therefore, we investigated the expression and clinicopathological significance of <e1>CEP55</e1> in patients with EOC and its role in regulating invasion and <e2>metastasis of ovarian</e2> cell lines.","Positive_Correlation"
"Male <e1>11b-HSD1</e1> Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or <e2>Nonalcoholic Fatty Liver Disease</e2>.","Positive_Correlation"
"Male 11b-HSD1 Knockout Mice Fed <e1>Trans-Fats</e1> and Fructose Are Not Protected From Metabolic Syndrome or <e2>Nonalcoholic Fatty Liver Disease</e2>.","Positive_Correlation"
"Male 11b-HSD1 Knockout Mice Fed <e1>Trans-Fats</e1> and Fructose Are Not Protected From <e2>Metabolic Syndrome</e2> or Nonalcoholic Fatty Liver Disease.","Positive_Correlation"
"Male 11b-HSD1 Knockout Mice Fed Trans-Fats and <e1>Fructose</e1> Are Not Protected From Metabolic Syndrome or <e2>Nonalcoholic Fatty Liver Disease</e2>.","Positive_Correlation"
"Male 11b-HSD1 Knockout Mice Fed Trans-Fats and <e1>Fructose</e1> Are Not Protected From <e2>Metabolic Syndrome</e2> or Nonalcoholic Fatty Liver Disease.","Positive_Correlation"
"Body weight, muscle and adipose tissue masses, and parameters of <e1>glucose</e1> homeostasis showed that <e2>11b-HSD1</e2>KO and LKO mice were not protected from systemic metabolic disease.","Association"
"Body weight, muscle and adipose tissue masses, and parameters of <e1>glucose</e1> homeostasis showed that 11b-HSD1KO and LKO mice were not protected from systemic <e2>metabolic disease</e2>.","Association"
"However, global deficiency of <e1>11b-HSD1</e1> did increase markers of <e2>hepatic inflammation</e2> and suggests a critical role for 11b-HSD1 in restraining the transition to NASH.","Association"
"However, global deficiency of <e1>11b-HSD1</e1> did increase markers of <e2>hepatic inflammation</e2> and suggests a critical role for 11b-HSD1 in restraining the transition to NASH.","Association"
"However, global deficiency of <e1>11b-HSD1</e1> did increase markers of <e2>hepatic inflammation</e2> and suggests a critical role for 11b-HSD1 in restraining the transition to NASH.","Association"
"However, global deficiency of <e1>11b-HSD1</e1> did increase markers of <e2>hepatic inflammation</e2> and suggests a critical role for 11b-HSD1 in restraining the transition to NASH.","Association"
"However, global deficiency of <e1>11b-HSD1</e1> did increase markers of <e2>hepatic inflammation</e2> and suggests a critical role for 11b-HSD1 in restraining the transition to NASH.","Association"
"However, global deficiency of <e1>11b-HSD1</e1> did increase markers of <e2>hepatic inflammation</e2> and suggests a critical role for 11b-HSD1 in restraining the transition to NASH.","Association"
"However, global deficiency of <e1>11b-HSD1</e1> did increase markers of <e2>hepatic inflammation</e2> and suggests a critical role for 11b-HSD1 in restraining the transition to NASH.","Association"
"However, global deficiency of <e1>11b-HSD1</e1> did increase markers of <e2>hepatic inflammation</e2> and suggests a critical role for 11b-HSD1 in restraining the transition to NASH.","Association"
"However, global deficiency of <e1>11b-HSD1</e1> did increase markers of <e2>hepatic inflammation</e2> and suggests a critical role for 11b-HSD1 in restraining the transition to NASH.","Association"
"However, global deficiency of <e1>11b-HSD1</e1> did increase markers of <e2>hepatic inflammation</e2> and suggests a critical role for 11b-HSD1 in restraining the transition to NASH.","Association"
"Inhibition of <e1>11b-HSD1</e1> has been suggested as a potential treatment for <e2>NAFLD</e2>.","Positive_Correlation"
"Inhibition of <e1>11b-HSD1</e1> has been suggested as a potential treatment for <e2>NAFLD</e2>.","Positive_Correlation"
"Inhibition of <e1>11b-HSD1</e1> has been suggested as a potential treatment for <e2>NAFLD</e2>.","Positive_Correlation"
"Inhibition of <e1>11b-HSD1</e1> has been suggested as a potential treatment for <e2>NAFLD</e2>.","Positive_Correlation"
"Inhibition of <e1>11b-HSD1</e1> has been suggested as a potential treatment for <e2>NAFLD</e2>.","Positive_Correlation"
"Inhibition of <e1>11b-HSD1</e1> has been suggested as a potential treatment for <e2>NAFLD</e2>.","Positive_Correlation"
"Inhibition of <e1>11b-HSD1</e1> has been suggested as a potential treatment for <e2>NAFLD</e2>.","Positive_Correlation"
"Inhibition of <e1>11b-HSD1</e1> has been suggested as a potential treatment for <e2>NAFLD</e2>.","Positive_Correlation"
"Inhibition of <e1>11b-HSD1</e1> has been suggested as a potential treatment for <e2>NAFLD</e2>.","Positive_Correlation"
"Inhibition of <e1>11b-HSD1</e1> has been suggested as a potential treatment for <e2>NAFLD</e2>.","Positive_Correlation"
"Glucocorticoids can promote <e1>steatosis</e1> by stimulating lipolysis within adipose tissue, <e2>free fatty acid</e2> delivery to liver and hepatic de novo lipogenesis.","Association"
"Glucocorticoids can promote <e1>steatosis</e1> by stimulating lipolysis within adipose tissue, <e2>free fatty acid</e2> delivery to liver and hepatic de novo lipogenesis.","Association"
"Glucocorticoids can promote <e1>steatosis</e1> by stimulating lipolysis within adipose tissue, <e2>free fatty acid</e2> delivery to liver and hepatic de novo lipogenesis.","Association"
"<e1>Glucocorticoids</e1> can be reactivated in liver through <e2>11b-hydroxysteroid dehydrogenase type 1</e2> (11b-HSD1) enzyme activity.","Positive_Correlation"
"<e1>Glucocorticoids</e1> can be reactivated in liver through <e2>11b-hydroxysteroid dehydrogenase type 1</e2> (11b-HSD1) enzyme activity.","Positive_Correlation"
"<e1>Glucocorticoids</e1> can promote steatosis by stimulating lipolysis within adipose tissue, <e2>free fatty acid</e2> delivery to liver and hepatic de novo lipogenesis.","Association"
"<e1>Glucocorticoids</e1> can promote steatosis by stimulating lipolysis within adipose tissue, <e2>free fatty acid</e2> delivery to liver and hepatic de novo lipogenesis.","Association"
"Single-strand conformation polymorphism analysis of the <e1>FMR1</e1> gene in <e2>autistic</e2> and mentally retarded children in Japan.","Association"
"Single-strand conformation polymorphism analysis of the <e1>FMR1</e1> gene in autistic and <e2>mentally retarded</e2> children in Japan.","Association"
"Although uncommon, point mutations in the <e1>FMR1</e1> gene may be a cause of <e2>autism</e2> and mental retardation in Japanese patients.","Association"
"Although uncommon, point mutations in the <e1>FMR1</e1> gene may be a cause of <e2>autism</e2> and mental retardation in Japanese patients.","Association"
"Although uncommon, point mutations in the <e1>FMR1</e1> gene may be a cause of <e2>autism</e2> and mental retardation in Japanese patients.","Association"
"Although uncommon, point mutations in the <e1>FMR1</e1> gene may be a cause of autism and <e2>mental retardation</e2> in Japanese patients.","Association"
"Although uncommon, point mutations in the <e1>FMR1</e1> gene may be a cause of autism and <e2>mental retardation</e2> in Japanese patients.","Association"
"Although uncommon, point mutations in the <e1>FMR1</e1> gene may be a cause of autism and <e2>mental retardation</e2> in Japanese patients.","Association"
"Pheochromocytoma unmasked by <e1>amisulpride</e1> and <e2>tiapride</e2>.","Drug_Interaction"
"<e1>Pheochromocytoma</e1> unmasked by <e2>amisulpride</e2> and tiapride.","Association"
"<e1>Pheochromocytoma</e1> unmasked by amisulpride and <e2>tiapride</e2>.","Association"
"OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with <e1>amisulpride</e1> and <e2>tiapride</e2>.","Drug_Interaction"
"OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with <e1>amisulpride</e1> and <e2>tiapride</e2>.","Drug_Interaction"
"OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with <e1>amisulpride</e1> and <e2>tiapride</e2>.","Drug_Interaction"
"OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with <e1>amisulpride</e1> and <e2>tiapride</e2>.","Drug_Interaction"
"OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with <e1>amisulpride</e1> and <e2>tiapride</e2>.","Drug_Interaction"
"OBJECTIVE: To describe the unmasking of <e1>pheochromocytoma</e1> in a patient treated with <e2>amisulpride</e2> and tiapride.","Association"
"OBJECTIVE: To describe the unmasking of <e1>pheochromocytoma</e1> in a patient treated with <e2>amisulpride</e2> and tiapride.","Association"
"OBJECTIVE: To describe the unmasking of <e1>pheochromocytoma</e1> in a patient treated with <e2>amisulpride</e2> and tiapride.","Association"
"OBJECTIVE: To describe the unmasking of <e1>pheochromocytoma</e1> in a patient treated with <e2>amisulpride</e2> and tiapride.","Association"
"OBJECTIVE: To describe the unmasking of <e1>pheochromocytoma</e1> in a patient treated with amisulpride and <e2>tiapride</e2>.","Association"
"OBJECTIVE: To describe the unmasking of <e1>pheochromocytoma</e1> in a patient treated with amisulpride and <e2>tiapride</e2>.","Association"
"OBJECTIVE: To describe the unmasking of <e1>pheochromocytoma</e1> in a patient treated with amisulpride and <e2>tiapride</e2>.","Association"
"OBJECTIVE: To describe the unmasking of <e1>pheochromocytoma</e1> in a patient treated with amisulpride and <e2>tiapride</e2>.","Association"
"DISCUSSION: Drug-induced symptoms of <e2>pheochromocytoma</e2> are often associated with the use of substituted <e1>benzamide drugs</e1>, but the underlying mechanism is unknown.","Association"
"Both drugs were immediately discontinued, and the patient recovered after subsequent <e1>nicardipine</e1> and <e2>verapamil</e2> treatment.","Cotreatment"
"CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and <e1>vomiting</e1> 2 hours after the first doses of <e2>amisulpride</e2> 100 mg and tiapride 100 mg.","Positive_Correlation"
"CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and <e1>vomiting</e1> 2 hours after the first doses of amisulpride 100 mg and <e2>tiapride</e2> 100 mg.","Positive_Correlation"
"CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe <e1>headache</e1> and vomiting 2 hours after the first doses of <e2>amisulpride</e2> 100 mg and tiapride 100 mg.","Positive_Correlation"
"CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe <e1>headache</e1> and vomiting 2 hours after the first doses of amisulpride 100 mg and <e2>tiapride</e2> 100 mg.","Positive_Correlation"
"CASE SUMMARY: A 42-year-old white man developed acute <e1>hypertension</e1> with severe headache and vomiting 2 hours after the first doses of <e2>amisulpride</e2> 100 mg and tiapride 100 mg.","Positive_Correlation"
"In our case, use of the Naranjo probability scale indicated a possible relationship between the <e1>hypertensive</e1> crisis and <e2>amisulpride</e2> and tiapride therapy.","Positive_Correlation"
"In our case, use of the Naranjo probability scale indicated a possible relationship between the <e1>hypertensive</e1> crisis and <e2>amisulpride</e2> and tiapride therapy.","Positive_Correlation"
"CASE SUMMARY: A 42-year-old white man developed acute <e1>hypertension</e1> with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and <e2>tiapride</e2> 100 mg.","Positive_Correlation"
"In our case, use of the Naranjo probability scale indicated a possible relationship between the <e1>hypertensive</e1> crisis and amisulpride and <e2>tiapride</e2> therapy.","Positive_Correlation"
"In our case, use of the Naranjo probability scale indicated a possible relationship between the <e1>hypertensive</e1> crisis and amisulpride and <e2>tiapride</e2> therapy.","Positive_Correlation"
"Phenylephrine but not <e1>ephedrine</e1> reduces frontal lobe oxygenation following anesthesia-induced <e2>hypotension</e2>.","Negative_Correlation"
"<e1>Phenylephrine</e1> but not <e2>ephedrine</e2> reduces frontal lobe oxygenation following anesthesia-induced hypotension.","Comparison"
"<e1>Phenylephrine</e1> but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced <e2>hypotension</e2>.","Negative_Correlation"
"We describe the effect of phenylephrine and <e1>ephedrine</e1> on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced <e2>hypotension</e2>.","Negative_Correlation"
"We describe the effect of phenylephrine and <e1>ephedrine</e1> on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced <e2>hypotension</e2>.","Negative_Correlation"
"We describe the effect of phenylephrine and <e1>ephedrine</e1> on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced <e2>hypotension</e2>.","Negative_Correlation"
"We describe the effect of phenylephrine and <e1>ephedrine</e1> on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced <e2>hypotension</e2>.","Negative_Correlation"
"We describe the effect of <e1>phenylephrine</e1> and <e2>ephedrine</e2> on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension.","Comparison"
"We describe the effect of <e1>phenylephrine</e1> and <e2>ephedrine</e2> on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension.","Comparison"
"We describe the effect of <e1>phenylephrine</e1> and <e2>ephedrine</e2> on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension.","Comparison"
"We describe the effect of <e1>phenylephrine</e1> and <e2>ephedrine</e2> on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension.","Comparison"
"We describe the effect of <e1>phenylephrine</e1> and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced <e2>hypotension</e2>.","Negative_Correlation"
"We describe the effect of <e1>phenylephrine</e1> and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced <e2>hypotension</e2>.","Negative_Correlation"
"We describe the effect of <e1>phenylephrine</e1> and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced <e2>hypotension</e2>.","Negative_Correlation"
"We describe the effect of <e1>phenylephrine</e1> and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced <e2>hypotension</e2>.","Negative_Correlation"
"The g.ORF15 + 652-653delAG mutation in the <e1>RPGR</e1> gene is the most frequent mutation in <e2>X-linked retinitis pigmentosa</e2> (XLRP).","Association"
"The g.ORF15 + 652-653delAG mutation in the <e1>RPGR</e1> gene is the most frequent mutation in <e2>X-linked retinitis pigmentosa</e2> (XLRP).","Association"
"The g.ORF15 + 652-653delAG mutation in the <e1>RPGR</e1> gene is the most frequent mutation in <e2>X-linked retinitis pigmentosa</e2> (XLRP).","Association"
"The <e1>g.ORF15 + 652-653delAG</e1> mutation in the RPGR gene is the most frequent mutation in <e2>X-linked retinitis pigmentosa</e2> (XLRP).","Positive_Correlation"
"The <e1>g.ORF15 + 652-653delAG</e1> mutation in the RPGR gene is the most frequent mutation in <e2>X-linked retinitis pigmentosa</e2> (XLRP).","Positive_Correlation"
"<e1>Complete atrioventricular block</e1> secondary to <e2>lithium</e2> therapy.","Positive_Correlation"
"In the present case, complete atrioventricular (AV) block with <e1>syncopal attacks</e1> developed secondary to <e2>lithium</e2> therapy, necessitating permanent pacemaker implantation.","Positive_Correlation"
"In the present case, complete atrioventricular (AV) block with <e1>syncopal attacks</e1> developed secondary to <e2>lithium</e2> therapy, necessitating permanent pacemaker implantation.","Positive_Correlation"
"In the present case, <e1>complete atrioventricular (AV) block</e1> with syncopal attacks developed secondary to <e2>lithium</e2> therapy, necessitating permanent pacemaker implantation.","Positive_Correlation"
"<e2>Sinus node dysfunction</e2> has been reported most frequently among the adverse cardiovascular effects of <e1>lithium</e1>.","Positive_Correlation"
"<e2>Sinus node dysfunction</e2> has been reported most frequently among the adverse cardiovascular effects of <e1>lithium</e1>.","Positive_Correlation"
"<e2>Sinus node dysfunction</e2> has been reported most frequently among the adverse cardiovascular effects of <e1>lithium</e1>.","Positive_Correlation"
"Sinus node dysfunction has been reported most frequently among the <e2>adverse cardiovascular effects</e2> of <e1>lithium</e1>.","Positive_Correlation"
"Sinus node dysfunction has been reported most frequently among the <e2>adverse cardiovascular effects</e2> of <e1>lithium</e1>.","Positive_Correlation"
"Sinus node dysfunction has been reported most frequently among the <e2>adverse cardiovascular effects</e2> of <e1>lithium</e1>.","Positive_Correlation"
"<e1>Organophosphate</e1>-induced convulsions and prevention of <e2>neuropathological damages</e2>.","Association"
"<e1>Organophosphate</e1>-induced <e2>convulsions</e2> and prevention of neuropathological damages.","Positive_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and <e1>soman</e1> are potent inhibitors of acetylcholinesterases (AChEs) and <e2>butyrylcholinesterases</e2> (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and <e1>soman</e1> are potent inhibitors of <e2>acetylcholinesterases</e2> (AChEs) and butyrylcholinesterases (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), <e1>sarin</e1> and soman are potent inhibitors of acetylcholinesterases (AChEs) and <e2>butyrylcholinesterases</e2> (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), <e1>sarin</e1> and soman are potent inhibitors of <e2>acetylcholinesterases</e2> (AChEs) and butyrylcholinesterases (BChEs).","Negative_Correlation"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug <e1>atropine sulfate</e1> (50.0 mg/kg BW) immediately or 30 min after the single SC injection of <e2>DFP</e2>.","Negative_Correlation"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug <e1>atropine sulfate</e1> (50.0 mg/kg BW) immediately or 30 min after the single SC injection of <e2>DFP</e2>.","Negative_Correlation"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug <e1>atropine</e1> sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of <e2>DFP</e2>.","Negative_Correlation"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug <e1>atropine</e1> sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of <e2>DFP</e2>.","Negative_Correlation"
"<e1>Atropine</e1>-MK801 did not offer any additional protection against <e2>DFP</e2> toxicity.","Negative_Correlation"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug <e1>atropine</e1> sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of <e2>DFP</e2>.","Negative_Correlation"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant <e1>diazepam</e1> (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug <e2>atropine sulfate</e2> (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant <e1>diazepam</e1> (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug <e2>atropine sulfate</e2> (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant <e1>diazepam</e1> (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug <e2>atropine sulfate</e2> (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant <e1>diazepam</e1> (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of <e2>DFP</e2>.","Negative_Correlation"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant <e1>diazepam</e1> (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of <e2>DFP</e2>.","Negative_Correlation"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant <e1>diazepam</e1> (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of <e2>DFP</e2>.","Negative_Correlation"
"Such organophosphorus (OP) compounds as <e1>diisopropylfluorophosphate</e1> (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and <e2>butyrylcholinesterases</e2> (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and <e2>butyrylcholinesterases</e2> (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and <e2>butyrylcholinesterases</e2> (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and <e2>butyrylcholinesterases</e2> (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and <e2>butyrylcholinesterases</e2> (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and <e2>butyrylcholinesterases</e2> (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and <e2>butyrylcholinesterases</e2> (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and <e2>butyrylcholinesterases</e2> (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and <e2>butyrylcholinesterases</e2> (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and <e2>butyrylcholinesterases</e2> (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as <e1>diisopropylfluorophosphate</e1> (DFP), sarin and soman are potent inhibitors of <e2>acetylcholinesterases</e2> (AChEs) and butyrylcholinesterases (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of <e2>acetylcholinesterases</e2> (AChEs) and butyrylcholinesterases (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of <e2>acetylcholinesterases</e2> (AChEs) and butyrylcholinesterases (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of <e2>acetylcholinesterases</e2> (AChEs) and butyrylcholinesterases (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of <e2>acetylcholinesterases</e2> (AChEs) and butyrylcholinesterases (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of <e2>acetylcholinesterases</e2> (AChEs) and butyrylcholinesterases (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of <e2>acetylcholinesterases</e2> (AChEs) and butyrylcholinesterases (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of <e2>acetylcholinesterases</e2> (AChEs) and butyrylcholinesterases (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of <e2>acetylcholinesterases</e2> (AChEs) and butyrylcholinesterases (BChEs).","Negative_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (<e1>DFP</e1>), sarin and soman are potent inhibitors of <e2>acetylcholinesterases</e2> (AChEs) and butyrylcholinesterases (BChEs).","Negative_Correlation"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), <e1>NMDA-receptor</e1> antagonist <e2>dizocilpine maleate</e2> (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Negative_Correlation"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist <e1>N(6)-cyclopentyl adenosine</e1> (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug <e2>atropine sulfate</e2> (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (<e1>CPA</e1>) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug <e2>atropine sulfate</e2> (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (<e1>CPA</e1>) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug <e2>atropine sulfate</e2> (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (<e1>CPA</e1>) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug <e2>atropine sulfate</e2> (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant <e2>diazepam</e2> (2.0 mg/kg BW), A(1)-adenosine receptor agonist <e1>N(6)-cyclopentyl adenosine</e1> (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant <e2>diazepam</e2> (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (<e1>CPA</e1>) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant <e2>diazepam</e2> (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (<e1>CPA</e1>) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant <e2>diazepam</e2> (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (<e1>CPA</e1>) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist <e1>N(6)-cyclopentyl adenosine</e1> (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of <e2>DFP</e2>.","Negative_Correlation"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (<e1>CPA</e1>) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of <e2>DFP</e2>.","Negative_Correlation"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (<e1>CPA</e1>) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of <e2>DFP</e2>.","Negative_Correlation"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (<e1>CPA</e1>) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of <e2>DFP</e2>.","Negative_Correlation"
"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), <e1>A(1)-adenosine receptor</e1> agonist <e2>N(6)-cyclopentyl adenosine</e2> (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Positive_Correlation"
"The rats received AChE reactivator <e1>pralidoxime-2-chloride</e1> (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug <e2>atropine sulfate</e2> (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (<e1>2PAM</e1>) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug <e2>atropine sulfate</e2> (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (<e1>2PAM</e1>) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug <e2>atropine sulfate</e2> (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (<e1>2PAM</e1>) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug <e2>atropine sulfate</e2> (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator <e1>pralidoxime-2-chloride</e1> (2PAM) (30.0 mg/kg BW), anticonvulsant <e2>diazepam</e2> (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (<e1>2PAM</e1>) (30.0 mg/kg BW), anticonvulsant <e2>diazepam</e2> (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (<e1>2PAM</e1>) (30.0 mg/kg BW), anticonvulsant <e2>diazepam</e2> (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (<e1>2PAM</e1>) (30.0 mg/kg BW), anticonvulsant <e2>diazepam</e2> (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator <e1>pralidoxime-2-chloride</e1> (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of <e2>DFP</e2>.","Negative_Correlation"
"The rats received AChE reactivator pralidoxime-2-chloride (<e1>2PAM</e1>) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of <e2>DFP</e2>.","Negative_Correlation"
"The rats received AChE reactivator pralidoxime-2-chloride (<e1>2PAM</e1>) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of <e2>DFP</e2>.","Negative_Correlation"
"The rats received AChE reactivator pralidoxime-2-chloride (<e1>2PAM</e1>) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of <e2>DFP</e2>.","Negative_Correlation"
"The rats received AChE reactivator <e1>pralidoxime-2-chloride</e1> (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist <e2>N(6)-cyclopentyl adenosine</e2> (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (<e1>2PAM</e1>) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist <e2>N(6)-cyclopentyl adenosine</e2> (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (<e1>2PAM</e1>) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist <e2>N(6)-cyclopentyl adenosine</e2> (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received AChE reactivator pralidoxime-2-chloride (<e1>2PAM</e1>) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist <e2>N(6)-cyclopentyl adenosine</e2> (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Cotreatment"
"The rats received <e1>AChE</e1> reactivator <e2>pralidoxime-2-chloride</e2> (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.","Positive_Correlation"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of <e1><e2>acetylcholine</e2>sterases</e1> (AChEs) and butyrylcholinesterases (BChEs).","Association"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of <e2>acetylcholine</e2>sterases (<e1>AChEs</e1>) and butyrylcholinesterases (BChEs).","Association"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of <e2>acetylcholine</e2>sterases (<e1>AChEs</e1>) and butyrylcholinesterases (BChEs).","Association"
"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of <e2>acetylcholine</e2>sterases (<e1>AChE</e1>s) and butyrylcholinesterases (BChEs).","Association"
"Such <e1>organophosphorus</e1> (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and <e2>butyrylcholinesterases</e2> (BChEs).","Negative_Correlation"
"Such organophosphorus (<e1>OP</e1>) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and <e2>butyrylcholinesterases</e2> (BChEs).","Negative_Correlation"
"Such organophosphorus (<e1>OP</e1>) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and <e2>butyrylcholinesterases</e2> (BChEs).","Negative_Correlation"
"Such <e1>organophosphorus</e1> (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of <e2>acetylcholinesterases</e2> (AChEs) and butyrylcholinesterases (BChEs).","Negative_Correlation"
"Such organophosphorus (<e1>OP</e1>) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of <e2>acetylcholinesterases</e2> (AChEs) and butyrylcholinesterases (BChEs).","Negative_Correlation"
"The acute toxicity of <e1>OPs</e1> is the result of their irreversible binding with <e2>AChEs</e2> in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.","Negative_Correlation"
"Such organophosphorus (<e1>OP</e1>) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of <e2>acetylcholinesterases</e2> (AChEs) and butyrylcholinesterases (BChEs).","Negative_Correlation"
"Such <e1>organophosphorus</e1> (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of <e2>acetylcholine</e2>sterases (AChEs) and butyrylcholinesterases (BChEs).","Association"
"Such organophosphorus (<e1>OP</e1>) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of <e2>acetylcholine</e2>sterases (AChEs) and butyrylcholinesterases (BChEs).","Association"
"The acute toxicity of <e1>OPs</e1> is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates <e2>acetylcholine</e2> (ACh) levels.","Association"
"Such organophosphorus (<e1>OP</e1>) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of <e2>acetylcholine</e2>sterases (AChEs) and butyrylcholinesterases (BChEs).","Association"
"The activation of spinal <e2>N-methyl-D-aspartate receptors</e2> may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of <e1>spinal cord ischemia</e1>.","Association"
"The activation of spinal <e2>N-methyl-D-aspartate receptors</e2> may contribute to degeneration of spinal motor neurons induced by neuraxial <e1>morphine</e1> after a noninjurious interval of spinal cord ischemia.","Association"
"We suggest that opioids may be neurotoxic in the setting of <e1>spinal cord ischemia</e1> via <e2>NMDA receptor</e2> activation.","Association"
"We suggest that <e1>opioids</e1> may be neurotoxic in the setting of <e2>spinal cord ischemia</e2> via NMDA receptor activation.","Association"
"We suggest that <e1>opioids</e1> may be <e2>neurotoxic</e2> in the setting of spinal cord ischemia via NMDA receptor activation.","Positive_Correlation"
"We suggest that <e1>opioids</e1> may be neurotoxic in the setting of spinal cord ischemia via <e2>NMDA receptor</e2> activation.","Association"
"We suggest that opioids may be <e1>neurotoxic</e1> in the setting of spinal cord ischemia via <e2>NMDA receptor</e2> activation.","Association"
"Second, we investigated the effect of IT <e1>MK-801</e1> (30 mug) on the histopathologic changes in the spinal cord after morphine-induced <e2>spastic paraparesis</e2>.","Association"
"Second, we investigated the effect of IT <e1>MK-801</e1> (30 mug) on the histopathologic changes in the spinal cord after morphine-induced <e2>spastic paraparesis</e2>.","Association"
"Second, we investigated the effect of IT <e1>MK-801</e1> (30 mug) on the histopathologic changes in the spinal cord after <e2>morphine</e2>-induced spastic paraparesis.","Association"
"Second, we investigated the effect of IT <e1>MK-801</e1> (30 mug) on the histopathologic changes in the spinal cord after <e2>morphine</e2>-induced spastic paraparesis.","Association"
"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF <e1>glutamate</e1>, which is involved in <e2>NMDA receptor</e2> activation.","Association"
"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF <e1>glutamate</e1>, which is involved in <e2>NMDA receptor</e2> activation.","Association"
"These data indicate that IT morphine induces <e1>spastic paraparesis</e1> with a concomitant increase in CSF glutamate, which is involved in <e2>NMDA receptor</e2> activation.","Association"
"These data indicate that IT morphine induces <e1>spastic paraparesis</e1> with a concomitant increase in CSF glutamate, which is involved in <e2>NMDA receptor</e2> activation.","Association"
"These data indicate that IT morphine induces <e1>spastic paraparesis</e1> with a concomitant increase in CSF glutamate, which is involved in <e2>NMDA receptor</e2> activation.","Association"
"We investigated the relationship between the degeneration of spinal motor neurons and activation of <e2>N-methyl-d-aspartate (NMDA) receptors</e2> after neuraxial <e1>morphine</e1> following a noninjurious interval of aortic occlusion in rats.","Association"
"We investigated the relationship between the degeneration of spinal motor neurons and activation of <e2>N-methyl-d-aspartate (NMDA) receptors</e2> after neuraxial <e1>morphine</e1> following a noninjurious interval of aortic occlusion in rats.","Association"
"We investigated the relationship between the degeneration of spinal motor neurons and activation of <e2>N-methyl-d-aspartate (NMDA) receptors</e2> after neuraxial <e1>morphine</e1> following a noninjurious interval of aortic occlusion in rats.","Association"
"We investigated the relationship between the degeneration of spinal motor neurons and activation of <e2>N-methyl-d-aspartate (NMDA) receptors</e2> after neuraxial <e1>morphine</e1> following a noninjurious interval of aortic occlusion in rats.","Association"
"We investigated the relationship between the degeneration of spinal motor neurons and activation of <e2>N-methyl-d-aspartate (NMDA) receptors</e2> after neuraxial <e1>morphine</e1> following a noninjurious interval of aortic occlusion in rats.","Association"
"We investigated the relationship between the degeneration of spinal motor neurons and activation of <e2>N-methyl-d-aspartate (NMDA) receptors</e2> after neuraxial <e1>morphine</e1> following a noninjurious interval of aortic occlusion in rats.","Association"
"We investigated the relationship between the degeneration of spinal motor neurons and activation of <e2>N-methyl-d-aspartate (NMDA) receptors</e2> after neuraxial <e1>morphine</e1> following a noninjurious interval of aortic occlusion in rats.","Association"
"After IT <e1>morphine</e1>, the cerebrospinal fluid (CSF) <e2>glutamate</e2> concentration was increased in group M relative to both baseline and group C (P < 0.05).","Positive_Correlation"
"After IT <e1>morphine</e1>, the cerebrospinal fluid (CSF) <e2>glutamate</e2> concentration was increased in group M relative to both baseline and group C (P < 0.05).","Positive_Correlation"
"After IT <e1>morphine</e1>, the cerebrospinal fluid (CSF) <e2>glutamate</e2> concentration was increased in group M relative to both baseline and group C (P < 0.05).","Positive_Correlation"
"After IT <e1>morphine</e1>, the cerebrospinal fluid (CSF) <e2>glutamate</e2> concentration was increased in group M relative to both baseline and group C (P < 0.05).","Positive_Correlation"
"After IT <e1>morphine</e1>, the cerebrospinal fluid (CSF) <e2>glutamate</e2> concentration was increased in group M relative to both baseline and group C (P < 0.05).","Positive_Correlation"
"After IT <e1>morphine</e1>, the cerebrospinal fluid (CSF) <e2>glutamate</e2> concentration was increased in group M relative to both baseline and group C (P < 0.05).","Positive_Correlation"
"After IT <e1>morphine</e1>, the cerebrospinal fluid (CSF) <e2>glutamate</e2> concentration was increased in group M relative to both baseline and group C (P < 0.05).","Positive_Correlation"
"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after <e1>morphine</e1>-induced <e2>spastic paraparesis</e2>.","Positive_Correlation"
"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after <e1>morphine</e1>-induced <e2>spastic paraparesis</e2>.","Positive_Correlation"
"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after <e1>morphine</e1>-induced <e2>spastic paraparesis</e2>.","Positive_Correlation"
"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after <e1>morphine</e1>-induced <e2>spastic paraparesis</e2>.","Positive_Correlation"
"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after <e1>morphine</e1>-induced <e2>spastic paraparesis</e2>.","Positive_Correlation"
"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after <e1>morphine</e1>-induced <e2>spastic paraparesis</e2>.","Positive_Correlation"
"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after <e1>morphine</e1>-induced <e2>spastic paraparesis</e2>.","Positive_Correlation"
"<e1>Growth-associated protein 43</e1> expression in hippocampal molecular layer of chronic <e2>epileptic</e2> rats treated with cycloheximide.","Association"
"<e2>Growth-associated protein 43</e2> expression in hippocampal molecular layer of chronic epileptic rats treated with <e1>cycloheximide</e1>.","Association"
"Growth-associated protein 43 expression in hippocampal molecular layer of chronic <e1>epileptic</e1> rats treated with <e2>cycloheximide</e2>.","Negative_Correlation"
"PURPOSE: <e1>GAP43</e1> has been thought to be linked with mossy fiber sprouting (MFS) in various experimental models of <e2>epilepsy</e2>.","Association"
"PURPOSE: <e1>GAP43</e1> has been thought to be linked with mossy fiber sprouting (MFS) in various experimental models of <e2>epilepsy</e2>.","Association"
"PURPOSE: <e1>GAP43</e1> has been thought to be linked with mossy fiber sprouting (MFS) in various experimental models of <e2>epilepsy</e2>.","Association"
"PURPOSE: <e1>GAP43</e1> has been thought to be linked with mossy fiber sprouting (MFS) in various experimental models of <e2>epilepsy</e2>.","Association"
"PURPOSE: <e1>GAP43</e1> has been thought to be linked with mossy fiber sprouting (MFS) in various experimental models of <e2>epilepsy</e2>.","Association"
"PURPOSE: <e1>GAP43</e1> has been thought to be linked with mossy fiber sprouting (MFS) in various experimental models of <e2>epilepsy</e2>.","Association"
"PURPOSE: <e1>GAP43</e1> has been thought to be linked with mossy fiber sprouting (MFS) in various experimental models of <e2>epilepsy</e2>.","Association"
"PURPOSE: <e1>GAP43</e1> has been thought to be linked with mossy fiber sprouting (MFS) in various experimental models of <e2>epilepsy</e2>.","Association"
"PURPOSE: <e1>GAP43</e1> has been thought to be linked with mossy fiber sprouting (MFS) in various experimental models of <e2>epilepsy</e2>.","Association"
"To investigate how <e2>GAP43</e2> expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by <e1>pilocarpine</e1> (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.","Association"
"To investigate how <e2>GAP43</e2> expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (<e1>Pilo</e1>), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.","Association"
"To investigate how <e2>GAP43</e2> expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (<e1>Pilo</e1>), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.","Association"
"To investigate how <e2>GAP43</e2> expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (<e1>Pilo</e1>), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.","Association"
"To investigate how <e2>GAP43</e2> expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (<e1>Pilo</e1>), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.","Association"
"To investigate how <e2>GAP43</e2> expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (<e1>Pilo</e1>), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.","Association"
"To investigate how <e2>GAP43</e2> expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (<e1>Pilo</e1>), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.","Association"
"To investigate how <e2>GAP43</e2> expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (<e1>Pilo</e1>), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.","Association"
"To investigate how <e2>GAP43</e2> expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (<e1>Pilo</e1>), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.","Association"
"To investigate how <e2>GAP43</e2> expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (<e1>Pilo</e1>), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.","Association"
"To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to <e1>status epilepticus</e1> induced by <e2>pilocarpine</e2> (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.","Positive_Correlation"
"To investigate how <e2>GAP43</e2> expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with <e1>cycloheximide</e1> (CHX), which has been shown to inhibit MFS.","Association"
"To investigate how <e2>GAP43</e2> expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with cycloheximide (<e1>CHX</e1>), which has been shown to inhibit MFS.","Association"
"To investigate how <e2>GAP43</e2> expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with cycloheximide (<e1>CHX</e1>), which has been shown to inhibit MFS.","Association"
"To investigate how <e2>GAP43</e2> expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with cycloheximide (<e1>CHX</e1>), which has been shown to inhibit MFS.","Association"
"To investigate how <e2>GAP43</e2> expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with cycloheximide (<e1>CHX</e1>), which has been shown to inhibit MFS.","Association"
"To investigate how <e2>GAP43</e2> expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with cycloheximide (<e1>CHX</e1>), which has been shown to inhibit MFS.","Association"
"To investigate how <e2>GAP43</e2> expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with cycloheximide (<e1>CHX</e1>), which has been shown to inhibit MFS.","Association"
"<e1>Daidzein</e1> activates choline acetyltransferase from MC-IXC cells and improves drug-induced <e2>amnesia</e2>.","Negative_Correlation"
"<e1>Daidzein</e1> activates <e2>choline acetyltransferase</e2> from MC-IXC cells and improves drug-induced amnesia.","Positive_Correlation"
"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of <e1>acetylcholine</e1> (ACh), is an important factor in the treatment of <e2>Alzheimer's disease</e2> (AD).","Association"
"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (<e1>ACh</e1>), is an important factor in the treatment of <e2>Alzheimer's disease</e2> (AD).","Association"
"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of <e1>acetylcholine</e1> (ACh), is an important factor in the treatment of <e2>Alzheimer's disease</e2> (AD).","Association"
"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse <e1>scopolamine</e1>-induced <e2>amnesia</e2>, according to the results of a Y-maze test.","Positive_Correlation"
"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse <e1>scopolamine</e1>-induced <e2>amnesia</e2>, according to the results of a Y-maze test.","Positive_Correlation"
"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse <e1>scopolamine</e1>-induced <e2>amnesia</e2>, according to the results of a Y-maze test.","Positive_Correlation"
"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse <e1>scopolamine</e1>-induced <e2>amnesia</e2>, according to the results of a Y-maze test.","Positive_Correlation"
"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse <e1>scopolamine</e1>-induced <e2>amnesia</e2>, according to the results of a Y-maze test.","Positive_Correlation"
"In order to investigate the effects of daidzein from Pueraria thunbergiana on <e1>scopolamine</e1>-induced <e2>impairments of learning and memory</e2>, we conducted a series of in vivo tests.","Positive_Correlation"
"In order to investigate the effects of daidzein from Pueraria thunbergiana on <e1>scopolamine</e1>-induced <e2>impairments of learning and memory</e2>, we conducted a series of in vivo tests.","Positive_Correlation"
"In order to investigate the effects of daidzein from Pueraria thunbergiana on <e1>scopolamine</e1>-induced <e2>impairments of learning and memory</e2>, we conducted a series of in vivo tests.","Positive_Correlation"
"In order to investigate the effects of daidzein from Pueraria thunbergiana on <e1>scopolamine</e1>-induced <e2>impairments of learning and memory</e2>, we conducted a series of in vivo tests.","Positive_Correlation"
"In order to investigate the effects of daidzein from Pueraria thunbergiana on <e1>scopolamine</e1>-induced <e2>impairments of learning and memory</e2>, we conducted a series of in vivo tests.","Positive_Correlation"
"<e1>Methanolic</e1> extracts from Pueraria thunbergiana exhibited an activation effect (46%) on <e2>ChAT</e2> in vitro.","Positive_Correlation"
"The <e1>choline acetyltransferase</e1> (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of <e2>Alzheimer's disease</e2> (AD).","Association"
"The choline acetyltransferase (<e1>ChAT</e1>) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of <e2>Alzheimer's disease</e2> (AD).","Association"
"The choline acetyltransferase (<e1>ChAT</e1>) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of <e2>Alzheimer's disease</e2> (AD).","Association"
"The <e1>choline acetyltransferase</e1> (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of <e2>acetylcholine</e2> (ACh), is an important factor in the treatment of Alzheimer's disease (AD).","Association"
"The choline acetyltransferase (<e1>ChAT</e1>) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of <e2>acetylcholine</e2> (ACh), is an important factor in the treatment of Alzheimer's disease (AD).","Association"
"The choline acetyltransferase (<e1>ChAT</e1>) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of <e2>acetylcholine</e2> (ACh), is an important factor in the treatment of Alzheimer's disease (AD).","Association"
"These results indicate that <e1>daidzein</e1> might play a role in <e2>acetylcholine</e2> biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.","Association"
"These results indicate that <e1>daidzein</e1> might play a role in <e2>acetylcholine</e2> biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.","Association"
"These results indicate that <e1>daidzein</e1> might play a role in <e2>acetylcholine</e2> biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.","Association"
"These results indicate that <e1>daidzein</e1> might play a role in <e2>acetylcholine</e2> biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.","Association"
"These results indicate that <e1>daidzein</e1> might play a role in <e2>acetylcholine</e2> biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.","Association"
"Administration of <e1>daidzein</e1> (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced <e2>amnesia</e2>, according to the results of a Y-maze test.","Negative_Correlation"
"Administration of <e1>daidzein</e1> (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced <e2>amnesia</e2>, according to the results of a Y-maze test.","Negative_Correlation"
"Administration of <e1>daidzein</e1> (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced <e2>amnesia</e2>, according to the results of a Y-maze test.","Negative_Correlation"
"Administration of <e1>daidzein</e1> (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced <e2>amnesia</e2>, according to the results of a Y-maze test.","Negative_Correlation"
"Administration of <e1>daidzein</e1> (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced <e2>amnesia</e2>, according to the results of a Y-maze test.","Negative_Correlation"
"In order to investigate the effects of <e1>daidzein</e1> from Pueraria thunbergiana on <e2>scopolamine</e2>-induced impairments of learning and memory, we conducted a series of in vivo tests.","Negative_Correlation"
"In order to investigate the effects of <e1>daidzein</e1> from Pueraria thunbergiana on <e2>scopolamine</e2>-induced impairments of learning and memory, we conducted a series of in vivo tests.","Negative_Correlation"
"In order to investigate the effects of <e1>daidzein</e1> from Pueraria thunbergiana on <e2>scopolamine</e2>-induced impairments of learning and memory, we conducted a series of in vivo tests.","Negative_Correlation"
"In order to investigate the effects of <e1>daidzein</e1> from Pueraria thunbergiana on <e2>scopolamine</e2>-induced impairments of learning and memory, we conducted a series of in vivo tests.","Negative_Correlation"
"In order to investigate the effects of <e1>daidzein</e1> from Pueraria thunbergiana on <e2>scopolamine</e2>-induced impairments of learning and memory, we conducted a series of in vivo tests.","Negative_Correlation"
"These results indicate that <e1>daidzein</e1> might play a role in acetylcholine biosynthesis as a <e2>ChAT</e2> activator, and that it also ameliorates scopolamine-induced amnesia.","Positive_Correlation"
"These results indicate that <e1>daidzein</e1> might play a role in acetylcholine biosynthesis as a <e2>ChAT</e2> activator, and that it also ameliorates scopolamine-induced amnesia.","Positive_Correlation"
"These results indicate that <e1>daidzein</e1> might play a role in acetylcholine biosynthesis as a <e2>ChAT</e2> activator, and that it also ameliorates scopolamine-induced amnesia.","Positive_Correlation"
"These results indicate that <e1>daidzein</e1> might play a role in acetylcholine biosynthesis as a <e2>ChAT</e2> activator, and that it also ameliorates scopolamine-induced amnesia.","Positive_Correlation"
"These results indicate that <e1>daidzein</e1> might play a role in acetylcholine biosynthesis as a <e2>ChAT</e2> activator, and that it also ameliorates scopolamine-induced amnesia.","Positive_Correlation"
"Effect of <e1>alpha-tocopherol</e1> and deferoxamine on <e2>methamphetamine</e2>-induced neurotoxicity.","Negative_Correlation"
"Effect of alpha-tocopherol and deferoxamine on <e1>methamphetamine</e1>-induced <e2>neurotoxicity</e2>.","Positive_Correlation"
"Effect of alpha-tocopherol and <e1>deferoxamine</e1> on <e2>methamphetamine</e2>-induced neurotoxicity.","Negative_Correlation"
"The level of <e1>lipid</e1> peroxidation was higher and the reduced glutathione concentration was lower in the <e2>MA</e2>-treated rats.","Positive_Correlation"
"The level of lipid peroxidation was higher and the reduced <e1>glutathione</e1> concentration was lower in the <e2>MA</e2>-treated rats.","Negative_Correlation"
"The concentrations of dopamine (DA), <e1>serotonin</e1> and their metabolites decreased significantly after <e2>MA</e2> administration, which was inhibited by the alpha-TC and DFO pretreatment.","Negative_Correlation"
"This study examined the effect of <e1>alpha-tocopherol</e1> (alpha-TC), a scavenger of <e2>reactive oxygen species</e2>, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.","Association"
"This study examined the effect of alpha-tocopherol (<e1>alpha-TC</e1>), a scavenger of <e2>reactive oxygen species</e2>, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.","Association"
"This study examined the effect of alpha-tocopherol (<e1>alpha-TC</e1>), a scavenger of <e2>reactive oxygen species</e2>, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.","Association"
"This study examined the effect of alpha-tocopherol (<e1>alpha-TC</e1>), a scavenger of <e2>reactive oxygen species</e2>, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.","Association"
"This study examined the effect of alpha-tocopherol (<e1>alpha-TC</e1>), a scavenger of <e2>reactive oxygen species</e2>, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.","Association"
"This study examined the effect of alpha-tocopherol (<e1>alpha-TC</e1>), a scavenger of <e2>reactive oxygen species</e2>, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.","Association"
"This study examined the effect of alpha-tocopherol (<e1>alpha-TC</e1>), a scavenger of <e2>reactive oxygen species</e2>, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.","Association"
"This suggests that <e1>alpha-TC</e1> and DFO ameliorate the MA-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Negative_Correlation"
"This suggests that <e1>alpha-TC</e1> and DFO ameliorate the MA-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Negative_Correlation"
"This suggests that <e1>alpha-TC</e1> and DFO ameliorate the MA-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Negative_Correlation"
"This suggests that <e1>alpha-TC</e1> and DFO ameliorate the MA-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Negative_Correlation"
"This suggests that <e1>alpha-TC</e1> and DFO ameliorate the MA-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Negative_Correlation"
"This suggests that <e1>alpha-TC</e1> and DFO ameliorate the MA-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Negative_Correlation"
"<e1>alpha-TC</e1> and DFO attenuated the MA-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Negative_Correlation"
"<e1>alpha-TC</e1> and DFO attenuated the MA-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Negative_Correlation"
"<e1>alpha-TC</e1> and DFO attenuated the MA-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Negative_Correlation"
"<e1>alpha-TC</e1> and DFO attenuated the MA-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Negative_Correlation"
"<e1>alpha-TC</e1> and DFO attenuated the MA-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Negative_Correlation"
"<e1>alpha-TC</e1> and DFO attenuated the MA-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Negative_Correlation"
"The concentrations of dopamine (DA), <e2>serotonin</e2> and their metabolites decreased significantly after MA administration, which was inhibited by the <e1>alpha-TC</e1> and DFO pretreatment.","Positive_Correlation"
"The concentrations of dopamine (DA), <e2>serotonin</e2> and their metabolites decreased significantly after MA administration, which was inhibited by the <e1>alpha-TC</e1> and DFO pretreatment.","Positive_Correlation"
"The concentrations of dopamine (DA), <e2>serotonin</e2> and their metabolites decreased significantly after MA administration, which was inhibited by the <e1>alpha-TC</e1> and DFO pretreatment.","Positive_Correlation"
"The concentrations of dopamine (DA), <e2>serotonin</e2> and their metabolites decreased significantly after MA administration, which was inhibited by the <e1>alpha-TC</e1> and DFO pretreatment.","Positive_Correlation"
"The concentrations of dopamine (DA), <e2>serotonin</e2> and their metabolites decreased significantly after MA administration, which was inhibited by the <e1>alpha-TC</e1> and DFO pretreatment.","Positive_Correlation"
"The concentrations of dopamine (DA), <e2>serotonin</e2> and their metabolites decreased significantly after MA administration, which was inhibited by the <e1>alpha-TC</e1> and DFO pretreatment.","Positive_Correlation"
"This study examined the effect of <e1>alpha-tocopherol</e1> (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the <e2>MA</e2>-induced neurotoxicity.","Negative_Correlation"
"This study examined the effect of alpha-tocopherol (<e1>alpha-TC</e1>), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the <e2>MA</e2>-induced neurotoxicity.","Negative_Correlation"
"This study examined the effect of alpha-tocopherol (<e1>alpha-TC</e1>), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the <e2>MA</e2>-induced neurotoxicity.","Negative_Correlation"
"This study examined the effect of alpha-tocopherol (<e1>alpha-TC</e1>), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the <e2>MA</e2>-induced neurotoxicity.","Negative_Correlation"
"This study examined the effect of alpha-tocopherol (<e1>alpha-TC</e1>), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the <e2>MA</e2>-induced neurotoxicity.","Negative_Correlation"
"This study examined the effect of alpha-tocopherol (<e1>alpha-TC</e1>), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the <e2>MA</e2>-induced neurotoxicity.","Negative_Correlation"
"This study examined the effect of alpha-tocopherol (<e1>alpha-TC</e1>), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the <e2>MA</e2>-induced neurotoxicity.","Negative_Correlation"
"The concentrations of <e2>dopamine</e2> (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the <e1>alpha-TC</e1> and DFO pretreatment.","Positive_Correlation"
"The concentrations of <e2>dopamine</e2> (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the <e1>alpha-TC</e1> and DFO pretreatment.","Positive_Correlation"
"The concentrations of <e2>dopamine</e2> (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the <e1>alpha-TC</e1> and DFO pretreatment.","Positive_Correlation"
"The concentrations of <e2>dopamine</e2> (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the <e1>alpha-TC</e1> and DFO pretreatment.","Positive_Correlation"
"The concentrations of <e2>dopamine</e2> (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the <e1>alpha-TC</e1> and DFO pretreatment.","Positive_Correlation"
"The concentrations of <e2>dopamine</e2> (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the <e1>alpha-TC</e1> and DFO pretreatment.","Positive_Correlation"
"<e1>Methamphetamine</e1> (MA)-induced dopaminergic <e2>neurotoxicity</e2> is believed to be associated with the increased formation of free radicals.","Positive_Correlation"
"Methamphetamine (<e1>MA</e1>)-induced dopaminergic <e2>neurotoxicity</e2> is believed to be associated with the increased formation of free radicals.","Positive_Correlation"
"Methamphetamine (<e1>MA</e1>)-induced dopaminergic <e2>neurotoxicity</e2> is believed to be associated with the increased formation of free radicals.","Positive_Correlation"
"Methamphetamine (<e1>MA</e1>)-induced dopaminergic <e2>neurotoxicity</e2> is believed to be associated with the increased formation of free radicals.","Positive_Correlation"
"Methamphetamine (<e1>MA</e1>)-induced dopaminergic <e2>neurotoxicity</e2> is believed to be associated with the increased formation of free radicals.","Positive_Correlation"
"Methamphetamine (<e1>MA</e1>)-induced dopaminergic <e2>neurotoxicity</e2> is believed to be associated with the increased formation of free radicals.","Positive_Correlation"
"Methamphetamine (<e1>MA</e1>)-induced dopaminergic <e2>neurotoxicity</e2> is believed to be associated with the increased formation of free radicals.","Positive_Correlation"
"Methamphetamine (<e1>MA</e1>)-induced dopaminergic <e2>neurotoxicity</e2> is believed to be associated with the increased formation of free radicals.","Positive_Correlation"
"Methamphetamine (<e1>MA</e1>)-induced dopaminergic <e2>neurotoxicity</e2> is believed to be associated with the increased formation of free radicals.","Positive_Correlation"
"Methamphetamine (<e1>MA</e1>)-induced dopaminergic <e2>neurotoxicity</e2> is believed to be associated with the increased formation of free radicals.","Positive_Correlation"
"This suggests that alpha-TC and DFO ameliorate the <e1>MA</e1>-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Positive_Correlation"
"This suggests that alpha-TC and DFO ameliorate the <e1>MA</e1>-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Positive_Correlation"
"This suggests that alpha-TC and DFO ameliorate the <e1>MA</e1>-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Positive_Correlation"
"This suggests that alpha-TC and DFO ameliorate the <e1>MA</e1>-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Positive_Correlation"
"This suggests that alpha-TC and DFO ameliorate the <e1>MA</e1>-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Positive_Correlation"
"This suggests that alpha-TC and DFO ameliorate the <e1>MA</e1>-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Positive_Correlation"
"This suggests that alpha-TC and DFO ameliorate the <e1>MA</e1>-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Positive_Correlation"
"This suggests that alpha-TC and DFO ameliorate the <e1>MA</e1>-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Positive_Correlation"
"This suggests that alpha-TC and DFO ameliorate the <e1>MA</e1>-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Positive_Correlation"
"alpha-TC and DFO attenuated the <e1>MA</e1>-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Positive_Correlation"
"alpha-TC and DFO attenuated the <e1>MA</e1>-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Positive_Correlation"
"alpha-TC and DFO attenuated the <e1>MA</e1>-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Positive_Correlation"
"alpha-TC and DFO attenuated the <e1>MA</e1>-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Positive_Correlation"
"alpha-TC and DFO attenuated the <e1>MA</e1>-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Positive_Correlation"
"alpha-TC and DFO attenuated the <e1>MA</e1>-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Positive_Correlation"
"alpha-TC and DFO attenuated the <e1>MA</e1>-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Positive_Correlation"
"alpha-TC and DFO attenuated the <e1>MA</e1>-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Positive_Correlation"
"alpha-TC and DFO attenuated the <e1>MA</e1>-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Positive_Correlation"
"Methamphetamine (MA)-induced <e1>dopaminergic</e1> <e2>neurotoxicity</e2> is believed to be associated with the increased formation of free radicals.","Positive_Correlation"
"Methamphetamine (MA)-induced <e1>dopamine</e1>rgic <e2>neurotoxicity</e2> is believed to be associated with the increased formation of free radicals.","Positive_Correlation"
"<e2>Methamphetamine</e2> (MA)-induced <e1>dopaminergic</e1> neurotoxicity is believed to be associated with the increased formation of free radicals.","Negative_Correlation"
"<e2>Methamphetamine</e2> (MA)-induced <e1>dopamine</e1>rgic neurotoxicity is believed to be associated with the increased formation of free radicals.","Negative_Correlation"
"The concentrations of dopamine (<e1>DA</e1>), serotonin and their metabolites decreased significantly after <e2>MA</e2> administration, which was inhibited by the alpha-TC and DFO pretreatment.","Negative_Correlation"
"This suggests that alpha-TC and <e1>DFO</e1> ameliorate the MA-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Negative_Correlation"
"This suggests that alpha-TC and <e1>DFO</e1> ameliorate the MA-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Negative_Correlation"
"This suggests that alpha-TC and <e1>DFO</e1> ameliorate the MA-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Negative_Correlation"
"This suggests that alpha-TC and <e1>DFO</e1> ameliorate the MA-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Negative_Correlation"
"This suggests that alpha-TC and <e1>DFO</e1> ameliorate the MA-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Negative_Correlation"
"This suggests that alpha-TC and <e1>DFO</e1> ameliorate the MA-induced <e2>neuronal damage</e2> by decreasing the level of oxidative stress.","Negative_Correlation"
"alpha-TC and <e1>DFO</e1> attenuated the MA-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Negative_Correlation"
"alpha-TC and <e1>DFO</e1> attenuated the MA-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Negative_Correlation"
"alpha-TC and <e1>DFO</e1> attenuated the MA-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Negative_Correlation"
"alpha-TC and <e1>DFO</e1> attenuated the MA-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Negative_Correlation"
"alpha-TC and <e1>DFO</e1> attenuated the MA-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Negative_Correlation"
"alpha-TC and <e1>DFO</e1> attenuated the MA-induced <e2>hyperthermia</e2> as well as the alterations in the locomotor activity.","Negative_Correlation"
"The concentrations of dopamine (DA), <e2>serotonin</e2> and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and <e1>DFO</e1> pretreatment.","Positive_Correlation"
"The concentrations of dopamine (DA), <e2>serotonin</e2> and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and <e1>DFO</e1> pretreatment.","Positive_Correlation"
"The concentrations of dopamine (DA), <e2>serotonin</e2> and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and <e1>DFO</e1> pretreatment.","Positive_Correlation"
"The concentrations of dopamine (DA), <e2>serotonin</e2> and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and <e1>DFO</e1> pretreatment.","Positive_Correlation"
"The concentrations of dopamine (DA), <e2>serotonin</e2> and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and <e1>DFO</e1> pretreatment.","Positive_Correlation"
"The concentrations of dopamine (DA), <e2>serotonin</e2> and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and <e1>DFO</e1> pretreatment.","Positive_Correlation"
"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and <e1>deferoxamine</e1> (DFO), an iron chelator, on the <e2>MA</e2>-induced neurotoxicity.","Negative_Correlation"
"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (<e1>DFO</e1>), an iron chelator, on the <e2>MA</e2>-induced neurotoxicity.","Negative_Correlation"
"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (<e1>DFO</e1>), an iron chelator, on the <e2>MA</e2>-induced neurotoxicity.","Negative_Correlation"
"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (<e1>DFO</e1>), an iron chelator, on the <e2>MA</e2>-induced neurotoxicity.","Negative_Correlation"
"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (<e1>DFO</e1>), an iron chelator, on the <e2>MA</e2>-induced neurotoxicity.","Negative_Correlation"
"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (<e1>DFO</e1>), an iron chelator, on the <e2>MA</e2>-induced neurotoxicity.","Negative_Correlation"
"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (<e1>DFO</e1>), an iron chelator, on the <e2>MA</e2>-induced neurotoxicity.","Negative_Correlation"
"The concentrations of <e2>dopamine</e2> (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and <e1>DFO</e1> pretreatment.","Positive_Correlation"
"The concentrations of <e2>dopamine</e2> (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and <e1>DFO</e1> pretreatment.","Positive_Correlation"
"The concentrations of <e2>dopamine</e2> (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and <e1>DFO</e1> pretreatment.","Positive_Correlation"
"The concentrations of <e2>dopamine</e2> (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and <e1>DFO</e1> pretreatment.","Positive_Correlation"
"The concentrations of <e2>dopamine</e2> (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and <e1>DFO</e1> pretreatment.","Positive_Correlation"
"The concentrations of <e2>dopamine</e2> (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and <e1>DFO</e1> pretreatment.","Positive_Correlation"
"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and <e1>deferoxamine</e1> (DFO), an <e2>iron</e2> chelator, on the MA-induced neurotoxicity.","Association"
"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (<e1>DFO</e1>), an <e2>iron</e2> chelator, on the MA-induced neurotoxicity.","Association"
"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (<e1>DFO</e1>), an <e2>iron</e2> chelator, on the MA-induced neurotoxicity.","Association"
"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (<e1>DFO</e1>), an <e2>iron</e2> chelator, on the MA-induced neurotoxicity.","Association"
"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (<e1>DFO</e1>), an <e2>iron</e2> chelator, on the MA-induced neurotoxicity.","Association"
"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (<e1>DFO</e1>), an <e2>iron</e2> chelator, on the MA-induced neurotoxicity.","Association"
"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (<e1>DFO</e1>), an <e2>iron</e2> chelator, on the MA-induced neurotoxicity.","Association"
"Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of <e1>contrast</e1>-induced <e2>nephropathy</e2> in patients with chronic kidney disease.","Positive_Correlation"
"CONCLUSIONS: The rate of contrast-induced <e2>nephropathy</e2>, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or <e1>iodixanol</e1> to high-risk patients, with or without diabetes mellitus.","Positive_Correlation"
"CONCLUSIONS: The rate of contrast-induced <e2>nephropathy</e2>, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or <e1>iodixanol</e1> to high-risk patients, with or without diabetes mellitus.","Positive_Correlation"
"CONCLUSIONS: The rate of contrast-induced <e2>nephropathy</e2>, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or <e1>iodixanol</e1> to high-risk patients, with or without diabetes mellitus.","Positive_Correlation"
"CONCLUSIONS: The rate of contrast-induced <e2>nephropathy</e2>, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or <e1>iodixanol</e1> to high-risk patients, with or without diabetes mellitus.","Positive_Correlation"
"CONCLUSIONS: The rate of contrast-induced <e2>nephropathy</e2>, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or <e1>iodixanol</e1> to high-risk patients, with or without diabetes mellitus.","Positive_Correlation"
"BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium <e1>iopamidol</e1> with that of the iso-osmolality contrast medium <e2>iodixanol</e2> in high-risk patients.","Comparison"
"BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium <e1>iopamidol</e1> with that of the iso-osmolality contrast medium <e2>iodixanol</e2> in high-risk patients.","Comparison"
"BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium <e1>iopamidol</e1> with that of the iso-osmolality contrast medium <e2>iodixanol</e2> in high-risk patients.","Comparison"
"BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium <e1>iopamidol</e1> with that of the iso-osmolality contrast medium <e2>iodixanol</e2> in high-risk patients.","Comparison"
"BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium <e1>iopamidol</e1> with that of the iso-osmolality contrast medium <e2>iodixanol</e2> in high-risk patients.","Comparison"
"BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium <e1>iopamidol</e1> with that of the iso-osmolality contrast medium <e2>iodixanol</e2> in high-risk patients.","Comparison"
"CONCLUSIONS: The rate of contrast-induced <e2>nephropathy</e2>, defined by multiple end points, is not statistically different after the intraarterial administration of <e1>iopamidol</e1> or iodixanol to high-risk patients, with or without diabetes mellitus.","Positive_Correlation"
"CONCLUSIONS: The rate of contrast-induced <e2>nephropathy</e2>, defined by multiple end points, is not statistically different after the intraarterial administration of <e1>iopamidol</e1> or iodixanol to high-risk patients, with or without diabetes mellitus.","Positive_Correlation"
"CONCLUSIONS: The rate of contrast-induced <e2>nephropathy</e2>, defined by multiple end points, is not statistically different after the intraarterial administration of <e1>iopamidol</e1> or iodixanol to high-risk patients, with or without diabetes mellitus.","Positive_Correlation"
"CONCLUSIONS: The rate of contrast-induced <e2>nephropathy</e2>, defined by multiple end points, is not statistically different after the intraarterial administration of <e1>iopamidol</e1> or iodixanol to high-risk patients, with or without diabetes mellitus.","Positive_Correlation"
"CONCLUSIONS: The rate of contrast-induced <e2>nephropathy</e2>, defined by multiple end points, is not statistically different after the intraarterial administration of <e1>iopamidol</e1> or iodixanol to high-risk patients, with or without diabetes mellitus.","Positive_Correlation"
"CONCLUSIONS: The rate of contrast-induced <e2>nephropathy</e2>, defined by multiple end points, is not statistically different after the intraarterial administration of <e1>iopamidol</e1> or iodixanol to high-risk patients, with or without diabetes mellitus.","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after <e2>iodixanol</e2> (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after <e2>iodixanol</e2> (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after <e2>iodixanol</e2> (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after <e2>iodixanol</e2> (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after <e2>iodixanol</e2> (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after <e2>iodixanol</e2> (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after <e2>iodixanol</e2> (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after <e2>iodixanol</e2> (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after <e2>iodixanol</e2> (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after <e2>iodixanol</e2> (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after <e2>iopamidol</e2> and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after <e2>iopamidol</e2> and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after <e2>iopamidol</e2> and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after <e2>iopamidol</e2> and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after <e2>iopamidol</e2> and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after <e2>iopamidol</e2> and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after <e2>iopamidol</e2> and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after <e2>iopamidol</e2> and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after <e2>iopamidol</e2> and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"<e1>SCr</e1> increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after <e2>iopamidol</e2> and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).","Positive_Correlation"
"CONCLUSIONS: The rate of <e1>contrast</e1>-induced <e2>nephropathy</e2>, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.","Positive_Correlation"
"CONCLUSIONS: The rate of <e1>contrast</e1>-induced <e2>nephropathy</e2>, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.","Positive_Correlation"
"Estrogen prevents <e2>cholesteryl ester</e2> accumulation in macrophages induced by the HIV protease inhibitor <e1>ritonavir</e1>.","Negative_Correlation"
"<e1>Estrogen</e1> prevents <e2>cholesteryl ester</e2> accumulation in macrophages induced by the HIV protease inhibitor ritonavir.","Negative_Correlation"
"Additionally, ritonavir treatment selectively increased the relative levels of <e1>PPARgamma</e1> mRNA, a transcription factor responsible for the regulation of <e2>CD36</e2> mRNA expression.","Association"
"This data suggests that E2 modifies the expression of <e1>CD36</e1> at the level of protein expression in monocyte-derived macrophages resulting in reduced <e2>cholesteryl ester</e2> accumulation following ritonavir treatment.","Association"
"This data suggests that E2 modifies the expression of <e1>CD36</e1> at the level of protein expression in monocyte-derived macrophages resulting in reduced <e2>cholesteryl ester</e2> accumulation following ritonavir treatment.","Association"
"This data suggests that E2 modifies the expression of <e1>CD36</e1> at the level of protein expression in monocyte-derived macrophages resulting in reduced <e2>cholesteryl ester</e2> accumulation following ritonavir treatment.","Association"
"This data suggests that E2 modifies the expression of <e1>CD36</e1> at the level of protein expression in monocyte-derived macrophages resulting in reduced <e2>cholesteryl ester</e2> accumulation following ritonavir treatment.","Association"
"<e1>E2</e1> did, however, significantly suppress <e2>CD36</e2> protein levels as measured by fluorescent immunocytochemistry.","Negative_Correlation"
"<e1>E2</e1> did, however, significantly suppress <e2>CD36</e2> protein levels as measured by fluorescent immunocytochemistry.","Negative_Correlation"
"<e1>E2</e1> did, however, significantly suppress <e2>CD36</e2> protein levels as measured by fluorescent immunocytochemistry.","Negative_Correlation"
"<e1>E2</e1> did, however, significantly suppress <e2>CD36</e2> protein levels as measured by fluorescent immunocytochemistry.","Negative_Correlation"
"<e1>E2</e1> did, however, significantly suppress <e2>CD36</e2> protein levels as measured by fluorescent immunocytochemistry.","Negative_Correlation"
"<e1>E2</e1> decreased the accumulation of <e2>cholesteryl ester</e2>s in macrophages following ritonavir treatment.","Negative_Correlation"
"<e1>E2</e1> decreased the accumulation of <e2>cholesteryl ester</e2>s in macrophages following ritonavir treatment.","Negative_Correlation"
"<e1>E2</e1> decreased the accumulation of <e2>cholesteryl ester</e2>s in macrophages following ritonavir treatment.","Negative_Correlation"
"<e1>E2</e1> decreased the accumulation of <e2>cholesteryl ester</e2>s in macrophages following ritonavir treatment.","Negative_Correlation"
"<e1>E2</e1> decreased the accumulation of <e2>cholesteryl ester</e2>s in macrophages following ritonavir treatment.","Negative_Correlation"
"Additionally, <e1>ritonavir</e1> treatment selectively increased the relative levels of <e2>PPARgamma</e2> mRNA, a transcription factor responsible for the regulation of CD36 mRNA expression.","Positive_Correlation"
"Additionally, <e1>ritonavir</e1> treatment selectively increased the relative levels of <e2>PPARgamma</e2> mRNA, a transcription factor responsible for the regulation of CD36 mRNA expression.","Positive_Correlation"
"Additionally, <e1>ritonavir</e1> treatment selectively increased the relative levels of <e2>PPARgamma</e2> mRNA, a transcription factor responsible for the regulation of CD36 mRNA expression.","Positive_Correlation"
"Additionally, <e1>ritonavir</e1> treatment selectively increased the relative levels of <e2>PPARgamma</e2> mRNA, a transcription factor responsible for the regulation of CD36 mRNA expression.","Positive_Correlation"
"Additionally, <e1>ritonavir</e1> treatment selectively increased the relative levels of <e2>PPARgamma</e2> mRNA, a transcription factor responsible for the regulation of CD36 mRNA expression.","Positive_Correlation"
"Additionally, <e1>ritonavir</e1> treatment selectively increased the relative levels of <e2>PPARgamma</e2> mRNA, a transcription factor responsible for the regulation of CD36 mRNA expression.","Positive_Correlation"
"Additionally, <e1>ritonavir</e1> treatment selectively increased the relative levels of <e2>PPARgamma</e2> mRNA, a transcription factor responsible for the regulation of CD36 mRNA expression.","Positive_Correlation"
"Additionally, <e1>ritonavir</e1> treatment selectively increased the relative levels of <e2>PPARgamma</e2> mRNA, a transcription factor responsible for the regulation of CD36 mRNA expression.","Positive_Correlation"
"Additionally, <e1>ritonavir</e1> treatment selectively increased the relative levels of PPARgamma mRNA, a transcription factor responsible for the regulation of <e2>CD36</e2> mRNA expression.","Positive_Correlation"
"Additionally, <e1>ritonavir</e1> treatment selectively increased the relative levels of PPARgamma mRNA, a transcription factor responsible for the regulation of <e2>CD36</e2> mRNA expression.","Positive_Correlation"
"Additionally, <e1>ritonavir</e1> treatment selectively increased the relative levels of PPARgamma mRNA, a transcription factor responsible for the regulation of <e2>CD36</e2> mRNA expression.","Positive_Correlation"
"Additionally, <e1>ritonavir</e1> treatment selectively increased the relative levels of PPARgamma mRNA, a transcription factor responsible for the regulation of <e2>CD36</e2> mRNA expression.","Positive_Correlation"
"Additionally, <e1>ritonavir</e1> treatment selectively increased the relative levels of PPARgamma mRNA, a transcription factor responsible for the regulation of <e2>CD36</e2> mRNA expression.","Positive_Correlation"
"Additionally, <e1>ritonavir</e1> treatment selectively increased the relative levels of PPARgamma mRNA, a transcription factor responsible for the regulation of <e2>CD36</e2> mRNA expression.","Positive_Correlation"
"<e1>Ritonavir</e1> increased the expression of the scavenger receptor, <e2>CD36</e2> mRNA, responsible for the uptake of LDL.","Positive_Correlation"
"Additionally, <e1>ritonavir</e1> treatment selectively increased the relative levels of PPARgamma mRNA, a transcription factor responsible for the regulation of <e2>CD36</e2> mRNA expression.","Positive_Correlation"
"Additionally, <e1>ritonavir</e1> treatment selectively increased the relative levels of PPARgamma mRNA, a transcription factor responsible for the regulation of <e2>CD36</e2> mRNA expression.","Positive_Correlation"
"<e2>E2</e2> decreased the accumulation of cholesteryl esters in macrophages following <e1>ritonavir</e1> treatment.","Association"
"<e2>E2</e2> decreased the accumulation of cholesteryl esters in macrophages following <e1>ritonavir</e1> treatment.","Association"
"<e2>E2</e2> decreased the accumulation of cholesteryl esters in macrophages following <e1>ritonavir</e1> treatment.","Association"
"<e2>E2</e2> decreased the accumulation of cholesteryl esters in macrophages following <e1>ritonavir</e1> treatment.","Association"
"<e2>E2</e2> decreased the accumulation of cholesteryl esters in macrophages following <e1>ritonavir</e1> treatment.","Association"
"<e2>E2</e2> decreased the accumulation of cholesteryl esters in macrophages following <e1>ritonavir</e1> treatment.","Association"
"<e2>E2</e2> decreased the accumulation of cholesteryl esters in macrophages following <e1>ritonavir</e1> treatment.","Association"
"<e2>E2</e2> decreased the accumulation of cholesteryl esters in macrophages following <e1>ritonavir</e1> treatment.","Association"
"We have previously demonstrated that <e1>ritonavir</e1> treatment increases <e2>atherosclerotic lesion</e2> formation in male mice to a greater extent than in female mice.","Positive_Correlation"
"We have previously demonstrated that <e1>ritonavir</e1> treatment increases <e2>atherosclerotic lesion</e2> formation in male mice to a greater extent than in female mice.","Positive_Correlation"
"We have previously demonstrated that <e1>ritonavir</e1> treatment increases <e2>atherosclerotic lesion</e2> formation in male mice to a greater extent than in female mice.","Positive_Correlation"
"We have previously demonstrated that <e1>ritonavir</e1> treatment increases <e2>atherosclerotic lesion</e2> formation in male mice to a greater extent than in female mice.","Positive_Correlation"
"We have previously demonstrated that <e1>ritonavir</e1> treatment increases <e2>atherosclerotic lesion</e2> formation in male mice to a greater extent than in female mice.","Positive_Correlation"
"We have previously demonstrated that <e1>ritonavir</e1> treatment increases <e2>atherosclerotic lesion</e2> formation in male mice to a greater extent than in female mice.","Positive_Correlation"
"We have previously demonstrated that <e1>ritonavir</e1> treatment increases <e2>atherosclerotic lesion</e2> formation in male mice to a greater extent than in female mice.","Positive_Correlation"
"We have previously demonstrated that <e1>ritonavir</e1> treatment increases <e2>atherosclerotic lesion</e2> formation in male mice to a greater extent than in female mice.","Positive_Correlation"
"Furthermore, peripheral blood monocytes isolated from <e1>ritonavir</e1>-treated females had less <e2>cholesteryl ester</e2> accumulation.","Negative_Correlation"
"Furthermore, peripheral blood monocytes isolated from <e1>ritonavir</e1>-treated females had less <e2>cholesteryl ester</e2> accumulation.","Negative_Correlation"
"Furthermore, peripheral blood monocytes isolated from <e1>ritonavir</e1>-treated females had less <e2>cholesteryl ester</e2> accumulation.","Negative_Correlation"
"Furthermore, peripheral blood monocytes isolated from <e1>ritonavir</e1>-treated females had less <e2>cholesteryl ester</e2> accumulation.","Negative_Correlation"
"Furthermore, peripheral blood monocytes isolated from <e1>ritonavir</e1>-treated females had less <e2>cholesteryl ester</e2> accumulation.","Negative_Correlation"
"Furthermore, peripheral blood monocytes isolated from <e1>ritonavir</e1>-treated females had less <e2>cholesteryl ester</e2> accumulation.","Negative_Correlation"
"Furthermore, peripheral blood monocytes isolated from <e1>ritonavir</e1>-treated females had less <e2>cholesteryl ester</e2> accumulation.","Negative_Correlation"
"Furthermore, peripheral blood monocytes isolated from <e1>ritonavir</e1>-treated females had less <e2>cholesteryl ester</e2> accumulation.","Negative_Correlation"
"Four (10.8%) patients in the conventional group and 1 (2.7%) in the unilateral group, P= 0.17 required <e1>epinephrine</e1> infusion to treat <e2>hypotension</e2>.","Negative_Correlation"
"Acute effects of <e1>N-(2-propylpentanoyl)urea</e1> on hippocampal amino acid neurotransmitters in pilocarpine-induced <e2>seizure</e2> in rats.","Negative_Correlation"
"Acute effects of <e1>N-(2-propylpentanoyl)urea</e1> on hippocampal amino acid neurotransmitters in <e2>pilocarpine</e2>-induced seizure in rats.","Negative_Correlation"
"Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in <e1>pilocarpine</e1>-induced <e2>seizure</e2> in rats.","Positive_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, <e2>aspartate</e2>, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, <e1>valproic acid</e1> (VPA).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, <e2>aspartate</e2>, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (<e1>VPA</e1>).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, <e2>aspartate</e2>, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (<e1>VPA</e1>).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, <e2>aspartate</e2>, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (<e1>VPA</e1>).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, <e2>aspartate</e2>, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (<e1>VPA</e1>).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, <e2>aspartate</e2>, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (<e1>VPA</e1>).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, <e2>aspartate</e2>, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (<e1>VPA</e1>).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (<e2>glutamate</e2>, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, <e1>valproic acid</e1> (VPA).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (<e2>glutamate</e2>, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (<e1>VPA</e1>).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (<e2>glutamate</e2>, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (<e1>VPA</e1>).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (<e2>glutamate</e2>, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (<e1>VPA</e1>).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (<e2>glutamate</e2>, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (<e1>VPA</e1>).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (<e2>glutamate</e2>, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (<e1>VPA</e1>).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (<e2>glutamate</e2>, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (<e1>VPA</e1>).","Negative_Correlation"
"VPU was more potent than <e1>VPA</e1>, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e2>pilocarpine</e2>-induced seizure whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"VPU was more potent than <e1>VPA</e1>, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e2>pilocarpine</e2>-induced seizure whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"VPU was more potent than <e1>VPA</e1>, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e2>pilocarpine</e2>-induced seizure whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"VPU was more potent than <e1>VPA</e1>, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e2>pilocarpine</e2>-induced seizure whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"VPU was more potent than <e1>VPA</e1>, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e2>pilocarpine</e2>-induced seizure whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"VPU was more potent than <e1>VPA</e1>, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e2>pilocarpine</e2>-induced seizure whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and <e2>GABA</e2>) of <e1>N-(2-propylpentanoyl)urea</e1> (VPU) in comparison to its parent compound, valproic acid (VPA).","Association"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and <e2>GABA</e2>) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Association"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and <e2>GABA</e2>) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Association"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and <e2>GABA</e2>) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Association"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and <e2>GABA</e2>) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Association"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and <e2>GABA</e2>) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Association"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, <e2>glycine</e2> and GABA) of <e1>N-(2-propylpentanoyl)urea</e1> (VPU) in comparison to its parent compound, valproic acid (VPA).","Association"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, <e2>glycine</e2> and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Association"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, <e2>glycine</e2> and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Association"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, <e2>glycine</e2> and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Association"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, <e2>glycine</e2> and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Association"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, <e2>glycine</e2> and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Association"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, <e2>aspartate</e2>, glycine and GABA) of <e1>N-(2-propylpentanoyl)urea</e1> (VPU) in comparison to its parent compound, valproic acid (VPA).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, <e2>aspartate</e2>, glycine and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, <e2>aspartate</e2>, glycine and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, <e2>aspartate</e2>, glycine and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, <e2>aspartate</e2>, glycine and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, <e2>aspartate</e2>, glycine and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (<e2>glutamate</e2>, aspartate, glycine and GABA) of <e1>N-(2-propylpentanoyl)urea</e1> (VPU) in comparison to its parent compound, valproic acid (VPA).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (<e2>glutamate</e2>, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (<e2>glutamate</e2>, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (<e2>glutamate</e2>, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (<e2>glutamate</e2>, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (<e2>glutamate</e2>, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, valproic acid (VPA).","Negative_Correlation"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of <e1>N-(2-propylpentanoyl)urea</e1> (VPU) in comparison to its parent compound, <e2>valproic acid</e2> (VPA).","Comparison"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, <e2>valproic acid</e2> (VPA).","Comparison"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, <e2>valproic acid</e2> (VPA).","Comparison"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, <e2>valproic acid</e2> (VPA).","Comparison"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, <e2>valproic acid</e2> (VPA).","Comparison"
"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (<e1>VPU</e1>) in comparison to its parent compound, <e2>valproic acid</e2> (VPA).","Comparison"
"<e1>VPU</e1> was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced <e2>seizure</e2> whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"<e1>VPU</e1> was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced <e2>seizure</e2> whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"<e1>VPU</e1> was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced <e2>seizure</e2> whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"<e1>VPU</e1> was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced <e2>seizure</e2> whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"<e1>VPU</e1> was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced <e2>seizure</e2> whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"<e1>VPU</e1> was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e2>pilocarpine</e2>-induced seizure whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"<e1>VPU</e1> was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e2>pilocarpine</e2>-induced seizure whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"<e1>VPU</e1> was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e2>pilocarpine</e2>-induced seizure whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"<e1>VPU</e1> was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e2>pilocarpine</e2>-induced seizure whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"<e1>VPU</e1> was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e2>pilocarpine</e2>-induced seizure whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"VPU was more potent than <e2>VPA</e2>, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced <e1>seizure</e1> whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"VPU was more potent than <e2>VPA</e2>, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced <e1>seizure</e1> whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"VPU was more potent than <e2>VPA</e2>, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced <e1>seizure</e1> whereas the corresponding value for VPA was 322 mg/kg.","Negative_Correlation"
"In vivo microdialysis demonstrated that an intraperitoneal administration of <e1>pilocarpine</e1> induced a pronounced increment of hippocampal glutamate and <e2>aspartate</e2> whereas no significant change was observed on the level of glycine and GABA.","Positive_Correlation"
"In vivo microdialysis demonstrated that an intraperitoneal administration of <e1>pilocarpine</e1> induced a pronounced increment of hippocampal glutamate and <e2>aspartate</e2> whereas no significant change was observed on the level of glycine and GABA.","Positive_Correlation"
"In vivo microdialysis demonstrated that an intraperitoneal administration of <e1>pilocarpine</e1> induced a pronounced increment of hippocampal glutamate and <e2>aspartate</e2> whereas no significant change was observed on the level of glycine and GABA.","Positive_Correlation"
"In vivo microdialysis demonstrated that an intraperitoneal administration of <e1>pilocarpine</e1> induced a pronounced increment of hippocampal glutamate and <e2>aspartate</e2> whereas no significant change was observed on the level of glycine and GABA.","Positive_Correlation"
"In vivo microdialysis demonstrated that an intraperitoneal administration of <e1>pilocarpine</e1> induced a pronounced increment of hippocampal glutamate and <e2>aspartate</e2> whereas no significant change was observed on the level of glycine and GABA.","Positive_Correlation"
"In vivo microdialysis demonstrated that an intraperitoneal administration of <e1>pilocarpine</e1> induced a pronounced increment of hippocampal glutamate and <e2>aspartate</e2> whereas no significant change was observed on the level of glycine and GABA.","Positive_Correlation"
"In vivo microdialysis demonstrated that an intraperitoneal administration of <e1>pilocarpine</e1> induced a pronounced increment of hippocampal <e2>glutamate</e2> and aspartate whereas no significant change was observed on the level of glycine and GABA.","Positive_Correlation"
"In vivo microdialysis demonstrated that an intraperitoneal administration of <e1>pilocarpine</e1> induced a pronounced increment of hippocampal <e2>glutamate</e2> and aspartate whereas no significant change was observed on the level of glycine and GABA.","Positive_Correlation"
"In vivo microdialysis demonstrated that an intraperitoneal administration of <e1>pilocarpine</e1> induced a pronounced increment of hippocampal <e2>glutamate</e2> and aspartate whereas no significant change was observed on the level of glycine and GABA.","Positive_Correlation"
"In vivo microdialysis demonstrated that an intraperitoneal administration of <e1>pilocarpine</e1> induced a pronounced increment of hippocampal <e2>glutamate</e2> and aspartate whereas no significant change was observed on the level of glycine and GABA.","Positive_Correlation"
"In vivo microdialysis demonstrated that an intraperitoneal administration of <e1>pilocarpine</e1> induced a pronounced increment of hippocampal <e2>glutamate</e2> and aspartate whereas no significant change was observed on the level of glycine and GABA.","Positive_Correlation"
"In vivo microdialysis demonstrated that an intraperitoneal administration of <e1>pilocarpine</e1> induced a pronounced increment of hippocampal <e2>glutamate</e2> and aspartate whereas no significant change was observed on the level of glycine and GABA.","Positive_Correlation"
"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e1>pilocarpine</e1>-induced <e2>seizure</e2> whereas the corresponding value for VPA was 322 mg/kg.","Positive_Correlation"
"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e1>pilocarpine</e1>-induced <e2>seizure</e2> whereas the corresponding value for VPA was 322 mg/kg.","Positive_Correlation"
"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e1>pilocarpine</e1>-induced <e2>seizure</e2> whereas the corresponding value for VPA was 322 mg/kg.","Positive_Correlation"
"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e1>pilocarpine</e1>-induced <e2>seizure</e2> whereas the corresponding value for VPA was 322 mg/kg.","Positive_Correlation"
"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e1>pilocarpine</e1>-induced <e2>seizure</e2> whereas the corresponding value for VPA was 322 mg/kg.","Positive_Correlation"
"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against <e1>pilocarpine</e1>-induced <e2>seizure</e2> whereas the corresponding value for VPA was 322 mg/kg.","Positive_Correlation"
"<e2>Delirium</e2> in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with <e1>paroxetine</e1>.","Positive_Correlation"
"Delirium in a patient with toxic <e1>flecainide</e1> plasma concentrations: the role of a pharmacokinetic drug interaction with <e2>paroxetine</e2>.","Drug_Interaction"
"<e2>Delirium</e2> in a patient with toxic <e1>flecainide</e1> plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine.","Positive_Correlation"
"DISCUSSION: Flecainide and pharmacologically similar agents that interact with <e1>sodium</e1> channels may cause <e2>delirium</e2> in susceptible patients.","Association"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a <e2>CYP2D6</e2> substrate, and <e1>paroxetine</e1>, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Negative_Correlation"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a <e2>CYP2D6</e2> substrate, and <e1>paroxetine</e1>, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Negative_Correlation"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a <e2>CYP2D6</e2> substrate, and <e1>paroxetine</e1>, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Negative_Correlation"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a <e2>CYP2D6</e2> substrate, and <e1>paroxetine</e1>, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Negative_Correlation"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a <e2>CYP2D6</e2> substrate, and <e1>paroxetine</e1>, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Negative_Correlation"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a <e2>CYP2D6</e2> substrate, and <e1>paroxetine</e1>, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Negative_Correlation"
"OBJECTIVE: To describe a case of flecainide-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with <e1>paroxetine</e1>.","Positive_Correlation"
"OBJECTIVE: To describe a case of flecainide-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with <e1>paroxetine</e1>.","Positive_Correlation"
"OBJECTIVE: To describe a case of flecainide-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with <e1>paroxetine</e1>.","Positive_Correlation"
"OBJECTIVE: To describe a case of flecainide-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with <e1>paroxetine</e1>.","Positive_Correlation"
"OBJECTIVE: To describe a case of flecainide-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with <e1>paroxetine</e1>.","Positive_Correlation"
"OBJECTIVE: To describe a case of flecainide-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with <e1>paroxetine</e1>.","Positive_Correlation"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between <e1>flecainide</e1>, a <e2>CYP2D6</e2> substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Association"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between <e1>flecainide</e1>, a <e2>CYP2D6</e2> substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Association"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between <e1>flecainide</e1>, a <e2>CYP2D6</e2> substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Association"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between <e1>flecainide</e1>, a <e2>CYP2D6</e2> substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Association"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between <e1>flecainide</e1>, a <e2>CYP2D6</e2> substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Association"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between <e1>flecainide</e1>, a <e2>CYP2D6</e2> substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Association"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between <e1>flecainide</e1>, a <e2>CYP2D6</e2> substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Association"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between <e1>flecainide</e1>, a <e2>CYP2D6</e2> substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Association"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between <e1>flecainide</e1>, a <e2>CYP2D6</e2> substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Association"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between <e1>flecainide</e1>, a <e2>CYP2D6</e2> substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Association"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between <e1>flecainide</e1>, a <e2>CYP2D6</e2> substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Association"
"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between <e1>flecainide</e1>, a <e2>CYP2D6</e2> substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.","Association"
"DISCUSSION: <e1>Flecainide</e1> and pharmacologically similar agents that interact with <e2>sodium</e2> channels may cause delirium in susceptible patients.","Association"
"DISCUSSION: <e1>Flecainide</e1> and pharmacologically similar agents that interact with <e2>sodium</e2> channels may cause delirium in susceptible patients.","Association"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced delirium associated with a pharmacokinetic drug interaction with <e2>paroxetine</e2>.","Drug_Interaction"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced delirium associated with a pharmacokinetic drug interaction with <e2>paroxetine</e2>.","Drug_Interaction"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced delirium associated with a pharmacokinetic drug interaction with <e2>paroxetine</e2>.","Drug_Interaction"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced delirium associated with a pharmacokinetic drug interaction with <e2>paroxetine</e2>.","Drug_Interaction"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced delirium associated with a pharmacokinetic drug interaction with <e2>paroxetine</e2>.","Drug_Interaction"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced delirium associated with a pharmacokinetic drug interaction with <e2>paroxetine</e2>.","Drug_Interaction"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced delirium associated with a pharmacokinetic drug interaction with <e2>paroxetine</e2>.","Drug_Interaction"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced delirium associated with a pharmacokinetic drug interaction with <e2>paroxetine</e2>.","Drug_Interaction"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced delirium associated with a pharmacokinetic drug interaction with <e2>paroxetine</e2>.","Drug_Interaction"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced delirium associated with a pharmacokinetic drug interaction with <e2>paroxetine</e2>.","Drug_Interaction"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced delirium associated with a pharmacokinetic drug interaction with <e2>paroxetine</e2>.","Drug_Interaction"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced delirium associated with a pharmacokinetic drug interaction with <e2>paroxetine</e2>.","Drug_Interaction"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with paroxetine.","Positive_Correlation"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with paroxetine.","Positive_Correlation"
"DISCUSSION: <e1>Flecainide</e1> and pharmacologically similar agents that interact with sodium channels may cause <e2>delirium</e2> in susceptible patients.","Positive_Correlation"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with paroxetine.","Positive_Correlation"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with paroxetine.","Positive_Correlation"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with paroxetine.","Positive_Correlation"
"DISCUSSION: <e1>Flecainide</e1> and pharmacologically similar agents that interact with sodium channels may cause <e2>delirium</e2> in susceptible patients.","Positive_Correlation"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with paroxetine.","Positive_Correlation"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with paroxetine.","Positive_Correlation"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with paroxetine.","Positive_Correlation"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with paroxetine.","Positive_Correlation"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with paroxetine.","Positive_Correlation"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with paroxetine.","Positive_Correlation"
"OBJECTIVE: To describe a case of <e1>flecainide</e1>-induced <e2>delirium</e2> associated with a pharmacokinetic drug interaction with paroxetine.","Positive_Correlation"
"<e1>Flecainide</e1> had been started 2 weeks prior for <e2>atrial fibrillation</e2>.","Negative_Correlation"
"<e1>Flecainide</e1> had been started 2 weeks prior for <e2>atrial fibrillation</e2>.","Negative_Correlation"
"Depression, <e2>impulsiveness</e2>, sleep, and memory in past and present polydrug users of <e1>3,4-methylenedioxymethamphetamine</e1> (MDMA, ecstasy).","Positive_Correlation"
"Depression, <e2>impulsiveness</e2>, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (<e1>MDMA</e1>, ecstasy).","Positive_Correlation"
"Depression, <e2>impulsiveness</e2>, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, <e1>ecstasy</e1>).","Positive_Correlation"
"<e2>Depression</e2>, impulsiveness, sleep, and memory in past and present polydrug users of <e1>3,4-methylenedioxymethamphetamine</e1> (MDMA, ecstasy).","Positive_Correlation"
"<e2>Depression</e2>, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (<e1>MDMA</e1>, ecstasy).","Positive_Correlation"
"<e2>Depression</e2>, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, <e1>ecstasy</e1>).","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and <e2>sleep disturbance</e2>, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and <e2>sleep disturbance</e2>, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and <e2>sleep disturbance</e2>, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and <e2>sleep disturbance</e2>, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and <e2>sleep disturbance</e2>, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and <e2>sleep disturbance</e2>, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, <e2>impulsiveness</e2>, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, <e2>impulsiveness</e2>, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, <e2>impulsiveness</e2>, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, <e2>impulsiveness</e2>, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, <e2>impulsiveness</e2>, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, <e2>impulsiveness</e2>, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of <e2>depression</e2>, impulsiveness, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of <e2>depression</e2>, impulsiveness, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of <e2>depression</e2>, impulsiveness, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of <e2>depression</e2>, impulsiveness, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of <e2>depression</e2>, impulsiveness, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of <e2>depression</e2>, impulsiveness, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of <e2>impaired memory</e2> and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of <e2>impaired memory</e2> and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of <e2>impaired memory</e2> and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of <e2>impaired memory</e2> and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of <e2>impaired memory</e2> and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"CONCLUSIONS: Given this record of <e2>impaired memory</e2> and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of <e1>ecstasy</e1> users is a major cause for concern.","Positive_Correlation"
"A comparison of severe hemodynamic disturbances between <e1>dexmedetomidine</e1> and <e2>propofol</e2> for sedation in neurocritical care patients.","Comparison"
"CONCLUSIONS: Severe hypotension and <e2>bradycardia</e2> occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or <e1>propofol</e1>.","Positive_Correlation"
"CONCLUSIONS: Severe hypotension and <e2>bradycardia</e2> occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or <e1>propofol</e1>.","Positive_Correlation"
"CONCLUSIONS: Severe hypotension and <e2>bradycardia</e2> occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or <e1>propofol</e1>.","Positive_Correlation"
"CONCLUSIONS: Severe hypotension and <e2>bradycardia</e2> occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or <e1>propofol</e1>.","Positive_Correlation"
"CONCLUSIONS: Severe hypotension and <e2>bradycardia</e2> occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or <e1>propofol</e1>.","Positive_Correlation"
"CONCLUSIONS: Severe <e2>hypotension</e2> and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or <e1>propofol</e1>.","Positive_Correlation"
"CONCLUSIONS: Severe <e2>hypotension</e2> and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or <e1>propofol</e1>.","Positive_Correlation"
"CONCLUSIONS: Severe <e2>hypotension</e2> and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or <e1>propofol</e1>.","Positive_Correlation"
"CONCLUSIONS: Severe <e2>hypotension</e2> and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or <e1>propofol</e1>.","Positive_Correlation"
"CONCLUSIONS: Severe <e2>hypotension</e2> and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or <e1>propofol</e1>.","Positive_Correlation"
"CONCLUSIONS: Severe hypotension and <e2>bradycardia</e2> occur at similar prevalence in neurocritical care patients who receive <e1>dexmedetomidine</e1> or propofol.","Positive_Correlation"
"CONCLUSIONS: Severe hypotension and <e2>bradycardia</e2> occur at similar prevalence in neurocritical care patients who receive <e1>dexmedetomidine</e1> or propofol.","Positive_Correlation"
"CONCLUSIONS: Severe hypotension and <e2>bradycardia</e2> occur at similar prevalence in neurocritical care patients who receive <e1>dexmedetomidine</e1> or propofol.","Positive_Correlation"
"CONCLUSIONS: Severe hypotension and <e2>bradycardia</e2> occur at similar prevalence in neurocritical care patients who receive <e1>dexmedetomidine</e1> or propofol.","Positive_Correlation"
"CONCLUSIONS: Severe <e2>hypotension</e2> and bradycardia occur at similar prevalence in neurocritical care patients who receive <e1>dexmedetomidine</e1> or propofol.","Positive_Correlation"
"CONCLUSIONS: Severe <e2>hypotension</e2> and bradycardia occur at similar prevalence in neurocritical care patients who receive <e1>dexmedetomidine</e1> or propofol.","Positive_Correlation"
"CONCLUSIONS: Severe <e2>hypotension</e2> and bradycardia occur at similar prevalence in neurocritical care patients who receive <e1>dexmedetomidine</e1> or propofol.","Positive_Correlation"
"CONCLUSIONS: Severe <e2>hypotension</e2> and bradycardia occur at similar prevalence in neurocritical care patients who receive <e1>dexmedetomidine</e1> or propofol.","Positive_Correlation"
"OBJECTIVE: <e1>Dexmedetomidine</e1> and <e2>propofol</e2> are commonly used sedatives in neurocritical care as they allow for frequent neurologic examinations.","Comparison"
"The primary objective of this study is to compare the prevalence of severe hemodynamic effects in neurocritical care patients receiving <e1>dexmedetomidine</e1> and <e2>propofol</e2>.","Comparison"
"The primary objective of this study is to compare the prevalence of severe hemodynamic effects in neurocritical care patients receiving <e1>dexmedetomidine</e1> and <e2>propofol</e2>.","Comparison"
"The primary objective of this study is to compare the prevalence of severe hemodynamic effects in neurocritical care patients receiving <e1>dexmedetomidine</e1> and <e2>propofol</e2>.","Comparison"
"The primary objective of this study is to compare the prevalence of severe hemodynamic effects in neurocritical care patients receiving <e1>dexmedetomidine</e1> and <e2>propofol</e2>.","Comparison"
"Effects of <e1>dehydroepiandrosterone</e1> in amphetamine-induced <e2>schizophrenia</e2> models in mice.","Negative_Correlation"
"Effects of <e1>dehydroepiandrosterone</e1> in <e2>amphetamine</e2>-induced schizophrenia models in mice.","Comparison"
"Effects of dehydroepiandrosterone in <e1>amphetamine</e1>-induced <e2>schizophrenia</e2> models in mice.","Positive_Correlation"
"CONCLUSION: We observed that <e1>DHEA</e1> reduced locomotor activity and increased <e2>catalepsy</e2> at both doses, while it had no effect on climbing behavior.","Positive_Correlation"
"CONCLUSION: We observed that <e1>DHEA</e1> reduced locomotor activity and increased <e2>catalepsy</e2> at both doses, while it had no effect on climbing behavior.","Positive_Correlation"
"CONCLUSION: We observed that <e1>DHEA</e1> reduced locomotor activity and increased <e2>catalepsy</e2> at both doses, while it had no effect on climbing behavior.","Positive_Correlation"
"CONCLUSION: We observed that <e1>DHEA</e1> reduced locomotor activity and increased <e2>catalepsy</e2> at both doses, while it had no effect on climbing behavior.","Positive_Correlation"
"CONCLUSION: We observed that <e1>DHEA</e1> reduced locomotor activity and increased <e2>catalepsy</e2> at both doses, while it had no effect on climbing behavior.","Positive_Correlation"
"CONCLUSION: We observed that <e1>DHEA</e1> reduced locomotor activity and increased <e2>catalepsy</e2> at both doses, while it had no effect on climbing behavior.","Positive_Correlation"
"OBJECTIVE: To examine the effects of <e1>dehydroepiandrosterone</e1> (DHEA) on animal models of <e2>schizophrenia</e2>.","Negative_Correlation"
"OBJECTIVE: To examine the effects of dehydroepiandrosterone (<e1>DHEA</e1>) on animal models of <e2>schizophrenia</e2>.","Negative_Correlation"
"OBJECTIVE: To examine the effects of dehydroepiandrosterone (<e1>DHEA</e1>) on animal models of <e2>schizophrenia</e2>.","Negative_Correlation"
"OBJECTIVE: To examine the effects of dehydroepiandrosterone (<e1>DHEA</e1>) on animal models of <e2>schizophrenia</e2>.","Negative_Correlation"
"OBJECTIVE: To examine the effects of dehydroepiandrosterone (<e1>DHEA</e1>) on animal models of <e2>schizophrenia</e2>.","Negative_Correlation"
"OBJECTIVE: To examine the effects of dehydroepiandrosterone (<e1>DHEA</e1>) on animal models of <e2>schizophrenia</e2>.","Negative_Correlation"
"OBJECTIVE: To examine the effects of dehydroepiandrosterone (<e1>DHEA</e1>) on animal models of <e2>schizophrenia</e2>.","Negative_Correlation"
"METHODS: Seventy Swiss albino female mice (25-35 g) were divided into 4 groups: <e2>amphetamine</e2>-free (control), amphetamine, 50, and 100 mg/kg <e1>DHEA</e1>.","Comparison"
"METHODS: Seventy Swiss albino female mice (25-35 g) were divided into 4 groups: <e2>amphetamine</e2>-free (control), amphetamine, 50, and 100 mg/kg <e1>DHEA</e1>.","Comparison"
"METHODS: Seventy Swiss albino female mice (25-35 g) were divided into 4 groups: <e2>amphetamine</e2>-free (control), amphetamine, 50, and 100 mg/kg <e1>DHEA</e1>.","Comparison"
"METHODS: Seventy Swiss albino female mice (25-35 g) were divided into 4 groups: <e2>amphetamine</e2>-free (control), amphetamine, 50, and 100 mg/kg <e1>DHEA</e1>.","Comparison"
"METHODS: Seventy Swiss albino female mice (25-35 g) were divided into 4 groups: <e2>amphetamine</e2>-free (control), amphetamine, 50, and 100 mg/kg <e1>DHEA</e1>.","Comparison"
"METHODS: Seventy Swiss albino female mice (25-35 g) were divided into 4 groups: <e2>amphetamine</e2>-free (control), amphetamine, 50, and 100 mg/kg <e1>DHEA</e1>.","Comparison"
"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and <e1>haloperidol</e1> (1.5 mg/kg sc) induced <e2>catalepsy</e2> tests were used as animal models of schizophrenia.","Positive_Correlation"
"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and <e1>haloperidol</e1> (1.5 mg/kg sc) induced <e2>catalepsy</e2> tests were used as animal models of schizophrenia.","Positive_Correlation"
"<e1>Amphetamine</e1> (3 mg/kg ip) induced <e2>hyper locomotion</e2>, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.","Positive_Correlation"
"<e1>Amphetamine</e1> (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of <e2>schizophrenia</e2>.","Positive_Correlation"
"Aconitine-induced <e1>Ca2+</e1> overload causes <e2>arrhythmia</e2> and triggers apoptosis through p38 MAPK signaling pathway in rats.","Positive_Correlation"
"Aconitine-induced Ca2+ overload causes <e1>arrhythmia</e1> and triggers apoptosis through <e2>p38 MAPK</e2> signaling pathway in rats.","Association"
"<e1>Aconitine</e1>-induced Ca2+ overload causes arrhythmia and triggers apoptosis through <e2>p38 MAPK</e2> signaling pathway in rats.","Association"
"<e1>Aconitine</e1>-induced <e2>Ca2+</e2> overload causes arrhythmia and triggers apoptosis through p38 MAPK signaling pathway in rats.","Positive_Correlation"
"<e1>Aconitine</e1>-induced Ca2+ overload causes <e2>arrhythmia</e2> and triggers apoptosis through p38 MAPK signaling pathway in rats.","Positive_Correlation"
"Emerging evidence indicates that voltage-dependent <e1>Na(+)</e1> channels have pivotal roles in the <e2>cardiotoxicity</e2> of aconitine.","Association"
"We found that <e1>Ca(2+)</e1> overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused <e2>arrhythmia</e2> in conscious freely moving rats.","Positive_Correlation"
"We found that <e1>Ca(2+)</e1> overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused <e2>arrhythmia</e2> in conscious freely moving rats.","Positive_Correlation"
"We found that <e1>Ca(2+)</e1> overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused <e2>arrhythmia</e2> in conscious freely moving rats.","Positive_Correlation"
"We found that <e1>Ca(2+)</e1> overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused <e2>arrhythmia</e2> in conscious freely moving rats.","Positive_Correlation"
"We found that <e1>Ca(2+)</e1> overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused <e2>arrhythmia</e2> in conscious freely moving rats.","Positive_Correlation"
"We found that <e1>Ca(2+)</e1> overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused <e2>arrhythmia</e2> in conscious freely moving rats.","Positive_Correlation"
"We found that <e1>Ca(2+)</e1> overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused <e2>arrhythmia</e2> in conscious freely moving rats.","Positive_Correlation"
"Hence, our results suggest that aconitine significantly aggravates Ca(2+) overload and causes <e1>arrhythmia</e1> and finally promotes apoptotic development via phosphorylation of <e2>P38</e2> mitogen-activated protein kinase.","Association"
"Hence, our results suggest that aconitine significantly aggravates Ca(2+) overload and causes <e1>arrhythmia</e1> and finally promotes apoptotic development via phosphorylation of <e2>P38</e2> mitogen-activated protein kinase.","Association"
"Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the <e2>cardiotoxicity</e2> of <e1>aconitine</e1>.","Positive_Correlation"
"Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the <e2>cardiotoxicity</e2> of <e1>aconitine</e1>.","Positive_Correlation"
"Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the <e2>cardiotoxicity</e2> of <e1>aconitine</e1>.","Positive_Correlation"
"Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the <e2>cardiotoxicity</e2> of <e1>aconitine</e1>.","Positive_Correlation"
"Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the <e2>cardiotoxicity</e2> of <e1>aconitine</e1>.","Positive_Correlation"
"Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the <e2>cardiotoxicity</e2> of <e1>aconitine</e1>.","Positive_Correlation"
"Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the <e2>cardiotoxicity</e2> of <e1>aconitine</e1>.","Positive_Correlation"
"Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the <e2>cardiotoxicity</e2> of <e1>aconitine</e1>.","Positive_Correlation"
"To investigate effects of <e1>aconitine</e1> on <e2>myocardial injury</e2>, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.","Positive_Correlation"
"To investigate effects of <e1>aconitine</e1> on <e2>myocardial injury</e2>, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.","Positive_Correlation"
"To investigate effects of <e1>aconitine</e1> on <e2>myocardial injury</e2>, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.","Positive_Correlation"
"To investigate effects of <e1>aconitine</e1> on <e2>myocardial injury</e2>, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.","Positive_Correlation"
"To investigate effects of <e1>aconitine</e1> on <e2>myocardial injury</e2>, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.","Positive_Correlation"
"To investigate effects of <e1>aconitine</e1> on <e2>myocardial injury</e2>, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.","Positive_Correlation"
"To investigate effects of <e1>aconitine</e1> on <e2>myocardial injury</e2>, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.","Positive_Correlation"
"To investigate effects of <e1>aconitine</e1> on <e2>myocardial injury</e2>, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.","Positive_Correlation"
"Hence, our results suggest that <e1>aconitine</e1> significantly aggravates Ca(2+) overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of <e2>P38</e2> mitogen-activated protein kinase.","Association"
"Hence, our results suggest that <e1>aconitine</e1> significantly aggravates Ca(2+) overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of <e2>P38</e2> mitogen-activated protein kinase.","Association"
"Hence, our results suggest that <e1>aconitine</e1> significantly aggravates Ca(2+) overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of <e2>P38</e2> mitogen-activated protein kinase.","Association"
"Hence, our results suggest that <e1>aconitine</e1> significantly aggravates Ca(2+) overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of <e2>P38</e2> mitogen-activated protein kinase.","Association"
"Hence, our results suggest that <e1>aconitine</e1> significantly aggravates Ca(2+) overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of <e2>P38</e2> mitogen-activated protein kinase.","Association"
"Hence, our results suggest that <e1>aconitine</e1> significantly aggravates Ca(2+) overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of <e2>P38</e2> mitogen-activated protein kinase.","Association"
"Hence, our results suggest that <e1>aconitine</e1> significantly aggravates Ca(2+) overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of <e2>P38</e2> mitogen-activated protein kinase.","Association"
"Hence, our results suggest that <e1>aconitine</e1> significantly aggravates Ca(2+) overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of <e2>P38</e2> mitogen-activated protein kinase.","Association"
"However, no reports are available on the role of <e2>Ca(2+)</e2> in <e1>aconitine</e1> poisoning.","Positive_Correlation"
"However, no reports are available on the role of <e2>Ca(2+)</e2> in <e1>aconitine</e1> poisoning.","Positive_Correlation"
"However, no reports are available on the role of <e2>Ca(2+)</e2> in <e1>aconitine</e1> poisoning.","Positive_Correlation"
"However, no reports are available on the role of <e2>Ca(2+)</e2> in <e1>aconitine</e1> poisoning.","Positive_Correlation"
"However, no reports are available on the role of <e2>Ca(2+)</e2> in <e1>aconitine</e1> poisoning.","Positive_Correlation"
"However, no reports are available on the role of <e2>Ca(2+)</e2> in <e1>aconitine</e1> poisoning.","Positive_Correlation"
"However, no reports are available on the role of <e2>Ca(2+)</e2> in <e1>aconitine</e1> poisoning.","Positive_Correlation"
"However, no reports are available on the role of <e2>Ca(2+)</e2> in <e1>aconitine</e1> poisoning.","Positive_Correlation"
"Hence, our results suggest that <e1>aconitine</e1> significantly aggravates Ca(2+) overload and causes <e2>arrhythmia</e2> and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.","Positive_Correlation"
"Hence, our results suggest that <e1>aconitine</e1> significantly aggravates Ca(2+) overload and causes <e2>arrhythmia</e2> and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.","Positive_Correlation"
"Hence, our results suggest that <e1>aconitine</e1> significantly aggravates Ca(2+) overload and causes <e2>arrhythmia</e2> and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.","Positive_Correlation"
"Hence, our results suggest that <e1>aconitine</e1> significantly aggravates Ca(2+) overload and causes <e2>arrhythmia</e2> and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.","Positive_Correlation"
"Hence, our results suggest that <e1>aconitine</e1> significantly aggravates Ca(2+) overload and causes <e2>arrhythmia</e2> and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.","Positive_Correlation"
"Hence, our results suggest that <e1>aconitine</e1> significantly aggravates Ca(2+) overload and causes <e2>arrhythmia</e2> and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.","Positive_Correlation"
"Hence, our results suggest that <e1>aconitine</e1> significantly aggravates Ca(2+) overload and causes <e2>arrhythmia</e2> and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.","Positive_Correlation"
"Hence, our results suggest that <e1>aconitine</e1> significantly aggravates Ca(2+) overload and causes <e2>arrhythmia</e2> and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.","Positive_Correlation"
